M E T H O D S I N M O L E C U L A R M E D I C I N E TM
Placenta and Trophoblast Methods and Protocols Volume I Edited by
Michael J. Soares Joan S. Hunt
Placenta and Trophoblast
M E T H O D S I N M O L E C U L A R M E D I C I N E™
John M. Walker, SERIES EDITOR 125. Myeloid Leukemia: Methods and Protocols, edited by Harry Iland, Mark Hertzberg, and Paula Marlton, 2006 124. Magnetic Resonance Imaging: Methods and Biological Applications, edited by Pottumarthi V. Prasad, 2006 123. Marijuana and Cannabinoid Research: Methods and Protocols, edited by Emmanuel S. Onaivi, 2006 122. Placenta Research Methods and Protocols: Volume 2, edited by Michael J. Soares and Joan S. Hunt, 2006 121. Placenta Research Methods and Protocols: Volume 1, edited by Michael J. Soares and Joan S. Hunt, 2006 120. Breast Cancer Research Protocols, edited by Susan A. Brooks and Adrian Harris, 2006 119. Human Papillomaviruses: Methods and Protocols, edited by Clare Davy and John Doorbar, 2005 118. Antifungal Agents: Methods and Protocols, edited by Erika J. Ernst and P. David Rogers, 2005 117. Fibrosis Research: Methods and Protocols, edited by John Varga, David A. Brenner, and Sem H. Phan, 2005 116. Inteferon Methods and Protocols, edited by Daniel J. J. Carr, 2005 115. Lymphoma: Methods and Protocols, edited by Timothy Illidge and Peter W. M. Johnson, 2005 114. Microarrays in Clinical Diagnostics, edited by Thomas O. Joos and Paolo Fortina, 2005 113. Multiple Myeloma: Methods and Protocols, edited by Ross D. Brown and P. Joy Ho, 2005 112. Molecular Cardiology: Methods and Protocols, edited by Zhongjie Sun, 2005 111. Chemosensitivity: Volume 2, In Vivo Models, Imaging, and Molecular Regulators, edited by Rosalyn D. Blumethal, 2005 110. Chemosensitivity: Volume 1, In Vitro Assays, edited by Rosalyn D. Blumethal, 2005 109. Adoptive Immunotherapy: Methods and Protocols, edited by Burkhard Ludewig and Matthias W. Hoffman, 2005 108. Hypertension: Methods and Protocols, edited by Jérôme P. Fennell and Andrew H. Baker, 2005 107. Human Cell Culture Protocols, Second Edition, edited by Joanna Picot, 2005 106. Antisense Therapeutics, Second Edition, edited by M. Ian Phillips, 2005 105. Developmental Hematopoiesis: Methods and Protocols, edited by Margaret H. Baron, 2005
104. Stroke Genomics: Methods and Reviews, edited by Simon J. Read and David Virley, 2004 103. Pancreatic Cancer: Methods and Protocols, edited by Gloria H. Su, 2004 102. Autoimmunity: Methods and Protocols, edited by Andras Perl, 2004 101. Cartilage and Osteoarthritis: Volume 2, Structure and In Vivo Analysis, edited by Frédéric De Ceuninck, Massimo Sabatini, and Philippe Pastoureau, 2004 100. Cartilage and Osteoarthritis: Volume 1, Cellular and Molecular Tools, edited by Massimo Sabatini, Philippe Pastoureau, and Frédéric De Ceuninck, 2004 99. Pain Research: Methods and Protocols, edited by David Z. Luo, 2004 98. Tumor Necrosis Factor: Methods and Protocols, edited by Angelo Corti and Pietro Ghezzi, 2004 97. Molecular Diagnosis of Cancer: Methods and Protocols, Second Edition, edited by Joseph E. Roulston and John M. S. Bartlett, 2004 96. Hepatitis B and D Protocols: Volume 2, Immunology, Model Systems, and Clinical Studies, edited by Robert K. Hamatake and Johnson Y. N. Lau, 2004 95. Hepatitis B and D Protocols: Volume 1, Detection, Genotypes, and Characterization, edited by Robert K. Hamatake and Johnson Y. N. Lau, 2004 94. Molecular Diagnosis of Infectious Diseases, Second Edition, edited by Jochen Decker and Udo Reischl, 2004 93. Anticoagulants, Antiplatelets, and Thrombolytics, edited by Shaker A. Mousa, 2004 92. Molecular Diagnosis of Genetic Diseases, Second Edition, edited by Rob Elles and Roger Mountford, 2004 91. Pediatric Hematology: Methods and Protocols, edited by Nicholas J. Goulden and Colin G. Steward, 2003 90. Suicide Gene Therapy: Methods and Reviews, edited by Caroline J. Springer, 2004 89. The Blood–Brain Barrier: Biology and Research Protocols, edited by Sukriti Nag, 2003 88. Cancer Cell Culture: Methods and Protocols, edited by Simon P. Langdon, 2003 87. Vaccine Protocols, Second Edition, edited by Andrew Robinson, Michael J. Hudson, and Martin P. Cranage, 2003 86. Renal Disease: Techniques and Protocols, edited by Michael S. Goligorsky, 2003
M E T H O D S I N M O L E C U L A R M E D I C I N E™
Placenta and Trophoblast Methods and Protocols Volume 1 Edited by
Michael J. Soares Institute of Maternal–Fetal Biology Division of Cancer and Developmental Biology Department of Pathology and Laboratory Medicine University of Kansas Medical Center, Kansas City, KS
and
Joan S. Hunt University Distinguished Professor, Vice Chancellor for Research Department of Anatomy and Cell Biology University of Kansas Medical Center, Kansas City, KS
© 2006 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. Methods in Molecular MedicineTM is a trademark of The Humana Press Inc. All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher. This publication is printed on acid-free paper. ∞ ANSI Z39.48-1984 (American Standards Institute) Permanence of Paper for Printed Library Materials. Cover illustration: Background: Figure 5 from Chapter 11 (Volume 1), “Mouse Trophoblast Stem Cells” by J. Quinn et al. Foreground: Figure 4 from Chapter 26 (Volume 1), “Vascular Corrosion Casting of the Uteroplacental and Fetoplacental Vasculature in Mice” by K. J. Whiteley et al. Cover design by Patricia F. Cleary. For additional copies, pricing for bulk purchases, and/or information about other Humana titles, contact Humana at the above address or at any of the following numbers: Tel.: 973-256-1699; Fax: 973-256-8341; E-mail:
[email protected]; or visit our Website: www.humanapress.com Photocopy Authorization Policy: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Humana Press Inc., provided that the base fee of US $30.00 per copy is paid directly to the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license from the CCC, a separate system of payment has been arranged and is acceptable to Humana Press Inc. The fee code for users of the Transactional Reporting Service is: [1-58829-404-8/06 $30.00 ]. eISBN 1-59259-983-4 Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1 Library of Congress Cataloging in Publication Data Placenta and trophoblast: methods and protocols / edited by Michael J. Soares and Joan S. Hunt. p. ; cm. — (Methods in molecular medicine ; 121-122) Includes bibliographical references and index. ISBN 1-58829-404-8 (alk. paper) — ISBN 1-58829-608-3 (alk. paper) 1. Placenta. 2. Molecular biology. [DNLM: 1. Placenta. 2. Molecular Biology. WQ 212 P6974 2005] I. Soares, Michael J. II. Hunt, Joan S. III. Series. QP281.P5435 2005 612.6’3—dc22 2005006428
Preface The aim of the two-volume set of Placenta and Trophoblast: Methods and Protocols is to offer contemporary approaches for studying the biology of the placenta. The chapters contained herein also address critical features of the female organ within which the embryo is housed, the uterus, and some aspects of the embryo–fetus itself, particularly those of common experimental animal models. In keeping with the organization used effectively in other volumes in this series, each chapter has a brief introduction followed by a list of required items, protocols, and notes designed to help the reader perform the experiments without difficulty. In both volumes, sources of supplies are given and illustrations highlight particular techniques as well as expected outcomes. A key aspect of these volumes is that the contributors are at the forefronts of their disciplines, thus ensuring the accuracy and usefulness of the chapters. Placenta research has progressed rapidly over the past several decades by taking advantage of the technical advances made in other fields. For example, the reader will note that many techniques, such as reverse transcriptase polymerase chain reaction, northern and western blotting, microarray analyses and in situ hybridization experiments, are routinely used for dissecting a wide range of experimental questions. Protein analysis and functional experiments on tissues and cells that comprise the maternal–fetal interface benefit from studies in endocrinology, immunology, and developmental biology. These volumes also present new ideas on investigating gene imprinting and gene transfer via viral vectors. In developing these volumes we encountered the problem of how to organize the contents so as to be reader-friendly. Our decision was to subdivide in large part by the chronology of pregnancy so that in vivo aspects of implantation come first, followed by in vitro systems of investigation, then protocols for phenotypic analyses of placentas of several species. Special techniques mentioned above conclude Volume I. Volume II continues with protocols for studying trophoblast invasion, followed by dissection of how invading trophoblast cells might be received by uterine immune cells. Returning to the placenta itself, methods for researching trophoblast endocrine and transport functions are followed by a final series of chapters on how placentas adapt to disease. In this latter group, two chapters offer help to investigators interested in animal models of human placental disorders and two address working with the oxygen switches that program gene expression in early pregnancy, a concept entirely unexplored
v
vi
Preface
less than a decade ago. The reader is referred to the Introductions in each of the two volumes for a more detailed description of the contents. This project would not have been possible without the contributions of many individuals. We wish to express our gratitude to the contributing authors for their time, effort, creativity, and their willingness to share their knowledge and expertise. Our deep appreciation and gratefulness also goes to Stacy McClure for her dedicated efforts in maintaining the organization of the manuscripts and the correspondence between the editors and the authors. During this process the publisher has provided us with helpful guidance and instruction essential for the completion of this effort. Finally, we hope that these volumes are useful and provide a valuable resource for both trainees and established scientists striving to advance our understanding of this unique, entirely essential organ of reproduction. Michael J. Soares Joan S. Hunt
Contents Preface .............................................................................................................. v Contributors .....................................................................................................xi Companion Table of Contents for Volume II .................................................. xv Companion CD-ROM .................................................................................... xix
PART I. INTRODUCTION 1 Placenta and Trophoblast: Methods and Protocols: Overview I Michael J. Soares and Joan S. Hunt ...................................................... 3
PART II. METHODS FOR STUDYING EMBRYO IMPLANTATION AND UTERINE BIOLOGY 2 Methodologies to Study Implantation in Mice Kaushik Deb, Jeff Reese, and Bibhash C. Paria .................................... 9 3 Blastocyst Culture D. Randall Armant .............................................................................. 35 4 Isolation of Hormone Responsive Uterine Stromal Cells: An In Vitro Model for Stromal Cell Proliferation and Differentiation Virginia Rider ...................................................................................... 57 5 Rat Decidual Cell Cultures Yan Gu and Geula Gibori ................................................................... 69 6 The Immortalization of Human Endometrial Cells Graciela Krikun, Gil Mor, and Charles Lockwood ............................. 79 7 Sheep Uterine Gland Knockout (UGKO) Model Thomas E. Spencer and C. Allison Gray ............................................. 85 8 A Baboon Model for Inducing Endometriosis Asgerally T. Fazleabas ......................................................................... 95 9 A Baboon Model for Simulating Pregnancy Asgerally T. Fazleabas ....................................................................... 101 10 The Common Marmoset Monkey as a Model for Implantation and Early Pregnancy Research Almuth Einspanier, Kai Lieder, Ralf Einspanier, and Bettina Husen ........................................................................ 111
vii
viii
PART III. IN VITRO TROPHOBLAST
Contents AND
PLACENTAL MODEL SYSTEMS
11 Mouse Trophoblast Stem Cells Jennifer Quinn, Tilo Kunath, and Janet Rossant ............................... 125 12 Connexins and Trophoblast Cell Lineage Development Mark Kibschull and Elke Winterhager .............................................. 149 13 Rcho-1 Trophoblast Stem Cells: A Model System for Studying Trophoblast Cell Differentiation Namita Sahgal, Lindsey N. Canham, Brent Canham, and Michael J. Soares ................................................................... 159 14 Bovine Trophoblast Cell Culture Systems: A Technique to Culture Bovine Trophoblast Cells Without Feeder Cells Kazuyoshi Hashizume, Arata Shimada, Haruo Nakano, and Toru Takahashi ...................................................................... 179 15 In Vitro Induction of Trophoblast from Human Embryonic Stem Cells Ren-He Xu ......................................................................................... 189 16 Isolation and Culture of Term Human Trophoblast Cells Margaret G. Petroff, Teresa A. Phillips, Hakhyun Ka, Judith L. Pace, and Joan S. Hunt .................................................. 203 17 Production of Human Trophoblast Cell Lines Guy St J. Whitley .............................................................................. 219 18 Culture and Transfection of Human Choriocarcinoma Cells Michael W. Wolfe ............................................................................. 229 19 In Vitro Methods for Studying Vascularization of the Murine Allantois and Allantoic Union with the Chorion Karen M. Downs .............................................................................. 241
PART IV. PHENOTYPIC ANALYSIS OF
THE
PLACENTA
20 Phenotypic Analysis of the Mouse Placenta David R. C. Natale, Maja Starovic, and James C. Cross ................... 275 21 Phenotypic Analysis of the Rat Placenta Rupasri Ain, Toshihiro Konno, Lindsey N. Canham, and Michael J. Soares ................................................................... 295 22 Analysis of the Structure of the Ruminant Placenta: Methods of Fixation, Embedding, and Antibody Localization at Light and Electron Microscope Levels F. B. P. Wooding ............................................................................... 315
Contents
ix
23 Characterization of the Bovine Placenta by Cytoskeleton, Integrin Receptors, and Extracellular Matrix Christiane D. Pfarrer ......................................................................... 323 24 Molecular Markers for Human Placental Investigation Berthold Huppertz ............................................................................ 337 25 Correlative Microscopy of Ultrathin Cryosections in Placental Research Toshihiro Takizawa and John M. Robinson ...................................... 351 26 Vascular Corrosion Casting of the Uteroplacental and Fetoplacental Vasculature in Mice Kathie J. Whiteley, Christiane D. Pfarrer, and S. Lee Adamson ....... 371 27 Analysis of Fetal and Maternal Microvasculature in Ruminant Placentomes by Corrosion Casting Rudolf Leiser and Christiane D. Pfarrer ........................................... 393
PART V. MOLECULAR ANALYSIS
AND
GENE TRANSFER TECHNIQUES
28 Microarray Analysis of Trophoblast Cells Vikram Budhraja and Yoel Sadovsky ................................................ 411 29 Gene Expression Microarray Data Analysis of Decidual and Placental Cell Differentiation Sue Kong, Bruce J. Aronow, and Stuart Handwerger ....................... 425 30 Assays to Determine Allelic Usage of Gene Expression in the Placenta Paul B. Vrana .................................................................................... 439 31 Adenoviral-Mediated Gene Delivery to Trophoblast Cells Bing Jiang and Carole R. Mendelson ................................................ 451 Index ............................................................................................................ 463
Contributors S. LEE ADAMSON • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada RUPASRI AIN • Institute of Maternal–Fetal Biology, Division of Cancer & Developmental Biology, Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS D. RANDALL ARMANT • Departments of Obstetrics & Gynecology, Anatomy & Cell Biology, Wayne State University School of Medicine, Detroit, MI BRUCE J. ARONOW • Division of Biomedical Informatics and Developmental Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH VIKRAM BUDHRAJA • Departments of Obstetrics & Gynecology, Cell Biology & Physiology, Washington University School of Medicine, St. Louis, MO BRENT CANHAM • Institute of Maternal–Fetal Biology, Division of Cancer & Developmental Biology, Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS LINDSEY N. CANHAM • Institute of Maternal–Fetal Biology, Division of Cancer & Developmental Biology, Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS JAMES C. CROSS • Genes & Development Research Group, Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, Alberta, Canada KAUSHIK DEB • Division of Reproductive and Developmental Biology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN KAREN M. DOWNS • Department of Anatomy, University of WisconsinMadison Medical School, Madison, WI ALMUTH EINSPANIER • Institute of Physiological Chemistry, Facility of Veterinary Medicine, University of Leipzig, Leipzig, Germany and Department of Reproductive Biology, German Primate Centre, Göttingen, Germany RALF EINSPANIER • Department of Veterinary Biochemistry, Free University of Berlin, Berlin, Germany ASGERALLY T. FAZLEABAS • Department of Obstetrics & Gynecology, Center for Women’s Health & Reproduction, University of Illinois, Chicago, IL GEULA GIBORI • Department of Physiology and Biophysics, University of Illinois, Chicago, IL C. ALLISON GRAY • Department of Animal Science, Center for Animal Biotechnology and Genomics, Texas A&M University, College Station, TX
xi
xii
Contributors
YAN GU • Center for Food Safety and Applied Nutrition, Food and Drug Administration, College Park, MD STUART HANDWERGER • Division of Endocrinology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH KAZUYOSHI HASHIZUME • Department of Veterinary Medicine, Laboratory of Veterinary Physiology, Iwate University, Morioka City, Iwate, Japan JOAN S. HUNT • Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS BERTHOLD HUPPERTZ • Department of Anatomy II, University Hospital RWTH Aachen, Aachen, Germany BETTINA HUSEN • Department of Reproductive Biology, German Primate Centre, Göttingen, Germany BING JIANG • Department of Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX HAKHYUN KA • Department of Biological Resources & Technology, Yonsei University, Wonju, Kangwon-Do, South Korea MARK KIBSCHULL • Institute of Anatomy, University Hospital Essen, University of Essen-Duisburg, Essen, Germany SUE KONG • Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH TOSHIHIRO KONNO • Institute of Maternal–Fetal Biology, Division of Cancer & Developmental Biology, Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS GRACIELA KRIKUN • Department of Obstetrics and Gynecology, Yale University, New Haven, CT TILO KUNATH • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada RUDOLF LEISER • Department of Veterinary Anatomy, Histology and Embryology, Justus-Liebig-University Giessen, Giessen, Germany KAI LIEDER • Institute of Physiological Chemistry, Facility of Veterinary Medicine, University of Leipzig, Leipzig, Germany and Department of Reproductive Biology, German Primate Centre, Göttingen, Germany CHARLES LOCKWOOD • Department of Obstetrics and Gynecology, Yale University, New Haven, CT CAROLE R. MENDELSON • Departments of Biochemistry and Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX GIL MOR • Department of Obstetrics and Gynecology, Reproductive Immunology Unit, Yale University School of Medicine, New Haven, CT
Contributors
xiii
HARUO NAKANO • Reproductive Biology and Technology Laboratory, Developmental Biology Department, National Institute of Agrobiological Sciences, Tsukuba, Japan DAVID R. C. NATALE • Genes & Development Research Group, Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, Alberta, Canada JUDITH L. PACE • Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS BIBHASH C. PARIA • Division of Reproductive and Developmental Biology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN MARGARET G. PETROFF • Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS CHRISTIANE D. PFARRER • Department of Obstetrics and Gynecology, JustusLiebig-University Giessen, Giessen, Germany TERESA A. PHILLIPS • Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS JENNIFER QUINN • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada JEFF REESE • Division of Reproductive and Developmental Biology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN VIRGINIA RIDER • Department of Biology, Pittsburg State University, Pittsburg, KS JOHN M. ROBINSON • Department of Physiology and Cell Biology, Ohio State University, Columbus, OH JANET ROSSANT • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada YOEL SADOVSKY • Departments of Obstetrics & Gynecology, Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO NAMITA SAHGAL • Institute of Maternal–Fetal Biology, University of Kansas Medical Center, Kansas City, KS ARATA SHIMADA • Reproductive Biology and Technology Laboratory, Developmental Biology Department, National Institute of Agrobiological Sciences, Tsukuba, Japan MICHAEL J. SOARES • Institute of Maternal–Fetal Biology, Division of Cancer & Developmental Biology, Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS THOMAS E. SPENCER • Department of Animal Science, Center for Animal Biotechnology and Genomics, Texas A&M University, College Station, TX
xiv
Contributors
MAJA STAROVIC • Genes and Development Research Group, Department of Biochemistry & Molecular Biology, University of Calgary, Calgary, Alberta, Canada TORU TAKAHASHI • Reproductive Biology and Technology Laboratory, Developmental Biology Department, National Institute of Agrobiological Sciences, Tsukuba, Japan TOSHIHIRO TAKIZAWA • Department of Anatomy, Nippon Medical School, Bunkyo-ku, Tokyo, Japan PAUL B. VRANA • Department of Biological Chemistry, College of Medicine, University of California Irvine, Irvine, CA KATHIE J. WHITELEY • Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada GUY ST J. WHITLEY • Department of Basic Medical Sciences, Biochemistry and Immunology, St George’s Hospital Medical School, University of London, London, United Kingdom ELKE WINTERHAGER • Institute of Anatomy, University Hospital Essen, University of Essen-Duisburg, Essen, Germany MICHAEL W. WOLFE • Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS F. B. P. WOODING • Department of Physiology, Cambridge, Cambridge, United Kingdom REN-HE XU • WiCell Research Institute, Madison, WI
Contents of Volume 2 Preface Contributors Companion Table of Contents for Volume I
PART I. INTRODUCTION 1 Placenta and Trophoblast: Methods and Protocols: Overview II Michael J. Soares and Joan S. Hunt
PART II. ANALYSIS
OF
TROPHOBLAST INVASION
2 In Vivo Analysis of Trophoblast Cell Invasion in the Human Robert Pijnenborg, Elizabeth Ball, Judith N. Bulmer, Myriam Hanssens, Stephen C. Robson, and Lisbeth Vercruysse 3 In Vitro Analysis of Trophoblast Invasion John D. Aplin 4 An In Vitro Model of Trophoblast Invasion of Spiral Arteries Judith E. Cartwright and Mark Wareing
PART III. ANALYSIS OF UTEROPLACENTAL IMMUNE CELLS AND THEIR FUNCTIONS 5 In Vivo Models for Studying Homing and Function of the Murine Uterine Natural Killer Cells B. Anne Croy and Xuemei Xie 6 Immune and Trophoblast Cells at the Rhesus Monkey Maternal–Fetal Interface Thaddeus G. Golos, Gennadiy I. Bondarenko, Edith E. Breburda, Svetlana V. Dambaeva, Maureen Durning, and Igor I. Slukvin 7 Methods for Isolation of Cells from the Human Fetal–Maternal Interface Anita Trundley, Lucy Gardner, Jacquie Northfield, Chiwen Chang, and Ashley Moffett
xvi
Contents for Volume 2
8 In Vitro Models for Studying Human Uterine and Placental Macrophages Ramsey H. McIntire, Margaret G. Petroff, Teresa A. Phillips, and Joan S. Hunt 9 Macrophage–Trophoblast Interactions Gil Mor, Shawn L. Straszewski-Chavez, and Vikki M. Abrahams 10 Methods for Evaluating Histocompatibility Antigen Gene Expression in the Baboon Daudi K. Langat, Asgerally T. Fazleabas, and Joan S. Hunt 11 Analysis of the Soluble Isoforms of HLA-G: mRNAs and Proteins Judith L. Pace, Pedro J. Morales, Teresa A. Phillips, and Joan S. Hunt
PART IV. ANALYSIS OF PLACENTA FUNCTION: TRANSPORT AND ENDOCRINOLOGY 12 In Vivo Techniques for Studying Placental Nutrient Uptake, Metabolism, and Transport Timothy R. H. Regnault and William W. Hay, Jr. 13 In Vitro Models for Studying Trophoblast Transcellular Transport Claudia J. Bode, Hong Jin, Erik Rytting, Peter S. Silverstein, Amber M. Young, and Kenneth L. Audus 14 In Vitro Methods for Studying Human Placental Amino Acid Transport: Placental Plasma Membrane Vesicles Jocelyn D. Glazier and Colin P. Sibley 15 In Vitro Methods for Studying Human Placental Amino Acid Transport: Placental Villous Fragments Susan L. Greenwood and Colin P. Sibley 16 Methods for Investigating Placental Fatty Acid Transport Yan Xu, Thomas J. Cook, and Gregory T. Knipp 17 Heterologous Expression Systems for Studying Placental Transporters Vadivel Ganapathy, You-Jun Fei, and Puttur D. Prasad 18 Analysis of Trophoblast Giant Cell Steroidogenesis in Primary Cultures Noa Sher and Joseph Orly 19 Establishment of an ELISA for the Detection of Native Bovine Pregnancy-Associated Glycoproteins Secreted by Trophoblast Binucleate Cells Jonathan A. Green and R. Michael Roberts
Contents for Volume 2
xvii
20 Alkaline Phosphatase Fusion Proteins as Tags for Identifying Targets for Placental Ligands Heiner Müller and Michael J. Soares 21 Bacterial Expression of Prolactin Family Proteins Arieh Gertler 22 Analysis of Placental Regulation of Hematopoiesis Beiyan Zhou and Daniel I. H. Linzer 23 Methods for Studying Interferon Tau Stimulated Genes Fuller W. Bazer and Thomas E. Spencer
PART V. ANALYSIS
OF
PLACENTA ADAPTATION
TO
DISEASE
24 Reduced Uterine Perfusion Pressure (RUPP) Model for Studying Cardiovascular–Renal Dysfunction in Response to Placental Ischemia Joey P. Granger, B. Babbette D. LaMarca, Kathy Cockrell, Mona Sedeek, Charles Balzi, Derrick Chandler, and William Bennett 25 In Vivo Rat Model of Preeclampsia S. Ananth Karumanchi and Isaac E. Stillman 26 A Novel Mouse Model for Preeclampsia by Transferring Activated Th1 Cells into Normal Pregnant Mice Ana Claudia Zenclussen 27 Working with Oxygen and Oxidative Stress In Vitro Graham J. Burton, D. Stephen Charnock-Jones, and Eric Jauniaux 28 Hypobaric Hypoxia as a Tool to Study Pregnancy-Dependent Responses at the Maternal–Fetal Interface Jennifer K. Ho-Chen, Rupasri Ain, Adam R. Alt, John G. Wood, Norberto C. Gonzalez, and Michael J. Soares 29 Infection with Listeria monocytogenes as a Probe for Placental Immunological Function Ellen M. Barber, Indira Guleria, and Jeffrey W. Pollard
Index
Companion CD-ROM This book is accompanied by a CD-ROM that contains all the color illustrations.
xix
Overview
3
1 Overview I Michael J. Soares and Joan S. Hunt
1. Introduction The placenta is a specialized pregnancy-specific structure that develops concurrently with development of the embryo and fetus. From an evolutionary perspective, the placenta was the essential factor in permitting viviparity, a reproductive strategy in which fetal development proceeds within the female reproductive tract. Viviparous species are able to provide greater protection from environmental risks and can more precisely control the development of their progeny while they reside in utero. The placenta is comprised of numerous cell types. Among the cell types are specialized epithelioid cells, called trophoblast, that possess several important functions enabling viviparous development (1,2). Trophoblast cells play key roles in protecting the embryo/fetus from noxious substances, programming maternal support, and preventing maternal immune rejection while at the same time ensuring appropriate bidirectional nutrient/waste flow required for growth and maturation of the embryo. Although placenta functions are highly conserved, species-specific elements of placenta organization and activity are evident. Consequently, placental research has benefited and will continue to benefit from a comparative approach. Each species presents experimentally valuable attributes that can be exploited to better understand the biology of the placenta and viviparity. Research on placentas involves not only work on the placenta itself, but also on the placenta’s maternal home, the uterus. Such studies include incorporation of experimental strategies beginning with the preparation of the uterus for embryo implantation and techniques directed at understanding embryo–uterine interactions. Cells involved in this initial interaction are trophoblast arising from the blastocyst and those associated with the uterine epithelium (3). Trophoblast cells expand in number and organize in species-specific patterns. In From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
3
01_Soares_1_6_F
3
8/29/05, 11:14 AM
4
Soares and Hunt
some species, trophoblast cells penetrate into the uterine compartment, establishing intimate relationships with the maternal vasculature, a process referred to as hemochorial placentation and most commonly found in primates and rodents (1,4). This type of placentation is also associated with a unique specialization of the uterine stromal compartment, which is termed decidualization. Other species exhibit minimal trophoblast invasion resulting in a segregation of maternal and trophoblast tissues. This type of placentation is referred to as epitheliochorial or synepitheliochorial and is seen in domesticated animals, including the pig and ruminants (1). A key feature of the uterine environment in animals possessing this superficial type of placentation is an extensive development of uterine glands. These structures provide vital nutritive support for the developing embryo and fetus throughout pregnancy in domesticated species, and also during early stages of gestation in primates. Thus, placentation is fundamental to creating the milieu in which the embryo and fetus develop. The quality of the embryonic and fetal environment has lasting effects, influencing postnatal health and disease (5,6). In this volume, the reader is guided through the major experimental strategies and steps required for placenta research on multiple species, focusing on modifications in the uterus, implantation, the nature of the trophoblast cell lineage, vascular development and genetic analysis. 2. Methods for Studying Embryo Implantation and Uterine Biology Part II of this volume focuses on protocols for learning more about the initial steps of pregnancy, including uterine preparation for pregnancy, blastocyst development, and the process of implantation. Detailed in vivo procedures for a comprehensive analysis of murine implantation are described in Chapter 2. These techniques range from animal husbandry to preparation of an implantation-receptive uterus and embryo transfer. Protocols for assessing in vitro blastocyst development and function are presented in Chapter 3, and include the utilization of methods for imaging blastocyst–extracellular matrix interactions. Chapters 4 through 6 outline strategies for isolating proliferative and differentiated uterine stromal cells. The in vitro analyses include the utilization of both rodent and human endometrial cells and permit the mechanistic examination of factors controlling endometrial cell growth and differentiation. In vivo experimental models are presented in Chapters 7 through 10. An in vivo technique for studying the role of uterine glands and their secretions in the establishment and maintenance of pregnancy is described in Chapter 7, whereas Chapter 8 provides an experimental in vivo strategy utilizing the baboon for studying endometriosis, a prominent uterine disorder causing infertility. This section
01_Soares_1_6_F
4
8/29/05, 11:14 AM
Overview
5
concludes with presentations of nonhuman primate models for investigating early pregnancy in vivo (Chapters 9 and 10). 3. In Vitro Trophoblast and Placental Model Systems In this section, emphasis shifts to the placenta and its unique cell lineage, the trophoblast. Key strategies for elucidating mechanisms controlling trophoblast cell growth, differentiation, and placental morphogenesis are presented. The experimental approaches include trophoblast cell and placental organ culture systems, and the chapters describe techniques for isolating and culturing rodent-, ruminant-, and primate-derived trophoblast cells. Chapters 11 and 12 provide detailed protocols for the establishment and manipulation of mouse trophoblast stem cells from blastocyst and extraembryonic ectoderm. In Chapter 13, the Rcho-1 rat trophoblast stem cell culture model, which is a wellcharacterized system for studying rodent trophoblast giant cell differentiation, is described. An in vitro procedure for the establishment and characterization of bovine trophoblast stem cells is presented in Chapter 14. Each of the above trophoblast cell systems can be expanded or induced to differentiate. Chapters 15–18 provide four different model systems for studying human trophoblast cells in vitro. They include the use of human embryonic stem cells, the isolation and culture of term trophoblast cells, the production of trophoblast cell lines, and the culture of choriocarcinoma cell lines. The merits and limitations of each system are described. Organ culture systems for analyzing the primordial placenta and allantois, their vascularization and interconnections are documented in Chapter 19. 4. Phenotypic Analysis of the Placenta In Part IV of this volume, protocols are provided for examination of placental development from rodents, ruminants, and primates. Chapters 20 and 21 present a comprehensive series of strategies for studying the development of the mouse and rat placenta. Techniques described include approaches for tissue dissection, trophoblast cell isolation, and structural and molecular analyses of the rodent placenta. Morphological approaches for investigating ruminant and primate placentas are described in Chapters 22 to 25. Immunocytochemical and in situ hybridization techniques and the appropriate immunological and molecular probes for studying rodent, ruminant, and primate placental development are provided in each chapter. Strategies for investigating the maternal and fetal vasculature associated with mouse and bovine placentas are described in Chapters 26 and 27. These methods provide precise structural information on uteroplacental blood vessel
01_Soares_1_6_F
5
8/29/05, 11:14 AM
6
Soares and Hunt
development. Uteroplacental vascular beds dictate nutrient delivery and are particularly susceptible to environmental insults and disease. 5. Molecular Analysis and Gene Transfer Techniques The concluding portions of Volume I contain methods relevant to gene discovery and analyses. For example, Chapters 28 and 29 describe techniques for DNA microarray analysis, a powerful gene discovery tool; Chapter 28 focuses on the design and execution of DNA microarray experiments; and Chapter 29 concentrates on data analysis. A characteristic of many placenta regulatory genes is their allele-specific expression, a process termed imprinting. A thorough guide to investigating gene imprinting is presented in Chapter 30. Analysis of gene function using in vitro models requires the establishment of reliable methods for gene manipulation. Chapter 31 describes the use of adenoviralmediated gene delivery systems that can be effectively used in primary trophoblast cells and trophoblast-derived cell lines. References 1. Wooding, F. B. P. and Flint, A. P. F. (1994) Placentation. In: Marshall’s Physiology of Reproduction, Fourth Edition, Vol. 3 (Lamming, G. E., Ed.), Chapman & Hall, London: pp. 233–460. 2. Rossant, J. and Cross, J. C. (2002) Extraembryonic lineages. In: Mouse Development (Rossant, J., and Tam, P. P. L., Eds.), Academic, San Diego: pp. 155–190. 3. Paria, B. C., Reese, J., Das, S. K., and Dey, S. K. (2002) Deciphering the crosstalk of implantation: advances and challenges. Science 296, 2185–2188. 4. Georgiades, P., Ferguson-Smith, A. C., and Burton, G. J. (2002) Comparative developmental anatomy of the murine and human definitive placentae. Placenta 23, 3–19 5. Bateson, P., Barker, D., Clutton-Brock, T., et al. (2004) Developmental plasticity and human health. Nature 430, 419–421. 6. Gluckman, P. D. and Hanson, M. A. (2004) Living with the past: evolution, development, and patterns of disease. Science 305, 1733–1736.
01_Soares_1_6_F
6
8/29/05, 11:14 AM
Mouse Implantation Methodologies
7
II METHODS FOR STUDYING EMBRYO IMPLANTATION AND UTERINE BIOLOGY
02_Deb_7_34_F
7
8/29/05, 11:15 AM
8
02_Deb_7_34_F
Deb, Reese, and Paria
8
8/29/05, 11:15 AM
Mouse Implantation Methodologies
9
2 Methodologies to Study Implantation in Mice Kaushik Deb, Jeff Reese, and Bibhash C. Paria Summary Pregnancy begins with fertilization of the ovulated oocyte by the sperm. After fertilization, the egg undergoes time-dependent mitotic division while trying to reach the blastocyst stage and the uterus for implantation. Uterine preparation for implantation is regulated by coordinated secretions and functions of ovarian sex steroids. The first sign of contact between the blastocyst and the uterus can be detected experimentally by an intravenous blue dye injection as early as the end of day 4 or the beginning of day 5 of pregnancy. This blastocyst–uterine attachment reaction leads to stromal decidual reaction only at sites of implantation. The process of implantation can be postponed and reinstated experimentally by manipulating ovarian estrogen secretion. Stromal decidualization can also be induced experimentally in the hormonally prepared uterus in response to stimuli other than the embryo. Fundamental biological questions surrounding these essential features of early pregnancy can be addressed through the application of various techniques and manipulation of this period of early pregnancy. This chapter describes the routine laboratory methodologies to study the events of early pregnancy, with special emphasis on the implantation process in mice. Key Words: Mouse; blastocyst; implantation; ovariectomy; vasectomy; delayed implantation; embryo transfer.
1. Introduction The mouse, as one of the most common laboratory animals, is widely used in basic biological research and could provide useful information that is relevant to human biology. This chapter focuses on some of the procedures for studying events of early pregnancy in mice. Following mating and fertilization, the embryo develops to the blastocyst stage. Attachment of the blastocyst into the uterine wall is an absolute requirement for further growth and collection of nutrients from the maternal vasculature. Hence, the implantation process is a critical event in the embryo’s life and a central step to the establishment of placentation and pregnancy.
From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
9
02_Deb_7_34_F
9
8/29/05, 11:15 AM
10
Deb, Reese, and Paria
The following description and methodologies are intended for investigators who wish to pursue research in various aspects of early pregnancy, with special reference to implantation-related processes. Studies on early pregnancy start with breeding to generate pregnant females. Ideally, experimental mice are maintained and bred in an institutional animal facility governed by the institutional animal care and use committee guidelines with the help of veterinarians who supervise the health and well being of animals. Natural breeding is routinely used for performing research on pregnancy.
1.1. The Reproductive Cycle in Mice The reproductive cycle in mice is known as the estrous cycle. The estrous cycle is the time period from the onset of estrus until the onset of the next estrus. The length of the estrous cycle varies depending on the animal species. The average length of the estrous cycle is 4–5 d in mice, but it is highly variable. The estrus stage signifies a period when females show signs of mating behavior. Mice spontaneously ovulate during each estrous cycle. Females become cyclic when they reach puberty by 4 wk of age. The different phases of the estrous cycle in adult females are regulated by a functional hypothalamo– pituitary–ovarian axis. Sexual maturity is coincident with pulsatile release of gonadotropin releasing hormone (GnRH) from the hypothalamus with rising levels of circulating gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) from the pituitary. While rising levels of FSH trigger follicular growth and maturation, ovulation occurs under the influence of increasing levels of LH. These changes are reflected in ovarian steroid production during each cycle. The stages of the estrous cycle are estrus, metaestrus, diestrus, and proestrus (1). These stages occur in each cycle and in a sequential manner. The day of estrus is usually designated as day 1 of the cycle. The stages of the estrous cycle are best determined by the cell types observed in the vaginal smear. Normally, vaginal smears should be examined in the morning (0800 to 0900 h). The estrous cycle is also divided into two ovarian phases: follicular phase and luteal phase. Follicular phase is the period of ovarian follicle development, and consists of proestrus and estrus. The luteal phase is the period of corpus luteum formation and function, and comprises metaestrus and diestrus. The uterus also undergoes hormonal changes during the estrous cycle. The uterus is distended during proestrus and estrus as a result of an increase in uterine vascular permeability and accumulation of fluid due to a higher level of circulating estrogen. The distention starts to decline in late estrus and it is no longer observed at diestrus. The wet and dry uterine weights are lowest at diestrus and heaviest at proestrus.
02_Deb_7_34_F
10
8/29/05, 11:15 AM
Mouse Implantation Methodologies
11
1.2. Breeding of Mice Sexual maturity in females occurs earlier than in males. Whereas females are normally used for breeding at 45–50 d of age, males are not ready until 60 d of age. Sexual maturity may be delayed a week or so in both males and females depending on the strain of mice. Typically, males can breed successfully longer than females because spermatogenesis continues throughout life. Many male mice tend to become overweight with age, which may negatively affect their ability to breed successfully. It is often recommended to retire old males (9 to 10 mo of age) and set up cages with new males.
1.2.1. Effect of Light Cycle on the Reproductive Behavior of Mice The light cycle controls the reproductive performance of females and males (2). Breeding conditions such as light cycle and timing must be carefully controlled and regulated. The artificial light–dark cycle of an animal facility is critical to the synchronous development of eggs. If female mice are purchased from a commercial supplier, they should be allowed approx 1 wk to adjust to the institutional animal room’s light–dark cycle. The release of LH, a pituitary hormone that induces ovulation, is regulated by the light–dark cycle. The animal rooms are usually maintained at 12 h light:12 h dark or 14 h light:10 h dark cycles. 1.2.2. Copulatory Plug Formation The presence of a vaginal plug in the morning following copulation with a male indicates successful mating. The ejaculate from the male’s accessory sex glands forms a short-lived, whitish-looking or cream-yellow-colored plug in the vagina of a female. The presence of a vaginal plug only indicates successful mating, but does not always mean that a pregnancy will occur from this mating. It should also be noted that sometimes plugs fall out of the vagina; this may result in pregnancy that initially remains unnoticed, especially if checked late in the morning. 1.3. Early Pregnancy After ovulation, eggs released by the ovaries enter the associated oviduct. Mouse ovaries are covered with the bursa (a thin membrane) and no egg can escape into the abdominal cavity. Fertilization of the egg occurs in the ampulla (ovarian end of the oviduct) after a successful mating. The egg completes its first maturation division by the time ovulation occurs. If the egg has not completed the first maturation division, it does so very quickly after ovulation. Female mice normally ovulate 8–10 ova in each cycle. Freshly ovulated eggs are surrounded by a mass of cumulus cells. The uterus in the mouse consists of
02_Deb_7_34_F
11
8/29/05, 11:15 AM
12
Deb, Reese, and Paria
two horns (duplex). After mating, sperm travel through both uterine horns to reach the site of fertilization. They penetrate the cumulus cells to fertilize eggs. Usually, more than one sperm enters the perivitelline space. However, only one sperm penetrates and fertilizes the egg. After fertilization, the zygote divides mitotically to eventually reach the blastocyst stage. After mating, the mating stimulus triggers prolactin release from the pituitary, which leads to the formation of a functional corpus luteum in the ovary, blocking further ovulation and cyclicity to continue pregnancy.
1.4. Experimental Delay in Implantation In many animals, implantation is delayed for an extended period, during which the blastocyst remains in a quiescent state called embryonic diapause (3,4). Delayed implantation in these animals seems to be a strategic plan for regulating the time of birth coincident with favorable environmental conditions. In some species, delayed implantation occurs under specific conditions. Mice show postpartum estrus immediately after parturition. If conception takes place immediately after parturition, embryos develop into blastocysts, but remain in a dormant state until the lactational stimuli from suckling pups are removed. In mice, implantation can be experimentally delayed by removing the ovarian source of steroids (5). The timing of normal blastocyst implantation is tightly controlled in mice. Normally, initiation of implantation occurs at night (2200–2300 h) of day 4 (6). Ovarian steroid hormones are necessary to prepare the endometrium for the process of implantation. In mice, both ovarian progesterone and estrogen are required for implantation. The ovary secretes a small amount of estrogen in addition to progesterone in the morning of day 4 of pregnancy in mice. This preimplantation estrogen secretion is an absolute requirement for blastocyst activation, preparation of the uterus, and initiation of the implantation process. Surgical removal of both ovaries in mice before the preimplantation ovarian estrogen secretion occurs on day 4 leads to delayed implantation.
1.5. Artificial Decidualization During normal pregnancy uterine stromal cells first proliferate and then differentiate to decidual cells in response to an implanting blastocyst (4). This process is known as decidualization. Decidualization starts following initiation of blastocyst implantation in mice. The decidua enlarges as the embryo grows. Decidual cells are characterized by the presence of polyploid nuclei, and glycogen and lipid in their cytoplasm. As the deciduum grows, it occupies the uterine lumen at the mesometrial side (dorsal to the embryo). The antimesometrial decidua is divided into two zones. A thin and dense cellular zone that immediately surrounds the blastocyst is known as the primary decidual
02_Deb_7_34_F
12
8/29/05, 11:15 AM
Mouse Implantation Methodologies
13
zone (PDZ). This is an avascular zone of the endometrium. The secondary decidual zone (SDZ) surrounds the PDZ. The SDZ is a broad, well-vascularized edematous zone. The decidual response can also be induced experimentally without the presence of an embryo (4). However, a proper hormonally prepared uterus is needed for this purpose. The uterus of a pseudopregnant female is a preferred choice. The uterus of a progesterone-primed (at least 48 h), ovariectomized mouse can also be used for this purpose. Methods pertinent to the investigation of early pregnancy in the mouse are described in this chapter. 2. Materials 2.1. Monitoring the Estrous Cycle
2.1.1. Collection of Vaginal Smears 1. 2. 3. 4.
Sexually mature female mice (45–50 d old). Clean mouse cage with a wire-top cage cover. Plastic dropper (Fisher Scientific, Hanover Park, IL, cat. no. 13-711-10). Saline (0.9% Sodium chloride solution, Baxter Healthcare Corporation, Deerfield, IL, cat. no. 281324). 5. Glass slides (Fisher Scientific, cat. no. 12-518-104).
2.1.2. Identification of the Stage of Estrous Cycle 1. Glass slides (Fisher Scientific, cat. no. 12-518-104). 2. A compound microscope with a 10× and 40× objectives.
2.2. Breeding and Plug Checking 2.2.1. Natural Breeding 1. Sexually mature female mice (45–50 d old). 2. Sexually mature male mice (60 d old). 3. Mouse cages.
2.2.2. Checking Copulatory Plug 1. Female mice mated with fertile males. 2. A pair of curved forceps (Fine Science Tools, Inc., Foster City, CA, cat. no. 11152-10).
2.3. Early Pregnancy Determination 2.3.1. Noninvasive Method Vaginal plug-positive mice.
02_Deb_7_34_F
13
8/29/05, 11:15 AM
14
Deb, Reese, and Paria
2.3.2. Invasive Method 2.3.2.1. EMBRYO COLLECTION FROM THE OVIDUCT AND UTERUS 1. 2. 3. 4. 5. 6. 7.
Vaginal plug-positive mice. 70% ethanol (Aaper Alcohol & Chemical Co., Shelbyville, KY). Paper towels. Forceps (Fine Science Tools, Inc., cat. nos. 11151-10, 11153-10, and 11150-10). Scissors (Fine Science Tools, Inc., cat. nos. 14558-11 and 15000-10). Falcon Petri dish (Fisher Scientific, cat. no. 08-757-100B). Whitten’s culture medium (per/100 mL): 514 mg NaCl, 36 mg KCl, 16 mg KH2PO4, 29 mg MgSO4, 190 mg NaHCO3, 53 mg calcium lactate, 100 mg glucose, 2 mg penicillin, 2 mg streptomycin sulfate, 0.5 mg phenol red, 3.5 mg pyruvic acid (sodium salt), 0.37 mL lactic acid (sodium salt), and 300 mg bovine serum albumin. 8. BD brand disposable 3-mL syringe (Fisher Scientific, cat. no. 14-829-14B). 9. Hamilton 31-gauge steel needle (Fisher Scientific, cat. no. 14-815-619). 10. 27-gauge BD PrecisionGlide sterile disposable needle (Fisher Scientific, cat. no. 14-826-48).
2.3.2.2. DETECTION OF EARLY IMPLANTATION SITES BY INTRAVENOUS DYE INJECTION 1. Anesthesia (Avertin). 2. Paper towels. 3. BD PrecisionGlide 1-mL syringe with 27-gauge, one-half-inch needle (Becton Dickinson & Co., Franklin Lakes, NJ; cat. no. 309623) 4. Blue dye (Chicago Blue B or Evans blue, or pontamine blue from Sigma Chemical Co.). 5. Saline (0.9% sodium chloride, Baxter Healthcare Corporation, cat. no. 281324). 6. Warm water.
2.4. Experimental Delay in Implantation 2.4.1. Ovariectomy 1. 2. 3. 4. 5. 6. 7. 8.
Seminal plug-positive female mice (day 4 of pregnancy). Anesthesia (Avertin). Animal clipper (Fisher Scientific, cat. no. 01-305-10). 70% Ethanol (Aaper Alcohol & Chemical Co.). Povidone-Iodine solution (Aplicare, Inc., Branford, CT). Forceps (Fine Science Tools, Inc., cat. nos. 11153-10 and 11150-10). Scissors (Fine Science Tools, Inc., cat. no. 14558-11). BD Autoclip wound clips (Fisher Scientific, cat. no. 01-804-5) and applier (Fisher Scientific, cat. no. 01-804).
2.4.2. Experimentally Delayed Implantation 1. Progesterone (Sigma Chemical Co., cat. no. P-1030) 2. Estradiol-17β (Sigma Chemical Co., cat. no. E-8875)
02_Deb_7_34_F
14
8/29/05, 11:15 AM
Mouse Implantation Methodologies
15
3. BD PrecisionGlide 1-mL syringe with 27-gauge, one-half-inch needle (Becton Dickinson & Co., cat. no. 309623).
2.5. Artificial Decidualization 2.5.1. Induction of Pseudopregnancy in Females Using Vasectomized Males 2.5.1.1. PREPARATION OF VASECTOMIZED MALES 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
Sexually mature male (60 d old). Anesthesia (Avertin). Animal clipper (Fisher Scientific, cat. no. 01-305-10). 70% Ethanol (Aaper Alcohol & Chemical Co.). Povidone-Iodine solution (Aplicare, Inc.). Forceps (Fine Science Tools, Inc., cat. nos. 11153-10 and 11150-10). Scissors (Fine Science Tools, Inc., cat. no. 14558-11). Ethicon nonabsorbable surgical suture (size 4.0; Ethicon, Inc., Somerville, NJ). Slide Warmer (Lab-line Instruments, Inc., Melrose Park, IL; Model No. 26020). BD Autoclip wound clips (Fisher Scientific, cat. no. 01-804-5) and applier (Fisher Scientific, cat. no. 01-804). 11. Saline (0.9% sodium chloride, Baxter Healthcare Corporation, cat. no. 281324).
2.5.1.2. INDUCTION OF PSEUDOPREGNANCY 1. Vasectomized male mice. 2. Sexually mature female mice (45–50 d old). 3. A pair of curved forceps for checking vaginal plugs (Fine Science Tools, Inc., cat. no. 11152-10).
2.5.1.3. HORMONAL PRIMING OF OVARIECTOMIZED MICE 1. Ovariectomized females rested for 10–15 d. 2. Sesame seed oil (Sigma Chemical Co., cat. no. S-3547). 3. BD PrecisionGlide 1-mL syringe with 27-gauge, one-half-inch needle (Becton Dickinson & Co., cat. no. 309623). 4. Progesterone (Sigma Chemical Co., cat. no. P-1030). 5. Estradiol-17β (Sigma Chemical Co., cat. no. E-8875). 6. Hotplate (Fisher Scientific, cat. no. 11-497-6A).
2.5.1.4. INDUCTION OF DECIDUALIZATION BY ARTIFICIAL MEANS 1. Day 4 pseudopregnant female or ovariectomized progesterone-treated female mice. 2. Anesthesia (Avertin). 3. Animal clipper (Fisher Scientific, cat. no. 01-305-10). 4. 70% Ethanol (Aaper Alcohol & Chemical Co.). 5. Povidone-Iodine solution (Aplicare, Inc.). 6. Forceps (Fine Science Tools, Inc., cat. nos. 11153-10 and 11150-10). 7. Scissors (Fine Science Tools, Inc., cat. no. 14558-11).
02_Deb_7_34_F
15
8/29/05, 11:15 AM
16
Deb, Reese, and Paria
8. BD PrecisionGlide 1-mL syringe with 27-gauge, one-half-inch needle (Becton Dickinson & Co., cat. no. 309623). 9. Sesame seed oil (Sigma Chemical Co., cat. no. S-3547). 10. BD Autoclip wound clips (Fisher Scientific, cat. no. 01-804-5) and applier (Fisher Scientific, cat. no. 01-804).
2.6. Intrauterine Blastocyst Transfer 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16.
Day 4 pseudopregnant or progesterone-treated ovariectomized mice. Anesthesia (Avertin). Paper towels. Animal clipper (Fisher Scientific, cat. no. 01-305-10). 70% Ethanol (Aaper Alcohol & Chemical Co.). Povidone-Iodine solution (Aplicare, Inc.). Forceps (Fine Science Tools, Inc., cat. nos. 11153-10 and 11150-10). Scissors (Fine Science Tools, Inc., cat. nos. 14558-11). 23-gauge BD PrecisionGlide needle (Fisher Scientific, cat. no. 14-826A). BD Autoclip wound clips (Fisher Scientific, cat. no. 01-804-5) and applier (Fisher Scientific, cat. no. 01-804). Slide Warmer (Lab-line Instruments, Inc., Model No. 26020). Saline (0.9% sodium chloride, Baxter Healthcare Corporation, cat. no. 281324). Serrefine clip (Fine Science Tools, Inc., cat. no. 18050-35). 1-mL Hamilton pipet controller syringe (Hamilton Company, Reno, NA; cat. no. 84001). 6-in thin capillary (1 mm diameter) glass pipet (World Precision Instruments, Inc., Sarasota, FL., cat. no. TW 100-6). Popper 16-gauge steel needle (Fisher Scientific, cat. no. 14-825-16J).
2.7. Commonly Used Anesthetics 1. Injectable anesthetic, Avertin: (components: Avertin [2,2,2-tribromoethanol, Sigma Aldrich Chemie GmbH, Steinheim, Germany; cat. no. T4,840-2] and tertamyl alcohol, Fisher Scientific, cat. no. A730-1]). 2. Short-lasting inhalant anesthetic, Isoflurane (Minrad, Inc., Buffalo, NY).
2.8. Common Injection Techniques 1. 2. 3. 4.
Mice. 70% Ethanol (Aaper Alcohol & Chemical Co.). Clean cage with a cage top. BD PrecisionGlide 1-mL syringe with 27-gauge, one-half-inch needle (Becton Dickinson & Co., cat. no. 309623).
2.9. Euthanasia 2.9.1. Cervical Dislocation 1. Mice. 2. Clean cage with a cage top.
02_Deb_7_34_F
16
8/29/05, 11:15 AM
Mouse Implantation Methodologies
17
2.9.2 Inhalants 2.9.2.1. CARBON DIOXIDE 1. Carbon dioxide cylinder (local gas supplier). 2. A cage specifically designed for killing mice.
2.9.2.2. ISOFLURANE 1. Isoflurane (Minrad, Inc.). 2. Cotton wool (Absorbent Cotton Co., Inc., Valley Park, MO) or gauze (Kendall Healthcare Products Co., Mansfield, MA). 3. Bell jar or a scew cap glass container (Fisher Scientific).
3. Methods 3.1. Monitoring the Mouse Estrous Cycle
3.1.1. Collection of Vaginal Smears 1. Grasp the tail of a mouse with the thumb and forefinger of one hand. 2. Place the mouse on the top of the cage cover (wire top). As the mouse attempts to move forward, quickly grasp the loose skin at the back of the neck using the thumb and forefinger of the other hand. The head of the mouse will be immobilized, if the skin is held properly. 3. Lift the mouse in your hand and secure the tail between the small finger and the palm of the same hand. 4. Keep the face of the mouse up and locate the vagina. 5. Fill a plastic dropper with a small amount of saline (0.05 to 0.1 mL 0.9% NaCl) and insert the tip superficially, but not deeply, into the vagina. 6. Gently squeeze the bulb of the dropper to release saline inside the vagina. Slowly release the pressure on the bulb to aspirate the vaginal lavage inside the dropper.
3.1.2. Identification of the Stage of the Estrous Cycle 1. Place a drop of aspirated vaginal fluid on a glass slide. 2. Unstained material is observed under a light microscope with 10× and 40× objective lenses to identify the stage of the estrous cycle. 3. The following criteria are used to identify the specific stage of the cycle: a. The estrus stage vaginal smear contains anucleated cornified cells (irregular shaped cells). b. The metaestrus stage vaginal smear is composed of a mixture of cornified epithelial cells and leukocytes. c. At diestrus, the smear contains predominantly leukocytes. d. At proestrus, the smear shows a predominance of nucleated epithelial cells.
3.2. Breeding and Plug Checking 3.2.1. Natural Breeding 1. In general, 2–3 mature females irrespective of their estrous cycle are placed into a male’s cage for breeding in the afternoon (1600–1800 h).
02_Deb_7_34_F
17
8/29/05, 11:15 AM
18
Deb, Reese, and Paria
2. If not bred, the same females should be used for breeding 3–4 d in a row because the pairing with males helps to synchronize the cycle in females. Males copulate with females at proestrus at around the midpoint of the dark cycle. 3. After a successful mating, the male should be given a rest of 2–3 d.
3.2.2. Checking Copulatory Plugs 1. A method for holding the mouse has already been described in the section on collection of vaginal smear (see Subheading 3.1.1.). 2. Hold the mouse in one hand with its face up. 3. Locate the vagina and use a small pair of curved forceps to spread the lips of the vulva to identify the plug. 4. When gently touched with a pair of forceps, the plug feels solid and blocks the vagina. It is a common practice to check the plug early in the morning, before 0900 h. The presence of a plug in the vagina is usually considered day 1 of pregnancy (see Note 1).
3.3. Detection of Early Pregnancy 3.3.1. Noninvasive Method 1. The presence of a plug in the vagina is defined as day 1 of pregnancy (see Note 2). 2. Implantation sites that look like a string of pearls in both uterine horns can be detected by palpating the abdomen from day 8 onward (see Note 3).
3.3.2. Invasive Method Dating of early pregnancy starts from the time of fertile mating to the time of implantation occurring late on day 4 or early on day 5 (5). Timing can be determined by assessing the developmental stage of the preimplantation embryo. Developmental stages of preimplantation embryo and their location in the reproductive tract are described in Table 1. Mice are normally sacrificed to collect preimplantation embryos. 3.3.2.1. PREPARATION OF MICE FOR EXCISION OF OVIDUCTS AND UTERINE HORNS 1. Place a euthanized mouse on its back (supine position) on a paper towel. 2. Swab the belly with 70% ethanol. 3. Holding the lower half of the abdominal skin with a pair of forceps, make a small lateral incision on the skin just below the forceps with a pair of scissors. 4. Holding the skin above the incision with your thumb and forefinger of one hand and below the cut with other hand, pull the skin towards head and tail to expose abdominal muscle. 5. Lift the abdominal wall muscle up with a pair of forceps and cut the abdominal muscle from the midline laterally on both sides to expose internal organs. 6. Push aside the intestine to visualize uteri, oviducts, and ovaries.
02_Deb_7_34_F
18
8/29/05, 11:15 AM
Mouse Implantation Methodologies
19
Table 1 Dating of Early Pregnancy Depending on the Developmental Stage of Preimplantation Embryos* Day of pregnancy
Developmental stage of embryos
Reproductive tract
1 2 3 (0100–0400 h) 3 (0500–1400 h) 3 (1500–2300 h) 4
One-cell zygote Two-cell Four-cell Eight-cell Morula Blastocyst
Oviduct Oviduct Oviduct Oviduct Oviduct Uterus
*The time of embryonic development may be slow or fast, depending on the strain of mice and light-dark cycle of an animal facility.
3.3.2.2. EXCISION AND FLUSHING OF OVIDUCTS 1. Using a pair of curved forceps, grasp the uterine horn just below the utero-tubal junction and cut the horn just below the pair of forceps (Fig. 1). 2. Then lift the uterine horn and clean the underlying fat pad and mesentery that are attached to the oviduct using a pair of iris scissors. 3. Separate the oviduct from the ovary using the same pair of scissors and place the oviduct in a Petri dish with a drop of Whitten’s media for flushing to recover embryos. 4. Repeat this procedure for the contralateral oviduct. 5. Place a fresh Petri dish on the stage of a stereo dissecting microscope. 6. Attach a 31-gauge needle with a blunt end that has been bent in the middle to form a 120° angle to a 1-mL or a 3-mL plastic syringe filled with Whitten’s medium. 7. Using a pair of forceps, place an oviduct on the dish under the microscope and manipulate the oviduct to locate the fimbriated end of the oviduct known as the infundibulum. 8. Hold the infundibulum loosely between the forceps and insert the needle inside the oviduct (Fig. 2). 9. Holding both the needle and the oviduct together, gently squeeze the syringe to pass the Whitten’s medium through the oviduct. This procedure should inflate the oviduct and flush the embryos from the oviduct into the dish. 10. Examine the flushing under the microscope to identify developmental stage of embryos.
3.3.2.3. EXCISION AND FLUSHING OF UTERI 1. Using a pair of forceps, grasp one uterine horn just above the cervical bifurcation and cut below the point of holding with a pair of scissors (Fig. 3). 2. Pull up the uterine horn and trim the horn free of fat and mesentery with a pair of scissors (Fig. 3).
02_Deb_7_34_F
19
8/29/05, 11:15 AM
20
Deb, Reese, and Paria
Fig. 1. Schematic representation to show excision of the mouse oviduct. The method of excision of mouse oviduct is described under Subheading 3.3.2.2.
Fig. 2. Schematic representation to show flushing of the mouse oviduct. The method of flushing oviducts is described under Subheading 3.3.2.2. The oviduct is flushed to recover preimplantation embryos.
3. Cut the other end of the horn just below the utero–tubal junction and keep the uterine horn in a clean moistened tissue paper to absorb blood. 4. Hold one of the uterine horns at the utero–tubal junction and insert the tip of a 27gauge needle, with a 3-mL plastic syringe filled with Whitten’s medium attached, inside the uterine lumen (Fig. 4).
02_Deb_7_34_F
20
8/29/05, 11:15 AM
Mouse Implantation Methodologies
21
Fig. 3. Schematic representation to show excision of uterine horns. The method of excision of mouse uterus is described under Subheading 3.3.2.3.
Fig. 4. Schematic representation to show flushing of the mouse uterine horn to recover blastocysts. The method of flushing uterine horns is described under Subheading 3.3.2.3. 5. Holding the needle and the uterine horn together, push the plunger of the syringe to flush the uterine luminal contents into a Petri dish. It is important to flush gently (Fig. 4). 6. Repeat this procedure to excise and flush the other uterine horn. 7. Check uterine flushings under a stereomicroscope for the presence of appropriate stages of developing embryos.
02_Deb_7_34_F
21
8/29/05, 11:15 AM
22
Deb, Reese, and Paria
3.3.2.4. DETERMINATION OF EARLY IMPLANTATION SITES BY INTRAVENOUS DYE INJECTION
Implantation sites in mice can be detected as early as late at night on day 4 (2200–2300 h) and onward, considering the presence of a copulatory plug as day 1 of pregnancy. This is achieved by intravenous injection of a macromolecular blue dye solution, normally via a tail vein (7). 1. Fill a 1-mL syringe attached to a 27-gauge needle with 1% blue dye solution (Chicago Blue B, Evans blue, or pontamine blue) avoiding any air bubbles inside the syringe. 2. After a mouse is anesthetized, dilate the tail veins by the application of a paper towel soaked in warm water. 3. Locate one of the two lateral veins in the tail (veins are located on both sides of the central artery) and place the mouse on that side. 4. Hold the tail gently between the thumb and forefinger and keep the tail parallel to the body of the mouse (Fig. 5). 5. Align the needle (bevel side up) with the plane of the vein. Insert the needle into the vein and slowly inject the desired amount of dye (0.1 mL/mouse, 0.25 mL/ rat). As a result of increased capillary permeability in the endometrial bed at the sites of implantation, the dye bound with the serum proteins accumulates in the interstitial space at the sites of blastocysts, showing distinct blue bands (Fig. 6). Chicago Blue B dye has been used for many years to identify implantation sites (see Note 4). 6. Animals are sacrificed 3–5 min after dye injection to identify blue bands in the uterus. Identification of uterine implantation sites from day 6 onward does not require blue-dye injection. Visual observation of prominent intermittent swellings in the uterus indicates that blastocyst implantation is in progress.
3.4. Experimental Delay in Implantation 3.4.1. Ovariectomy 1. Under anesthesia, shave the lumbar dorsum bilaterally and place day 4 pregnant animals in a prone position (face down). 2. Clean the exposed skin of the back with a 10% povidone-iodine scrub followed by 70% alcohol for aseptic surgery. 3. Make a midline skin incision near the abdominal cavity (on the back). 4. Turn the animal to one side (left or right). Pull the skin incision laterally away from the spine and make an incision on the abdominal muscle to locate the paraovarian fatty tissue (light whitish-yellow-colored fat) (Fig. 3). 5. Lift out the para-ovarian fatty tissue and excise the ovary by making a sharp cut between the oviduct and the ovary. 6. Rejoin the fat tissue with the oviduct in the abdominal cavity. 7. Repeat the same procedure on the other side. If the incisions are small, there is no need to close the incisions in the abdominal muscle. 8. Close the midline skin incision using wound clips.
02_Deb_7_34_F
22
8/29/05, 11:15 AM
Mouse Implantation Methodologies
23
Fig. 5 (see companion CD for color version). Detection of implantation sites by intravenous injection of macromolecular dye into tail vein. The method of intravenous Chicago Blue B dye injection into tail vein is described under Subheading 3.3.2.4.
Fig. 6 (see companion CD for color version). Implantation sites in uterine horns on day 5 of pregnancy as detected by intravenous Chicago blue B dye injection. The method of intravenous Chicago Blue B dye injection into tail vein is described under Subheading 3.3.2.4.
02_Deb_7_34_F
23
8/29/05, 11:15 AM
24
Deb, Reese, and Paria
3.4.2. Experimentally Delayed Implantation During experimentally delayed implantation, blastocysts enter a state of dormancy or diapause and the uterus enters a neutral state (3,4). This condition can be maintained for several days and sometimes even weeks by continuing daily progesterone (1 or 2 mg/mouse) injection. However, the number of dormant blastocysts is gradually reduced if this delayed condition is maintained for a long time. Uterine luminal closure and blastocyst apposition occur during delayed implantation, but the attachment and invasion of trophoblast cells and decidual transformation of uterine stromal cells do not occur. Activation of the dormant blastocyst and implantation can be achieved by giving an injection (subcutaneous) of estradiol-17β (3–25 ng/0.1 mL of sesame seed oil). The implantation sites in the uterus can be detected by tail-vein injection of blue dye (see Subheading 3.3.2.4.) 18–24 h after estradiol-17β injection (8) (see Note 5).
3.5. Artificial Decidualization 3.5.1. Induction of Pseudopregnancy in Females Using Vasectomized Males Regular cyclic females are mated with vasectomized infertile males to induce pseudopregnancy. 3.5.1.1. VASECTOMY
Vasectomy is performed on fertile male mice at 6–8 wk of age. Surgical resection of the vas deferens eliminates sperm from the ejaculate. 1. Place an anesthetized male on the table in supine position (face up). 2. Shave the lower half of the abdomen (anterior to the genital) to remove hair, swab, and make a midline ventral incision (one-half of an inch) in the skin anterior to the genitalia. 3. Using a pair of curved forceps and scissors, pull the abdominal muscle up and cut the muscle in the midline (a white line in the muscle). Wipe the incision site with a lint-free tissue dampened with saline to remove excess cut hair. 4. Push the left scrotum with fingers so that the testis moves up into the abdominal cavity. The testis will be out together with the vas deferens. 5. Grasp the left vas deferens gently with forceps and lift a section clear of the incision. Tuck the curved forceps underneath the vas deferens and allow them to spread. Maintaining this position, use the suture to make two firm knots in the vas deferens, about 4–5 mm apart, tying both knots firmly. 6. Cut out a section of vas deferens between the knots. 7. Place all tissues back inside the abdominal cavity and push the testis back into the scrotum. Repeat the procedure on the right side of the body. 8. When both sides have been done, sew up the incision in the body wall with separate sutures.
02_Deb_7_34_F
24
8/29/05, 11:15 AM
Mouse Implantation Methodologies
25
9. Close up the skin with two to three auto clips. The mouse should be wrapped in a tissue to keep it warm (loss of body heat is common in abdominal surgery) or, alternatively, placed on a heating pad, and allowed to recover. Animals that are placed under anesthetic should always be supervised and monitored until fully awake. 10. Following the operation, the mice are allowed to recover for 2 wk before being test-bred to confirm their sterility. One or two female mice are placed with the vasectomized male and are checked for plugs the following morning. Plug-positive females are sacrificed on day 2, and their oviducts are flushed with saline. The eggs should be at unfertilized, one-cell stage. The presence of two-cell embryos would indicate incomplete vasectomy.
3.5.1.2. INDUCTION OF PSEUDOPREGNANCY
The uterine environment of most laboratory animals becomes receptive to implantation only after mating. Vaginal–cervical stimulation during mating results in ovarian hormonal changes that alter the estrous cycle in preparation for a possible pregnancy. Pseudopregnancy can be achieved in one of two ways: (1) by mating a female to a sterile (vasectomized) male or (2) by mechanical stimulation of the vagina and cervix with a rod or vibrating tool. Currently, natural mating of a mature female with a vasectomized male (1:1) is a preferred choice of producing pseudopregnant females. Detection of a copulatory plug in the vagina of a female mated with a vasectomized male is defined as day 1 of pseudopregnancy. Procedures for breeding and checking plugs are as described previously (see also Note 6). 3.5.1.3. HORMONAL PRIMING OF OVARIECTOMIZED MICE
The method of ovariectomy is described earlier (see Subheading 3.4.1.). In general, cyclic young females are ovariectomized and rested for a couple of weeks to eliminate ovarian steroids from the circulation. After recovery, ovarian steroid hormones are administered to prepare the uterus for a chemical or physical stimulus. Either progesterone alone or a regimen of progesterone and estrogen-17β supplementation are used to sensitize the uterus for the decidual cell reaction (9,10). 1. Treatment schedule of progesterone alone: ovariectomized mice receive progesterone (1 mg/d/mouse) injection (subcutaneous) for 3 d (days 1–3). The induction of deciduoma is initiated on day 4 by infusing oil inside the uterine lumen. Daily progesterone injection is continued after the stimulus to maintain the decidualization response (9). 2. Treatment schedule of estradiol-17β and progesterone: ovariectomized mice receive injections of estradiol-17β (100 ng/d/mouse) for 3 d (days 1–3), no treatment on days 4 and 5, progesterone (1 mg/d/mouse) plus estradiol-17β (10 ng/d/
02_Deb_7_34_F
25
8/29/05, 11:15 AM
26
Deb, Reese, and Paria mouse) on days 6–8. The induction of deciduoma is initiated on day 8 by infusing oil inside the uterine lumen (10). Daily progesterone (1 mg/d/mouse) injection is continued after the stimulus to maintain the decidualization response.
3.5.1.4. INDUCTION OF DECIDUALIZATION BY ARTIFICIAL MEANS
Artificial decidualization is usually induced by injecting sesame seed (or corn) oil or by placing a silk thread inside the uterus. Injection of sesame seed oil inside the uterus is a less invasive procedure and a preferred method to induce decidualization. 1. Fill a plastic 1-mL syringe attached to a 27-gauge needle with sesame seed oil. 2. Prepare the female and expose one uterine horn as previously described (see Subheading 3.4.1.). 3. Hold the uterine horn with a pair of forceps very close to the tip (slightly below the utero–tubal junction) and slowly inject about 20 µL of oil inside the uterine lumen. Because the luminal fluid volume is very low, the uterine horn will temporarily swell during the course of oil injection (see Note 7).
3.6. Intrauterine Blastocyst Transfer 3.6.1. Induction of Pseudopregnancy in Females The method of inducing pseudopregnancy in females is described in an earlier section (see Subheading 3.5.1.2.). The pseudopregnant mouse contributes a womb for the transfer embryos. Commercially available outbred albino CD-1 females are a great choice for recipient mice.
3.6.2. Hormonal Priming of Ovariectomized Mouse for Embryo Transfer These females are often used to study the role of the steroid hormones, progesterone and estrogen, for preparation of the uterus for implantation. The method of performing ovariectomy and the preparation of progesterone-treated ovariectomized mice are described above (see Subheadings 3.4.1. and 3.5.1.3.). 1. Ovariectomized females start to receive daily subcutaneous injection of progesterone (1 or 2 mg/mouse/0.1 mL of sesame seed oil) for two consecutive days before they are ready to receive a blastocyst. Progesterone injections make the uterus achieve the prereceptive state. 2. This progesterone-primed prereceptive uterus achieves receptivity in response to a single subcutaneous injection of estradiol-17β (25 ng/mouse/0.1 mL sesame seed oil) (10). It has been established that a minimum of 48 h of uterine exposure to progesterone is necessary before an injection of estradiol-17β is provided in order to attain uterine receptivity in mice. 3. The blastocyst transfer is usually performed on the third day at the time of the third progesterone injection and an estradiol-17β injection.
02_Deb_7_34_F
26
8/29/05, 11:15 AM
Mouse Implantation Methodologies
27
4. Implantation of the blastocyst can be checked by blue-dye methods 24 h after the blastocyst transfer and estrogen injection.
3.6.3. Preparation of a Blastocyst Transfer Pipet 1. Take a 6-inch thin capillary (1 mm diameter) glass pipet and rotate it in a fine flame approx 1 inch from one end. As soon as the glass becomes soft, withdraw the glass from the heat and quickly pull both ends apart. 2. Check the diameter of the pulled pipet under a microscope and break the end at a place where the diameter will be greater (approx 200 µm) than the size of a blastocyst. One can use an oilstone to mark the breaking point of the glass for an even tip. 3. Fire-polish the tip of the pipet by quickly touching the flame (an uneven tip may damage the blastocyst and the uterus). 4. Bend the tube (at a 120–130° angle) over a flame about one-half of an inch from the unpulled end. 5. Place the unpulled end of the pipet inside a 16-gauge steel needle and seal it (make it air-tight) with “super” glue. The leakage of solution can be tested by passing water through the needle. 6. This pipet-and-needle assembly is then fitted to special 1-mL Hamilton pipetcontroller syringe. This special syringe has a plunger assembly with a thumbwheel cap inside of a glass barrel. Pull approx 0.2 mL of sterile water into the pipet barrel by pulling the pipet-controller plunger assembly. Fill the inside plunger with water by turning the plunger thumb-wheel counterclockwise (all the way to the end). Avoid drawing any bubbles inside the syringe. Connect the luer tip of the pipet-controller syringe barrel and the embryo transfer pipet. Turn the plunger thumb-wheel clockwise to push the water into the transfer pipet. Fix the water level in the middle of the transfer pipet. The transfer pipet is now ready for loading blastocysts.
3.6.4. The Blastocyst Transfer Technique 1. Prepare a pseudopregnant or hormonally treated ovariectomized mouse as described above (see Subheadings 3.5.1.2. and 3.5.1.3.). 2. Anesthetize the mouse with avertin administered intraperitoneally. 3. Place the anesthetized mouse on a clean piece of tissue paper on a clean table in a prone position (head down). 4. Shave its lower back and both sides of the abdomen. Swab the shaven area with a 10% povidone-iodine scrub and 70% ethanol. 5. Turn the mouse toward one side. Using a pair of forceps, hold the skin of the abdomen and make a small cut (approx 1 cm long) with a pair of scissors. 6. Next, hold and slightly pull the abdominal muscle and make a small incision in the abdominal muscle, avoiding the blood vessels of the muscle. If the cut has been made in the right place, the ovarian fat pad is easily visible. If not, slightly lift the edge of the body wall and try to locate the fat pad. 7. Once the fat pad is located, gently lift the fat pad out the body. Ovary, oviducts, and a part of the uterus will come out with the fat pad (Fig. 7).
02_Deb_7_34_F
27
8/29/05, 11:15 AM
28
Deb, Reese, and Paria
Fig. 7 (see companion CD for color version). Schematic representation to show exteriorization of utero-tubal junction in the anesthetized mouse. The method of exteriorization of utero–tubal junction is described under Subheading 3.6.4.
8. Attach a serrefine clip to the fat pad (do not to clip the ovary). In the absence of the ovary in the hormone-treated ovariectomized mice, clip the fat and mesentery near the oviduct. Try not to touch the uterine horns during this procedure. 9. Locate the tip and gently hold the uterine horn with a pair of forceps approx 1 cm below the utero–tubal junction (Fig. 7). 10. Five to seven blastocysts must be transferred to each horn. Take up a minute amount of embryo culture medium (Whitten’s media) in the very tip of the transfer pipet by moving the plunger cap counterclockwise. Next, make a small bubble by taking up a little air. Then take up some more medium—roughly the same volume as you hope to transfer the blastocysts in. Take up another bubble, the same size as before. Then take up blastocysts in the smallest possible volume of medium, lining them up side by side in the transfer pipet (see Note 8). 11. Once the pipet is loaded and the uterine horn positioned, gently grasp the top of the uterine horn inside a pair of forceps. 12. While still holding the horn with one hand, use the other hand to gently insert a 26-gauge hypodermic needle through the uterine wall (close to the oviduct) and into the lumen (Fig. 8). Choose an area of the horn that is relatively devoid of blood vessels because blood will clot in the tip of the pipet and block it. Remove
02_Deb_7_34_F
28
8/29/05, 11:15 AM
Mouse Implantation Methodologies
29
Fig. 8 (see companion CD for color version). Insertion of a transfer pipette into the uterine horn for embryo transfer. The method of blastocyst transfer inside uterine lumen is described under Subheading 3.6.4.
13.
14.
15. 16.
02_Deb_7_34_F
the needle and carefully (so as not to lose the site of the hole), without averting your eyes, pick up the loaded transfer pipet. Gently insert the transfer pipet tip about 3 mm into the uterine lumen (Fig. 8). Gently release the blastocysts into the uterus by turning the plunger cap clockwise. Be careful not to allow any air into the uterus. Once the transfer is complete, quickly rinse the transfer pipet in some Whitten’s medium and check to see if there were any blastocysts stuck in the transfer pipet. If there were, transfer these blastocysts again. With the transfer complete, the serrefine clip can now be removed and the uterine horn gently eased back into the body. Do not touch the uterus, but ease it back by lifting the edges of the incision in the body wall and allowing the horn to fall back in, without actually handling it. This procedure is then repeated on the other uterine horn. The incision in the body wall is not sutured. The skin is closed with Michelle clips—two per incision is usually sufficient. Once surgery is complete, the mouse is placed in a clean cage and warmed to facilitate recovery (see Note 9).
29
8/29/05, 11:15 AM
30
Deb, Reese, and Paria
3.7. Chemicals Commonly Used to Anesthetize the Mouse There are three components of anesthesia: analgesia (pain relief), amnesia (loss of memory), and immobilization (no movement). Because general anesthetics affect the central nervous system and anesthesia is required by law to prevent pain and distress in research animals, it must not be taken lightly. It is not necessary to withhold food and water from rodents prior to anesthesia.
3.7.1. Avertin (A Commonly Used Injectable Anesthetic) 1. Preparation of an Avertin (components: Avertin [2,2,2-tribromoethanol] and tertamyl alcohol) stock solution (1.6 g/mL): a. Add 15.5 mL T-amyl alcohol to 25 g of Avertin in a dark bottle. b. Stir on magnetic stirrer until the avertin is dissolved (approx 12 h). c. Store in the dark at room temperature (see Note 10). 2. Preparation of an Avertin working solution (20 mg/mL): a. Mix 0.5 mL Avertin stock solution and 39.5 mL normal saline in a beaker. b. Seal container with parafilm, wrap in foil to exclude light, and stir on magnetic stirrer for about 12 h or until dissolved. c. Avertin working solutions must be kept refrigerated in a dark bottle until used and should be replaced at least every month. d. Sterilize through 0.2-µm filter and store at 4°C. Working solutions should be replaced at least every month. 3. Dosages (0.4–0.6 mg/g body weight). 0.45–0.75 mL/mouse administered intraperitoneally (see Note 11).
3.7.2. Commonly Used Short-Lasting Inhalant Anesthetic (Isoflurane) 1. Approximately 1 mL isoflurane is placed on a cotton ball in a bell jar or screwtop glass jar. 2. The mouse is then inserted inside the jar and removed when it is fully unconscious (unconsciousness can be judged by pinching the toe). 3. Duration of these anesthetics is 30 s to 2 min. 4. A nose cone containing a small amount of anesthetic is placed in front of the nose to maintain the depth of anesthesia.
3.8. Injection Techniques in the Mouse Four types of injections are commonly used in mice: subcutaneous (SC), intraperitoneal (IP), intravenous (IV), and intramuscular (IM). Animals must be adequately restrained or anesthetized to receive injection.
3.8.1. Subcutaneous Injection (Anesthesia Not Required) 1. Grasp the base of the tail with the thumb and forefinger of one hand. 2. Place the mouse on the top of the cage cover (wire top). Clear the back of the neck with an alcohol swab.
02_Deb_7_34_F
30
8/29/05, 11:15 AM
Mouse Implantation Methodologies
31
3. Hold the syringe attached to a 27-gauge needle parallel to the head. 4. As the mouse attempts to move forward, quickly insert the tip of the needle in the scruff (loose skin on the back of the neck) at a very shallow angle and lift the skin with the needle to avoid underlying muscle. Now inject the solution and remove the needle slowly to avoid leaking. The larger the volume of injected solution, the greater the likelihood of leakage. It is also advisable to pinch the injection side with your thumb and forefinger to prevent leaking.
3.8.2. Intraperitoneal Injection (Anesthesia Not Required) 1. The procedures for grabbing and holding the mouse are described earlier. 2. Clean the injection site of one side of the abdomen with an alcohol swab. The caudal left abdominal quadrant is the preferred place for IP injection in order to avoid the cecum on the right. 3. Tilt the animal toward its head in order to allow the abdominal contents to fall away from the injection site. 4. Quickly insert a 27-gauge needle attached to a 1-mL sterile syringe containing the drug down through the abdominal wall to the peritoneal cavity and inject the animal. It is not uncommon to inject volumes up to 1 mL by this route.
3.8.3. Intravenous Injection (Anesthesia Required) This method is similar to the method of injection of blue dye through tail vein (Fig. 1).
3.8.4. Intramuscular Injection (Anesthesia Not Required) 1. Grasp the mouse as described in the methodology for subcutaneous injection. 2. The quadricep muscle and the posterior thigh are acceptable sites for intramuscular injections. Clean the injection sites with an alcohol swab. 3. Insert the needle through the skin into the muscle and inject the desired amount.
3.9. Euthanasia Cervical dislocation is the most common method of killing mice. However, mice can be killed using inhalants.
3.9.1. Cervical Dislocation 1. Hold the mouse at the base of the tail with the thumb and forefinger of one hand. 2. Keep the mouse on the cage top. As the mouse tries to move forward, quickly place the thumb and the forefinger of other hand behind the skull and hold firmly on the cage top. 3. Next, pull the tail in the direction away from the body. This will dislocate the neck. This should be performed very quickly.
02_Deb_7_34_F
31
8/29/05, 11:15 AM
32
Deb, Reese, and Paria
3.9.2. Inhalants 3.9.2.1. CARBON DIOXIDE
Carbon dioxide inhalation is the most efficient and acceptable method of euthanasia. 1. 2. 3. 4.
A mouse cage with a solid lid is connected to a carbon dioxide gas cylinder. Place the mice in the cage and cover the cage with a lid. Open the carbon dioxide cylinder and fill the cage with gas. The animals will die within 1–2 min.
3.9.2.2. ISOFLURANE
Isoflurane overdose can also be used to kill mice. 1. A cotton wool or gauze soaked with isoflurane is placed inside a bell jar or a screw-cap glass container. 2. Place the mouse inside the jar. The mice will die within 1 min (see Note 12).
4. Notes 1. The process of detecting copulatory plugs should be performed gently because stimulation of the vagina may induce pseudopregnancy. 2. Pregnant mice usually do not breed when placed with male mice. There is no other visual or noninvasive method for definitive identification of early pregnancy. 3. Abdominal distention is apparent in most mice by day 8 or later depending on the litter size and degree of swelling of the implantation sites. 4. This is a relatively simple procedure but requires practice. If the needle is inside the vein, injection will be smooth. If the syringe plunger does not move smoothly and resistance is felt while injecting or swelling around the injection site occurs, withdraw the needle and try again slightly above the first injection site (proximal to the body). It is always advisable to start injecting from the tip of the tail. After several attempts, it is advisable to change the needle because the tip becomes blunt. 5. The purpose of describing delayed implantation is that this model provides a powerful tool to examine steroid hormone regulation of uterine and embryonic changes with respect to embryo–uterine interactions during implantation. 6. The pseudopregnant female will display the hormonal profile of a normal pregnant female for several days after mating. The hormonal milieu of pseudopregnancy begins to differ from pregnancy after 7 to 8 d as a result of the absence of a developing embryo inside the uterus. 7. Injection of too much oil inside the lumen may migrate to the other uterine horn and cause decidualization. Prominent swelling of the uterus will indicate the extent of stromal cell decidualization in response to the artificial stimulus. Swelling of the uterus due to decidualization will be visible 48 h after the oil injection. The intraluminal oil injection to a pseudopregnant mouse uterus on day
02_Deb_7_34_F
32
8/29/05, 11:15 AM
Mouse Implantation Methodologies
8.
9.
10.
11.
12.
33
4 afternoons (1300–1400 h) will yield the best results. If ovariectomized mice are used, animals should be exposed to progesterone (SC injection) for at least 48 h (daily injection of 2 mg progesterone per 0.1 mL sesame seed oil per day for 2 d) before the injection of oil inside the uterine lumen. These animals must also be maintained with daily progesterone injection after the induction of decidualization. Loading blastocysts into the transfer pipet will take some practice. If it is likely to take more than a few minutes to load the transfer pipet, then do not expose the uterine horn until the pipet has been loaded. This prevents drying out and further trauma to the uterine horn. Alternatively, the uterine horn, ovary, and so on may be moistened repeatedly with a sterile cotton bud and saline. Animal welfare guidelines recommend that all vertebrates undergoing procedures that might cause more than momentary pain or distress be treated with analgesics, unless it can be scientifically justified that the treatment will interfere with the experimental procedure. Analgesics should be given immediately after the surgery. A simple skin incision may only require 24 h of analgesic treatment. Rodents subjected to abdominal surgery or similar procedures normally require analgesic for the first 12 h. It is not appropriate to wait until signs of pain or distress are demonstrated before administering analgesics. In rodents, the signs of pain following surgery are manifested as decreases in food and water consumption. Consult your veterinarian and animal care committee for specific postoperative care in your institute, because these procedures are based on institutional rules and regulations. The Avertin stock solution is light-sensitive and hydroscopic. Keep Avertin in a dark bottle at room temperature. The Avertin stock solution is quite stable at room temperature It will take about 3–5 min for the mouse to become fully anesthetized (lack of toepinch reflex). An additional 0.1–0.2 mL can be administered if required. The mouse will remain anesthetized for approx 15–20 min and recover within 30–60 min. Keep the mouse warm during recovery. The effective dosage is dependent upon the weight of the mouse. Isoflurane should be used in a fume hood to minimize the risk of exposure to the gas by the operator.
Acknowledgments We gratefully acknowledge Dr. S. K. Dey for helpful discussions and expert advice. This work was supported by National Institutes of Health (NIH) grant HD 42636, HD 40193, HD 44741 and HD 37394 to B.C.P. References 1. Allen, E. (1922) The estrous cycle in the mouse. Am. J. Anat. 30, 297–371. 2. Snell, G. D., Fekete, E., Hummel, K. P., and Law, L. W. (1940) The relation of mating, ovulation and estrous smear in the house mouse to time of day. Anat. Rec. 76, 39–54.
02_Deb_7_34_F
33
8/29/05, 11:15 AM
34
Deb, Reese, and Paria
3. Carson, D. D., Bagchi, I., Dey, S. K., et al. (2000) Embryo implantation. Dev. Biol. 223, 217–237. 4. Dey, S. K. (1996) Implantation. In: Reproductive Endocrinology, Surgery and Technology (Adashi, E. Y., Rock, J. A., and Rosenwaks, Z, Eds.), LippincottRaven, New York: pp. 421–434. 5. Yoshinaga, K. and Adams, C. E. (1966) Delayed implantation in spayed, progesterone treated adult mouse. J. Reprod. Fert. 12, 593–595. 6. Das, S. K., Wang, X. N., Paria, B. C., et al. (1994) Heparin-binding EGF like growth factor gene is induced in the mouse uterus temporally by blastocysts solely at the site of its apposition: a possible ligand for interaction with blastocyst EGFreceptor in implantation. Development 120, 1071–1083. 7. Psychoyos, A. (1973) Endocrine control of egg implantation. In: Handbook of Physiology, Williams and Wilkins, Baltimore, MD: pp.187–215. 8. Paria, B. C., Huet-Hudson, Y. M., and Dey, S. K. (1993) Blastocyst’s state of activity determines the “window” of implantation in the mouse receptive uterus. Proc. Natl. Acad. Sci. USA 90, 10,159–10,162. 9. Paria, B. C., Tan, J., Lubahn, D. B., Dey, S. K., and Das, S. K. (1999) Uterine decidual response occurs in estrogen receptor-α-deficient mice. Endocrinology 140, 2704–2710. 10. Wordinger, R. J., Jackson, F. L., and Morrill, A. (1986) Implantation, deciduoma formation and live births in mast cell-deficient mice (W/Wv). J. Reprod. Fertil. 77, 471–476.
02_Deb_7_34_F
34
8/29/05, 11:15 AM
Blastocyst Culture
35
3 Blastocyst Culture D. Randall Armant Summary Experimental models of blastocyst development based on in vitro culture have played a prominent role in advancing our understanding of peri-implantation development, a process that is relatively inaccessible in vivo. Blastocyst culture provides a robust approach for examining embryonic interactions with the microenvironment under highly controlled conditions. Major events that occur in utero can be followed in vitro, including blastocyst expansion, hatching, and adhesion to extracellular matrices. This chapter will describe a method for obtaining and culturing mouse blastocysts. Morphological changes that occur during blastocyst culture will be discussed and related to the corresponding development in utero. Finally, quantitative assays will be detailed for monitoring peri-implanatation development of the trophoblast in vitro. Key Words: Blastocyst; mouse; trophoblast; embryo culture; hatching; implantation; attachment reaction; adhesion; migration; fibronectin binding assay; outgrowth; microspheres; image analysis; morphometry; extracellular matrix; fibronectin; Matrigel; collagen gel.
1. Introduction Preimplantation development in mice takes place between embryonic days (E) 0.0 and E 3.5, resulting in the formation of a blastocyst. As with all preimplantation stages, the blastocyst can complete development outside of the female reproductive tract under the direction of an endogenous developmental program. The early stages of peri-implantation development are recapitulated in vitro, including blastocyst expansion, cell proliferation, and hatching from the zona pellucida. After hatching, interactions with the uterus that occur in vivo from E 4.0 to E 6.5 can be simulated by following the attachment of the blastocyst to the culture plate and, if an appropriate extracellular matrix (ECM) is provided, monitoring the migratory or invasive activity of trophoblast cells. The maternal milieu plays a central role in augmenting blastocyst development. Blastocyst culture provides an experimental system for investigating From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
35
03_Armant_35_56_F
35
8/29/05, 11:15 AM
36
Armant
interactions between the embryo and individual components of the maternal environment. Using this approach, it has been possible to establish several molecular mechanisms that contribute to the embryonic–maternal dialogue.
1.1. Blastocyst Formation and Architecture Spatial information plays a critical role in blastocyst formation. During preimplantation development, the trophectoderm differentiates from cells lining the outside of the compacted morula (Fig. 1). Developmental cues garnered by the presence or absence of asymmetrical cell contacts determine cell fate after compaction (1). Outside cells differentiate into trophectoderm, the first epithelium and precursor of all trophoblast lineages, whereas inside cells become the pluripotent inner cell mass (ICM). During trophectoderm differentiation, tight junctions form between the outside blastomeres and they begin to actively transport fluid into the embryo, generating a blastocoel. As the blastocyst forms, the trophectoderm is stretched and the cluster of cells that forms the ICM becomes confined to a sector of the trophectoderm wall (2). The trophoblast originates from the trophectoderm layer of the blastocyst during peri-implantation development. Therefore, much can be learned about trophoblast development by culturing blastocysts in vitro. The blastocoel physically separates some of the trophectoderm cells from the ICM and, thus, provides spatial cues for differentiation of the mural trophectoderm. Polar trophectoderm comprises the outside cells that directly contact the ICM (3). Under the direction of the ICM, polar trophectoderm cells proliferate rapidly until displaced into the mural trophectoderm, where cell division slows considerably (4,5). In the mouse, mural trophectoderm cells endoreduplicate their DNA and differentiate into invasive giant trophoblast cells.
1.2. Modeling Implantation In Vitro Mural trophectoderm cells convert during implantation to an invasive phenotype, the trophoblast, by altering their adhesive interactions, dissociating from one another, and penetrating the endometrium (6,7). Trophoblast cells eventually infiltrate the maternal vascular system. The undifferentiated trophectoderm cells possess a nonadhesive apical surface. Uterine edema promotes tight apposition between the hatched blastocyst and uterine epithelium, leading quickly to attachment between the luminal epithelium of the uterus and the apical surface of the trophectoderm. The attachment reaction precipitates the death of luminal epithelial cells directly contacting the blastocyst, which allows the trophoblast giant cells to adhere to the underlying basal lamina. In the final stages of implantation, trophoblast cells complete their differentiation to the invasive phenotype. These developmental events are recapitulated during in vitro blastocyst culture, provided certain requirements detailed in this
03_Armant_35_56_F
36
8/29/05, 11:15 AM
Blastocyst Culture
37
Fig. 1. Formation of the mouse blastocyst. At the eight-cell stage, the embryo compacts to produce a morula (A). After the next cell division, the embryo begins to produce a cavity or blastocoel and forms a blastocyst by the 32-cell stage (B). Two populations of cells emerge during blastocyst formation. The inside cells of the morula (white) become the inner cell mass (ICM), a group of pluripotent stem cells eccentrically positioned within the blastocyst. Cells in the outer layer of the morula (gray) form the first epithelium, the trophectoderm, which differentiates into the trophoblast lineages of the placenta. The blastocyst expands by accumulating additional fluid within the blastocoel and hatches free of the zona pellucida (C). In the mouse, polar trophectoderm cells contacting the ICM proliferate, while the remaining mural trophectoderm cells differentiate into trophoblast giant cells.
chapter are met. Blastocyst differentiation in vitro from gestation day (GD) 4 to GD 7 (see Note 1) is slow, as assessed by activities that are believed to correspond to developmental events occurring in utero (Table 1). However, the introduction of growth factors normally provided by the uterus can accelerate in vitro development significantly (8).
1.2.1. Expansion and Hatching Developing blastocysts accumulate fluid, expanding their circumference as the blastocoel volume increases (Fig. 1C). Expansion of the blastocoel can be monitored by morphometric measurement and proceeds linearly from GD 4 to
03_Armant_35_56_F
37
8/29/05, 11:15 AM
38
Armant
Table 1 Comparison of Blastocyst Developmenta Developmental events (in vitro counterpart)
Time in utero
Time in vitro Morning of:
Early blastocyst Expanded and hatching Attachment reaction (in vitro attachment) Adhesion to basal lamina (ECM-binding activityb) Invasion of stroma/ECM (trophoblast outgrowth)
E 3.5 E 3.8 E 4.0 E 5.0 E 6.2
GD 4 GD 5 GD 6 GD 7 GD 7-10
aDevelopment of blastocysts in utero from embryonic day 3.5 (E 3.5) to E 6.2 compared with that of blastocysts collected from the uterus on gestation day (GD) 4 at 0900 h and cultured in serum-free medium. In vitro, blastocysts attach nonspecifically to plates on GD 6. They adhere specifically to surfaces or microspheres coated with extracellular matrix (ECM) proteins on GD 7. Invasive activity is assessed from GD 7 onward by monitoring trophoblast outgrowth on ECM. bDiscussed in this chapter as fibronectin-binding activity
GD6 (9). On GD 7, adhesion-competent blastocysts collapse, perhaps as a result of the breakdown of trophoblast junctions prior to outgrowth. During blastocyst expansion, the zona pellucida ruptures as a result of proteolytic activity produced by the trophectoderm (10). The combined action of proteases and pressure generated by blastocyst expansion produces an opening in the zona pellucida that the trophectoderm eventually squeezes through in order to hatch (Fig. 2A). Hatching is usually completed by mid-day on GD 5, leaving behind an empty zona pellucida. In utero, additional proteases that are present in the uterine luminal fluid completely dissolve the zona pellucida on E 3.8–4.0. Hatching is easily observed during blastocyst culture and can be quantified by counting embryos that are unhatched, hatching, or completely free of the zona pellucida (11).
1.2.2. Attachment Phase Attachment between the apical surfaces of the trophectoderm and luminal epithelium in utero has been documented by ultrastructural analysis (7) and its molecular basis is under intense investigation (12). There is a clear distinction between this attachment of opposing apical cell surfaces, a rare event for epithelia, and the adhesion of trophoblast cells to components of the basal lamina and stromal ECM that occurs later. The attachment reaction begins in mice at approximately E 4.0 (13). Direct evidence that trophoblast cells become physically attached to the epithelium is derived primarily from observations made in vitro. As blastocysts differentiate during co-culture with a monolayer of uterine epithelial cells, they become difficult to dislodge by shaking the culture
03_Armant_35_56_F
38
8/29/05, 11:15 AM
Blastocyst Culture
39
Fig. 2. Differentiation of the blastocyst in vitro. The blastocyst expands and hatches by squeezing through a tear in the zona pellucida (A). Around the time that the trophoblast becomes adhesion competent, the blastocyst collapses (B). An empty zona to the left clearly shows the opening formed during hatching. The earliest sign of trophoblast outgrowth is the appearance of spreading cells near the base of the embryo (arrowheads; C). During the next 24 to 72 h, the field of migrating trophoblast cells surrounding the embryo increases in area (D–F). The clump of cells at the center of the outgrowth consists of remnants of the ICM and undifferentiated trophoblast cells.
vessel (14,15). Because blastocysts cultured to GD 6 will attach nonspecifically to the culture plate as readily as to a cell monolayer, it is questionable whether their attachment to cultured cells is physiologically significant. However, the ability of cultured blastocysts to attach in vitro is developmentally regulated, and may represent cellular events associated with attachment to the luminal epithelium in utero. There are sweeping changes in surface charge and proteoglycan expression known to occur coincidentally with the attachment reaction (16) that could make blastocysts “sticky” in culture. The ability of blastocysts to attach in medium supplemented only with bovine serum albumin (BSA) peaks on GD 6 and ceases shortly before they begin to adhere and outgrow on GD 7 (17,18), further suggesting that transient attachment to culture plates could represent differentiation related to the attachment reaction in utero. Therefore, assessment of blastocyst attachment during the course of in vitro
03_Armant_35_56_F
39
8/29/05, 11:15 AM
40
Armant
culture can provide useful information regarding developmental progression, but it should be recognized as an event separate from trophoblast adhesion to ECM.
1.2.3. Adhesion/Invasion Phase Adhesion commences in utero between E 5.0 and 5.2, based on ultrastructural observation of mural trophoblast cells adhering to the endometrial basal lamina that is exposed upon sloughing of luminal epithelial cells (19). Experimental studies using cultured blastocysts have shed important light on the molecular basis of trophoblast adhesion to ECM. Mouse blastocysts will adhere and their trophoblast cells will spread and outgrow in serum-free media on substrata containing highly purified preparations of ECM proteins (20). Trophoblast invasion of three-dimensional ECM has also been investigated using blastocysts cultured in collagen gels, basement membranes or ECM purified from the endometrium (21,22). Blastocyst outgrowth culture was developed using serum supplementation (23), and provided a useful model system of periimplantation development (24,25). It can be inferred that the ability of mouse trophoblast cells to outgrow in vitro correlates with their competence to implant in utero (26). Trophoblast cells are promiscuous in their choice of adhesion proteins, readily outgrowing on fibronectin, laminin, vitronectin, collagens, entactin, and other components of the ECM (20,27–30). The rate of blastocyst differentiation in culture can be determined by assessing embryos for the first sign of trophoblast outgrowth, which presents as a spreading monolayer of cells around the base of the embryo concomitant with disappearance of the spherical blastocyst morphology (Fig. 2). A commonly used strategy for assessing the influence of culture conditions and additives on blastocyst differentiation is to compare outgrowth rates. In serum-free culture on ECM-coated surfaces, blastocysts become adhesive and commence trophoblast outgrowth between GD 6 and GD 7 (Table 1). Whereas the developmental program of the blastocyst proceeds in the absence of an adhesive substratum, trophoblast cells must contact the ECM to undergo morphological transformation (31). Without the provision of ECM proteins or serum, the late blastocyst collapses and remains essentially intact until it finally degenerates. If blastocysts are transferred to an ECM after they become adhesion-competent on GD 7, signs of spreading trophoblast are apparent within 1–2 h. By GD 8, their ability to adhere diminishes, suggesting that there is a finite window of time for trophoblast adhesion. The trophoblast appears to be unable to recover once the window is past (31). We have developed an alternate approach to more precisely gage adhesive trophoblast differentiation (18). Prior to observable outgrowth, trophoblast
03_Armant_35_56_F
40
8/29/05, 11:15 AM
Blastocyst Culture
41
Fig. 3. Adhesion of fibronectin coated microspheres to mouse blastocysts. Groups of five embryos are viewed by fluorescence microscopy after decoration with fluorescent microspheres coated with FN-110, as detailed in the text. Before assay, blastocysts cultured to gestation day 7 were incubated for 1 h with either bovine serum albumin (A) or 50 µg/mL FN-110 (B). Arrowhead in B denotes polar trophoblast.
cells must become adhesive at their apical surfaces, dissociate cell–cell junctions, spread, and begin to migrate. The time between acquisition of adhesion competence and our ability to detect migrating trophoblast cells posed a serious technical limitation for experimentally assessing blastocyst development. We were able to monitor early signs of adhesive activity on the apical surface of trophoblast cells by decorating intact blastocysts with fluorescent microspheres coated with adhesive ECM proteins (18) (Fig. 3). Coating microspheres with a proteolytic fragment of fibronectin containing the central cell adhesion-promoting domain (FN-110), we demonstrated that binding was specific and dependent on appropriate integrins. The onset of fibronectinbinding activity correlated with trophoblast outgrowth on plates coated with fibronectin, demonstrating a physiological relationship between the two experimental approaches. The fibronectin-binding assay, quantified using fluorescence microscopy and image analysis, has proven highly useful in experimental designs to test agents that delay (31) or accelerate (8) the rate of blastocyst development. Using this approach, we found that adhesion to fibronectin at the apical surface of the trophoblast is upregulated after an initial exposure to fibronectin for 1–3 h (18) (Fig. 3). Furthermore, fibronectin was shown to ligate integrins localized at the apical surface of the trophectoderm, activating intracellular
03_Armant_35_56_F
41
8/29/05, 11:15 AM
42
Armant
signaling pathways that increase fibronectin-binding activity (32). The trafficking of additional proteins, including the αIIb integrin subunit, into the apical domain of the trophoblast plasma membrane is induced by fibronectin-mediated integrin signaling and contributes to the intensified adhesion (33). Used in combination with molecular and cytological approaches to assess the expression and localization of adhesion complex components, the evaluation of adhesive activity during trophoblast differentiation has provided new insights into the developmental mechanisms that guide blastocyst implantation (34). This chapter details protocols for the production and culture of mouse blastocysts, as well as assays used to monitor the developmental progression of blastocysts in vitro. The laboratory manual by Hogan and colleagues (35) can be consulted for additional information regarding embryo culture methods and specialized laboratory techniques. 2. Materials 1. B6SJLF1/J male mice, 3 to 9 mo old (Jackson Laboratory, Bar Harbor, ME) (see Note 2). 2. Outbred (e.g., CF1, CD1, Swiss-Webster) female mice, 4–6 wk old (Charles River Laboratories, Wilmington, MA) (see Note 3). 3. Pregnant mare serum gonadotropin (PMSG; Sigma Chemical Co., St. Louis, MO) and human chorionic gonadotropin (hCG; Sigma), each in phosphate-buffered saline (PBS) at 50 IU/mL. Stocks (100X) are prepared in distilled water at 5000 IU/mL and stored at –70°C. 4. Dissecting scissors (surgical and fine) and forceps (No. 5). 5. 27-gauge hypodermic needle and 1–2 mL syringe. 6. Embryo culture medium: Ham’s F-10 culture medium (Invitrogen, Carlsbad, CA), supplemented with 4 mg/mL BSA (A3311, Sigma), 75 µg/mL penicillin (P4687, Sigma) and 75 µg/mL streptomycin (S1277, Sigma) (see Note 4). 7. M2 medium (M5910, Sigma) is prepared with 4 mg/mL BSA and antibiotics, as for Ham’s F-10 medium (see Note 5). 8. Water-extracted oil: light mineral oil (Aldrich Chemical Co. Inc., Milwaukee, WI) is shaken with one part sterile distilled water to nine parts oil and allowed to phase separate. 9. Small Petri dishes (351007 or 351008, BD Biosciences, Bedford, MA). 10. Micropipets prepared from Pasteur pipets heated in a flame and pulled to a diameter of 75–100 µm. Latex tubing with a mouthpiece is attached for mouth operation, as described in Hogen et al. (35). 11. Dissecting stereomicroscope. 12. A nonhumidified tissue culture incubator set at 37°C and 5% CO2 (see Note 6). 13. Matrigel™, collagen type I and collagen type IV (BD Biosciences). 14. Human plasma fibronectin, mouse laminin-1 from Engelbreth-Holm-Swarm (EHS) sarcoma (both from Invitrogen), human plasma vitronectin (Calbiochem, La Jolla, CA) and α1-acid glycoprotein (Sigma). Protein stocks are prepared at
03_Armant_35_56_F
42
8/29/05, 11:15 AM
Blastocyst Culture
15.
16.
17. 18.
43
1 mg/mL in PBS and stored frozen in small aliquots that are slowly thawed on ice before dilution to the appropriate final concentration. Peptides for coating plates: FN-110 (08-103, Upstate Biotech, Lake Placid, NY), a 110 kDa proteolytic fragment of fibronectin with adhesive activity, and GRGDSP (03-34-0035, Calbiochem), a synthetic peptide containing the critical sequence that mediates adhesion in the cell binding domain of fibronectin. Both peptides are prepared and stored as in item 14. Inverted microscope with fluorescence detection system (DM-IRB, Leica, Wetzlar, Germany), interfaced through a B/W CCD digital camera (Orca, Hamamatsu Photonics K.K., Hamamatsu City, Japan) with computer-based image analysis software (Simple PCI, Compix Inc., Canberry Township, PA), or a comparable system from other manufacturers. Fluorescent polystyrene microspheres (Bangs Laboratories, Fishers, IN) approx 1 µm in diameter (see Note 7). Heparitinase (from Flavobacterium heparinum; E.C. 4.2.2.8; 100704-1, Seikagaku America, East Falmouth, MA) prepared at 0.1 U/mL in Hank’s balanced salt solution (Invitrogen).
3. Methods 3.1. Blastocyst Production and Culture
3.1.1. Superovulation and Mating 1. Female mice are superovulated by injection of 5 IU PMSG, followed 44–48 h later with 5 IU of hCG. Injections of 0.1 mL are given intraperitoneally between 1200 and 1600 h (see Note 8). 2. Immediately after the hCG injection, each female is paired for mating overnight with a stud male. 3. The females are checked the next morning for a vaginal plug (solidified semen at the entrance to the vagina) by lifting the tail and probing with a small spatula or blunt rod. Plugs must be checked early, as they may fall out by the late morning. 4. The pregnant female mice are then separated from males and may be housed in groups until the desired stage of pregnancy is reached. Nonpregnant animals may be re-used for superovulation and mating after resting them for 2–3 wk. 5. Embryos can also be obtained without superovulation by monitoring the estrus cycle of each female to determine the appropriate time for mating (35).
3.1.2. Blastocyst Collection Blastocysts are collected from the uterus (see Note 9) before they hatch from the zona pellucida on E 3.5 (Fig. 1B). 1. Before collecting embryos, set up at least two microdrop cultures (see Note 10). In addition to the microdrop cultures, fill a Petri dish with M2 medium for collecting uterine horns. All plates should be equilibrated in a tissue culture incubator for at least 30 min before embryo collection begins.
03_Armant_35_56_F
43
8/29/05, 11:15 AM
44
Armant
2. Pregnant mice are euthanized by cervical dislocation, the body is doused with 70% ethanol, and a small ventral incision is made with surgical scissors in the abdominal skin. The skin is then grasped on either side of the incision and pulled apart to expose the underlying body wall. The peritoneal cavity is opened using fine scissors to make a lateral incision through the ventral abdominal wall at a level approximating the top of the rear legs. After pushing the intestines upward to expose the reproductive tract, grasp the junction between the oviduct and the left uterine horn with fine forceps. Free as much fat and membrane from the uterine horn as possible. 3. Cut the uterotubal junction on the side of the forceps towards the oviduct. A second cut just above the junction of the two uterine horns will free the left horn. Place the uterine horn into M2 medium and repeat the procedure with the right uterine horn. 4. After collection, each uterine horn is flushed with 1 mL of M2 medium using a syringe needle inserted into the lumen of the horn at the uterotubal junction. The junction wall is held tightly to the needle with forceps as medium is gently released from the syringe into the lumen, exiting at the opposite end into an empty Petri dish. Collection of embryos is made easier by preventing the medium from reaching the wall of the Petri dish. 5. Using a stereomicroscope, the medium is scanned for blastocysts, which are collected by mouth-operated micropipet (see Note 11). 6. Embryos are transferred to microdrop cultures and separated from debris or contaminating epithelial cells by transfer through at least three more drops of medium. They can then be transferred to new microdrop cultures or harvested for other purposes.
3.1.3. Blastocyst Culture 1. Microdrop cultures containing blastocysts are incubated without humidification in a tissue culture incubator at 37°C and 5% CO2. Embryos may be cultured singly or in groups, allowing 1–2 µL of medium per embryo. 2. Once the blastocysts have hatched from the zona pellucida, it is better to culture them singly to prevent their aggregation. Another advantage of culturing blastocysts singly is the ability to monitor the development of each embryo individually. It is not necessary to change the culture medium unless the ratio of embryos to culture medium is significantly increased.
3.2. Blastocyst Developmental Assays In addition to monitoring the rates of blastocyst expansion and hatching, as described under Subheading 1.2.1., there are several measures of late blastocyst differentiation that can be quantified experimentally. The attachment reaction requires interactions with the uterine epithelium, but the corresponding stage of blastocyst differentiation occurs during culture after the blastocyst hatches, causing the embryo to transit from completely free floating to immo-
03_Armant_35_56_F
44
8/29/05, 11:15 AM
Blastocyst Culture
45
bile on the culture plate surface. A fibronectin binding assay can be used to directly measure the adhesion competence of trophoblast cells, demonstrating adhesive activity on the apical surface prior to the onset of outgrowth (18). Blastocyst outgrowth on ECM is representative of the period of trophoblast invasion and may be quantified either by determining the percentage of blastocysts with migrating trophoblast cells, or by measuring the area occupied by trophoblast cells as they migrate outward. Later, we provide protocols for assessing these measures of blastocyst differentiation during development in vitro. Normally, blastocysts are cultured on BSA-coated surfaces until GD 5, allowing them to hatch from the zona pellucida and approach the attachment competent stage. Most embryos will hatch independently, but those that fail should be freed of the zona by repeatedly drawing the blastocyst in and out of a micropipet drawn to a diameter slightly smaller than that of the embryo. Hatched or dezonaed blastocysts are best cultured singly in small microdrops to avoid their aggregation. It is convenient to arrange the microdrops in a circular pattern on the Petri dish for easy scanning when assessing their progress. Once embryos are added to culture medium, minimize their exposure to ambient room conditions by rapidly returning them to the incubator after each observation.
3.2.1. Blastocyst Attachment Attachment is determined by swirling or tapping the culture plate while observing the embryo through a stereomicroscope. Unattached blastocysts will move relative to debris or marks in the plastic, whereas attached embryos remain firmly in place. Removing the zona pellucida prematurely does not alter the timing of blastocyst attachment during culture (24). However, delayed hatching will obscure detection of attachment and subsequent outgrowth. Therefore, it is expedient to mechanically remove zonae from any blastocysts that have not hatched by the end of GD 5. Whereas attachment is transient in medium containing only BSA, it is continuous with trophoblast adhesion and outgrowth on surfaces coated with ECM components or in serum-supplemented medium. The time between the onset of attachment and the beginning of outgrowth can be as long as 12–24 h, although supplementation with serum or growth factors can shorten it to less than 1 h. 3.2.2. Trophoblast Outgrowth To form a blastocyst outgrowth (Fig. 2), trophoblast cells must adhere to an ECM that can be provided by supplementing the medium with serum, which contains fibronectin and vitronectin. Alternatively, blastocysts will outgrow in a defined serum-free medium when cultured either on polystyrene surfaces coated with individual ECM proteins or on gels composed of purified collagen or a complex basement membrane (Matrigel).
03_Armant_35_56_F
45
8/29/05, 11:15 AM
46
Armant
3.2.2.1. OUTGROWTH ON GELS 1. Several types of collagen, prepared in acidified solution, can be used to form a gel by neutralization with culture medium and incubation at 37°C. Gel formation will not occur if the solution is maintained at 0–4°C. 2. Matrigel is a complex, collagen-rich basement membrane that is provided frozen in a neutral solution. It is thawed overnight at 4°C to prevent gel formation. 3. A volume of ice-cold Matrigel or neutralized collagen sufficient to generate the desired gel thickness is removed with a chilled pipet, quickly deposited on a surface, and warmed to 37°C to promote gel formation. 4. The newly formed gel is rinsed several times with culture medium and equilibrated in an incubator before introducing embryos. 5. For microdrop culture, this procedure can be carried out on the surface of a Petri dish using 1–5-µL drops of collagen or Matrigel. 6. After gelation at 37°C in a humidified chamber, a small amount of medium is applied to wet each gel and the plate is flooded with mineral oil. 7. Medium above the gel is changed and embryos are introduced through the oil using micropipets, as described under Subheading 3.1.2. 8. Using an inverted microscope, each embryo is observed at regular intervals to determine if migrating trophoblast cells are present at the base of the blastocyst. Mouse trophoblast cells outgrow on the surface of Matrigel, but penetrate type I collagen gels to produce a three-dimensional outgrowth (21). Trophoblast cells of certain other species with highly invasive implantation, including guinea pigs (21), nonhuman primates (36), and humans (37), are capable of invading Matrigel.
3.2.2.2. OUTGROWTH ON COATED PLASTIC 1. Coating the culture surface with individual ECM proteins is best accomplished using non-tissue culture-treated plastic (e.g., Petri dish, plates made with untreated polystyrene). In addition to intact proteins (fibronectin, laminin-1, collagen, vitronectin, entactin), we have used a proteolytic fragment of fibronectin that contains the central cell binding domain (FN-110), the E8 proteolytic fragment of laminin-1 or synthetic peptides having the Arg-Gly-Asp-Ser sequence recognized by several integrins (27,38,39). 2. Matrix proteins or peptides are diluted from stock solutions to 50 µg/mL in sterile PBS at room temperature (PBS diluent must contain no additional protein) and added immediately to the culture surface. Higher protein concentrations are required to coat glass surfaces. 3. For microdrop cultures, drops of the precoating solution are placed on a Petri dish, which is flooded with oil and incubated overnight at 4°C–37°C. The precoating solution is then removed and the surface washed several times with sterile PBS containing 4 mg/mL BSA. The same solution is used to block the coated surface for 1 h. Care should be taken not to scrape the treated culture surface with a pipet. The PBS/BSA solution is then replaced with serum-free
03_Armant_35_56_F
46
8/29/05, 11:15 AM
Blastocyst Culture
47
Fig. 4. Determination of outgrowth area. A blastocyst was cultured to gestational day (GD) 5, transferred to a plate coated with fibronectin and further cultured until GD 9. The resulting embryo with outgrowing trophoblast cells appears in A. The image is assessed for area using image analysis software by tracing the outer edge of the outgrowth using a computer mouse, as depicted in B. Calibration performed using an image of a stage micrometer obtained at the same magnification allows the software to determine the delineated outgrowth area in µm2.
medium and allowed to equilibrate in a tissue culture incubator before inserting embryos. 4. Observation with a steromicroscope is adequate for assessing outgrowth, although an inverted microscope used at higher magnification can be helpful. The blastocoel collapses shortly before embryos begin to outgrow (Fig. 2B). When scoring outgrowth cultures, blastocysts are assessed for a spreading monolayer of trophoblast cells around the base of the embryo concomitant with disappearance of the spherical blastocyst morphology (Fig. 2C–F). Positive scores are given to embryos as soon as the first signs of trophoblast outgrowth are visualized (Fig. 2C).
3.2.3. Measurement of Outgrowth Area Once trophoblast outgrowth is intitiated, the area occupied by the cells can be measured to determine rates of cell spreading and migration. 1. Images of blastocyst outgrowths are obtained daily from GD 6 to GD 10 using an inverted microscope (200× magnification) interfaced through a digital camera with an image analysis system. 2. Using software that includes morphometry capabilities, the perimeter of each outgrowth is traced with a computer mouse (Fig. 4) and converted to area in µm2, based on prior calibration of the system with a stage micrometer.
03_Armant_35_56_F
47
8/29/05, 11:15 AM
48
Armant
3. After the progression of outgrowth area expansion has been established in a time study, subsequent experiments may be conducted by choosing one time point that is within the linear range of increasing outgrowth area (see Note 12).
3.2.4. Measurement of Fibronectin-Binding Activity Although the binding assay described here is intended for measuring cell adhesion to fibronectin, a similar approach can be adapted for other proteins that mediate trophoblast adhesion. For large proteins, it is best whenever possible to coat polystyrene microspheres with a small active fragment of the protein to increase ligand density. We have coated fluorescent microspheres with proteolytic fragments containing the cell binding domains of fibronectin, laminin, and entactin to assess the adhesive activity of developing blastocysts. The fibronectin-binding assay is performed in three steps. 1. It is necessary to remove charged heparan sulfate from the surface of the trophoblast to prevent nonspecific binding of microspheres through electrostatic interactions. 2. Fibronectin-binding activity at the apical surface of the blastocyst must be upregulated through exposure to soluble or immobilized fibronectin for reasons discussed under Subheading 1.2.3. 3. Blastocysts are incubated with fibronectin-coated microspheres and high affinity binding is assessed.
Procedures for each of these steps will be detailed, along with protocols for preparing fibronectin-coated microspheres and quantifying microsphere binding to blastocysts. 3.2.4.1.PREPARATION OF MICROSPHERES 1. Fluorescent microspheres (1.0-µm diameter) are supplied as 2.5% solutions and must be washed to remove surfactants. 2. Centrifuge 200 µL of the microspheres suspension in a 0.6-mL tube at 10,000g for 1 min. 3. Remove the supernatant, add 200 µL sterile PBS and vortex to resuspend. 4. Repeat steps 2 and 3 twice. 5. Centrifuge the suspension at 10,000g for 1 min. 6. Remove the supernatant and add 200 µL sterile PBS containing 144 µg/mL FN-110. 7. Agitate the suspension at room temperature for 24 h on a vortex mixer set to its lowest speed. 8. Repeat steps 2 and 3 three times. 9. Remove the supernatant and add 200 µL sterile PBS containing 1 mg/mL α1-acid glycoprotein as a blocking step (see Note 13). 10. Repeat step 7. 11. Repeat steps 2 and 3 three times. 12. Remove the supernatant and add 200 µL PBS containing 10 mg/mL BSA (PBS/ BSA).
03_Armant_35_56_F
48
8/29/05, 11:15 AM
Blastocyst Culture
49
13. Store microspheres at 4°C for up to 2 mo (final concentration is 2.5%). 14. To begin an experiment, remove 10 to 20 µL of the microsphere suspension, and dilute 1:10 (final concentration of 0.25%) in ice-cold PBS/BSA. For a negative control, dilute 1:10 with PBS/BSA containing 1 mg/mL of fibronectin. 15. Prepare ice-cold drops of washing solutions and microspheres in microdrop culture and keep cold in refrigerator until use.
3.2.4.2. LIGAND-MEDIATED UPREGULATION OF BINDING ACTIVITY
Upregulate fibronectin-binding activity by incubating blastocysts for 1 h at 37°C in Ham’s F10 medium containing 50 µg/mL FN-110 (Fig. 3). This can also be accomplished by culturing blastocysts for 3 h on a Petri dish coated with fibronectin, as described in the initial reports of this method (18,31). However, it is recommended that soluble ligand be used to upregulate fibronectinbinding activity, as some of the blastocysts become damaged or too adherent to recover from the ligand-coated plate. Blastocysts incubated on non-coated plates in medium containing only BSA will provide an indication of the extent of increase in binding activity, which should be three- to sixfold (see Note 14) 3.2.4.3. REMOVAL OF SURFACE HEPARAN SULFATE
After exposure to ligand, transfer blastocysts through three drops of medium. Blastocysts are then incubated in 0.1 U/mL heparitinase for 30 min at 37°C in a tissue culture incubator. 3.2.4.4. INCUBATION WITH MICROSPHERES 1. Wash blastocysts in ice-cold PBS/BSA three times by sequential transfer through microdrops. 2. Incubate blastocysts with FN-110 coated microspheres (0.25% in PBS/BSA) at 4°C for 30 min (see Note 15). 3. Wash blastocysts four times in PBS/BSA at 4°C by transfer through microdrops. This will remove microspheres bound nonspecifically from the embryos. 4. Fix the embryos for 1 h at 4°C in a microdrop of PBS containing 3% paraformadehyde.
3.2.4.5. QUANTIFICATION OF MICROSPHERE BINDING
The fibronectin-binding activity is determined by quantifying the fluorescence intensity of microspheres bound to the blastocysts using microscopy and image analysis. 1. Embryos labeled with fluorescent microspheres are viewed directly through the bottom of a microdrop culture dish using a microscope equipped with epifluorescence illumination and filters that will provide the appropriate excitation and emission frequencies for the fluorescent microspheres.
03_Armant_35_56_F
49
8/29/05, 11:15 AM
50
Armant
Fig. 5. Determination of fibronectin-binding activity. An image of fluorescent microspheres bound to a blastocyst (A) is obtained by focusing on its outer edge. Two methods are shown for quantifying the fluorescence intensity of the bound microspheres using image analysis software. One method (B) is to trace the outer edge of the image with the computer mouse, beginning at the arrowhead, and then double back a short distance inward from the edge until reaching the origin. The enclosed area, consisting of the in-focus region of the image, is then used by the program to determine the average grey level. An alternate method (C) is to create a fixed shape that is placed along the in-focus edge of the image with the computer mouse (gray squares shown) to obtain an average gray level.
2. Locate an embryo in bright field and then switch to fluorescence illumination. Bring the fluorescent microspheres at the outer edge of the blastocyst into focus, which will yield the strongest signal. 3. Adhesiveness to fibronectin tends to localize at the abembryonic pole of the mouse blastocyst (Fig. 3B), opposite the ICM (18). Rotate the blastocyst so the ICM is positioned to the center of the image and fluorescence is generally continuous around the perimeter of the embryo (Fig. 5A). 4. A digital fluorescent image of each embryo is captured using a charge-coupled device (CCD) camera and stored in the computer. 5. Use an image analysis program to determine the grey level of selected regions of each image (see Note 16). The outer edge of the blastocyst may be selected by tracing with a mouse (Fig. 5B). Another technique is to use a “square” or “circle” tool to randomly sample ten to twenty areas along the embryo perimeter to obtain an average grey level (Fig. 5C).
3.2.5. Data Analysis and Statistics All experiments should be repeated at least three times to demonstrate reproducibility. Record observations at the same times during development in each replicate experiment so data from all experiments can be pooled for final analysis. A balance must be struck between obtaining too few measurements to construct precise rates of change and removing embryos from the
03_Armant_35_56_F
50
8/29/05, 11:15 AM
Blastocyst Culture
51
incubator for observation too frequently, which could compromise their viability and alter development. The rates of blastocyst expansion, hatching, attachment, and outgrowth are all determined by repetitive observation as embryos develop in culture, scoring the percentage of embryos that have achieved the respective endpoint. Choose a specific time during development to initiate the experiment, designated as 0 h. Examination of the embryos three to five times daily will usually provide robust data. A total N of 30 to 50 embryos in each experimental group usually provides sufficient power for statistical analysis. It is preferable to obtain overall percentages by pooling data from all experiments rather than to calculate percentages for each individual experiment and then average the percentages. Probit analysis, available in the SPSS statistical software package (SPSS Inc., Chicago, IL), is used to calculate a T50 (the time when half of the embryos are scored positively) for each experimental group and generate confidence intervals (CIs) to indicate whether there are statistically significant differences between groups. The T50 is a measure of developmental rate, where faster progression results in a lower T50 value. If their 95% CIs do not overlap, T50s are statistically different (p < 0.05). Outgrowth area and fibronectin-binding activity are measured once or twice daily. Values are pooled from all experiments and the data for each experimental group is subjected to analysis of variance. A total N of 15 to 30 embryos in each experimental group usually provides sufficient power for statistical analysis. 4. Notes 1. Fertilization and commencement of embryonic development occur within a few hours of ovulation, around midnight after pairing mice for mating. Therefore, in vivo development is estimated to begin at midnight, which is designated E 0.0. Zygotes can be collected from the oviduct the following morning at E 0.5, whereas blastocysts are collected from the uterus 3 d later at E 3.5. A different system is used to track in vitro development after embryos are removed from the reproductive tract. The day after mating is designated GD 1. For example, if blastocysts are collected from pregnant dams on E 3.5, development in vitro from that time forth begins with GD 4. The distinction between developmental time in vivo and in vitro is important because the rate is highly variable in vitro, depending on culture conditions, and does not necessarily correspond to the stage attained at that time in vivo (Table 1). 2. Other mouse strains may be used. Males of F1 strains, such as B6SJLF1/J, are particularly good studs that successfully mate at rates in excess of 80%. 3. Other mouse strains may be used. Outbred female mice are easily induced to superovulate. Hogan et al. (35) provide a list of inbred and F1 strains that are high and low ovulators.
03_Armant_35_56_F
51
8/29/05, 11:15 AM
52
Armant
4. We use Ham’s F-10 medium for blastocyst culture, but many other medium formulations work well. The principal requirements for complete blastocyst differentiation in culture are the inclusion of amino acids (23,25,40). Other complex media (e.g., CMRL 1066, Dulbecco’s modified Eagle’s medium [DMEM], RPMI 1620) are satisfactory. We have no experience in the production of trophoblast outgrowths with the newer media developed specifically for preimplantation blastocyst culture. Those supplemented with amino acids, such as KSOM+AA (11), are likely to work well. 5. M2 is useful for embryo collection because it is a HEPES-buffered medium that will maintain pH at ambient CO2 levels. 6. Microdrop culture (see Note 10) is performed in a nonhumidified incubator. Humidification causes moisture to collect on the surface of the oil, eventually dripping through the oil and diluting the culture medium. 7. Microspheres are available in various fluorescent colors to match most fluorescence detection systems. They are also available conjugated to reactive groups for covalent coupling to proteins. Alternate commercial sources of this product include Molecular Probes (Eugene, OR) and Polysciences (Warrington, PA). 8. Mice should be housed in an approved animal care facility with a regulated lighting cycle. For the protocol described here, lights were set to turn on at 0700 h and turn off at 2100 h (14 h light/10 h dark). If blastocyst collection is desired at a time of day other than morning, the light cycle and injection schedule should be adjusted accordingly. 9. It is also possible to generate blastocysts by initiating in vitro development at earlier preimplantation stages, collecting embryos from the oviduct (35). Generally, embryo production diminishes with gestational age, but earlier initiation of in vitro development delays blastocyst formation. Removing blastocysts from the uterus is technically less challenging than flushing oviducts. Both approaches will generate embryos that can be cultured through the peri-implantation stages. 10. Some comments on the microdrop culture, as described by Hogan et al. (35), are provided. Drops (2–10 µL) of embryo culture medium are arrayed on a Petri dish. If a tissue culture-treated plate is used, the drops tend to run together. The plate is then flooded with water-extracted mineral oil to cover the drops and prevent their evaporation. At the outset, plates should be marked on the underside with a laboratory pen to keep track of individual embryos or groups that will be cultured on the plate. 11. Micropipets (see p. 134 of ref. 35) are made by heating a glass Pasteur pipet about half way up the narrow end over a Bunsen burner. Once the glass is fluid, move the pipet out of the flame and quickly pull a thin strand of glass, which should remain hollow. Break it to create an opening that has a diameter 25–50% larger than a blastocyst. Latex hosing with a mouth piece is attached with a cotton filter to the pipet to control suction. While observing embryos through a stereomicroscope, place the pipet in medium or through oil into a microdrop until it rests next to an embryo. Controlling the suction, draw the embryo just into the end of the pipet. Removing the pipet from the medium stops the suction. Once it
03_Armant_35_56_F
52
8/29/05, 11:15 AM
Blastocyst Culture
12.
13.
14.
15.
16.
53
is inserted into another microdrop, create pressure to deliver the embryo. Take care not to draw the embryo in too far or to expel all of the medium in the pipet, as bubbles will be produced. Turn the dish to position the drop on the side opposite your hand so the pipet can be held at a shallow angle. With a little practice, this technique can be quickly mastered. Microspheres of 50–100 µm diameter are useful for learning the technique without using valuable embryos. The area occupied by the blastocyst prior to outgrowth should be taken into consideration in analyzing outgrowth area. For example, the average area of blastocysts before beginning outgrowth could be determined and subtracted from measurements obtained during outgrowth to calculate the increase in outgrowth area. This will provide a more accurate basis for comparing experimental groups. The strong negative charge of α1-acid glycoprotein conferred by multiple sialic acid moieties reduces nonspecific interactions of the microspheres with negatively charged cell surfaces. Adhesion incompetent blastocysts will produce low levels of fibronectin-binding activity that are unaffected by prior upregulation with fibronectin or by competition with soluble fibronectin during incubation with microspheres. By calculating the difference in fibronectin-binding activity between embryos upregulated with fibronectin and those exposed only to BSA or embryos assayed in the presence of competing fibronectin (∆ fibronectin-binding activity), blastocysts from different stages of development are most accurately assessed for adhesion competence. Prior to adding embryos, it may be necessary to resuspend microspheres that have settled during the chilling process using a micropipette to mix the medium. The microsphere suspension will obscure your view of the embryos, making it difficult to locate them after the 30-min incubation. This problem may be reduced by placing the embryos in the shallow portion of the drop, near its edge. Medium drawn from the top of the drop can be blown over the embryos to assist in their recovery. For an eight-bit imaging program, grey level will range from 0 (black) to 255 (white). By setting the program to determine the average grey level (not the total grey level), it will not matter if the area you are tracing over each embryo varies.
Acknowledgments This research was supported by National Institutes of Health grants HD 36764 and AA12057. The author thanks Dr. Zitao Liu, Dr. Jun Wang and Mr. Po Jen Chiang for preparing images of mouse embryos that were used for illustrations. References 1. Johnson, M. H. and Ziomek, C. A. (1983) Cell interactions influence the fate of mouse blastomeres undergoing the transition from the 16- to the 32-cell stage. Dev. Biol. 95, 211–218.
03_Armant_35_56_F
53
8/29/05, 11:15 AM
54
Armant
2. Watson, A. J. and Barcroft, L. C. (2001) Regulation of blastocyst formation. Front. Biosci. 6, D708–D730. 3. Gardner, R. L., Papaioannou, V. E., and Barton, S. C. (1973) Origin of the ectoplacental cone and secondary giant cells in mouse blastocysts reconstituted from isolated trophoblast and inner cell mass. J. Embryol. Exp. Morphol. 30, 561–572. 4. Gardner, R. L. (1983) Origin and differentiation of extraembryonic tissues in the mouse. Int. Rev. Exp. Pathol. 24, 63–133. 5. Gardner, R. L. (2000) Flow of cells from polar to mural trophectoderm is polarized in the mouse blastocyst. Hum. Reprod. 15, 694–701. 6. Cross, J. C., Werb, Z., and Fisher, S. J. (1994) Implantation and the placenta: key pieces of the development puzzle. Science 266, 1508–1518. 7. Carson, D. D., Bagchi, I., Dey, S. K., et al. (2000) Embryo Implantation. Dev. Biol. 223, 217–237. 8. Armant, D. R., Wang, J., and Liu, Z. (2000) Intracellular signaling in the developing blastocyst as a consequence of the maternal-embryonic dialogue. Semin. Reprod. Med. 18, 273–287. 9. Stachecki, J. J., Yelian, F. D., Schultz, J. F., Leach, R. E., and Armant, D. R. (1994) Blastocyst cavitation is accelerated by ethanol- or ionophore- induced elevation of intracellular calcium. Biol. Reprod. 50, 1–9. 10. O’Sullivan, C. M., Liu, S. Y., Karpinka, J. B., and Rancourt, D. E. (2002) Embryonic hatching enzyme strypsin/ISP1 is expressed with ISP2 in endometrial glands during implantation. Mol. Reprod. Dev. 62, 328–334. 11. Biggers, J. D., McGinnis, L. K., and Raffin, M. (2000) Amino acids and preimplantation development of the mouse in protein-free potassium simplex optimized medium. Biol. Reprod. 63, 281–293. 12. Kimber, S. J. (2000) Molecular interactions at the maternal-embryonic interface during the early phase of implantation. Semin. Reprod. Med. 18, 237–253. 13. Blankenship, T. N. and Given, R. L. (1995) Loss of laminin and type IV collagen in uterine luminal epithelial basement membranes during blastocyst implantation in the mouse. Anat. Rec. 243, 27–36. 14. Salomon, D. S. and Sherman, M. I. (1975) Implantation and invasiveness of mouse blastocysts on uterine monolayers. Exp. Cell Res. 90, 261–268. 15. Glass, R. H., Spindle, A. I., and Pedersen, R. A. (1979) Mouse embryo attachment to substratum and interaction of trophoblast with cultured cells. J. Exp. Zool. 208, 327–336. 16. Smith, S. E., French, M. M., Julian, J., Paria, B. C., Dey, S. K., and Carson, D. D. (1997) Expression of heparan sulfate proteoglycan (perlecan) in the mouse blastocyst is regulated during normal and delayed implantation. Dev. Biol. 184, 38–47. 17. Sellens, M. H. and Sherman, M. I. (1980) Effects of culture conditions on the developmental programme of mouse blastocysts. J. Embryol. Exp. Morphol. 56, 1–22. 18. Schultz, J. F. and Armant, D. R. (1995) Beta1- and beta3-class integrins mediate fibronectin binding activity at the surface of developing mouse peri-implantation
03_Armant_35_56_F
54
8/29/05, 11:15 AM
Blastocyst Culture
19.
20.
21.
22.
23. 24.
25. 26.
27.
28.
29.
30.
31.
32.
55
blastocysts. Regulation by ligand-induced mobilization of stored receptor. J. Biol. Chem. 270, 11,522–11,531. Blankenship, T. N. and Given, R. L. (1992) Penetration of the uterine epithelial basement membrane during blastocyst implantation in the mouse. Anat. Rec. 233, 196–204. Armant, D. R., Kaplan, H. A., and Lennarz, W. J. (1986) Fibronectin and laminin promote in vitro attachment and outgrowth of mouse blastocysts. Dev. Biol. 116, 519–523. Wordinger, R. J., Brun-Zinkernagel, A. M., and Jackson, T. (1991) An ultrastructural study of in-vitro interaction of guinea-pig and mouse blastocysts with extracellular matrices. J. Reprod. Fert. 93, 585–597. Armant, D. R. and Kameda, S. (1994) Mouse trophoblast cell invasion of extracellular matrix purified from endometrial tissue: a model for peri-implantation development. J. Exp. Zool. 269, 146–156. Gwatkin, R. B. (1966) Defined media and development of mammalian eggs in vitro. Ann. N. Y. Acad. Sci. 139, 79–90. Sherman, M. I. and Atienza-Samols, S. B. (1978) In vitro studies on the surface adhesiveness of mouse blastocysts, in Human Fertilization (Ludwig, H. and Tauber, P. F., eds.). Georg Thieme, Stuttgart, Germany: pp. 179–183. Spindle, A. I. and Pedersen, R. A. (1973) Hatching, attachment, and outgrowth of mouse blastocysts in vitro: fixed nitrogen requirements. J. Exp. Zool. 186, 305–318. Enders, A. C., Chavez, D. J., and Schlafke, S. (1981) Comparison of implantation in utero and in vitro, in Cellular and Molecular Aspects of Implantation (Glasser, S. R. and Bullock, D. W., eds.). Plenum, New York, NY: pp. 365–382. Armant, D. R., Kaplan, H. A., Mover, H., and Lennarz, W. J. (1986) The effect of hexapeptides on attachment and outgrowth of mouse blastocysts cultured in vitro: evidence for the involvement of the cell recognition tripeptide Arg-Gly-Asp. Proc. Natl. Acad. Sci. USA 83, 6751–6755. Sutherland, A. E., Calarco, P. G., and Damsky, C. H. (1988) Expression and function of cell surface extracellular matrix receptors in mouse blastocyst attachment and outgrowth. J. Cell Biol. 106, 1331–1348. Carson, D. D., Tang, J. P., and Gay, S. (1988) Collagens support embryo attachment and outgrowth in vitro: effects of the Arg-Gly-Asp sequence. Dev. Biol. 127, 368–375. Yelian, F. D., Edgeworth, N. A., Dong, L. J., Chung, A. E., and Armant, D. R. (1993) Recombinant entactin promotes mouse primary trophoblast cell adhesion and migration through the Arg-Gly-Asp (RGD) recognition sequence. J. Cell Biol. 121, 923–929. Schultz, J. F., Mayernik, L., Rout, U. K., and Armant, D. R. (1997) Integrin trafficking regulates adhesion to fibronectin during differentiation of mouse peri-implantation blastocysts. Dev. Genet. 21, 31–43. Wang, J., Mayernik, L., and Armant, D. R. (2002) Integrin signaling regulates blastocyst adhesion to fibronectin at implantation: intracellular calcium transients and vesicle trafficking in primary trophoblast cells. Dev. Biol. 245, 270–279.
03_Armant_35_56_F
55
8/29/05, 11:15 AM
56
Armant
33. Rout, U. K., Wang, J., Paria, B. C., and Armant, D. R. (2004) alpha5beta1, alphaVbeta3 and the platelet-associated integrin alphaIIbbeta3 coordinately regulate adhesion and migration of differentiating mouse trophoblast cells. Dev. Biol. 268, 135–151. 34. Wang, J. and Armant, D. R. (2002) Integrin-mediated adhesion and signaling during blastocyst implantation. Cells Tissues Organs 172, 190–201. 35. Hogan, B. L., Beddington, R. S., Constantini, F., and Lacy, E. (1994) Manipulating the Mouse Embryo. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 36. Lopata, A., Kohlman, D. J., Bowes, L. G., and Watkins, W. B. (1995) Culture of marmoset blastocysts on matrigel: a model of differentiation during the implantation period. Anat. Rec. 241, 469–486. 37. Kliman, H. J. and Feinberg, R. F. (1990) Human trophoblast-extracellular matrix (ECM) interactions in vitro: ECM thickness modulates morphology and proteolytic activity. Proc. Natl. Acad. Sci. USA 87, 3057–3061. 38. Yelian, F. D., Yang, Y., Hirata, J. D., Schultz, J. F., and Armant, D. R. (1995) Molecular interactions between fibronectin and integrins during mouse blastocyst outgrowth. Mol. Reprod. Dev. 41, 435–448. 39. Armant, D. R. (1991) Cell interactions with laminin and its proteolytic fragments during outgrowth of mouse primary trophoblast cells. Biol. Reprod. 45, 664–672. 40. Martin, P. M., Sutherland, A. E., and Van Winkle, L. J. (2003) Amino acid transport regulates blastocyst implantation. Biol. Reprod. 69, 1101–1108.
03_Armant_35_56_F
56
8/29/05, 11:15 AM
Stromal Cells In Vitro
57
4 Isolation of Hormone Responsive Uterine Stromal Cells An In Vitro Model for Stromal Cell Proliferation and Differentiation Virginia Rider Summary The female sex hormones estrogen and progesterone stimulate proliferation and differentiation of human and rodent uterine cells. The purpose of this chapter is to provide a method for isolating hormone-responsive rat uterine stromal cell lines that can be used to study steroid control of the cell cycle. Uteri from ovariectomized rats are differentially digested with trypsin to separate epithelial and stromal cells. The stromal cells are cultured in a standard growth medium containing 10% fetal bovine serum. After several passages, the purity of the stromal cell lines is determined using immunocytochemistry. Cell proliferation is studied by culturing the stromal cells in serum-free medium containing sex steroids and other mitogens. Cell cycle progression is assessed by flow cytometry, 3H-thymidine and BrdU incorporation, whereas proliferation is monitored using the MTT assay. Cell cycle regulators are visualized by Northern and Western blotting whereas cyclin–cyclin-dependent kinase activity is monitored using immune complex kinase assays. Uterine stromal cell lines isolated using the methods reported in this chapter provide a suitable model system to investigate the signal transduction events that stimulate hormone-dependent control of the cell cycle. Key Words: Uterus; stromal cells; decidua; cell cycle; estrogen; progesterone.
1. Introduction The growth and function of any tissue is dependent on regulated proliferation and differentiation of its cellular components. Within endocrine target tissues of the reproductive tract, hormones exert specific temporal, spatial, and interactive effects. Estrogens are associated generally with cell proliferation in uterine and breast tissues, whereas progesterone is considered more as the hormone promoting cellular differentiation in these organs. However, progesterone is a potent mitogen for stromal cells in the uterus and the lobuloalveolar cells in the mammary gland (1). The preeminence of progesterone in female
From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
57
04_Rider_57_68_F
57
8/29/05, 11:16 AM
58
Rider
reproduction has been highlighted by studies from mice lacking the progesterone receptor by targeted mutagenesis (2). The progesterone receptor “knockout” mouse exhibits abnormalities in all aspects of reproduction including sexual behavior, mammary gland development, ovulation, and implantation (2). The rodent uterus is a well-characterized model system for studying the hormonal control of uterine cell proliferation and differentiation (3–8). Under the influence of estrogen at days 2 and 3 post coitum, the luminal and glandular epithelial cells proliferate (3,8). At day 4 of pregnancy in the rat, proliferation switches from epithelial to stromal compartments (5). Stromal cells do not divide without progesterone, and proliferation is blocked by progesterone antibodies and progesterone receptor antagonists (8,9). During normal pregnancy, the uterine stromal cells proliferate and differentiate (decidualize) into decidual cells (11). The stromal cells located at the antimesometrial region of the endometrium are the first to show signs of differentiation. These cells uncouple DNA replication from cytokinesis and become polyploid (11,12). The differentiation of the uterine stroma spreads from cells located in the antimesometrial and periluminal regions outwards towards the myometrium (13). Decidualization of stromal cells is more restricted to the periluminal region in the rat compared with the mouse (13). Because the decidual cells located in the antimesometrial region of the uterus express different proteins than the mesometrial cells, it is possible that these two cell populations arise from different progenitors. However, stromal cells isolated from these two regions and placed in culture lose their differentiated gene expression (14). This suggests that stromal cells arise from a single stem cell population and differences in gene expression are due to positional effects within the endometrium rather than inherent genetic differences. This is an important concept because it suggests that the mesometrial and antimesometrial stromal cells share the same lineage, but differences in phenotype occur because localized effects are exerted on stromal cells depending on their position within the endometrium. If this interpretation is correct, then it should be possible to stimulate either the mesometrial or antimesometrial differentiation programs when the appropriate signal transduction cascades involved have been identified. Major progress in understanding the control of the cell cycle has come from proliferative studies of cells in model culture systems (reviewed in refs. 15– 18). It is our view that conceptual advancement about steroid mediated proliferation and differentiation will be generated using cell culture systems that recapitulate key hormone-dependent control of cell cycle events. Moreover, it seems essential to clearly define steroid-dependent effects on the proliferative cycle vs the differentiation pathway. Although these two events are likely intertwined, there must be important signals that direct stromal cells from a
04_Rider_57_68_F
58
8/29/05, 11:16 AM
Stromal Cells In Vitro
59
proliferative pathway into the differentiation program. The development of suitable culture systems to study endocrine-dependent regulation in endometrial cells have proved problematic because these target cells often lose their responsiveness to sex hormones in culture (19). Many of the earlier studies on this topic (19–21) were concerned with steroid mediated control of epithelial cell proliferation. Epithelial cells present additional and unique problems in culture because their functions in vivo depend on cell polarity (apical vs basal surfaces) as well as junctional connections between the cells. Our laboratory has been interested in uterine stromal cells (22–29) because these cells proliferate and differentiate in response to sex steroids to form the maternal part of the placenta. We anticipated that the structural organization of stromal cells in vivo could obviate some of the problems encountered with the epithelial cell culture systems. Stromal cells exist as individual cells surrounded by the extracellular matrix and do not appear to be constrained by polarity in the same manner as epithelial cells. Moreover, early reports suggested that progesterone-dependent proliferation was maintained in cultured human (30) and rat (31) uterine stromal cells. Uterine stromal cells, isolated by the methods reported in this chapter, provide a suitable model system to investigate the signal transduction events that stimulate hormone-dependent proliferation and ultimately to more fully understand the signals required for differentiation. 2. Materials 2.1. Culture Media 1. Standard growth medium. Medium 199 culture medium supplemented with Earle’s salts and L-glutamine (Fisher Scientific, Hanover Park, IL) containing 100 U/mL penicillin (Sigma), 100 µg/mL streptomycin (Sigma), and 10% heat-inactivated fetal bovine serum (FBS; Sigma) (see Note 1). Medium is stored at 4°C. 2. Serum-free medium. Dulbecco’s modified Eagle’s medium, phenol red-free (Gibco, Grand Island, NY) in a 3:1 mixture with MCDB-105 (Sigma) containing supplements including 100 U/mL penicillin (Sigma), 100 µg/mL streptomycin (Sigma), 5 µg/mL bovine insulin (Sigma), 10 µg/mL human transferrin (Sigma), 50 µg/mL ascorbic acid (Sigma), and 1 mg/mL reagent grade bovine serum albumin (Sigma). The medium is sterilized by filtration and stored at 4°C. 3. Freezing medium. Medium 199 culture medium supplemented with Earle’s salts and L-glutamine (Fisher Scientific, Hanover Park, IL) containing 100 U/mL penicillin (Sigma), 100 µg/mL streptomycin (Sigma), 10% dimethlysulfoxide (DMSO; Sigma) and 20% heat-inactivated FBS (Sigma). The medium is stored at 4°C. 4. Trypan blue (0.4%). Trypan blue powder (Sigma) is dissolved in phosphate-buffered saline (PBS) and sterilized by filtration. The solution is stored at 22°C. It is diluted 1:1 with the cell sample to be counted.
04_Rider_57_68_F
59
8/29/05, 11:16 AM
60
Rider
2.2. Reagents and Hormones 1. Tissue dissociation buffer. PBS without calcium and magnesium containing 0.25% trypsin, 20 mM HEPES, 50 U/mL penicillin (Sigma), 50 µg/mL streptomycin (Sigma). This solution should be made fresh on the day of use. 2. Cell dissociation medium. A trypsin-ethylenediamine tetraacetic acid (EDTA) solution containing 0.05% trypsin and 0.02% EDTA in Hanks’s balanced salt solution (1X trypsin-EDTA, Sigma). Hanks’s medium is stored at 4°C. 3. 6α-Methyl-17α-hydroxy-progesterone acetate (Sigma). 10 mM stock made up in ethanol. Final concentration is 1 µM. Steroids in ethanol are stored at 22°C for short periods (<2 mo) or at 4°C for longer-term storage (see Note 2). 4. β-Estradiol (Sigma). 100 µM stock made up in ethanol. Final concentration is 10 nM. Hormones in ethanol are stored at 22°C for short periods (<2 mo) or at 4° for longer-term storage.
2.3. Proliferation Assays 1. [ 3H]thymidine: 20–30 Ci/mmol, Amersham Pharmacia Biotech (Arlington Heights, IL). 2. Nitrocellulose membrane filters, Whatman BA85 (Fairfield, NJ). 3. 5-Bromo-2'-deoxyuridine (BrdU), BrdU Labeling and Detection Kit, Roche Molecular Biochemicals (Indianapolis, IN). 4. MTT reagent (3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazoliumbromide; Thiazolyl blue). Dissolve the MTT reagent in PBS to a final concentration of 5 mg/mL. Filter-sterilize and store at –20°C. The working solution is protected from light and stored at 4°C. 5. Chamber slides. Eight-well Lab-Tek chamber slides (Nunc, Naperville, IL) are used to visualize BrdU incorporation. 6. Solubilization/stop solution. The stop solution is prepared by dissolving 100 g of sodium dodecyl sulfate (SDS) in approximately 400 mL of N,N'-dimethylformamide diluted 1:1 in reagent grade water. When the SDS has dissolved, 1 N HCL (12.5 mL) and 80% acetic acid (12.5 mL) are added to the mixture. The final volume is adjusted to 500 mL with the dimethylformamide: water (1:1) mixture.
3. Methods 3.1. Cell Isolation 1. Sexually mature rats (150–175 g body weight) are ovariectomized and rested for 10 ds prior to stromal cell isolation. 2. Uterine horns are removed under anesthesia and trimmed of fat and mesentery. The tissue is kept on ice. 3. The uterine horns are slit open longitudinally under a dissecting microscope. The uterine horns from each rat are placed in a 60-mm culture dish (Fisher) containing 3.0 mL of tissue dissociation medium.
04_Rider_57_68_F
60
8/29/05, 11:16 AM
Stromal Cells In Vitro
61
4. The tissue is incubated at 37°C for 35 min. The dish is vortexed at low speed for 10 s. 5. The tissue dissociation medium is removed and replaced with 2.0 mL of fresh dissociation medium. 6. The uterine horns are incubated at 37°C for 60 min. The dish is vortexed at low speed for 10 s. 7. The dissociation medium containing the cells is transferred to a 15-mL sterile culture tube containing 0.1 vol of FBS. The uteri are washed with dissociation medium and the wash is added to the sterile tube. 8. The medium containing the dissociated cells is centrifuged at 500g for 5 min. 9. The supernatant is discarded. 10. The cell pellet is suspended in 3.0 mL of standard growth medium. 11. When all of the uteri have been processed, the cell suspensions are combined and centrifuged at 500g for 5 min. 12. The supernatant is discarded and the cell pellet is suspended in 10 mL of standard growth medium. The cells are seeded on two 60-mm dishes, 5 mL each. 13. The cells are cultured in standard growth medium in an atmosphere of 5% CO2 and 95% air in a humidified chamber at 37°C (see Note 3). 14. Purity of the cells should be assessed using immunocytochemical analysis with vimentin, desmin, and cytokeratin antibodies (32) (see Note 4). 15. Estrogen receptor transcripts can be measured using reverse transcription and polymerase chain amplification (28). Progesterone (25) and estrogen (Fig. 1) receptor proteins are detected by Western immunoblotting. 16. The response to mitogenic agents, including sex steroids, can be assessed by flow cytometry (26,27) and the MTT assay (25). Entry into DNA replication is assessed by 3H-thymidine incorporation (26) and BrdU incorporation (29). 17. Temporal expression of cell cycle regulators can be monitored by Northern and Western blotting. Activity of cyclin–cyclin-dependent kinases can be monitored using immune complex kinase assays (27).
3.2. Routine Passaging 1. Stromal cells are washed once with 1X PBS to remove serum. 2. The cells are incubated in 1X trypsin-EDTA at 37°C for 5 min (see Note 5). 3. The released cells are collected with a pipet and immediately added to a 15-mL sterile tube containing 0.1 vol of FBS. The flask is washed with 1X PBS and the wash is added to the 15-mL tube. 4. The cells are pelleted by centrifugation at 500g for 5 min. 5. The supernatant is removed and the pellet is suspended in normal growth medium (see Note 6).
3.3. Freezing and Thawing Cells 1. The cells are released from the T75 flasks using 1X trypsin-EDTA. 2. The cells are suspended in normal growth medium. An aliquot (25 µL) is removed and counted (see Note 7).
04_Rider_57_68_F
61
8/29/05, 11:16 AM
62
Rider
Fig. 1. Rat uterine stromal cell lines express estrogen receptor (ER)-α protein. Uterine stromal cells (UIII, passage 22) were cultured in medium 199 containing 10% fetal bovine serum as detailed elsewhere (26). Cell extracts were prepared (27) and size fractionated by sodium dodecyl sulfate-polyacrylamide gel (10%) electrophoresis. As a positive control for ER-αexpression, extract from T47D breast cancer cells (34) was electrophoresed on the same gel. The proteins were transferred to a nitrocellulose membrane by standard methods (27). The membrane was reacted with a mouse ERαantibody (1:500 dilution, AER611, NeoMarkers, Freemont, CA) and an anti-mouse secondary antibody (1:25,000 dilution). The blot was incubated with the SuperSignal West Femto Maximum Sensitivity Substrate kit (Pierce, Rockford, IL) and exposed to X-ray film for 1 min. The size of the major reactive species shown by the arrow at Mr 65,000 was determined from molecular size standards (BioRad, Hercules, CA). This protein is consistent with the size for ER-α. In the absence of primary antibody the major reactive protein was not detected (data not shown). Lane 1: Rat uterine stromal cell extract. Lane 2: T47D breast cancer cell extract. Arrows on the left indicate the position of the molecular size standards.
3. The cells are centrifuged at 500g for 5 min and the supernatant is carefully removed from the resulting cell pellet. 4. The cells are suspended in 1 mL of freezing medium and the suspension is placed into a cryovial. 5. The cryovial is kept at –80°C for at least 8 h before freezing the cells in liquid nitrogen (see Note 8). 6. To thaw the cells, the cryovial is removed from the liquid nitrogen and quickly placed in a water bath at 37°C. The thawed cells are transferred into a T75 flask containing 10 mL of growth medium with 20% FBS (see Note 9). 7. The day after thawing the cells, the medium containing 20% serum is removed and replaced by normal growth medium (10% FBS).
04_Rider_57_68_F
62
8/29/05, 11:16 AM
Stromal Cells In Vitro
63
3.4. Proliferation Assays 3.4.1. Preparation of the Cells 1. A sufficient number of cells are propagated from the stock (see Note 10). 2. The cells (1–3 × 104) are seeded into 24-well plates in normal growth medium (see Note 11). 3. The cells are allowed to attach for 2 h. The growth medium is removed and the cells are washed twice with 1X PBS. 4. Quiescence is induced in the cells by culturing in serum-free medium for 72 h (see Note 12). 5. The cells are stimulated to re-enter the cell cycle with fresh serum-free medium containing mitogenic agents or an equal volume of vehicle (negative control).
3.4.2. [3H]Thymidine Incorporation 1. 2. 3. 4. 5.
Proliferation agents are added to quiescent cells and plates are incubated for 20 h. The cells are pulsed for 2 h with 1 µCi [3H] thymidine per well. The cells are washed twice with ice-cold 1X PBS. The plates are incubated at –20°C for 60 min to detach the cells. The cells are suspended in trichloroacetic acid (10%). Incorporated [3H] thymidine is separated from unincorporated by retention on nitrocellulose membrane filters. 6. Filters are washed three times with ice-cold 5% trichloroacetic acid and counted using liquid scintillation.
3.4.3. BrdU Incorporation 1. Stromal cells (6–7 × 103) are plated into chamber slides and quiescence is induced by culture for 72 h in serum-free medium. 2. Stimulated cells are pulsed for 30 min with BrdU-containing medium (10 µmol/L). 3. The cells are fixed and reacted with anti-BrdU antibodies according to the manufacturer’s protocol.
3.4.4. MTT Assay 1. Stimulated cells are cultured in 250 µL of serum-free medium containing mitogenic agents for 48 h. 2. At the end of culture the MTT reagent (25 µL) is added to each well. The cells are incubated at 37°C from 30 min to 4 h, depending on the number of cells (see Note 13). 3. Following the incubation period, the reaction is stopped using 750 µL of solubilization/stop solution. 4. The 24-well tray is placed in a humidified chamber at 37°C overnight. 5. The absorbance is determined using a spectrophotometer with wave-length settings of 570 nm, 700 nm, and 570–700 nm. 6. Treatment effects are compared by one-way analysis of variance with appropriate post hoc tests.
04_Rider_57_68_F
63
8/29/05, 11:16 AM
64
Rider
4. Notes 1. We have used heat-inactivated FBS from a variety of distributors. The cells respond well in all of the FBS samples we have tested. Once the cell lines are established, the cells grow rapidly and the medium should be changed as the color shifts from red to orange. Confluent cells should be split and seeded into new flasks or frozen and kept in liquid nitrogen. We do not maintain cells in continuous culture because the hormonal responsiveness is better if they are frozen down between experiments. The cells should not be allowed to overgrow. 2. Stromal cells have been stimulated to proliferate with both progesterone (25) and medroxy progesterone acetate (27). Because the endpoint of the assays (proliferation) occurs within 48 h after stimulation, there is no obvious difference in the proliferative response to these two hormones. 3. This is the most critical aspect of the isolation procedure. During the first few days of culture, there will be substantial cell death. As the cells begin to grow, it is tempting to split and seed them into culture flasks. However, it is important to maintain the cells for approx 10 d in the original 60-mm dishes or until they are confluent. If the cells are split too soon, they will die. The cells should be seeded into a T25 (25 cm2) flask when first split. If the density of the cells is too low upon transfer, they will die. 4. After the fourth passage, the stromal cell lines will stabilize and growth will be rapid. The purity of the cells can be assessed using antibodies that distinguish stromal from epithelial cells. We have not assessed purity prior to the fourth passage. The advantage of obtaining stromal cell lines over freshly isolated stromal cells is that the cell lines are more homogeneous. Regardless of the care taken in the isolation procedure, the initial cell isolates will be contaminated with nonstromal cells (endothelial cells, immune cells, glandular epithelial cells). During the first weeks after isolation, and for the first few passages, there is considerable cell death. The cells that remain express stromal cell markers exclusively (25). 5. Stromal cells adhere tightly to the surface of the culture flasks. It generally requires 5 min for the cells to detach but this should be monitored under the microscope. Cells left in trypsin too long will incur damage to their membranes and die. 6. It is important to split the cells before overgrowth occurs. In general, there will be between 3–5 × 106 cells per T75 flask. For routine passaging, we split the cells 1:2 and culture in 10 mL of normal growth medium per flask. 7. For freezing the cells, it is optimal to have between 2–5 × 106 total cells. The cells are suspended in 1 mL of freezing medium. When the cells are thawed, the frozen cells are split into two T75 flasks (0.5 mL each) in a total volume of 10 mL. 8. The basic procedure is to always freeze the cells slowly and thaw rapidly. Cells will maintain viability at –80°C for several days. However, they will not be viable stored at that temperature for long periods of time. Their viability (>90 %) is excellent when stored in liquid nitrogen. 9. The viability of the frozen cells is better when they are cultured initially in medium containing 20%, rather than 10%, FBS. However, this medium is not opti-
04_Rider_57_68_F
64
8/29/05, 11:16 AM
Stromal Cells In Vitro
10. 11.
12.
13.
65
mal for cell growth and maintenance. The medium containing 20% FBS is replaced with medium containing 10% FBS 24 h after thawing the cells. For each individual experiment a sufficient number of cells are propagated such that cells within a given experiment are from the same passage. The consistency in cell number in each well for a given experiment is critical for measuring significant differences among treatments. Plating density is another crucial factor. If the cells overgrow in the serum-free medium because the initial plating density is too high they will undergo apoptosis in response to mitogenic agents. If too few cells are plated, they will die in the serum-free medium. We find that once the optimal number of cells is determined, the mitogenic response is consistent, regardless of passage number. With the rat uterine stromal cell lines, the percentage of cells in G1 phase after 72 h of serum-starvation is approx 70%. When cells are serum starved for 48 h, only about 60% are at G1 phase. The greater the percentage of cells in G1 phase, at the start of the experiment, the greater the synchronous response to mitogenic agents. Cell number is critical for determining the amount of time samples are incubated with the MTT reagent. The MTT assay relies on the conversion of MTT into a formazan product by the activity of mitochondrial dehydrogenases (33). The relationship between cell number and absorbance should be determined in pilot studies. If the cells are incubated with MTT reagent for too long, the assay is not valid because linearity between cell number and absorbance is lost. Under the conditions described here for stromal cell proliferation assays we find the 30– 60 min incubation time is optimal.
Acknowledgments The author would like to thank Oliver Flieger, Marta Piva, Stephanie Jones, Bruce Kimler and William Justice for contributing to the methods used to isolate and characterize endocrine-dependent stromal cell proliferation. This research is supported by the National Science Foundation (NSF IBN-0091504). References 1. Clarke, C. L. and Sutherland, R. L. (1990) Progestin regulation of cellular proliferation. Endocr. Rev. 11, 266–301. 2. Lyndon, J. P., DeMayo, F. J., Funk, C. R., et al. (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9, 2266–2278. 3. Finn, C. A. and Martin, L. (1967) Patterns of cell division in the mouse uterus during early pregnancy. J. Endocrinol. 39, 593–597. 4. Quarmby, V. E. and Korach, K. S. (1984) The influence of 17β estradiol on patterns of cell division in the uterus. Endocrinology 114, 694–702. 5. Rider, V. and Psychoyos, A. (1994) Inhibition of progesterone receptor function results in loss of basic fibroblast growth factor expression and stromal cell proliferation during uterine remodeling in the pregnant rat. J. Endocrinol. 140, 239–249.
04_Rider_57_68_F
65
8/29/05, 11:16 AM
66
Rider
6. Galassi, L. (1968) Autoradiographic study of the decidual cell reaction in the rat. Dev. Biol. 17, 75–84. 7. Martin, L. and Finn, C. A. (1968) Hormonal regulation of cell division in epithelial and connective tissues of the mouse uterus. J. Endocrinol. 4, 1363–1371. 8. Cullingford, R. W. and Pollard, J. W. (1988) RU486 completely inhibits the action of progesterone on cell proliferation in the mouse uterus. J. Reprod. Fert. 83, 909–914. 9. Rider, V., Wang, M-Y., Finn, C. and Heap, R. B. (1986) Antifertility effect of passive immunization against progesterone is influenced by genotype. J. Endocrinol. 108, 117–121. 10. Finn, C. A. (1971) The biology of decidual cells. Adv. Reprod. Physiol. 5, 1–26. 11. Moulton, B. C. and Koenig, B. B. (1984) Uterine deoxyribonucleic acid synthesis during preimplantation in precursors of stromal cell differentiation during decidualization. Endocrinology 115, 1203–1307. 12. McConnel, K. N., Sillar, R. G., Young, B. D., and Green, B. (1982) Ploidy and progesterone-receptor distribution in flow sorted deciduomal nuclei. Mol. Cell. Endocrinol. 25, 99–104. 13. Krehbiel, R. H. (1937) Cytological studies of the decidual reaction in the rat during early pregnancy and in the production of deciduomata. Physiol. Zool. 10, 213–241. 14. Gu, Y. and Gibori, G. (1995) Isolation, culture and characterization of the two cell subpopulations forming the rat decidua: differential gene expression for activin, follistatin and decidual-related prolactin protein. Endocrinology 136, 2451–2458. 15. Musgrove, E. A. and Sutherland, R. L. (1994) Cell cycle control by steroid hormones. Cancer Biol. 5, 381–389. 16. Pardee, A. B. (1989) G1 events and regulation of cell proliferation. Science 246, 603–608. 17. Sherr, C. J. (1993) Mammalian G1 cyclins. Cell 73, 1059–1065. 18. Mani, S.K., Julian, J., Lampelo, S., and Glasser, S.R. (1992) Initiation and maintenance of in vitro decidualization are independent of hormonal sensitization in vivo. Biol. Reprod. 47, 785–799. 19. Fukamachi, H. and McLachlan, J. A. (1991) Proliferation and differentiation of mouse uterine epithelial cells in primary serum-free culture: estradiol-17 beta suppresses uterine epithelial proliferation cultured on a basement membrane-like substratum. In Vitro Cell Dev. Biol. 27A, 907–913. 20. Jacobs, L. L., Sehgal, P. B., Julian, J., and Carson D. D. (1992) Secretion and hormonal regulation of interleukin-6 production by mouse uterine stromal and polarized epithelial cells cultured in vitro. Endocrinology 131, 1037–1046. 21. Whitworth, C. M., Mulholland, J., Dunn, R. C., and Glasser S. R. (1994) Growth factor effects on endometrial epithelial cell differentiation and protein synthesis in vitro. Fertil. Steril. 61, 91–96.
04_Rider_57_68_F
66
8/29/05, 11:16 AM
Stromal Cells In Vitro
67
22. Rider, V., Piva, M., Cohen, M. E., and Carlone, D. L. (1995) Alternative splicing and differential targeting of fibroblast growth factor receptor 1 in the pregnant rat uterus. Endocrinology 136, 3137–3145. 23. Rider, V., Carlone, D. L., and Foster, R.T. (1997) Oestrogen and progesterone control basic fibroblast growth factor messenger RNA in the rat uterus. J. Endocrinol. 154, 75–84. 24. Rider, V., Carlone, D. L., Witrock, D., Cai, C., and Oliver, N. (1992) Uterine fibronectin content and localization are modulated during implantation. Dev. Dynamics 195, 1–14. 25. Piva, M., Flieger, O., and Rider, V. (1996) Growth factor control of cultured rat uterine stromal cell proliferation is progesterone dependent. Biol. Reprod. 55, 1333–1342. 26. Rider, V., Kimler, B. F., and Justice, W. M. (1998) Progesterone-growth factor interactions in uterine stromal cells. Biol. Reprod. 59, 464–469. 27. Jones, S. R., Kimler, B. F., Justice, W. M., and Rider, V. (2000) Transit of normal rat uterine stromal cells through G1 phase of the cell cycle requires progesteronegrowth factor interactions. Endocrinology 141, 637–648. 28. Rider, V. (2002) Progesterone and the control of uterine cell proliferation and differentiation. Front. Biosci. 7, d1545–d1555. 29. Rider, V., Thomson, E., and Seifert, C. (2003) Transit of rat uterine stromal cells through G1 phase of the cell cycle requires temporal and cell-specific hormonedependent changes on cell cycle regulators. Endocrinology 144, 5450–5458. 30. Irwin, J. C., Utian, W. H., and Eckert, R. L. (1991) Sex steroids and growth factors differentially regulate the growth and differentiation of cultured human endometrial stromal cells. Endocrinology 129, 2385–2392. 31. Cohen, H., Pageaux, H.-F., Melinand, C., Fayard, J.-M., and Laugier, C. (1993) Normal rat uterine stromal cells in continuous culture: characterization and progestin regulation of growth. Eur. J. Cell Biol. 6, 1116–1125. 32. Glasser, S. K., Lampelo, S., Munir, I. M., and Julian, J. (1987) Expression of desmin, laminin and fibronectin during in situ differentiation (decidualization) of rat uterine stromal cells. Differentiation 35, 463–474. 33. Mossman, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63. 34. Edwards, D. P., Kuhnel, B., Estes, P. A., and Nordeen, S.K. (1989) Human progesterone receptor binding to mouse mammary tumor virus deoxyribonucleic acid: dependence on hormone and nonreceptor nuclear factor(s). Mol. Endocrinol. 3, 381–391.
04_Rider_57_68_F
67
8/29/05, 11:16 AM
04_Rider_57_68_F
68
8/29/05, 11:16 AM
Rat Decidual Cell Cultures
69
5 Rat Decidual Cell Cultures Yan Gu and Geula Gibori Summary Pregnancy requires profound reorganization of the different tissues forming the uterus. Growth and differentiation of the uterine endometrial cells give rise to the decidual tissue, a transitory organ, which plays a key role in fetal survival. In this chapter, we describe a technique for the dispersion and the separation of the two different decidual cell subpopulations with high yield and viability. We also detail a cell culture method, which allows the maintenance of the function and life span of these highly purified decidual cells when cultured either separately or in a co-culture system. Key Words: Rat; pseudopregnancy; decidualization; enzymatic tissue dispersion; antimesometrial and mesometrial decidual cells; cell culture.
1. Introduction A marked response to implantation and pregnancy in rodents and primates is the growth and transformation of the uterine endometrial stromal cells known as decidualization. In humans, decidualization normally occurs with each menstrual cycle, and the formation of the decidual tissue depends primarily on levels of progesterone and estradiol in the circulation. However, in other species, including rodents, decidualization requires, in addition to adequate levels of these hormones, an exogenous trigger, which may be either the contact of the blastocyst with the endometrium or artificial stimulation at the luminal surface of uterine horns. Decidualization of the endometrial stroma, induced by either the blastocyst in pregnant rats or by artificial stimuli in pseudopregnant rats, gives rise to at least two major cell populations located in opposite sides of the uterus. The cells that decidualize in the antimesometrial region (opposite to where blood vessels gain access to the uterus) become more extensively differentiated than the cells in the mesometrial region, which undergo only limited differentiation. These two decidual cell populations differ not only in their morphology, but also by the genes they express and the putative roles they play From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
69
05_Gu_69_78_F
69
8/29/05, 11:16 AM
70
Gu and Gibori
in pregnancy. Moreover, the selective expression of each gene in a defined cell population is tightly regulated through a cell-to-cell communication between these two decidual cell subpopulations (1–3). The antimesometrial cells that decidualize first form what is known as antimesometrial decidua in pseudopregnant rats and decidua capsularis in pregnant animal. The mesometrial decidua forms the decidua basalis, which is the site of trophoblast invasion. Because the decidual tissue of either pregnant or pseudopregnant rats is similar in its formation, regression, and secretory capacity, the pseudopregnant rat has been extensively used as a model to study this organ in the absence of contaminating trophoblast cells. Because the antimesometrial decidua is formed primarily by giant-sized, polyploid, and closely packed cells whereas the mesometrial decidua is formed by much smaller, loosely packed cells, it is relatively easy to separate these two subpopulations by the differences in their size and density. In this chapter, we describe a method for obtaining highly purified subpopulations of rat antimesometrial and mesometrial decidual cells, to facilitate the study of their function, gene expression, and cell-to-cell communication. We illustrate in detail the procedures of the induction of decidualization in pseudopregnant rats, enzymatic dispersion of decidual tissues, separation of two decidual cells by elutriation, and decidual cell cultures, either in separated or in co-culture system. We also discuss some common problems one may encounter in this method and how they might be overcome. 2. Materials 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15.
Sprague-Dawley rats (Harlan Sprague-Dawley, Madison, WI). Hank’s balanced salt solution (HBSS) without Ca2+ and Mg2+. Fluorescein diacetate (FDA). Trypan blue. Nylon mesh. Oxygen tank. Peristaltic pump (Pharmacia, Peapack, NJ). In-line surge suppressor (Cole Parmer, Chicago, IL). Water-jacketed Cellstir (Wheaton Scientific, Millville, NJ). Elutriator (JE-6B rotor with a Sanderson chamber). 10- or 20-mL syringe. Bubble trap. Three-way connecters. Connecting rubber tubes. Cell Culture Inserts with Cyclopore membrane (Falcon Plasticware, BD Biosciences, Bedford, MA ). 16. Enzyme Dispersion Solution: RPMI-1640 without glutamine containing collagenase type I (50 U/mL), dispase (2.4 U/mL), and deoxyribonuclease (200 U/mL).
05_Gu_69_78_F
70
8/29/05, 11:16 AM
Rat Decidual Cell Cultures
71
17. HBSS Elutriation Buffer: HBSS with 25 mM HEPES and 0.1% bovine serum albumin (BSA), pH 7.4. 18. Decidual cell culture medium: RPMI-1640 supplemented with 10% fetal bovine serum (FBS), 2X antibiotic-antimycotic, 1X glutamine, 1X nonessential amino acids, 1X sodium pyruvate, and 0.5% D-glucose.
3. Methods 3.1. Animals
3.1.1. Pseudopregnancy The decidual tissue described here is collected from pseudopregnant female rats. 1. Rats are housed in a controlled environmental temperature (22°C) and kept under a photoperiod of 14 h of light and 10 h of darkness. Rat chow and water are provided ad libitum. 2. To generate rats pseudopregnant, young Sprague-Dawley female rats at proestrus are mated with vasectomized males. The day a vaginal plug is found is designated as day 1 of pseudopregnancy (see Note 1).
3.1.2. Induction of Decidualization Decidualization of uterine endometrium is artificially induced by a traumatic stimulus on day 5 of pseudopregnancy. 1. Under ether anesthesia, a dorsal insertion is made at the low abdominal of a pseudopregnant female rat and the uterine horns are exposed. 2. The antimesometrial luminal surface of both uterine horns is gently scratched by a hooked needle inserted at the end of uterine horn next to the ovary. 3. Decidualization can be checked by abdominal palpation a few days after the surgical procedure (see Notes 2 and 3).
3.2. Separation of Decidual Cells 1. After decidualization of the uterine endometrium, the decidual tissue can be collected at different stages of pseudopregnancy, ideally from pseudopregnant animals between days 8 and 14. 2. Rats are sacrificed by an overdose of ether; uterine horns are dissected out and washed with ice-cold phosphate-buffered saline (PBS). 3. The dissected uterine horns are cut open along the longitude axis. 4. Decidual tissue can be easily scrapped off from uterine horns and is kept moist and cold until enzymatic dispersion (see Note 4).
3.2.1. Enzymatic Dispersion 1. The dissected decidual tissue is washed with ice-cold PBS thoroughly to remove excess blood, pooled, quickly minced to 2- to 3-mm3 pieces on ice, and then incubated in Enzyme Dispersion Solution with mild stirring in a water-jacketed
05_Gu_69_78_F
71
8/29/05, 11:16 AM
72
Gu and Gibori
2. 3.
Cellstir at 35°C for 45–60 min. Generally, 3–4 g of pooled decidual tissues per 100- to 150-mL enzyme solution should give a complete dispersion. However, in case of an incomplete dispersion occurring after the first incubation, as a result of either the presence of excessive tissue or aged enzymes used or other reasons, the undissolved tissues are allowed to settle for 1 min. The supernatant containing dispersed cells is collected and kept at 4°C. Fresh enzyme solution is added again and the incubation is repeated as described above. Such dispersed decidual cells are filtered through a nylon mesh to remove any undissolved tissue debris and centrifuged at 200g for 5 min at 4°C. Cell pellets are gently resuspended in 10 mL HBSS Elutriation Buffer and are kept in room temperature until elutriation.
4. 5.
3.2.2. Separation of Different Decidual Cells by Elutriation Antimesometrial and mesometrial decidual cell subpopulations are separated by elutriation on the basis of cell size difference. The technique described here is modified from a similar one previously developed for separating luteal cells (5,6). The elutriation system includes a JE-6B elutriator, whose rotor is fitted with a Sanderson chamber, a peristaltic pump, an in-line surge suppressor, a 10- or 20-mL syringe, an air bubble trap, several three-way connecters, and connecting rubber tubes. 3.2.2.1. PREPARATION OF PERISTALTIC PUMP AND ELUTRIATOR 1. Prior to the elutriation, the HBSS elutriation buffer is gassed with 80% oxygen for 1 h at 22°C with a mild stirring. 2. Meanwhile, the Sanderson chamber is siliconized by adding 1 mL of dichlorodimethylsilane to the inside of the chamber and allowed to evaporate in a closed beaker for a few minutes. 3. After the chamber is attached into the elutriator’s rotor, the elutriator, peristaltic pump, air bubble trap, and all connecting tubes are washed with 1 L of distilled water, then 500 mL of 70% ethanol or peroxide as instructed by the manufacturer, and finally 500 mL of HBSS elutriation buffer. 4. The elutriation system should be calibrated after the system is sterilized. The settings of peristaltic pump are calibrated according to the required flow rate (mL/min) and proper speed of the elutriator’s rotor (rpm). An in-line surge suppressor is added into the system to prevent pulsations caused by the peristaltic pump and to trap any air bubbles in addition to the air bubble trap. Also, a pressure gauge is attached into the system between the peristaltic pump and elutriator for monitoring the pressure in the elutriator’s chamber.
3.2.2.2. ELUTRIATION PROCEDURES 1. While the elutriation system is running with the setting for the Fraction 1 collection, dispersed decidual cells suspended in 10 mL HBSS elutriation buffer are
05_Gu_69_78_F
72
8/29/05, 11:16 AM
Rat Decidual Cell Cultures
73
Table 1 Settings of Peristaltic Pump Flow Rate and Elutriator Speed Fractions of elutriation
Revolution of elutriator (rpm)
Pump flow rate (mL/min)
Volume (mL)
1
1600
11
200
2
1600
22
200
3 4
1600 1000
27 25
200 200
2. 3. 4. 5. 6. 7.
Resulting contents Red blood cells, other blood cells Mesometrial decidual cells Mixed decidual cells Antimesometrial decidual cells
slowly injected into the elutriator through the air bubble trap using a 10- or 20-mL syringe, as shown in the elutriator’s menu. Sometimes a blockage in the elutriation system can occur during the injection as a result of either a fast injection or overload of excessive cells in the system. The blockage can be seen as a sharp and constant increase of the chamber pressure and visible cell build-up in the chamber. The pressure and cell build-up in the elutriator’s chamber must be monitored constantly. If an appropriate amount of cells are slowly injected into the elutriation system, the chamber pressure showing in the pressure gage should not rise. Elutriation is carried out at the room temperature. Four 200-mL fractions are collected using different pump flow rate and revolution parameters as shown in Table 1. Each fraction is collected in four 50-mL conical centrifuge tubes and contains different cell subpopulations. As shown in Table 1, highly purified mesometrial decidual cells are collected in fraction 2, and antimesometrial decidual cells are primarily collected in fraction 4. Cells from the same fractions are pooled together, washed twice with HBSS elutriation buffer, and finally resuspended in the Decidual Cell Culture Medium. Cell viability is determined by the trypan blue dye exclusion (7) and/or fluorescein diacetate staining method (8), approx 80% in general (see Notes 5–7).
3.3. Decidual Cell Culture 3.3.1. Separated Decidual Cell Culture 1. Elutriated antimesometrial or mesometrial decidual cells can be separately plated at a density about 3 × 106 viable cells per 3 mL culture medium per 5 cm2 into culture plates or flasks (see Note 8). 2. Cells are incubated at 37°C under an atmosphere of 5% CO2-95% air for 16–18 h to allow attachment. 3. The cells are washed at least three times with FBS free culture medium prior to appropriate treatments or experiments (9,10).
05_Gu_69_78_F
73
8/29/05, 11:16 AM
74
Gu and Gibori
Fig. 1 (see companion CD for color version). Elutriated and cultured decidual cells. Decidual tissues were obtained from day-9 pseudopregnant rats. Antimesometrial and mesometrial decidual cells were enzymatically dispersed, separated by elutriation, and stained with fluorescein diacetate in a suspension (upper panel). Upper left: small mesometrial decidual cells (~10–15 µm in diameter). Upper right: large antimesometrial decidual cells (~30 µm or greater, depending on their differentiation stage). Elutriated decidual cells were then seeded for 24 h and their distinct morphology shown in the lower panel. Lower left: mesometrial cells are small and mostly binucleated, contain less lipid droplets, and remain undifferentiated, with a fibroblast-like appearance in culture. Lower right: antimesometrial decidual cells are large and polynucleated, with a syncytial-like appearance, and are rich in lipid droplets (red or dark black dots).
4. At this point, microscopic observation should be performed to check the cell attachment. Both antimesometrial and mesometrial decidual cells should have completed the attachment and spread after 16–18 h incubation. After 24 h, the distinct morphological appearance of each decidual cell type should be clearly visible in the culture, as shown in Fig. 1.
3.3.2. Decidual Cell Co-Culture System 1. If a co-culture is desired, then one cell type, e.g., antimesometrial decidual cells (3 × 10 6 viable cells), is seeded onto individual cell culture inserts (an
05_Gu_69_78_F
74
8/29/05, 11:16 AM
Rat Decidual Cell Cultures
75
Fig. 2. The co-culture system for antimesometrial and mesometrial decidual cells. Upper panel: antimesometrial cells are seeded onto a cell culture insert and mesometrial cells are seeded into a well of six-well culture plate. Lower panel: a reversed co-culture arrangement of panel A.
2.
3.
4. 5. 6. 7.
approx 5-cm2 area) and another type, e.g., mesometrial decidual cells (3 × 106 viable cells), is plated into wells of an appropriate culture plate (see Note 9). The inserts are then placed into the wells of the plate as shown in Fig. 2, and the culture medium (~2.5 mL) is added to the wells to reach and maintain a level equal to that in the insert. The arrangement of cell types in this co-culture and the viable cell density in each portion of the co-culture should be determined according to the design of each experiment. Cells should be incubated at 37°C under an atmosphere of 5% CO2-95% air for 16–18 h to allow attachment. The cells are washed at least three times with FBS-free culture medium prior to appropriate treatments or experiments (9). Microscopic observation should be performed at this point to check the cell attachment for those cells seeded in the wells. At the end of a culture, decidual cells can be easily scraped from both the inserts and wells for extraction of proteins or nucleic acids. If it is desired, the cells can also be dissolved enzymatically or chemically (see Note 10).
4. Notes 1. Pseudopregnancy can be also induced by physical stimulation of the vagina of rats on estrus using a glass rod. In ovariectomized female rodents, pseudopregnancy can also be induced by a sequential progesterone and estradiol treatment. However, the decidualization reaction in such induced pseudopregnant females generally is not as strong as that seen in females mated with infertile males. 2. The decidualization can also be induced by intrauterine injection of oil. However, this method generally does not induce a strong decidualization reaction in uterine endometrium as seen by the surgical scratching procedure. 3. There is a narrow window for the induction of decidualization. On day 5 of pseudopregnancy and/or pregnancy, the uterine endometrium of the female rat becomes very sensitive to a physical stimulation. Therefore, the surgical proce-
05_Gu_69_78_F
75
8/29/05, 11:16 AM
76
4.
5.
6.
7.
05_Gu_69_78_F
Gu and Gibori dure should be performed on day 5 of pseudopregnancy. If the induction is performed before or after this window, the degree of decidualization reaction will be severely reduced. Thus, the accurate day count of pseudopregnancy is a critical factor. In case a unilateral decidualized uterine horn is desired, one must treat the other uterine horn with extreme carefulness and gentleness because a rough touch sometimes can result in a certain degree of decidualization. Decidual tissue is a transitory organ with constant dynamic changes in its anatomical appearance and physiological function. Decidual tissue sometimes can be collected as early as on day 7 of pseudopregnancy. The decidual reaction reaches the peak on days 9–10 of the pseudopregnancy. Then the degeneration of decidual tissue starts and becomes apparent on day 13. On day 15 or after, most degenerated decidual tissue is liquefied. In general, this elutriation cell separation method gives a highly purified mesometrial decidual cell subpopulation because the basis of separation of two cell types is dependent on the physical size of cells. On the other hand, sometimes mesometrial decidual cells form clumps, either as a result of the incomplete enzymatic dispersion or adhesion, which may have a comparable size as an antimesometrial decidual cell. Therefore antimesometrial decidual cell population is relatively easier to get contaminated by those mesometrial cell clumps. Apparently, complete enzymatic dispersion is critical for obtaining a pure antimesometrial cell population. An alternative dissecting method (see Note 7) can also reduce such cross-contamination if time permits. As mentioned under Subheading 3.2.2.2., if the appropriate amounts of dispersed decidual cells are slowly injected into the elutriation system, the chamber pressure should not increase. Another way to monitor the injection speed and/or amount of injected cells is to keep watching the cell build-up in the chamber through the observation window in the elutriator as described in the menu. Sometimes, either a fast injection or, especially, the injection of excessive decidual cells can cause a cell-build-up inside the chamber and consequently results in a blockage in the chamber, indicated by the sharply increased pressure and visible cell build-up, i.e., the cells occupied more than half of the chamber. If the blockage takes place, the elutriator should be stopped and quickly flushed with elutriation buffer. After collecting the elutriation buffer during the flushing, the cells can be pelleted by centrifugation at room temperature, re-suspended in 10– 20 mL HBSS buffer, and re-injected into the elutriation system with a slower injection speed and/or the proper amount cells as described under Subheading 3.2.2.2. To reduce the cross-contamination of the two different types of decidual cells, especially reduce the contamination of antimesometrial cells from mesometrial cells (clumps), the antimesometrial and mesometrial decidual tissues can be first dissected out from each other by cutting uterine horns at both sides along the middle lines between the center of antimesometrial and mesometrial decidua, as described previously (11). Then, process the tissue separately by following the procedures described under Subheadings 3.2.1. and 3.2.2.
76
8/29/05, 11:16 AM
Rat Decidual Cell Cultures
77
8. The number of yielded cells per gram of decidual tissue varies, depending on the pseudopregnancy stage of an animal. In general, at the peak of decidual reaction (day 9 of pseudopregnancy), one gram of decidual tissue can yield approx 3 × 106 antimesometrial and 6 × 106 mesometrial decidual cells. 9. The cell plating density should be considered according to the experimental design, especially when a co-culture system is employed. As shown in Fig. 1, the size of an antimesometrial cell is much larger than that of a mesometrial cell, but on the other hand, the number of antimesometrial cells yield per gram of decidual tissue is much fewer than mesometrial cells. Therefore, one must decide whether a same plating density for both cell types should be used or it is necessary. It is also worthy to note that if both cell subpopulations are plated equally with a high density in culture, it may result in a confluence stage for antimesometrial cells even just after the attachment period, but not for mesometrial cells. 10. Cultured decidual cells also show dynamic changes in their function as seen in decidual tissue in vivo. However, it is not clear yet whether these functional changes observed in vitro completely reflect and/or parallel that in vivo. For example, the expression of prolactin receptor mRNA in decidual mesometrial cells from day-9 pseudopregnant rats is abundant during the first 24-h culture. It starts to decline at 48 h, and completely disappears after 72 h in cultured mesometrial cells.
References 1. O’Shea, J. D., Kleinfeld, R. G., and Morrow, H. A. (1983) Ultrastructure of decidualization in the pseudopregnant rat. Am. J. Anat. 166, 271–298. 2. Gibori, G. (1994) The decidual hormones and their role in pregnancy recognition, in Endocrinology of Embryo-Endometrium Interactions (Glasser, S.R., Mulholland, J., and Psychoyos, A., eds.). Plenum, New York: pp.217–221. 3. Gu, Y. and Gibori, G. (1999) Deciduoma, in Encyclopedia of Reproduction (Knobil, E. and Neill, J.D., eds). Academic, San Diego: pp. 836–842. 4. Fitz, T. A., Mayan, M. H., Sawyer, H. R., and Niswender, G. D. (1982) Characterization of two steroidogenic cell types in the ovine corpus luteum. Biol. Reprod. 27, 703–711. 5. Nelson, S. E., McLean, M. P., Jayatilak, P. G., and Gibori, G. (1992) Isolation, characterization, and culture of cell subpopulation forming the pregnant rat corpus luteum. Endocrinology 130, 954–966. 6. Nelson, S. E. and Gibori, G. (1993) Dispersion, separation and culture of different cell population of the rat corpus luteum, in Methods in Reproduction Toxicology (Chapin, R. E. and Heidel, J., eds.). Academic, New York: pp 340–359. 7. Tennant, J. R. (1964) Evaluation of the trypan blue technique for determination of cell viability. Transplantation 2, 685–694. 8. Rotman, B. and Papermaster, B. W. (1966) Membrane properties of living mammalian cells as studies by enzymatic hydrolysis of flourogenic esters. Proc. Natl. Acad. Sci. USA 55, 134–141.
05_Gu_69_78_F
77
8/29/05, 11:16 AM
78
Gu and Gibori
9. Gu, Y. and Gibori, G. (1995) Isolation, culture, and characterization of the two cell subpopulations forming the rat decidua: differential gene expression for activin, follistatin, and decidual prolactin-related protein. Endocrinology 136, 2451–2458. 10. Gu, Y., Soares, M. J., Srivastava, R. K., and Gibori, G. (1994) Expression of decidual prolactin-related protein in the rat decidua. Endocrinology 135, 1422– 1427. 11. Martel, D., Monier, M. N., Psychoyos, A., and De Feo, V. J. (1984) Estrogen and progesterone receptors in the endometrium, myometrium and metrial gland of the rat during the decidualization process. Endocrinology 114, 1627–1634.
05_Gu_69_78_F
78
8/29/05, 11:16 AM
Immortalization of Human Endometrial Cells
79
6 The Immortalization of Human Endometrial Cells Graciela Krikun, Gil Mor, and Charles Lockwood Summary The loss of replicative potential with each cell division has been attributed to the progressive shortening of telomeres. This “mitotic clock” occurs because most normal human cells are telomerase-negative. Telomerase is a multicomponent enzyme that prevents loss of telomeric DNA associated with normal cell division. Transfection of cells with vectors expressing the catalytic subunit of human telomerase (hTERT) is often sufficient for immortalization. In this article, we will address this approach in the establishment of immortalized endometrial cells and its value in facilitating in vitro studies. Key Words: Uterus; endometrium; endometrial cells; stromal cells; glandular epithelial cells; endothelial cells; immortalization; telomerase.
1. Introduction Scarcity of human tissue and the inability to passage and maintain cells in culture for long periods of time makes immortalization of primary cells an ideal research tool. Unfortunately, the process of immortalization often results in abnormal karyotypes and aberrant functional characteristics. To avoid the latter drawback, several laboratories, including our own, have introduced telomerase into cultured primary cells. Telomerase is a multicomponent enzyme that comprises a template RNA plus an essential catalytic protein subunit (human telomerase [hTERT]) (1). This method results in immortalization of many target cells by preventing the normal shortening of telomeres observed in adult somatic cells during mitosis. Telomeres are specialized DNA/ protein structures, which are located at the ends of eukaryotic chromosomes. They contain tandemly repeated DNA sequences, which have a role in maintaining the chromosomes during cell division by serving as the templates for telomerase (2).
From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
79
06_Krikun_79_84_F
79
8/29/05, 11:17 AM
80
Krikun, Mor, and Lockwood
The function of telomerase is to add TTAGGG repeats to telomeres by reverse-transcribing the RNA template, and thus compensating for the loss of telomeric DNA associated with normal cell division (3). Indeed, the average length of telomeres is shortened by 10 to 200 basepairs (bp) per division, resulting in senescence and, ultimately, cell death (4). Whereas most normal adult human cells are telomerase-negative (5), germ cells and immortal cells express telomerase and maintain telomere length through countless cell divisions (6). Although introduction of exogenous hTERT expression is sufficient for immortalization or life span elongation of certain cells, other cells need additional steps to render them immortalized. Indeed, the successful immortalization of endometrial glandular epithelial cells required not only the introduction of hTERT, but also the inactivation of the Rb/p16 and the p53 pathway (7). By contrast, myometrial cells were successfully immortalized by hTERT alone (1). Both the glandular epithelial and myometrial cells were karyotypically normal, retained their phenotype and showed no indication of cancer-associated changes (1,7). Recently, our laboratory demonstrated the ability to immortalize human endometrial stromal cells by transfection with hTERT (8). These cells were karyotypically, morphologically, and phenotypically similar to the primary parent cells and were responsive to estradiol and progestin. In this review, we describe the procedure undertaken for human endometrial stromal cell (HESC) immortalization. 2. Materials 1. 2. 3. 4. 5. 6. 7.
8. 9. 10. 11. 12.
Antibiotic and antimycotic (ABAM; Gibco , Grand Island, NY). ITS+(tm) Premix (Becton-Dickinson/Collaborative Research, Bedford, MA). Glutamine (Gibco). Hank’s balanced salt solution (HBSS) (Gibco). Stripped calf serum (SCS) (Gemini, Woodland, CA). Type I collagenase (Worthington, Lakewood, NJ). Basal medium (BM): Dulbecco’s modified Eagle’s medium (DMEM) + Nutrient Mixture F-12 HAM (Sigma, St. Louis, MO) supplemented with NaHCO3 (1.2 g/L), 10 mL ABAM/L, 10 mL/L ITS+, 100 mL SCS, and 50 mL/L glutamine adjusted to pH 7.3 and filtered through a 0.2-µm sieve (see Note 1). 45 mesh stainless-steel sieve (Newark Wire-Cloth Co.). Human hTERT-expressing cell line: pA317 hTERT plus puromycin resistance (Geron Corp. Menlo Park, CA). Medium for initial growth of pA317 cell line: DMEM (high-glucose with L-glutamine) +10% fetal bovine serum + ABAM. Polybrene (Sequabrene, Sigma). TRAPeze enzyme-linked immunosorbent assay (ELISA) Detection Kit (Chemicon International, Inc., Temecula, CA)
06_Krikun_79_84_F
80
8/29/05, 11:17 AM
Immortalization of Human Endometrial Cells
81
3. Methods 3.1. Human Endometrial Stromal Cell Isolation and Cell Culture After obtaining written informed consent and institutional approval, early secretory endometria from reproductive age women are obtained from hysterectomies for benign conditions (e.g., myomas). The endometrium is collected and transported in BM to a sterile laminar flow hood and processed as follows: 1. The tissue is washed with HBSS. After most of the blood has been removed, the tissue is finely minced in 10 mL HBSS and spun for 10 min at 4°C at 500g. 2. Approximately 300 mg of the wet pellet is resuspended in 10 mL of Hams F10 + 10% SCS containing 0.25% type I collagenase for 90 min in a vigorously shaking water bath at 37°C (see Note 2). 3. In a sterile laminar hood, the digestate is filtered through a 45 mesh stainless steel sieve to remove the glands. The supernatant is spun as described above and the pellet is resuspended in DMEM + 10% SCS. 4. Cells are seeded in polystyrene plastic cell culture flasks. After 40 min, the medium is changed to remove any floating material. 5. The HESCs are grown to confluence in BM+ at 37°C in a standard humidified 95% air/5% CO2 incubator.
3.2. Immortalization Protocol Immortalization of primary HESCs derived from the mid-secretory phase is achieved by transfection of telomerase using a retroviral system. This system employs the pA317 cell line expressing hTERT and puromycin resistance.
3.2.1. Preparation of Supernatants for Transfection 1. pA317 hTERT are seeded in DMEM and grown to log phase but not allowed to reach 90% confluence. At this point, the medium is changed with a minimal amount of fresh medium (6 mL for each T75 flask) overnight (see Note 3). 2. The medium is harvested the following morning and replaced with a minimal amount of fresh medium, which is collected at the end of the day. 3. The collected media is filtered through a 0.45-µm filter to remove pA317 cells or any cellular debris and add Polybrene (4 µg/mL). This is the medium, which will be used to transfect the target cells.
3.2.2. Transfection of Target Cells (HESCs) With the Viral Supernatant 1. Check that the target cells (HESCs) are in good log phase growth (they must be dividing at the time of transfection). 2. Prior to the day of the transfection, add fresh BM to the HESCs. 3. On the day of transfection, remove the medium and replace it with the harvested viral supernatant (above) containing Polybrene. 4. Place in a standard cell culture incubator at 37°C for eight h. 5. Remove medium, repeat transfection procedure and leave in incubator overnight.
06_Krikun_79_84_F
81
8/29/05, 11:17 AM
82
Krikun, Mor, and Lockwood
6. The next day, discard the transfection medium and add BM. 7. After a 48 h incubation, trypsinize the cells and culture them under selection media (BM plus puromycin [800 ng/mL]) (see Note 4).
3.3. Telomerase Detection Telomerase activity is assayed using the TRAPeze ELISA Detection Kit per manufacturer’s instructions. 1. HESCs are lysed and incubated with a biotinylated substrate oligonucleotide (included in the kit), which allows the hTERT subunit to add telomeric repeats for 30 min. 2. The products are amplified by polymerase chain reaction (PCR) with a biotinylated primer and DNP-labeled dCTP (included in the kit). 3. The resulting tagged PCR products are immobilized onto streptavidin-coated microtiter plates via biotin–streptavidin interactions, and then detected by antiDNP antibody conjugated to horseradish peroxidase. 4. The amount of product is determined following incubation with 3,3',5,5'tetramethylbenzidine by determining absorbance at 450 and 595 nm. 5. Telomerase activity is determined as the difference between the two absorbance readings (Abs450–Abs595). 6. Positive and negative controls are provided in the kit.
3.4. Freezing the Immortalized Cells 1. Cells are washed twice with phosphate-buffered saline (PBS), trypsinized, (for 2 mL of trypsinized cells, 5 mL of complete medium is added to neutralize). 2. The dispersed cells are collected in a conical tube and an additional 5 mL of media are added to rinse the flask. 3. After centrifuging (800g, 5 min, 4°C), the cell pellet is collected, resuspended in BM + puromycin containing 10% dimethyl sulfoxide (DMSO) (very slowly), aliquoted and frozen (–20°C for 4–5 h, then –80°C overnight, then in liquid N2).
3.5. Thawing and Growing the Immortalized Cells 1. Cells are first thawed on ice. 2. When the cells are thawed they are added to a T75 culture flask and approx 12 mL of media + puromycin added. 3. After 4–5 h the medium is changed. 4. When confluent, the experimental conditions are carried out without puromycin in the medium of choice.
4. Notes 1. To avoid nonspecific estrogenic effects, DMEM must not contain phenol red. 2. During the 90 min collagenase digestion, the tubes are vortexed vigorously to break up the clumped fragments.
06_Krikun_79_84_F
82
8/29/05, 11:17 AM
Immortalization of Human Endometrial Cells
83
3. Passage 1:10 when the flask reaches 80–90% confluence using Trypsin-ethylenediamine tetraacetic acid (EDTA); do not allow the cells to become over confluent. 4. Typical doses of puromycin used for selection are between 0.5 and 2.5 µg/mL. Because each cell has a different sensitivity to puromycin, testing the sensitivity prior to the transfection process is recommended. For this, treat the cells with increasing concentrations of puromycin for 24 or 48 h and determine cell viability by trypan blue, MTT, or any other cell viability assay.
Acknowledgments We would like to acknowledge Mizanur Rahman, MD, Rebeca Caze, MS, Ayesha Alvero, MD., Seth Guller, PhD, Frederick Schatz, PhD, Eva Sapi, PhD, Paula Aldo, and Mazin Qumsiyeh, MD for their input in this project. This work was supported in part by grants from the National Institutes of Health: RO1 HD33937-06 (CJL) and RO1 HL70004-01A1 (CJL). References 1. Condon, J., Yin, S., Mayhew, B., et al. (2002) Telomerase immortalization of human myometrial cells. Biol. Reprod. 7, 506–514. 2. Emrich, T., Chang, S.-Y., Karl, G., Panzinger, B., and Santini, C. (2002) Quantitative detection of telomerase components by real-time, online RT-PCR analysis with the LightCycler, in Methods in Molecular Biology, Vol. 191: Telomeres and Telomerases: Methods and Protocols (Double, J. A. and Thompson, M. J., eds.). Humana, Totowa, NJ: pp. 99–108. 3. Toouli, C. D., Huschtscha, L. I., Neumann, A. A., et al. (2002) Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit. Oncogene 21, 128–139. 4. Chiu, C. P. and Harley, C. B. (1997) Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc. Soc. Exp. Biol. Med. 214, 99–106. 5. Weinrich, S. L., Pruzan, R., Ma, L., et al. (1997). Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet. 17, 498–502 6. Bibby, M. C. (2002) Introduction to telomeres and telomerase, in Methods in Molecular Biology, Vol. 191: Telomeres and Telomerases: Methods and Protocols (Double, J. A. and Thompson, M. J., eds.). Humana, Totowa, NJ: pp. 1–12. 7. Kyo, S., Nakamura, M., Kiyono, T., et al. (2003) Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am. J. Pathol. 163, 2259–2269. 8. Krikun, G., Mor, G., Alvero, A., et al.. (2004) A novel immortalized human endometrial stromal cell line with normal progestational response. Endocrinology 145, 2291–2296.
06_Krikun_79_84_F
83
8/29/05, 11:17 AM
06_Krikun_79_84_F
84
8/29/05, 11:17 AM
Sheep UGKO Model
85
7 Sheep Uterine Gland Knockout (UGKO) Model Thomas E. Spencer and C. Allison Gray Summary Endometrial gland development is a postnatal event in the ovine uterus that can be inhibited epigenetically by chronic exposure of ewe lambs to a synthetic progestin after birth. The uterus of neonatally progestinized ewes lack endometrial glands and display a uterine gland knockout (UGKO) phenotype. Progestin ablation of endometrial gland development is specific, because it does not affect development of extra-uterine reproductive tract structures or the hypothalamic–pituitary–ovarian axis. The UGKO ewe is a useful model for study of uterine development and the role of endometrial glands in uterine function during the estrous cycle and pregnancy. UGKO ewes exhibit altered estrous cycles due to the inability of the uterus to produce luteolytic pulses of prostaglandin F2α. UGKO ewes are infertile, and blastocysts hatch normally but fail to survive or elongate during early pregnancy. This pregnancy defect is primarily due to the absence of endometrial glands and their secretions rather than alterations in expression of either anti-adhesive or adhesive molecules on the endometrial epithelium. Genomics and proteomics are being used to identify specific components of histotroph that are absent or diminished in the UGKO ewe and will serve as markers of endometrial function and uterine receptivity. Key Words: Sheep; uterus; endometrium; gland; histotroph; epigenetic; steroid; progesterone; neonate; pregnancy; implantation; conceptus; defect; embryo loss.
1. Introduction The bicornuate ovine uterus consists of two uterine horns connected by a short uterine body. The uterine wall can be divided functionally into the endometrium and myometrium. The adult endometrium of ruminants (sheep, cattle, and goats) consists of two epithelial cell types (luminal epithelium [LE] and glandular epithelium [GE]), stratified stromal compartments that include a densely organized adluminal zone of fibroblastic cells (stratum compactum) extending into a more loosely organized zone in the deeper or basal endometrium (stratum spongiosum), blood vessels, and immune cells. Grossly, the adult ovine endometrium is divided into raised, aglandular From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
85
07_Spencer_85_94_F
85
8/29/05, 11:17 AM
86
Spencer and Gray
caruncular and intensely glandular intercaruncular areas (1). The caruncular areas have LE and compact stroma, and are the sites of implantation and placentation (2). Synepitheliochorial placentation in sheep involves the fusion of placental cotyledons with endometrial caruncles to form placentomes, which support fetal–maternal gas exchange and placental nutrient transport. Intercaruncular endometrial areas contain large numbers of uterine glands that synthesize and secrete a complex array of proteins and related substances, termed histotroph, into the uterine lumen (3). Epithelial products in this category include a wide variety of enzymes, growth factors, cytokines, lymphokines, hormones, transport proteins, and other substances (4,5). Uterine epithelial secretions are thought to influence conceptus survival and development, onset of pregnancy recognition signals, and growth of both the placenta and fetus in humans, other primates, domesticated animals, and laboratory animals (3,4,6–12). Endometrial glands are characteristic features of all mammalian uteri. Endometrial gland development (adenogenesis) in domesticated and laboratory animals occurs rapidly after birth (9,13). Withdrawal of fetal tissues from a progesterone-dominated prenatal environment at birth was proposed to be an endocrine cue for adenogenesis in the neonatal ovine uterus (14). Subsequently, Frank F. Bartol and his colleagues at Auburn University, Alabama (15) demonstrated that exposure of ewe lambs to the synthetic progestin from birth to postnatal day (PND) 13 inhibited endometrial adenogenesis. Removal of the progestin block to adenogenesis on PND 13 permitted glands to develop by PND 26. However, these glands were not well developed and were histologically abnormal. This original observation served as the foundation for the hypothesis that prolonged exposure of neonatal ewes to a progestin during the entire critical period of endometrial adenogenesis could be used as a tool to permanently inhibit endometrial gland differentiation, thereby producing a uterine gland knockout (UGKO) phenotype in the adult (9,13). Indeed, chronic exposure of neonatal lambs to progestins for 8, 16, or 32 wk from birth was shown to prevent uterine adenogenesis and induce a unique, stable adult endometrial phenotype characterized by the histological absence of uterine glands (13,16,17). Interestingly, exposure of neonatal ewes to a progestin does not affect development or function of the brain, hypothalamic– pituitary–ovarian axis, ovary, or Müllerian duct-derived reproductive tract tissues, including the oviduct, cervix or vagina (18,19). However, the uteri of UGKO ewes weighs less and has shorter horns (18). As illustrated in Fig. 1, the UGKO uterine wall is essentially devoid of endometrial glands and lacks stromal delineation characteristic of intercaruncular endometrium in normal ewes (18). Consistent with a reduction in uterine size and weight, endometrial width, area and luminal epithelial length are decreased in the UGKO uterus,
07_Spencer_85_94_F
86
8/29/05, 11:17 AM
Sheep UGKO Model
87
Fig. 1. Histological comparison of day-14 pregnant uteri from control and uterine gland knockout (UGKO) ewes. The uteri were fixed in paraformaldehyde, sectioned (5 µm), and stained with hematoxylin and eosin. (A) Control uterus that contained two normal day 14 conceptuses. (B) UGKO uterus that failed to support conceptus development. (C) UGKO uterus that contained only a single tubular conceptus. (D) UGKO uterus that contained a single fragile filamentous conceptus. The UGKO phenotype was produced by exposing neonatal ewe lambs to a 19-norprogestin from birth for 8 wk. Legend: L, lumenal epithelium; G, glandular epithelium; S, stroma; M, myometrium (original magnification ×166).
whereas myometrial width and morphology are not different from normal ewes (18). The specific targeting of only the uterine endometrium by the progestin exposure makes it an attractive model with which to study mechanisms regulating endometrial organization and gland morphogenesis, also termed adenogenesis, in the neonate, as well as the functional role of endometrial glands in the adult. Recent studies of the UGKO ewe model revealed an essential role for endometrial glands and their secretions in normal estrous cycles and in periimplantation conceptus survival and growth. Mature UGKO ewes are unable to exhibit normal estrous cycles as a result of insufficient production of
07_Spencer_85_94_F
87
8/29/05, 11:17 AM
88
Spencer and Gray
luteolytic pulses of prostaglandin F2α (PGF2α) by the uterus (17). Luteolytic pulses of PGF2α are produced by oxytocin, from the posterior pituitary and/or corpus luteum, binding to oxytocin receptors expressed by the endometrial luminal and glandular epithelia (20). Oxytocin receptor gene expression in the ovine uterus is predominantly controlled by ovarian steroid hormones, estrogen and progesterone, and their receptors in the endometrial epithelium (20). No differences in expression of receptors for estrogen, progesterone, or oxytocin were observed in the UGKO uterus (17). The inability of the UGKO uterus to produce luteolytic pulses of PGF2α was hypothesized to result from the lack of superficial or ductal GE, coupled with an overall reduction in LE surface area, that reduced the numbers of oxytocin receptors that could respond to oxytocin (17,20). Nonetheless, exogenous PGF2α induces luteolysis in UGKO ewes, and they display normal estrus mating behavior (17). Adult UGKO ewes are unable to establish pregnancy, despite repeated matings to rams of proven fertility (17,18,21,22). Transfer of normal, hatched blastocysts into the uteri of timed recipient UGKO ewes failed to ameliorate this defect and to establish pregnancy (21). Morphologically normal blastocysts are present in uterine flushes of bred UGKO ewes on day 6 or 9 post mating, but not on day 14 (21,22). On day 14, uterine flushes of mated UGKO ewes contain either no conceptus or a severely growth-retarded tubular conceptus (21,22). The peri-implantation period of pregnancy in sheep is marked by rapid elongation of the conceptus from a tubular to filamentous form between days 11 and 16 and production of interferon (IFN)-τ, the signal for maternal recognition of pregnancy (20). Although the growth-retarded conceptuses recovered from mated UGKO ewes produced little or no IFN-τ, the endometrium of UGKO ewes responded appropriately to intrauterine infusions of recombinant ovine IFN-τ with increased expression of IFN-τ-stimulated genes (22). These results supported the hypothesis that the inability of the UGKO uterus to support peri-implantation conceptus survival and growth was primarily due to an absence of histotroph derived from endometrial gland secretions. Implantation in ruminants is a highly coordinated process that involves apposition, adhesion, and attachment of the conceptus trophectoderm to luminal epithelium (23). In sheep, the blastocyst enters the uterus on day 4 and hatches from the zona pellucida on day 7. Apposition of conceptus trophectoderm and luminal epithelium is initiated between days 10 and 14, followed by adhesion on day 15 and attachment within days 16 to 18. Elongation of spherical blastocysts to a filamentous form is thought to require transient attachment and adhesion of conceptus trophectoderm to luminal epithelium. Initially, the nonadhesive property of the luminal epithelium appears to be partially due to apical expression of mucins, such as mucin glycoprotein one (Muc-1), that
07_Spencer_85_94_F
88
8/29/05, 11:17 AM
Sheep UGKO Model
89
sterically impair interactions between trophectoderm and adhesive glycoproteins, such as integrins, as a result of their extensive glycosylation and extended extracellular structure (24). Immunoreactive Muc-1 expression by luminal epithelium decreases between days 9 and 17 of early pregnancy in normal (24) and UGKO (22) ewes. Extracellular matrix and integrins are thought to be responsible for trophectoderm attachment and adhesion to LE (25,26). During the peri-implantation period of pregnancy in ewes, integrin subunits αv, α4, α5, β1, β3, and β5 are constitutively expressed on both conceptus trophectoderm and the apical surface of luminal epithelium (24). Integrin expression on endometrial luminal epithelium of UGKO ewes is not different from normal ewes (22). Furthermore, expression of receptors for estrogen (estrogen receptor [ER]α), progesterone (progesterone receptor [PR]), and oxytocin (oxytocin receptor [OTR]), as well as several LE-specific genes, does not differ between the endometrium of UGKO and that of normal ewes (17,22). Thus, by these measures, the endometrial LE does not appear to be defective in UGKO ewes. Uterine flushes of UGKO ewes were analyzed for the presence of osteopontin (OPN) and glycosylated cell adhesion molecule one (GlyCAM-1) proteins, which are expressed by the endometrial glands of the ovine uterus and are suggested to play a role in regulation of conceptus implantation (27,28). Uterine flushes of day-14 bred UGKO ewes contained lower amounts of GlyCAM-1 and no OPN compared with day-14 pregnant ewes (22). These results were expected, because GlyCAM-1 is expressed by both the endometrial LE and GE (28), whereas OPN is expressed solely by the endometrial glands (29). A general marker of endometrial gland differentiation in the developing postnatal and adult uterus is the prolactin receptor (30–33), because it is exclusively expressed in the endometrial GE, but not in the LE or superficial ductal GE. During pregnancy, the endometrial glands undergo a program of hyperplasia and hypertrophy that is accompanied by the onset of OPN and uterine milk protein (UTMP; also named ovine uterine serpin or OvUS) gene expression (29,30,34). The expression of the UTMP gene disappears in the endometrial glands immediately after parturition, suggesting that parturition terminates the terminal differentiation program of pregnancy (20,35). Genomics and proteomics are being used to identify specific components of histotroph that are absent or diminished in the UGKO ewe, thereby causing the peri-implantation defect in conceptus survival and growth (16,22). A better understanding of the components of histotroph may lead to the development of better maturation medium for in vitro production of embryos. In addition, these important histotroph components will serve as useful markers of endometrial function and fertility in both domestic animals and humans. Therefore, the UGKO ewe is an attractive model with which to study mechanisms regulating endometrial organization and adenogenesis in the neonate, as well as the functional role of endometrial glands in adult ewes.
07_Spencer_85_94_F
89
8/29/05, 11:17 AM
90
Spencer and Gray
2. Materials 2.1. Animals Newborn female sheep (Ovis aries).
2.2. Hormone Treatments 1. Synchromate B® norgestomet implant that releases approx 6 mg of norgestomet (Nor; 17α-acetoxy-11β-methyl-19-norpreg-4-ene-3,20 dione), a potent synthetic 19-norprogestin, over a 14-d period (Rhone Merieux, Athens, GA). This product may not be currently available. 2. Medroxyprogesterone acetate (MPA) biodegradable pellets that release approx 200 mg of MPA over a 60-d period (Innovative Research of America, Boca Raton, FL). This product will substitute for norgestomet (C. A. Gray and T. E. Spencer, unpublished results). 3. Estradiol-17β valerate or estradiol-17β benzoate may also be used in the neonatal ewe lamb to produce the UGKO phenotype (33). However, the adult phenotype of neonatally estrogenized ewes has not been investigated.
3. Methods 1. The skin in the area of implant administration is sheared and disinfected with betadine followed by an alcohol scrub. 2. A sterile scalpel blade is used to make a small incision through the skin in the periscapular area. 3. The progestin implant is inserted subcutaneously in the periscapular area of ewe lambs within 12 h of birth. The progestin inhibits differentiation and development of the endometrial glandular epithelial cells from the luminal epithelium in the uterus of the neonatal ewe. Progestin ablation of endometrial adenogenesis is permanent and produces the UGKO phenotype. Any delay in progestin implant administration may not be 100% effective to inhibit endometrial gland differentiation. Unpublished observations indicate that administration of the progestin implants on day 7 after birth does not inhibit endometrial gland development (C. A. Gray and T. E. Spencer, unpublished observations). 4. If the Synchromate B implant is used, a new implant must be administered to the ewes on PND 14, 28, and 42 to ensure exposure to the progestin from birth to at least PND 56 (see Note 1). 5. Implanted ewe lambs are maintained according to standard animal husbandry practices until they reach puberty. 6. After puberty, the UGKO ewes will exhibit altered estrous cycles of 17 to 43 d in length. Luteolysis and behavioral estrus can be induced in UGKO ewes using exogenous PGF2α (Lutalyse®, Kalamazoo, MI). 7. The uterus should be removed and assessed to confirm the absence of endometrial glands (see Note 2). A general marker of endometrial glandular epithelium in the ovine uterus is expression of the long and short forms of the prolactin
07_Spencer_85_94_F
90
8/29/05, 11:17 AM
Sheep UGKO Model
91
receptor gene (30,31). The mRNA for the prolactin receptor is expressed only in the endometrial glandular epithelium of the uterus of postnatal, cyclic, pregnant, and postpartum ewes (30,31,35). During early pregnancy, expression of the progesterone receptor is lost from the endometrial glands between days 11 and 17 post mating (day 0 = mating) (36). Loss of the PR is accompanied by the onset of OPN and UTMP gene expression in the endometrial glandular epithelium (29,30). The expression of OPN and UTMP genes are indicative of terminal differentiation of the endometrial glands of pregnancy, because their expression is abrogated after parturition in the postpartum uterus (35). Interestingly, the terminally differentiated endometrial glands of pregnancy are devoid of detectable PR gene expression (37), but the PR returns in the endometrial glands after parturition, concomitant with the loss of OPN and UTMP gene expression (35).
4. Notes 1. Exposure of neonatal ewes to a progestin for 8, 16, or 32 weeks prevented endometrial adenogenesis and produced the UGKO phenotype in adult ewes (17). 2. Three endometrial phenotypes are consistently observed in norgestomet-treated ewes: (1) no glands; (2) slight glandular invaginations into the stroma; and (3) limited numbers of cyst- or glandlike structures in the stroma (17) (see Fig. 1). Most neonatally progestinized ewes exhibit the first phenotype as adults. The uterus of individual sheep only exhibit one of the phenotypes, because the phenotype is homogenous within a horn. The different endometrial phenotypes do not appear to result from genetic differences in responsiveness to neonatal progestins, but rather are due to the timing of progestin implant administration. The implant must be administered very soon after birth to inhibit the program of endometrial gland differentiation and development. Another potential cause of the differing endometrial phenotypes is infection at the site of implant administration, which decreases systemic delivery of the progestin. No specific differences in cyclicity have been observed in ewes with one of the endometrial phenotypes compared with the other phenotypes. However, ewes whose uterus exhibits limited numbers of cyst- or glandlike structures may possess the ability to nurture the conceptus to a more advanced stage of development (e.g., fragile filamentous) as compared to ewes with the other phenotypes (e.g., no conceptus or tubular, growth-retarded conceptus) (22). Regardless of the endometrial phenotypes, all three types of UGKO ewes are not capable of sustaining pregnancy much past day 14 and exhibit a peri-implantation type of pregnancy defect (21,22).
Acknowledgments The authors would like to thank Frank F. Bartol, Fuller W. Bazer, and Kristin M. Taylor, as well as former graduate students in the Bazer/Spencer Laboratory, for their participation in the development of the sheep UGKO model. This work was supported by grants from the United States Department of Agriculture (USDA) (98-35203-6322 & 2001-02259).
07_Spencer_85_94_F
91
8/29/05, 11:17 AM
92
Spencer and Gray
References 1. Wimsatt, W. A. (1950) New histological observations on the placenta of the sheep. Am. J. Anat. 87, 391–436. 2. Amoroso, E. C. (1952) Placentation, in Marshall’s Physiology of Reproduction, Vol. 2 (Parkes, A. S., ed.). Little Brown, Boston: pp. 127–311. 3. Bazer, F. W. (1975) Uterine protein secretions: relationship to development of the conceptus. J. Anim. Sci. 41, 1376–1382. 4. Martal, J., Chene, N., Camous, S., et al. (1997) Recent developments and potentialities for reducing embryo mortality in ruminants: the role of IFN-tau and other cytokines in early pregnancy. Reprod. Fertil. Dev. 9, 355–380. 5. Kane, M. T., Morgan, P. M., and Coonan, C. (1997) Peptide growth factors and preimplantation development. Hum. Reprod. Update 3, 137–157. 6. Bell, S. C. (1988) Secretory endometrial/decidual proteins and their function in early pregnancy. J. Reprod. Fertil. Suppl. 36, 109–125. 7. Beier, H. M. (2000) The discovery of uteroglobin and its significance for reproductive biology and endocrinology. Ann. N.Y. Acad. Sci. 923, 9–24. 8. Carson, D. D., Bagchi, I., Dey, S. K., et al. (2000) Embryo implantation. Dev. Biol. 223, 217–237. 9. Gray, C. A., Bartol, F. F., Tarleton, B. J., et al. (2001) Developmental biology of uterine glands. Biol. Reprod. 65, 1311–1323. 10. Burton, G. J., Watson, A. L., Hempstock, J., Skepper, J. N., and Jauniaux, E. (2002) Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J. Clin. Endocrinol. Metabol. 87, 2954–2959. 11. Roberts, R. M. and Bazer, F. W. (1988) The functions of uterine secretions. J. Reprod. Fertil. 82, 875–892. 12. Fazleabas, A. T., Hild-Petito, S., and Verhage, H. G. (1994) Secretory proteins and growth factors of the baboon (Papio anubis) uterus: potential roles in pregnancy. Cell. Biol. Int. 18, 1145–1153. 13. Bartol, F. F., Wiley, A. A., Floyd, J. G., et al. (1999) Uterine differentiation as a foundation for subsequent fertility. J Reprod. Fertil. Suppl. 54, 287–302 14. Wiley, A. A., Bartol, F. F., and Barron, D. H. (1987) Histogenesis of the ovine uterus. J. Anim. Sci. 64, 1262–1269. 15. Bartol, F. F., Wiley, A. A., Coleman, D. A., Wolfe, D. F., and Riddell, M. G. (1988) Ovine uterine morphogenesis: effects of age and progestin administration and withdrawal on neonatal endometrial development and DNA synthesis. J. Anim. Sci. 66, 3000–3009. 16. Spencer, T. E., Stagg, A. G., Joyce, M. M., et al. (1999) Discovery and characterization of endometrial epithelial messenger ribonucleic acids using the ovine uterine gland knockout model. Endocrinology 140, 4070–4080. 17. Gray, C., Bartol, F. F., Taylor, K. M., et al. (2000) Endometrial glands are required for preimplantation conceptus elongation and survival. Biol. Reprod. 62, 448–456. 18. Gray, C. A., Bazer, F. W., and Spencer, T. E. (2001) Effects of neonatal progestin exposure on female reproductive tract structure and function in the adult ewe. Biol. Reprod. 64, 797–804.
07_Spencer_85_94_F
92
8/29/05, 11:17 AM
Sheep UGKO Model
93
19. Gray, C. A., Taylor, K. M., Bazer, F. W., and Spencer, T. E. (2000) Mechanisms regulating norgestomet inhibition of endometrial gland morphogenesis in the neonatal ovine uterus. Mol. Reprod. Dev. 57, 67–78. 20. Spencer, T. E., and Bazer, F. W. (2002) Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front. Biosci. 7, d1879– d1898. 21. Gray, C. A., Taylor, K. M., Ramsey, W. S., et al. (2001) Endometrial glands are required for preimplantation conceptus elongation and survival. Biol. Reprod. 64, 1608–1613. 22. Gray, C. A., Burghardt, R. C., Johnson, G. A., Bazer, F. W., and Spencer, T. E. (2002) Evidence that absence of endometrial gland secretions in uterine gland knockout ewes compromises conceptus survival and elongation. Reproduction 124, 289–300. 23. Guillomot, M. (1995) Cellular interactions during implantation in domestic ruminants. J. Reprod. Fertil. Suppl. 49, 39–51. 24. Johnson, G. A., Bazer, F. W., Jaeger, L. A., et al. (2001) Muc-1, integrin, and osteopontin expression during the implantation cascade in sheep. Biol. Reprod. 65, 820–828. 25. Burghardt, R. C., Johnson, G. A., Jaeger, L. A., et al. (2002) Integrins and extracellular matrix proteins at the maternal-fetal interface in domestic animals. Cells Tissues Organs 171, 202–217. 26. Johnson, G. A., Burghardt, R. C., Bazer, F. W., and Spencer, T. E. (2003) Osteopontin: roles in implantation and placentation. Biol. Reprod. 69, 1458–1471. 27. Johnson, G. A., Burghardt, R. C., Spencer, T. E., Newton, G. R., Ott, T. L., and Bazer, F. W. (1999) Ovine osteopontin: II. Osteopontin and alpha(v)beta(3) integrin expression in the uterus and conceptus during the periimplantation period. Biol. Reprod. 61, 892–899. 28. Spencer, T. E., Bartol, F. F., Bazer, F. W., Johnson, G. A., and Joyce, M. M. (1999) Identification and characterization of glycosylation-dependent cell adhesion molecule 1-like protein expression in the ovine uterus. Biol. Reprod. 60, 241–250. 29. Johnson, G. A., Spencer, T. E., Burghardt, R. C., and Bazer, F. W. (1999) Ovine osteopontin: I. Cloning and expression of messenger ribonucleic acid in the uterus during the periimplantation period. Biol. Reprod. 61, 884–891. 30. Stewart, M. D., Johnson, G. A., Gray, C. A., et al. (2000) Prolactin receptor and uterine milk protein expression in the ovine endometrium during the estrous cycle and pregnancy. Biol. Reprod. 62, 1779–1789. 31. Taylor, K. M., Gray, C. A., Joyce, M. M., Stewart, M. D., Bazer, F. W., and Spencer, T. E. (2000) Neonatal ovine uterine development involves alterations in expression of receptors for estrogen, progesterone, and prolactin. Biol. Reprod. 63, 1192–1204. 32. Carpenter, K. D., Gray, C. A., Noel, S., Gertler, A., Bazer, F. W., and Spencer, T. E. (2003) Prolactin regulation of neonatal ovine uterine gland morphogenesis. Endocrinology 144, 110–120.
07_Spencer_85_94_F
93
8/29/05, 11:17 AM
94
Spencer and Gray
33. Carpenter, K. D., Gray, C. A., Bryan, T. M., Welsh, T. H., Jr., and Spencer, T. E. (2003) Estrogen and antiestrogen effects on neonatal ovine uterine development. Biol. Reprod. 69, 708–717. 34. Johnson, G. A., Burghardt, R. C., Joyce, M. M., et al. (2003) Osteopontin is synthesized by uterine glands and a 45-kDa cleavage fragment is localized at the uterine-placental interface throughout ovine pregnancy. Biol. Reprod. 69, 92–98. 35. Gray, C. A., Stewart, M. D., Johnson, G. A., and Spencer, T. E. (2003) Postpartum uterine involution in sheep: histoarchitecture and changes in endometrial gene expression. Reproduction 125, 185–198. 36. Spencer, T. E. and Bazer, F. W. (1995) Temporal and spatial alterations in uterine estrogen receptor and progesterone receptor gene expression during the estrous cycle and early pregnancy in the ewe. Biol. Reprod. 53, 1527–1543. 37. Spencer, T. E., Johnson, G. A., Burghardt, R. C., and Bazer, F. W. (2004) Progesterone and placental hormone actions on the uterus: insights from domestic animals. Biol. Reprod. 71, 2–10.
07_Spencer_85_94_F
94
8/29/05, 11:17 AM
Baboon Model of Endometriosis
95
8 A Baboon Model for Inducing Endometriosis Asgerally T. Fazleabas Summary Endometriosis is a disease that is associated with severe pelvic pain and is a major cause of infertility in women. It is an enigmatic disease whose etiology and pathophysiology has been studied to a limited extent. The events associated with the establishment of the disease and mechanisms associated with infertility are difficult to assess in a systemic manner in women. In order to understand the early and progressive events associated with the establishment of the disease, we have developed a baboon model in which the disease can be induced. This induction manifests itself in a manner that recapitulates the spontaneous disease. The advantage of the induced model is that the progressive changes in both the ectopic and eutopic endometrium can be studied in a nonhuman primate model at specific times during the menstrual cycle and as the disease process continues. Key Words: Baboon; Papio anubis; endometriosis; uterus; endometrium.
1. Introduction Endometriosis is defined as the presence of endometrium-like tissue outside of the uterine cavity. It is one of the most common causes of infertility and chronic pelvic pain and affects 1 in 10 women in the reproductive-age group (1). This incidence increases up to 30% in patients with infertility and up to 45% in patients with chronic pelvic pain (2). Endometriosis is an estrogendependent gynecological condition. According to Sampson’s theory (3), fragments of menstrual endometrium are refluxed through the fallopian tubes into the peritoneal cavity, then attach to and grow on peritoneal surfaces. However, the fundamental mechanisms by which menstrual endometrium adheres, proliferates, and establishes a functional vasculature in an ectopic site remain to be elucidated. We propose that endometriosis develops in two distinct phases. Phase I is invasive and dependent on ovarian steroids. Phase II, which is the active phase of the disease, is characterized by endogenous estrogen biosynthesis. From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
95
08_Fazleabas_95_100_F
95
8/29/05, 11:17 AM
96
Fazleabas
The baboon is a valuable and clinically relevant model with which to study the etiology and consequences to fertility of this enigmatic disease (4). Experimental evidence indicates that intrapelvic injections of menstrual endometrium can induce endometriosis in this primate, thereby supporting the basic tenets of the Sampson’s hypothesis (3). Furthermore, because hormonal manipulations are possible, we can also address the role that ovarian and extra-ovarian hormones play in the establishment and maintenance of this disease. 2. Materials 1. Laproscopic equipment with video and photographic accessories. 2. Unimar Pipelle (Cooper Surgical Inc., Shelton, CT)
3. Methods 3.1. Induction of Disease The experimentally induced baboon endometriosis model was first established by D’Hooghe et al. (5). We have modified the original procedure, which is described in this chapter and in refs. 6 and 7). Menstrual endometrium (approx 1 g) is harvested on day 2 of menses using a Unimar Pipelle just prior to laparoscopy. The Pipelle is inserted through the external cervical os into the uterine lumen. The cervical os is visualized by dilating the vagina using a pediatric speculum. Menstrual fluid and tissue is aspirated into the Pipelle by rotating it gently within the lumen and applying suction aspiration. Usually, two Pipelles filled with fluid and tissue is sufficient for inoculation and the induction of endometriosis (see Notes 1 and 2). The peritoneal cavity and reproductive tract is visualized by laparoscopy and the absence of any lesions or adhesions is documented by video recording (see Note 3). Under laparoscopic guidance, the menstrual tissue in the Pipelle is deposited at three sites: the pouch of Douglas, the broad ligament adjacent to the oviducts, and on the uterus. At the subsequent menses, the animals undergo a second laparoscopy and endometrial re-seeding at the same ectopic sites. Following the second seeding, and the third menses, laparoscopy is performed to evaluate the extent of endometriosis (6). Additional laparoscopies are performed at periodic intervals every 3 mo following the initial inoculation (see Note 4). Figure 1A shows a blue lesion documented by video recording and the corresponding histological appearance of the lesions. The presence of glands and stroma at this ectopic site that was seeded using menstrual endometrium meets the classical pathological definition of endometriosis (Fig. 1B,C). Following video documentation, endometriotic lesions and portions of normal peritoneum can be biopsied using a harmonic scalpel under laparoscopic guidance. If both the eutopic and ectopic tissue is required, an endometriectomy
08_Fazleabas_95_100_F
96
8/29/05, 11:17 AM
Baboon Model of Endometriosis
97
Fig. 1. (A) Video micrograph of a blue lesion on the peritoneum. (B,C) Histological sections of endometriotic lesions showing the presence of both glands and stroma.
can be performed on the appropriate day of the menstrual cycle as described in Chapter 9. These tissues can then be processed for histological, biochemical, or molecular analyses (7).
3.2. Evaluation of the Lesions At the time of laparoscopy, the size and shape of the lesion is documented on a pelvic diagram sheet and the color and anatomical location is recorded. The stage of the disease can be classified using a modification of the revised American Society for Reproductive Medicine staging criteria. Details for this scoring method in the baboon have been published (8). Endometriosis can take on a variety of appearances. A wide range of lesion types described in humans are also evident in the baboon model. For example, red, raised nodules on the superficial peritoneum or reddish-blue proliferative endometriotic nodules are most commonly encountered in the baboon during the early stages (see ref. 6 and Fig. 1A). The opaque white peritoneal nodules that lack hemosiderin are also evident. The classic brownish focal adhesions are only observed at the later stages following inoculation (6). In the baboon,
08_Fazleabas_95_100_F
97
8/29/05, 11:17 AM
98
Fazleabas
the majority of lesions that result following inoculation of menstrual endometrium are observed on the peritoneum and uterine surface. There is no evidence of ovarian implants, termed “endometriomas,” which are commonly observed in women. The lesions that are present on the peritoneum and uterine surface at the early stages (1–3 mo) are primarily raised red lesions or reddish blue lesions. Larger lesions obtained from the animals at the later stages of the disease (>10 mo) are more readily comparable with the “chocolate cysts” described in humans. There is also evidence of significant adhesion of the peritoneum to the ovary as the disease progresses. Filmy adhesions in the peritoneal cavity are commonly observed and lesions on the bladder are not uncommon. Another characteristic of the disease is the presence of peritoneal fluid, which is not readily seen in animals without disease. Microscopic evaluation of endometriotic lesions should reveal endometrial glands and stroma along with evidence of fibrosis and hemorrhage (Fig. 1B,C). Pathological confirmation of the disease traditionally requires the presence of at least two of these components. In our baboon model, we established the criteria that both endometrial glands and stroma must be evident in lesions classified as endometriosis (6). Based on these criteria, we have been able to document that baboon lesions following the artificial induction of the disease do have distinct endometrial glands and stroma (see refs. 6 and 7, and Fig. 1B,C). These procedures indicate that intraperitoneal inoculations of menstrual endometrium result in endometriotic lesions that substantiate the Sampson hypothesis (3) in a nonhuman primate model. 4. Notes 1. Baboons, unlike rhesus macaques, usually have a straight cervix without extensive folds. Occasionally, there are baboons whose cervixes are difficult to navigate with the Pipelle. It is prudent to evaluate the animals in a mock cycle either during menses or in the proliferative stage of the menstrual cycle to evaluate the accessibility of the uterine cavity. 2. To study direct hormonal effects on lesion formation, the ovariectomized baboon model could be utilized. Using the steroid hormone replacement regimen described in ref. 9, a progesterone withdrawal bleed is induced following 28 d of estradiol and progesterone treatment. The baboons usually have a menstrual bleed 48 h following progesterone withdrawal. Menstrual tissue collected from these animals can be used for inoculation to induce endometriosis. Steroid hormone or control treatments could then be initiated in the ovariectomized animals. 3. Baboons are also afflicted with spontaneous endometriosis, and this disease is progressive throughout the animal’s lifespan (8). Therefore, it is critical that prior to the induction of endometriosis using the induced model, a thorough laparoscopic evaluation be performed to rule out spontaneous disease in the study animals.
08_Fazleabas_95_100_F
98
8/29/05, 11:17 AM
Baboon Model of Endometriosis
99
4. For control studies, we inoculate the peritoneal cavity with endometrial tissue obtained at the mid secretory phrase of the menstrual cycle. In our experience, this tissue does not attach to the peritoneum and form active endometriotic lesions, as do tissues from the menstrual effluent (6).
Acknowledgments The expert assistance of the Veterinary Staff at the Biological Resources Laboratory and the technical assistance of Ms. Allison Brudney is gratefully acknowledged. These studies have been supported by National Institutes of Health (NIH) grant HD40093. References 1. Eskenazi, B. and Warner, M. L. (1997) Epidemiology of endometriosis. Obstet. Gynecol. Clin. North Am. 24, 235–258. 2. Gruppo italiano. (1994) Prevalence and anatomical distribution of endometriosis in women with selected gynaecological conditions: results from a multicentric Italian study. Gruppo italiano per lo studio dell’endometriosi. Hum. Reprod. 9, 1158–1162. 3. Sampson, J. A. (1927) Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am. J. Obstet. Gynecol. 14, 422–469. 4. D’Hooghe, T. M. (1997) Clinical relevance of the baboon as a model for the study of endometriosis. Fertil. Steril. 68, 613–625. 5. D’Hooghe, T. M., Bambra, C. S., Raeymaekers, B. M., De Jonge, I., Lauweryns, J. M. and Koninckx, P. R. (1995) Intrapelvic injection of menstrual endometrium causes endometriosis in baboons (Papio cynocephalus and Papio anubis). Am. J. Obstet. Gynecol. 173, 125–134. 6. Fazleabas, A. T., Brudney, A., Gurates, B., Chai, D., and Bulun, S. E. (2002) A primate model for endometriosis, in Proceedings of a NIH Workshop on Endometriosis: Emerging Research and Intervention Strategies (Yoshinaga, K. and Parrot, E., eds.). Ann. N. Y. Acad. Sci. 955, 308–317. 7. Fazleabas, A. T., Brudney, A., Chai, D., Langoi, D., and Bulun, S. E. (2003) Steroid receptor and aromatase expression in baboon endometriotic lesions. Fertil. Steril. 80(Suppl 2), 820–827. 8. D’Hooghe, T. M., Bambra, C. S., Raeymaekers, B. M., and Koninckx, P. R. (1996) Serial laparoscopies over 30 months show that endometriosis in captive baboons (Papio anubis, Papio cynocephalus) is a progressive disease. Fertil. Steril. 65, 645–649. 9. Fazleabas, A. T., Miller, J. B., and Verhage, H. G. (1988) Synthesis of estrogen and progesterone dependent proteins by the baboon (Papio anubis) endometrium. Biol. Reprod. 39, 729–736.
08_Fazleabas_95_100_F
99
8/29/05, 11:17 AM
08_Fazleabas_95_100_F
100
8/29/05, 11:17 AM
Baboon Model of Pregnancy
101
9 A Baboon Model for Simulating Pregnancy Asgerally T. Fazleabas Summary Estrogen and progesterone secreted by the corpus luteum regulate the function of the uterine endometrium in preparation for pregnancy. Embryonic signals superimposed on this steroid hormone-primed uterus further modulate the uterine environment to make it conducive to pregnancy. Understanding the signaling mechanisms that initiate the embryonic–maternal dialog in humans is not feasible. In an effort to elucidate the role of chorionic gonadotropin as a mediator of endometrial function in addition to its luteotrophic role, we have developed a simulated pregnant model in the baboon. Infusion of chorionic gonadotropin in a manner that mimics blastocyst transit induces major changes in the morphology and secretory activity of the endometrium. This model provides a method by which the function of various embryonic factors on endometrial can be tested in an in vivo model. Key Words: Baboon; Papio anubis; pregnancy; chorionic gonadotropin; implantation.
1. Introduction The establishment of pregnancy requires a synchronous interaction between the embryo and the endometrium. These interactions are necessary to both prolong corpus luteum function and modulate the uterine environment to permit a normal embryo to attach and invade a receptive uterine endometrium (1–4). In ruminants and pigs, embryo signals act in a paracrine manner on the uterine endometrium to inhibit the pulsatile release of the luteolytic factor, prostaglandin F2α. In contrast, the primate embryonic signal, chorionic gonadotropin (CG), has a direct luteotrophic effect on the corpus luteum. The presence of luteinizing hormone (LH)/CG receptors have been documented to the present in the primate endometrium (5,6), and in vitro stimulation of both epithelial and stromal endometrial cells activates signal transduction and gene transcription (7–11). To determine if CG further modulates the estrogen and progesterone primed receptive endometrium in vivo, we have developed a nonhuman primate simulated pregnant model. The baboon (Papio anubis) was used as the nonhuman primate of choice. From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
101
09_Fazleabas_101_110_F
101
8/29/05, 11:18 AM
102
Fazleabas
2. Materials 1. 2. 3. 4. 5. 6. 7. 8.
V4 Polyvinyl Cannula (BioLab Products, Lake Havasu City, AZ). Dow Corning silastic capsules (Dow Corning, Midland, MI). Silastic medical adhesive Type A (Dow Corning, Midland, MI). Alzet osmotic minipump 2ML1 (Alza Corp, Palo Alto, CA). Recombinant human CG (hCG; Serono Pharmaceuticals). Microsurgical dissection instruments. 4.0 nonabsorbable suture on a tapered needle. Coat-a-Count Estradiol Assay kit (Diagnostic Products Corporation, Los Angeles, CA).
3. Methods Ovulation is monitored in normally cycling female baboons by measuring serum estradiol levels beginning 7 d following the first day of visible menses. Day 1 of ovulation is designated to be 48 h following the estradiol surge.
3.1. Placement of Cannula On day 6 post ovulation, baboons are sedated with Ketamide hydrochloride (10 mg/kg) and transferred to intravenous administration of Thiopentol. The animals are maintained on a surgical plane of anesthesia with isofluorane and oxygen. Under sterile operating conditions, the oviducts are exteriorized following a mid-ventral incision. Using a pair of microdissection scissors, an initial cut is made through the mesosalpinx of the oviduct in a region of the isthmus with no convolutions. Care must be taken not to cut through the entire mesosalpinx. The oviductal lumen is visualized using microdissection forceps to ensure that the lumen is open. The polyvinyl cannula with a medical adhesive bead attached 1–2 cm from the tip is inserted into the oviductal lumen (Fig. 1). Generally, the cannula will extend approx 1 cm into the oviductal lumen. The cannula is sutured in place with 4.0 nonabsorbable suture and the cut edges of the mesosalpinx are pulled over the adhesive bead and sutured in place (Fig. 1). Once the cannula is secure in the oviduct, a small subcutaneous flank incision is made on the side of the body wall that the cannula is attached. The body wall is punctured using blunt dissection with a hemostat and the polyvinyl cannula is exteriorized. The open end of the cannula is attached to the Alzet minipump (Fig. 1).
3.2. Preparation of Alzet Minipump The 2ML1 Alzet pump holds 2 mL of fluid and lasts for 7 d with a flow rate of 10 µL/h. For hCG infusion, the solution containing 1.25 IU/10 µL is made up in a 2.5-mL volume. The Alzet minipump is primed in sterile saline over-
09_Fazleabas_101_110_F
102
8/29/05, 11:18 AM
Baboon Model of Pregnancy
103
Fig. 1 (see companion CD for color version). A diagrammatic illustration of the placement of the cannula within the oviduct and the subcutaneous attachment to the Alzet minipump for the infusion studies.
night at 37°C. For control studies, the hCG is heat-inactivated by boiling the solution for 30 min. The manufacturer provides detailed information for filling and preparing the osmotic minipump. The appropriately primed minipump is inserted into the open end of the cannula. Prior to insertion, the dead space within the cannula is gently primed
09_Fazleabas_101_110_F
103
8/29/05, 11:18 AM
104
Fazleabas
with part of the balance 0.5 mL of solution. A 21-gauge stub adapter needle attached to a 1-cc syringe is inserted into the cannula and the solution is gently infused to fill up the dead space. The cannula is then attached to the metal prong on the Alzet pump and held in place by 2.0 silk sutures. The pump is then inserted into a subcutaneous pocket and the infusion is initiated (Fig. 1).
3.3. Harvesting of Endometrial Tissues Endometrial tissue is harvested on either day 10 or day 14 post ovulation. Day 10 corresponds to the approximate day of implantation in the baboon and day 14 corresponds to the earliest time point at which an implantation site can be readily identified (12). The 24-h infusion rate of 30 IU hCG is equivalent to the amount of baboon CG secreted by dispersed baboon trophoblast cells cultured in vitro (13). The 4-d infusion period (days 6–10 post ovulation) corresponds to the window of time when the blastocyst is present within the uterine cavity and is associated with the initial phases of attachment and invasion. Thus, this simulated pregnant model mimics the intrauterine hormonal milieu associated with blastocyst transit and attachment in the baboon (see Notes 1 and 2). The uterus is carefully exteriorized following a mid-ventral incision (Fig. 2B). The myometrium is gently injected with 2 mL of vasopressin (20 IU/mL) using a 3-cc syringe and a 25-gauge needle. This constricts the blood vessels in the myometrium and decreases the bleeding during the myometrial incision. Using a number 11 scalpel blade, a longitudinal incision is made through the myometrium until the functionalis tissue is exposed (Fig. 2D). The functionalis is gently peeled away from the basalis using the pointed end of a metal weighing spatula (Fig. 2E,F). This procedure is termed an endometriectomy. Following removal of the endometrial tissue, the myometrial incision is closed by continuous suture using 4.0 Vicryl and a small tapered needle (Fig. 2G). Prior to closing the myometrial incision, the uterine cavity is flushed extensively with warm sterile saline to minimize bleeding and adhesions. If the corpus luteum is required for analysis, a small incision is made at the site of the ovarian stigma using a number 15 scalpel blade. The corpus luteum is gently teased out of the ovary using a small curved hemostat. The incision is closed with 4.0 Vicryl suture. Following the endometriectomy and lutectomy, the peritoneal cavity is extensively flushed with warm saline until there is minimal blood in the flush. This extensive flushing prevents significant adhesion formation and permits the multiple use of these animals as permitted by the Institutional Animal Care and Use Committee (IACUC) guidelines.
09_Fazleabas_101_110_F
104
8/29/05, 11:18 AM
Fig. 2. Step-by-step illustration of the endometriectomy procedure in the baboon to harvest endometrial tissues.
Baboon Model of Pregnancy
09_Fazleabas_101_110_F
105
105
105
8/29/05, 11:18 AM
106
Fazleabas
The peritoneum and fascia are closed using 2.0 Vicryl on a tapered needle using a simple interrupted suture technique. The subcutaneous tissue is closed with a 3.0 Vicryl simple continuous suture line and the skin is then closed with 3.0 Vicryl with a continuous subcuticular suture (Fig. 2H). This is a subdermal suture that ensures that the skin suture will not be loosened by the animal. The Alzet minipump that has been placed subcutaneously is then removed following a subcutaneous incision. The tip of the cannula attached to the pump is cut and it is anchored to the body wall using a 0.5-cm piece of silastic tubing and a 2.0 silk suture. This provides a landmark for locating the cannula for the next infusion (see Note 3). The skin incision is closed using 3.0 Vicryl and a subdermal suture. The amount of solution left in the pump is measured by aspirating the fluid using a 25-gauge needle provided by the manufacturer. This provides assurance that the expected volume of hormone has been infused and that the pump has functioned appropriately (see Notes 4 and 5).
3.5. Analysis of Endometrial Tissues The endometrial tissues obtained by endometriectomy are transported to the laboratory in ice-cold Ca2+/Mg2+-free Hank’s balanced salt solution (see Note 6). The tissue is carefully dissected under a microscope under sterile conditions so that the luminal surface is exposed. Using a sharp, single-edged blade, portions of the tissue are fixed in the appropriate fixatives for histological and immunocytochemical analyses or for in situ hybridization (9). Tissues can also be snap frozen in liquid nitrogen for RNA extraction (9) or subjected to enzymatic digestion for stromal and epithelial cell isolation (14,15). In general, following CG stimulation, the amount of functionalis tissue harvested is approx 500–700 g. Figure 3 provides a composite example of the response of the baboon endometrium to CG stimulation during the window of receptivity (9). None of the changes are evident if the hCG had been heat inactivated prior to infusion (9). Fig. 3. (opposite page) Endometrial responses to human chorionic gonadotropin (hCG) infusion on day 10 post ovulation. A shows the characteristic endometrial plaque response in the luminal epithelial cells usually seen in response to CG stimulation and early pregnancy (9,14). B shows the induction of α-smooth muscle actin in the subepithelial stroma that is characteristic of a predecidual response in the baboon (14,15). C shows secretory proteins labeled with 35S methionine evaluated by twodimensional gel electrophoresis following organ culture (18). The boxed area represents glycodelin, which is a protein that undergoes both transcriptional (reverse transcriptase-polymerase chain reaction) and posttranslational (Western blotting [WB]) modification in response to CG and is localized specifically to the glandular epithelium (D) (9,19).
09_Fazleabas_101_110_F
106
8/29/05, 11:18 AM
Baboon Model of Pregnancy
107
107
09_Fazleabas_101_110_F
107
8/29/05, 11:18 AM
108
Fazleabas
4. Notes 1. The cannulated animals could serve as their own controls. Surgeries could be scheduled on day 10 or 14 post ovulation of a regular menstrual cycle. Endometrial tissues can be obtained by endometriectomy in the absence of CG stimulation, which reduces between animal variability with or without treatment. If this procedure is selected, the cannula is inserted into the oviduct after the endometriectomy. The open end of the cannula is exteriorized through the flank incision and sutured to the body wall using a 0.5-cm piece of silastic tubing. The animals are rested for three consecutive menstrual cycles prior to the next surgery. For CG treatment, a small incision is made above the silastic anchor and the cannula is gently extruded from under the skin. The cannula is flushed with the treatment solution and inserted into the metal tip of the Alzet minipump. The pump is placed in the subcutaneous pocket and the treatment initiated on day 6 post ovulation. These manipulations do not require an incision into the animal’s body cavity at the initiation of treatment. 2. To determine if the effects are directly on the uterine endometrium, the treatment paradigm could be done in ovariectomized animals following hormone replacement (16). The cannula is placed into the oviduct at the time of ovariectomy and anchored to the body wall. CG stimulation can be initiated following the sequential treatment with estrogen and progesterone implants to mimic hormonal changes during the menstrual cycle (9,16,17). 3. Over a period of time, the cannula that is placed subcutaneously for easy access becomes brittle. This appears to be primarily to the result of a granulation reaction. Because it is less pliable, insertion into the metal post on the Alzet osmotic minipump can be more difficult. This can be overcome by expanding the open end of the cannula with 21-gauge stub adapter or by using the tip of the dissecting scissors to expand the top of the tubing. Once inserted into the pump, the cannula is secured using 2.0 silk ties. 4. The procedure describes infusion of CG to determine the role of the major primate embryonic signal on uterine receptivity. However, this cannulation procedure can be used for infusing a variety of other hormones or growth factors in the presence or absence of CG to determine individual or synergistic effects of these factors on endometrial function during the window of receptivity. 5. Stimulation with CG via the Alzet pump and cannula is only effective upto 14 or 15 days post ovulation. Longer infusions do not provide sufficient luteotrophic stimulation to maintain the corpus luteum. If long-term treatment with CG (up to day 18 post ovulation) is required, then the animals can be given hCG injections twice daily for up to 12 d, beginning on day 6 post ovulation. This regimen mimics hormonal and endometrial changes that are comparable to the initial stages of pregnancy. Details of this procedure have been previously published (17). 6. In both cycling and CG treated animals the uterine lumen can be flushed at the time of surgery to obtain uterine flushings. Following exteriorization of the uterus, the assisting surgeon clamps the cervix and the oviducts with his fingers. Five to ten milliliters of Ca2+/Mg2+-free Hands Buffered saline is aspirated into a
09_Fazleabas_101_110_F
108
8/29/05, 11:18 AM
Baboon Model of Pregnancy
109
10-mL syringe attached to a 21-gauge needle. Another empty 10-cc syringe is also attached to a 21-gauge needle. With the cervix and oviducts clamped off, the syringe containing the media is inserted through the myometrium into the uterine lumen. A small volume (1 mL) of fluid is injected to dilate the lumen. The empty syringe is then inserted into the lumen and the uterus infused (Fig. 2C). The uterine flushings are forced into the empty syringe by positive pressure. The syringes and needles are slowly withdrawn and the intrusion points on the myometrium are cauterized via conductance through the needle as it is being removed.
Acknowledgments The expert assistance of the Veterinary Staff at the Biological Resources Laboratory and the technical assistance of Ms. Allison Brudney is gratefully acknowledged. These studies have been supported by National Institutes of Health (NIH) grants HD29964 and HD42280. References 1. Paria, B. C., Reese, J., Das, S. K., and Dey S. K. (2002) Deciphering the cross-talk of implantation: advances and challenges. Science 296, 2185–2188. 2. Jaeger, L. A., Johnson, G. A., Ka, H., et al. (2001) Functional analysis of autocrine and paracrine signaling at the uterine-conceptus interface in pigs. Reprod. Suppl. 58, 191–207. 3. Spencer, T. E. and Bazer, F. W. (2002) Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front. Biosci. 7, d1879– d1898. 4. Fazleabas, A. T. and Strakova, Z. (2002) Endometrial function: cell specific changes in the uterine environment. Mol. Cell. Endocrinol. 186, 143–147. 5. Rao, C. V. (2001) An overview of the past, present, and future of nongonadal LH/ hCG actions in reproductive biology and medicine. Semin. Reprod. Med. 19, 7–17. 6. Licht, P., von Wolff, M., Berkholz, A., and Wildt, L. (2003) Evidence for cycledependent expression of full-length human chorionic gonadotropin/luteinizing hormone receptor mRNA in human endometrium and decidua. Fertil. Steril. 79 (Suppl 1), 718–723. 7. Licht, P., Russu, V., Lehmeyer, S., and Wildt, L. (2001) Molecular aspects of direct LH/hCG effects on human endometrium-lessons from intrauterine microdialysis in the human female in vivo. Reprod. Biol. 1, 10–19. 8. Licht, P., Russu, V., and Wildt, L. (2001) On the role of human chorionic gonadotropin (hCG) in the embryo–endometrial microenvironment: implications for differentiation and implantation. Semin. Reprod. Med. 19, 37–47. 9. Fazleabas, A. T., Donnelly, K. M., Srinivasan, S., Fortman, J. D., and Miller, J. B. (1999). Modulation of the baboon (Papio anubis) uterine endometrium by chorionic gonadotrophin during the period of uterine receptivity. Proc. Natl. Acad. Sci. USA 96, 2453–2458. 10. Banaszak, S., Donnelly, K. M., Brudney, A., Chai, D., Chwalisz, K., and Fazleabas, A. T. (2000) Modulation of the action of chorionic gonadotrophin on
09_Fazleabas_101_110_F
109
8/29/05, 11:18 AM
110
Fazleabas
the baboon endometrium by a progesterone receptor antagonist (ZK 137.316). Biol. Reprod. 63, 819–823. 11. Srisuparp, S., Strakova, Z., Brudney, A., et al. (2003) Signal transduction pathways activated by chorionic gonadotrophin (CG) in the primate endometrial epithelial cells. Biol. Reprod. 68, 457–464. 12. Jones, C. J., Enders, A. C., and Fazleabas, A. T. (2001) Early implantation events in the baboon (Papio anubis) with special reference to the establishment of anchoring villi. Placenta 22, 440–456. 13. Bambra, C. S. and Tarara, R. (1990) Immunohistochemical localization of chorionic gonadotrophin on baboon placenta, dispersed trophoblast cells and those derived from blastocysts grown in vitro. J. Reprod. Fertil. 88, 9–16. 14. Kim, J. J., Jaffe, R. C., and Fazleabas, A. T. (1998) Comparative studies on the in vitro decidualization process in baboons (Papio anubis) and humans. Biol. Reprod. 59, 160–168. 15. Kim, J. J., Jaffe, R. C., and Fazleabas, A. T. (1999) Insulin-like growth binding protein 1 in baboon endometrial stromal cells: regulation by filamentous actin and requirement for de novo protein synthesis. Endocrinology 140, 997–1004. 16. Fazleabas, A. T., Miller, J. B., and Verhage, H. G. (1988) Synthesis of estrogen and progesterone dependent proteins by the baboon (Papio anubis) endometrium. Biol. Reprod. 39, 729–736. 17. Hild-Petito, S., Donnelly, K. M., Miller, J. B., Verhage, H. G., and Fazleabas, A. T. (1995) A baboon (Papio anubis) simulated-pregnant model: cell specific expression of insulin-like growth factor binding protein-1 (IGFBP-1), type I IGF receptor (IGF-I R) and retinol binding protein (RBP) in the uterus. Endocrine 3, 639–651. 18. Fazleabas, A. T., Donnelly, K. M., Mavrogianis, P. A., and Verhage, H. G. (1993) Secretory and morphological changes in the baboon (Papio anubis) uterus and placenta during early pregnancy. Biol. Reprod. 49, 695–704. 19. Hausermann, H. M., Donnelly, K. M., Bell, S. C., Verhage, H. G., and Fazleabas, A. T. (1998) Regulation of the glycosylated β-lactoglobulin homologue, glycodelin [placental protein 14 (PP14 )] in the baboon uterus. J. Clin. Endocrinol. Metab. 83, 1226–1233.
09_Fazleabas_101_110_F
110
8/29/05, 11:18 AM
Marmoset Implantation/Early Pregnancy Model
111
10 The Common Marmoset Monkey as a Model for Implantation and Early Pregnancy Research Almuth Einspanier, Kai Lieder, Ralf Einspanier, and Bettina Husen Summary This chapter describes methods used to investigate implantation in the common marmoset monkey, Callithrix jacchus. A reverse-transcriptase polymerase chain reaction-strategy with which to detect transcripts for steroid receptors and enzymes involved in estradiol biosynthesis is described, and an immunohistochemistry approach for detecting proteins within the implantation site is presented. Key Words: Marmoset; early pregnancy; steroid receptors; aromatase; 17β-hydroxysteroid dehydrogenase type 1 and type 7.
1. Introduction The marmoset monkey (Callithrix jacchus) belongs to the New World Monkeys and is widely used as a primate model for reproductive medicine (1,2). One of its advantages is its small size, which is the reason why it is easy to handle and breed. The marmoset has a high fecundity and has no restricted breeding season like other laboratory primates such as rhesus monkeys. Because its cycle can be controlled by prostaglandin F2α (PGF2α) application (3), exact prognosis of ovulation and therefore status of pregnancy is possible. The marmoset monkey has a placenta hemochorialis like humans and, consequently, it shows similarities to the human situation in morphology and function (4). Our knowledge about factors concerning the implantation process in humans is limited as a result of ethical constraints, which make primate models necessary. Furthermore, there is an urgent need for more information on mechanisms of implantation. This is easily understandable in view of current progress in reproductive medicine, especially because pregnancy rates in assisted reproduction are still unsatisfactory (5).
From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
111
10_Einspanier_111_122_F
111
8/29/05, 11:18 AM
112
Einspanier et al.
Implantation requires an appropriately developed embryo and a receptive endometrium primed by relevant endocrine as well as paracrine factors. This permits a remodelling of the endometrium to provide optimal development and nutrition of the embryo including appropriate embryo-maternal interactions. Suitable methods for studies on implantation using the marmoset monkey model will be presented in this paper. 2. Materials 2.1. Reproductive Staging of Animals 1. Adult (>18 mo old) marmoset monkeys. Characteristics: 8- to 10-d follicular phase and 18- to 20d luteal phase (1); no visible menstruation, nonseasonal primate. 2. PGF2α (0.8 µg per animal, Estrumate, Pitman-Moore, Germany) application can induce luteolysis when applied between days 10–15 of luteal phase (6). 3. Immunoassays (6): a. Progesterone for monitoring cycle stage (detection range: 0.1–50 ng/mL). b. Relaxin (RLX) for early pregnancy detection (detection range: 0.02–5 ng/mL). 4. Ultrasound examination with 7.5-, 10-, and 15-MHz probes (Logiq 400 Pro CL, General Electrics, Solingen, Germany) of ovarian and uterine activity throughout the cycle and pregnancy.
2.2. Reverse-Transcription-Polymerase Chain Reaction 1. 2. 3. 4. 5. 6. 7. 8. 9.
RNeasy Mini-Kit (Qiagen, Hilden, Germany). SuperScript II reverse transcriptase (Invitrogen, Karlsruhe, Germany). RNase H (Invitrogen, Karlsruhe, Germany). Oligo(dT)12–18 primer (500 µg/mL) (Hermann GbR, Freiburg, Germany). Taq-DNA-Polymerase (Eppendorf GmbH, Hamburg, Germany). Pfu Polymerase (Fermentas GmbH, St. Leon-Rot, Germany). dNTP-set 1 (Roth GmbH, Karlsruhe, Germany). Oligonucleotide primers for marmoset mRNA-transcripts (see Table 1). GeneRuler(tm) 100-basepair (bp) DNA Ladder plus and 6X Loading Dye Solution (Fermentas, St. Leon-Rot, Germany).
2.3. Immunohistochemistry 1. 2. 3. 4.
Fixation solution: 4% paraformaldehyde, pH 7.3. Buffer for microwave pretreatment: 10 mM citrate buffer, pH 6.0 at 120°C. Tris-buffered saline (TBS), poly-L-lysine (0.01%). ABC-method (DAKO Diagnostika, Hamburg, Germany; Vectastain, Vector Laboratories, Burlingame, CA, USA). 5. Primary antibodies: a. Monoclonal mouse antibody against estradiol α receptor (ERα; cat. no. B10, Euromedex; Souffel Weyersheim, France).
10_Einspanier_111_122_F
112
8/29/05, 11:18 AM
10_Einspanier_111_122_F
113
X03635 (human) Z86038 AF272013
Estrogen receptor α (ERα)
Progesterone receptor (PR)
17-β-Hydroxysteroid dehydrogenase type 1 (17HSD1) 17HSD7
18S rRNA housekeeping gene (18S)
AY034779
Aromatase (ARO)
AF176811
AF263468
GenBank
Transcript
5' CTG CTG AGG TCA CCA TTG TA 3' 5' GAG AAA CGG CTA CCA CAT CCA A 3'
CTC CAC AC 3' 5' GTA TTC CAA ATG AAA GCC AAG C 3' 5' GGC CTG CAC TTG GCC GTA CG 3'
5' ATG ACC ATG ACC
5' ACA ACT CGG CCC CTC TTT AT 3'
Forward primer
Table 1 Oligonucleotide Primers Used for Marmoset Transcript Amplification
5' CCA GAT GAG CTG AGA TGG AT 3' 5' GAC ACT CAG CTA AGA GCA TCG A 3'
5' AGG AGC TGC AAT CAG CAT TT 3' 5' CGG AGA CAC GCT GTT GAG T 3' 5' AAC CAA TTG CCT TGA TGA GC 3' 5' GGC CTG CAG CAT CCG CAC AG 3'
Reverse primer
64
60
60
60
58
60
Annealing temperature (°C)
317
344
330
591
315
498
Product (bp)
Marmoset Implantation/Early Pregnancy Model 113
8/29/05, 11:18 AM
114
6. 7. 8. 9. 10. 11. 12. 13. 14.
Einspanier et al. b. Monoclonal mouse antibody against progesterone receptor (PR; cat. no. AT 4.14, Dianova, Hamburg, Germany). c. Affinity-purified polyclonal rabbit antisera against 17β-hydroxysteroid dehydrogenase type 1 (17HSD1), 17β-hydroxysteroid dehydrogenase type 7 (17HSD7), and aromatase (ARO) (7). d. Polyclonal rabbit antibodies against cytokeratin (Biotrend, Köln, Germany) and vimentin (Biotrend, Köln, Germany). 3% H2O2. Biotinylated goat-anti-rabbit immunoglobulin (Ig)G (Vector Laboratories, Burlingame, CA, USA). Streptavidin–horeseradish peroxidase (HRP) (DAKO; Vector) AEC-Substrate Chromogen (DAKO, Vector Laboratories). Meyer´s hematoxylin (Merck, Darmstadt, Germany) for nuclear counterstaining. Histogel medium (Vector Laboratories) or ImmunoMount mounting medium (Shandon, Pittsburgh, PA, USA) and Neo-Mount (Merck, Darmstadt, Germany). Axiophot microscope (Zeiss, Oberkochen, Germany). Openlab 3.0. digital image analysis (Improvision, Coventry, UK). Controls: control tissue (positive, negative), IgG, pre-immune sera, peptides.
3. Methods 3.1. Reproductive Staging of Animals (see Notes 1–4) The analysis of progesterone and RLX content in the peripheral blood (~2 times per week) provide a method of cycle (~28 d) and pregnancy (~144 d) classification. Application of PGF2α during mid luteal phase (10–15 d luteal phase) induces luteolysis of the formed corpora lutea and the initiation of new growing follicles. Eight to ten days later, ovulation of preovulatory follicles (1–4) occurs, followed by an increase of blood progesterone concentrations above 10 ng/mL (1). For exact tissue collection, cycle staging is further confirmed by transabdominal ultrasound examination (8). This examination is carried out on unshaved as well as unsedated marmoset monkeys for a time period of approx 10 min. By ultrasound examination, identification of the number of follicles and corpora lutea is possible, as well as the status of the uterus (pregnant vs nonpregnant, see Note 4). RLX content analysis in peripheral blood allows early pregnancy detection at day 15 of luteal phase (6).
3.2. Tissue Samples Uteri are collected by hysterectomy from cyclic and pregnant common marmoset monkeys (German Primate Centre, Germany) and immediately fixed in 4% buffered formaldehyde up to 8 h or in liquid nitrogen. The following cycle stages are routinely collected: mid luteal phase (days 8–12 of luteal phase; nonpregnant) and pregnancy stages (days 17–135 of pregnancy). Samples from
10_Einspanier_111_122_F
114
8/29/05, 11:18 AM
Marmoset Implantation/Early Pregnancy Model
115
early pregnancy include uterine tissue comprising the implantation site, whereas samples from days 95–135 of pregnancy consist of separated uterine and placental tissues (see Notes 2–4).
3.3. RNA Extraction and RT-PCR 1. For reverse-transcription (RT)-polymerase chain reaction (PCR), frozen tissue (–80°C) is homogenized in RLT lysis buffer containing 0.1% [v/v] β-mercaptoethanol. Total RNA is extracted using RNeasy Mini Kit following the manufacturer’s protocol. 2. The yield of total RNA is spectroscopically determined at 260 nm. 3. Quality and quantity of Callithrix RNA is verified after denaturing electrophoresis on a 1% (w/v) formaldehyde containing agarose gel followed by ethidium bromide staining as described elsewhere (9). 4. An amount of 2 µg total RNA, in a 20-µL reaction volume, is reverse transcribed to obtain cDNA using SuperScript II reverse transcriptase and oligo(dT)12–18 primers. Reaction mixtures and first-strand-synthesis is performed according to the manufacturer’s protocol. 5. Marmoset-specific PCR fragments encoding for ER, PR, ARO and 18S are amplified using Taq-polymerase as previously described (9), whereas Pfupolymerase is used for 17HSD1 and 17HSD7 (50 pmol of each primer). 6. The PCR is performed for 35 cycles at the optimized annealing temperature of each primer pair. 7. 10 µL of each PCR product mixed with 2 µL of 6X Loading Dye Solution is run on 1.5% agarose gels containing 1 µg/mL ethidium bromide. For sizing of PCR products, the GeneRuler(tm) 100-bp DNA Ladder Plus is used. 8. As a negative control, water is substituted for RNA and used for the RT-PCR. 9. All reactions are performed three times for each RNA preparation. 10. Specificity of RT-PCR products should be checked by subcloning and DNA sequencing. 11. Amplification of the housekeeping gene 18S rRNA is used to provide internal standardization and to demonstrate RNA integrity and loading. 12. Results from an RT-PCR analysis is shown in Fig. 1 (see Notes 5–8).
3.4. Immunohistochemistry (see Notes 4 and 9–11) 3.4.1. Pretreatment for Paraffin Sections 1. Uteri are fixed in 4% buffered formaldehyde not longer than 8 h and embedded in paraffin. 2. Five micron sections are mounted on poly-L-lysine-coated slides (0.01%). 3. Paraffin sections are incubated at 45°C for 1 h, and then dewaxed in xylol two times for 15 min each, followed by descending ethanol concentrations (2 × 5 min 100% and each 3 min in 90%, 80%, 70%, 50% ethanol) and washed for 5 min in purified water.
10_Einspanier_111_122_F
115
8/29/05, 11:18 AM
116
Einspanier et al.
Fig. 1. Uterine expression of estradiol receptor α (ERα), progesterone (PR), aromatase (ARO), 17β-hydroxysteroid dehydrogenase type 1 (17HSD1), and 17βhydroxysteroid dehydrogenase type 7 (17HSD7) at days 8 and 9 of the secretory phase (nonconceptive), days 29, 35, 98, and 135 of pregnancy in the common marmoset monkey. Samples did not contain placental tissue. 18S was monitored as housekeeping gene to verify similar RNA amounts within each sample.
4. For steroid receptor detection, the paraffin sections are subjected to an antigen retrieval protocol, incubating them for 10 min in 10 mM citrate buffer, pH 6.0 at 120°C, then allowing them to cool over 30 min.
3.4.2. Pretreatment for Cryostat Sections 1. Seven micron sections are mounted on poly-L-lysine-coated slides (0.01%). 2. Sections are air-dried under the lamina flow for 2 h followed by 10 min fixation in 4 % buffered formaldehyde or spray-fixation with buffered formaldehyde. 3. Followed by a quick washing step in purified water.
3.4.3. Immunohistochemistry Protocol 1. Deparaffinized sections are washed two times for 5 min in TBS and incubated in 3% H2O2 for 30–45 min at room temperature in a moist chamber. 2. The tissue sections are then blocked with 10% normal goat or mouse serum for 45 min. 3. After removing the solution from the slide, sections are then incubated with the primary antiserum overnight at 4°C in a moist chamber, using dilutions of 1:5000 (ARO), 1:1000 (17HSD1 and 17HSD7), 1:500 (ERα and PR) and 1:100 (vimentin and cytokeratin), respectively. 4. The tissue sections are washed twice for 5 min with TBS. 5. Following the washing step, the tissue sections are incubated with biotinylated goat-anti-rabbit IgG (5 µg/mL in TBS) for 30 min at room temperature and rinsing 2 times each 5 min with TBS again. 6. Tissue sections are washed and then incubated with streptavidin-HRP for 30 min at 37°C in a moist chamber. Followed by rinsing two times for 5 min with TBS.
10_Einspanier_111_122_F
116
8/29/05, 11:18 AM
Marmoset Implantation/Early Pregnancy Model
117
7. Visualization of the immune reaction is achieved by applying either AEC-Substrate-Chromogen for 20–30 min or DAB-Chromogen for 15 min, followed by washing with tap water. 8. For nuclear staining, sections can be optional counterstained with Meyer´s hematoxylin. 9. Sections are then mounted with Histogel medium or ImmunoMount mounting medium. After 2 h, drying cover slips are sealed with Neo-Mount. 10. To control for specificity of the antibodies, immunohistochemistry is performed separately with either immune sera or pre-immune sera at the same dilutions. Alternatively, when available the primary antiserum can be blocked by 1 h of preincubation at room temperature with an excess concentration of the peptide used for immunization. Also positive as well as negative tissue should be used to test specificity of reaction. 11. Results are analyzed and documented with Axiophot microscope using Openlab 3.0. digital image analysis. 12. Results from immunohistochemical analyses of marmoset uterine tissues are shown in Fig. 2 (see Notes 9–11).
4. Notes 1. Experiments with marmosets should be approved by the local ethics commission on animal welfare. 2. In the wild, marmoset monkeys live in social groups of 8–15 members; therefore, a social structure is recommended for their welfare in captivity. Moreover, single housing of females often results in variation of cycle length. For reproductive studies, at least pair housing (one adult male and female) is required. Also, if collection of tissue from nonpregnant females is necessary, it is recommended that females be kept with vasectomized or castrated males. 3. The use of trained monkey is advantageous for blood collection, injections, or ultrasound examination. Training greatly decreases stress. Stress can induce irregular cycles or abortion, resulting from high glucocorticoid levels. 4. Collection of appropriately staged tissue is dependent on accurate endocrinological monitoring. The marmoset is a particularly good model as compared with Old World monkeys because of its sensitivity to PGF2α. PGF2α induces luteolysis and the initiation of a new wave of follicle development. As ovulation approaches, more frequent blood collections facilitate accurate determination of ovulation and the initiation of pregnancy. This requires the availability of rapid assay systems within 24 h. Hormonal profiles for progesterone, estradiol, chorionic gonadotropin, and RLX provide the requisite information for determining cycle and pregnancy staging. Further confirmation of cycle or pregnancy stage is given by using ultrasound examination. Detection of pregnancy is possible on day 15 of luteal phase by the appearance of a double endometrial echo indicating fluid accumulation in the uterus (8). Taken together, all of these methods enable exact staging and therefore collection of the marmoset tissues for experimentation on early pregnancy.
10_Einspanier_111_122_F
117
8/29/05, 11:18 AM
118
Einspanier et al.
Fig. 2 (see companion CD for color version). Localization of immunoreactive estradiol receptor α (ERα), progesterone (PR), aromatase (ARO), 17β-hydroxysteroid dehydrogenase type 1 (17HSD1), and 17β-hydroxysteroid dehydrogenase type 7 (17HSD7), at day 25 of pregnancy. Bars indicate 50 µm. Steroid receptor expression is located within the cell nucleus, whereas the other immunoreactions are within the cytoplasm.
10_Einspanier_111_122_F
118
8/29/05, 11:18 AM
Marmoset Implantation/Early Pregnancy Model
119
5. Marmoset organs and implantation sites in general are of limited size. Accurate manual dissection under the stereomicroscope is a prerequisite for valid results. When drawing conclusions from RT-PCR experiments, the origin of RNA extracted must be clearly defined. Possible “contamination” by surrounding tissue with a presumed differing gene expression profile has to be considered. It is recommended to verify RT-PCR data by immunohistochemistry and vice versa. 6. Two alternative methods for disrupting and homogenizing frozen tissues in RLT buffer containing β-mercaptoethanol (β-Me/RLT) are used. For tissues smaller than 4 mm3, a conventional rotor-stator homogenizer is used to lyse the tissue directly in the appropriate volume of buffer β-Me/RLT. For larger tissue samples or whole organs, a cryostat microtome is used for sectioning into 30-µm slides at –30°C, which are then lysed in buffer β-Me/RLT. Quick lysis of cryopreserved samples is important during homogenization in order to inactivate endogenous RNases. 7. Be cautious of contamination with RNase in processes like RNA isolation and reverse transcription. The risk of contamination can be decreased by using a dedicated set of automatic pipettors or by using disposal tips with aerosol barrier filters certified to be free of RNase. Preparation of all solutions and buffers with RNase-free glassware, diethylpyrocarbonate (DEPC)-treated water, and chemicals reserved for work with RNA is also recommended. Additionally, use microfuge tubes certified to be free of RNase. 8. Homologous Callithrix sequences are not available; therefore the HUSAR program package has been used to deduce PCR primers with heterologous cDNAs (e.g., from human or mouse). Annealing temperature as well as cycle number is crucial for the reliability of the resulting transcript determination. More than 40 cycles should never been used to estimate relative mRNA concentrations. All PCR products generated with heterologous primer pairs should be sequenced. Newly generated sequences should then be used to design new homologous primer pairs. For quantification purposes real-time RT-PCR is recommended. 9. The literature describing immunohistological detection of steroid receptors is not entirely consistent. One contributing factor is the use of different fixation times. We have analyzed different fixation periods for steroid receptor detection in marmoset tissues. We observe a massive decline in steroid receptor expression in tissues 1 cm3 with fixation durations longer than 24 h, optimal fixation duration is up to 8 h. Shrinkage or distortions of these fragile tissues can also occur with too long fixation period. 10. An example of our use of these techniques is described as follows. First, the temporal dynamics of steroid receptor expression has been analyzed in total RNA preparations from whole marmoset uteri throughout nonconceptive as well as conceptive cycles. Transcripts for both, ERα and PR, are expressed throughout mid luteal phase and entire pregnancy (Fig. 1). Secondly, using immunohistology, ERα is strongly expressed within both maternal and fetal compartments during early pregnancy (day 25), whereas PR is mainly expressed within the maternal compartment. The expression levels (gene and protein) for both steroid
10_Einspanier_111_122_F
119
8/29/05, 11:18 AM
120
Einspanier et al.
receptors are relatively constant as pregnancy progresses (Figs. 1 and 2). Examination of local expression and distribution patterns provides insights into embryo– uterine interactions during implantation. The absence of apparent differences in steroid receptor expression between nonconceptive and conceptive uteri suggest other regulatory factors are involved. Similarly to ERα, the three enzymes catalyzing the last steps in the synthesis of estradiol (ARO, 17HSD1, and 17HSD7) are detectable in nonconceptive and conceptive marmoset uteri by RT-PCR (Fig. 1). 17HSD1 mRNA expression is minimal and restricted to early pregnancy, whereas 17HSD7 is expressed later in pregnancy (day 95) and is undetectable by the end of pregnancy. ARO is detected at day 35 of pregnancy and through the remainder of pregnancy. Transcripts for enzymes involved in estradiol synthesis are present in the uterus at the time of implantation (7). Again, the immunohistochemical results for ARO, 17HSD1, and 17HSD7 are consistent with the RT-PCR analyses (see Fig. 1). There is a local up regulation of 17HSD1 and 17HSD7 mainly in the fetal compartments with weak expression in the maternal compartment during early pregnancy (day 25 of pregnancy). ARO is weakly expressed in the fetal as well as in the maternal compartments during early pregnancy (Fig. 2). These complementary approaches for monitoring gene and protein expression provide insights into the etiology of pregnancy failure and potential therapeutic strategies. The common marmoset is an excellent model to obtain appropriately staged tissues, which closely mimics important features of human reproduction (4). 11. Fetal vs maternal compartments can be distinguished using vimentin and cytokeratin immunostaining. Trophoblasts are visualized by using cytokeratin staining, whereas decidual cells and stromal cells at the implantation side show positive staining for vimentin.
Acknowledgments The authors would like to thank the German Primate Centre for the marmoset tissue. This work was supported by grants from the Deutsche Forschungsgemeinschaft [DFG Ei 333/6-3 and Ei333/11-4 (A.E.) and Ei 296/ 10-2 (R.E.)]. References 1. Hearn, J. P. (1983) The common marmoset (Callithrix jacchus), in Reproduction in New World Primates. New Models in Medical Science (Hearn, J. P., ed.). MTP, Lancaster, UK: pp. 181–215. 2. Einspanier, A. and Gore, M. (2005) Definition of primate model: female fertility, in The Laboratory Primate: Reproduction Part 1 (Wolfe-Coate, S., ed.). Elsevier. 3. Summers, P. M., Wennink, C. J., and Hodges, J. K. (1985) Cloprostenol-induced luteolysis in the marmoset monkey (Callithrix jacchus). J. Reprod. Fertil. 73, 133–138.
10_Einspanier_111_122_F
120
8/29/05, 11:18 AM
Marmoset Implantation/Early Pregnancy Model
121
4. Enders, A. C. and Lopata, A. (1999) Implantation in the marmoset monkey: expansion of the early implantation side. Anat. Rec. 256, 279–299. 5. ASRM Report (1999) Assisted reproductive technology in the united states: 1996 results generation from the American Society for Reproductive Medicine/Society for assisted reproductive technology registry. Fertil. Steril. 71, 798–806. 6. Einspanier, A., Nubbemeyer, R., Schlote, S., et al. (1999) Relaxin in the marmoset monkey: secretion pattern in the ovarian cycle and early pregnancy. Biol. Reprod. 61, 512–520. 7. Husen, B., Adamski, J., Brüns, A., et al. (2003). Characterization of 17βhydroxysteroid dehydrogenase type 7 in reproductive tissues of the marmoset monkey. Biol. Reprod. 68, 2092–2099. 8. Oerke, A. K., Einspanier, A., and Hodges, J. K. (1995) Detection of pregnancy and monitoring patterns of uterine and fetal growth in the marmoset monkey (Callithrix jacchus) by real time ultrasonography. Am. J. Primatol. 36, 1–13. 9. Gabler, C., Plath-Gabler, A., Einspanier, A., and Einspanier, R.(1998) Insulinlike growth factors and their receptors are differentially expressed in the oviduct of the common Marmoset Monkey (Callithrix jacchus) during the ovulatory cycle. Biol. Reprod. 58, 1451–1457.
10_Einspanier_111_122_F
121
8/29/05, 11:18 AM
10_Einspanier_111_122_F
122
8/29/05, 11:18 AM
Mouse Trophoblasts
III IN VITRO TROPHOBLAST AND PLACENTAL MODEL SYSTEMS
123
124
Quinn, Kunath, and Rossant
Mouse Trophoblasts
125
11 Mouse Trophoblast Stem Cells Jennifer Quinn, Tilo Kunath, and Janet Rossant Summary The trophectoderm is one of the earliest cell types to differentiate in the forming mammalian embryo. It is responsible for the initial implantation and the formation of the trophoblast components of the placenta, an organ essential for nutrient and waste exchange between the fetus and its mother. The trophoblast can be modeled in vitro using trophoblast stem cells. Trophoblast stem cells require fibroblast growth factor (FGF)4, heparin, and contact with embryonic fibroblasts, or fibroblast-conditioned medium. They grow as tight epithelial colonies, which express markers of the early trophectoderm and have been shown to contribute to all of the components of the placenta through chimera studies. These cells can be passaged indefinitely and can be differentiated by removal of FGF4 and fibroblasts and will express genetic markers of later placental cell types. This chapter will discuss the initial derivation of trophoblast stem cells from the blastocyst stage, maintenance, differentiation, flow cytometry and transfection techniques that can be used with these cells. Key Words: Trophoblast stem cell; trophectoderm; derivation; culture maintenance; differentiation; flow cytometry; transfection.
1. Introduction In a mouse blastocyst at embryonic day (E) 3.5, the specification of the trophectoderm and the inner cell mass is the first differentiation to occur. By E 4.5, there are three cell types: the primitive endoderm, which will form the visceral and parietal endoderm; the primitive ectoderm, which will form the embryo proper; and the trophectoderm, which will produce all the trophoblast tissues (1,2). The trophoblast is essential for survival of the mammalian conceptus because it mediates implantation and ultimately creates the placenta, which allows nutrient and waste exchange between the fetus and its mother (3). The outer cells of the blastocyst—the trophectoderm—can be divided into two distinct components: polar and mural (4). The mural trophectoderm is comprised of the cells that are most distal to the inner cell mass. These cells will differentiate into primary trophoblast giant cells. Giant cells undergo From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
125
126
Quinn, Kunath, and Rossant
endoreduplication, which results in large polyploid cells (5). The mural trophectoderm and its resulting primary giant cells are important for the initial implantation of the blastocyst (3). This differentiation continues laterally toward the border of the inner cell mass (4). The polar trophectoderm is located in direct contact with the inner cell mass (4). These cells remain diploid and continue to divide, giving rise to the trophoblast lineage. This includes the extra-embryonic ectoderm and the ectoplacental cone and, eventually, the components of the mature chorioallantoic placenta—the spongiotrophoblast, labyrinth and giant cell layer (3). This chapter discusses trophoblast stem cells as an in vitro model of the trophoblast cell lineage. Embryonic stem cells from the primitive ectoderm are a well-established in vitro model (6–8). These cells can be genetically manipulated and have provided insight into the development of the embryo and essential genes involved in this process (9). Trophoblast stem (TS) cells may be used in a similar fashion to elucidate the mechanism of differentiation and the role of genes and cell types in the development of the placenta. Trophoblast stem cells are diploid, permanent, and self-renewing when they are maintained in stem cell conditions. They express markers of the trophectoderm, extra-embryonic ectoderm, and ectoplacental cone (see Note 1). TS cells can be derived from E 3.5 blastocysts, the extra-embryonic ectoderm from E 6.5 conceptuses, and the chorionic ectoderm from E 7.5 to E 10 embryos (10–12). Specific mutant TS cell lines can be developed if the gene in question is not required for stem cell initiation or maintenance. TS cells require: fibroblast growth factor (FGF)4 , heparin, and embryonic fibroblasts (EMFIs) or embryonic fibroblast-conditioned medium (FCM) to maintain their stem cell morphology of tight adherent epithelial colonies. These cells have been shown to contribute to all trophectoderm derivates through chimera experiments and can be maintained in culture indefinitely (10). When stem cell factors are removed, TS cells differentiate and show an increase in expression of genetic markers for the spongiotrophoblast, labyrinth, and giant cells and decrease in expression of genes from the blastocyst, extraembryonic ectoderm, and ectoplacental cone. Ultimately, these cells become terminally differentiated giant cells with large cytoplasm and high ploidy (10). This chapter describes methods for TS cell derivation from blastocysts, maintenance, differentiation, fluorescence-activated cell sorting (FACS), and transfection. 2. Materials 2.1. Embryonic Fibroblasts 1. Dulbecco’s modified Eagle’s medium (DMEM) (Sigma, St. Louis, MO, Cat. Nos. D2650 and D5879).
Mouse Trophoblasts
127
2. Trypsin/ethylenediamine tetraacetic acid (EDTA) (Invitrogen Life Technologies, Carlsbad, CA, cat. no. 25200-056). 3. DMEM + 10% fetal bovine serum (FBS). 4. Mitomycin C (Sigma, cat. no. M0503). 5. 0.45-µm filter (Corning, Acton, MA, cat. no. 430945). 6. TS cell medium: to 500 mL RPMI 1640 + antibiotics (penicillin/streptomycin at 50 µg/mL each final concentration; Invitrogen, cat nos. 61870 or 11875), add the following: a. 130 mL FBS, final concentration 20% (Invitrogen). b. 6.5 mL, 100 mM sodium pyruvate (final concentration 1 mM) (Invitrogen). c. 6.5 mL, 10 mM β-mercaptoethanol (final concentration 100 µM) (Sigma). d. 6.5 mL, 200 mM L-glutamine (final concentration 2 mM) (Invitrogen). 7. 2X Freezing medium. 50% FBS, 30% TS medium, 20% dimethylsulfoxide (DMSO); cool to 4°C. 8. 1000X FGF4 human recombinant FGF4 (Sigma, cat. no. F2278), 25 µg a. Resuspend lyophilized FGF4 in its vial with 1.0 mL of phosphate-buffered saline (PBS)/0.1% w/v fraction V bovine serum albumin (BSA). b. Mix well with P200 and make 10 aliquots of 100 µM into 1.5-mL microfuge tubes and freeze at –70°C. c. Thaw each aliquot as needed and store at 4°C; do not re-freeze. 10 mL PBS/ 0.1% (w/v) BSA is prepared by dissolving BSA (Sigma, cat. no. A3311) in PBS without Ca 2+/Mg 2+; filter through a 0.45-µL syringe filter, and make 1-mL aliquots in microfuge tubes; store at –70°C and thaw one tube when a vial of FGF4 must be reconstituted. 9. 1000X Heparin (Sigma, cat. no. H3149 10,000 U): a. Resuspend heparin in PBS to a final concentration of 1.0 mg/mL (1000X). b. Make nine aliquots of 1.1 mL in 1.5 microfuge tubes. c. Store at –70°C. d. Thaw aliquots as needed and store at 4°C. e. Heparin can also be prepared as a 10,000X (10 mg/mL) stock in PBS without Ca2+/Mg2+ and stored at –70°C. This can be used multiple times to make batches of 1000X heparin. 10. 70% FCM + F4H. 70% FCM, 30% TS medium, 1/1000 FGF4, 1/1000 heparin. 11. TS Medium + F4H. TS medium, 1/1000 FGF4, 1/1000 heparin. 12. PBS without calcium and magnesium. 13. Tissue culture equipment. 14. Hemocytometer to count cells. 15. Isopropanol freezing container.
2.2. TS Cell Derivation 1. M2 Medium (Specialty Media, Phillipsburg, NJ, MR-015-D). 2. KSOM Medium (Specialty Media, MR-121-D). 3. Pulled glass pipet (12-in.).
128
Quinn, Kunath, and Rossant
4. Mouth pipetting equipment (tubing [one-thirty-second of an inch wall, VWR Scientific Products, West Chester, PA, cat. no. 62996-350], p1000 pipet tip, cotton plug, aspirator mouth piece). 5. TS cell culture medium. 6. PBS without calcium and magnesium. 7. 70% FCM + F4H. 70% FCM, 30% TS medium, 1/1000 FGF4, 1/1000 heparin. 8. TS Medium + F4H. TS medium, 1/1000 FGF4, 1/1000 heparin.. 9. Tissue culture equipment. 10. Hemocytometer to count cells.
2.3. TS Cell Maintenance 1. 2. 3. 4. 5. 6. 7. 8.
TS cell culture medium. PBS without calcium and magnesium. 70% FCM + F4H. 70% FCM, 30% TS medium, 1/1000 FGF4, 1/1000 heparin. TS Medium + F4H. TS medium, 1/1000 FGF4, 1/1000 heparin. Tissue culture equipment. Hemocytometer to count cells. 2X Freezing medium: 50% FBS, 30% TS medium, 20% DMSO, cool to 4°C. Isopropanol freezing container.
2.4. TS Cell Differentiation 1. 2. 3. 4. 5. 6.
TS cell culture medium. PBS without calcium and magnesium. 70% FCM + F4H. 70% FCM, 30% TS medium, 1/1000 FGF4, 1/1000 heparin. TS Medium + F4H. TS medium, 1/1000 FGF4, 1/1000 heparin. Tissue culture equipment. Hemocytometer to count cells.
2.5. Flow Cytometry 1. 2. 3. 4. 5. 6. 7. 8. 9.
70% Ethanol. Propidium iodide (PI; Molecular Probes, Eugene, OR), 1 mg/mL in water. Triton-X 100, 0.1% final concentration (Sigma). RNase A. PI/Triton X-100 staining solution with RNase A: to 10 mL of 0.1% Triton X-100 in PBS, add 2 mg DNase-free RNase A and 200 µL of 1 mg/mL PI. Polypropylene or polystyrene tubes (5 mL). Hoechst 33342, 1 mg/mL in water. 70-µm Cell Strainer (BD Biosciences, Bedford, MA, Falcon cat. no. 352350). Flow cytometer with 488-nm argon laser.
2.6. Transfection 1. LipofectAMINE PLUS (Gibco-BRL, Gaithersburg, MD, cat. no. 10964-013): RPMI culture medium, PLUS reagent, lipofectamine.
Mouse Trophoblasts 2. 3. 4. 5.
129
GenePulser cuvet (BioRad, Hercules, CA, cat. no.165-2088). Linearized DNA. PBS. Drugs for selection, e.g., G418 (200 µg/mL), puromycin (1 µg/mL), hygromycin (150 µg/mL).
3. Methods The methods detailed in this chapter describe the (1) the isolation and culturing of mouse embryo fibroblasts, (2) derivation of TS cells from blastocysts, (3) maintenance, and (4) differentiation of TS cells, as well as (5) protocols to perform flow cytometry to sort cells and analyze DNA content and (6) to perform DNA transfection.
3.1. Embryonic Fibroblasts The protocol for isolating and culturing mouse embryo fibroblasts is based on the procedure previously described (9).
3.1.1. Isolation and Expansion of EMFI Cultures 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22.
Dissect one litter of E 15.5 to E 16.5 embryos into PBS. Remove embryos’ limbs, brains, and internal organs. Place the carcasses into 50-mL Falcon tubes with PBS. Rinse with DMEM three times. Aspirate the medium. Mince the embryos into small pieces. Add 10 mL Trypsin/EDTA to minced pieces in 50-mL tube. Add 5 mL of sterile glass beads and a stir bar. Incubate at 37°C for 30 min while stirring. Repeat steps 8–10. Split cell suspension into two 50-mL Falcon tubes, each containing 3 mL FBS. Wash the original Falcon tube twice with DMEM + 10% FBS and add to tubes from step 11. Centrifuge at 200g for 5 min. Aspirate supernatant. Resuspend pellet in 50 mL of DMEM + 10% FBS. Use trypan blue to quantify viable nucleated cells. Plate 5 × 106 cells per 15-cm tissue culture dish containing DMEM + 10% FBS. Change the medium the next day. Continue feeding every 2 d until cells reach confluency. Split cells 1:6. Continue to feed every 2 d until cells reach confluency. Freeze in chilled 2X Freezing medium (follow steps outlined under Subheading 3.3.).
130
Quinn, Kunath, and Rossant
3.1.2. EMFI Feeders 1. Thaw one vial of EMFIs in five 15-cm tissue culture dishes containing DMEM + 10% FBS. 2. When cells are confluent (approx 3 d), treat with 100 µL mitomycin C (1 mg/mL) in DMEM + 10% FBS. 3. Use as feeders. 4. Mitomycin treated EMFIs can be frozen for later use.
3.1.3. Fibroblast-Conditioned Medium FCM is used to culture TS cells in the absence of EMFIs. 1. Plate mitomycin-treated primary EMFIs in 100-mm dishes (2 × 106 cells; 2 × 105 cells/mL). 2. Culture in approx 11 mL TS medium. 3. Incubate for 72 h. 4. Lift TS media into 14-mL Falcon tubes. 5. Spin at 200g for 4 min to remove floating cells and debris. 6. Filter through 0.45-µm filter. 7. Aliquot. 8. Store at –20°C. 9. Thaw each aliquot as needed and store at 4°C; do not re-freeze. 10. Follow steps 2–8 to prepare two more batches of FCM. 11. Discard the cells. EMFIs are only used up to 10 d after the mitomycin treatment.
3.2. TS Cell Derivation The initial derivation of trophoblast stem cells is described under Subheadings 3.2.1.–3.2.5. These sections cover the methods for obtaining, isolating, and culturing blastocysts as well as the early culturing techniques required for TS cell derivation and maintenance. The time lines indicated are generalized and can differ between genotypes and even between blastocysts from the same litter. It is common to observe the cells every 2 d throughout the process of derivation and maintenance.
3.2.1. Obtaining Blastocysts TS cells arise from the trophectoderm layer of the blastocyst. Thus, the first step involved in deriving TS cells is to obtain blastocysts to culture (see Notes 2 and 3). 1. Day 0. Place female mice in estrus with preteased males mid-afternoon. By 1000 h the following morning, check for a plug to ensure that the mice have mated. This is E 0.5. It is assumed that the mating took place at 2400 h. Continue to house the pregnant female with adequate food and water on a 12-h light/dark cycle for three more days.
Mouse Trophoblasts
131
2. E 3, AM. In a four-well tissue culture dish, plate 0.5 mL mitomycin-treated EMFIs at a density of 5 × 104 cells/mL in TS medium + F4H in each well. Place in a standard incubator at 37°C/5% CO2. A mouth pipet is needed to collect and transfer the blastocysts once they are removed from the mother. To prepare a mouth pipet, insert mouthpiece into one end of 15 cm of tubing (diameter one-thirtysecond inch), and at the opposite end insert a p1000 pipet tip, filled with cotton (9) (see Note 4) 3. E 3, PM. Prepare a pipet with a suitable diameter to maneuver the blastocysts. A 12-in, glass pipet must be heated at the junction where the glass thickens until it becomes slightly pliable. At this point, pull the pipet in one fluid motion until it is about 50 cm long. Break off so that about 10 cm of the thin diameter glass remains (9). Store pipet with thin end up in a clean location. The pipet can be used for several flushings, but should be made fresh each day.
3.2.2. Collecting Blastocysts The following steps describe the process of removing blastocysts from the mother on E 3, PM, so that they can be plated in order to derive TS cells. 1. Set up dissection area with a cloth/diaper for the initial dissection, dissection tools (scissors, forceps), and spray bottle with 70% ethanol. 2. Place KSOM in syringe in 37°C/5%CO2 incubator. 3. Sacrifice female mouse by cervical dislocation (9). 4. Spray abdomen with ethanol to wet fur. 5. Use scissors to cut through skin and body wall. 6. Remove uterus by cutting below oviduct on both horns and above cervix. 7. Place uterine horns in 10-cm dish and view with dissecting microscope. 8. Insert 1-cc syringe with a 20-gauge needle filled with M2 into oviduct end of the uterus. 9. Flush with approx 0.3 cc M2, then flush same horn from cervix end (see Note 5). 10. Repeat for second uterine horn. 11. Use mouth pipet with small amount of M2 and a few bubbles to control fluid flow in order to collect and transfer the blastocysts through four drops of M2 (in a 60mm tissue culture dish). 12. Use mouth pipet with small amounts of M2 to transfer blastocysts through four drops of KSOM heated to 37°C (in 60-mm tissue culture dish). 13. Use mouth pipet to place all embryos in center of an organ culture dish in KSOM. 14. Use mouth pipet to transfer one blastocyst per well onto EMFIs with TS med + F4H (see Note 6 and Fig. 1). 15. Place in incubator. This is day 0 of the blastocyst outgrowth stage. It is normal for the blastocyst to remain floating in the medium for awhile (see Note 7).
3.2.3. Blastocyst Outgrowth and First Disaggregation Within 24–36 h after the initial plating, the blastocyst should attach to the plate and hatch from the zona pellucida. By the third day, in TS cell conditions,
132
Quinn, Kunath, and Rossant
Fig. 1. Fully expanded blastocyst collected by uterine flushing which can be used to derive trophoblast stem cells. The polar trophectoderm (PT) overlying the inner cell mass (ICM) will give rise to most of the trophectoderm derivatives and the mural trophectoderm (MT) will mediate implantation and give rise to primary giant cells. Phase contrast, scale bar 50 µm.
a blastocyst outgrowth should form. When this outgrowth is disaggregated, it will allow the formation of stem cell colonies. If there is no outgrowth, or the blastocyst has not yet attached, the culture still requires fresh media by the third day after initial plating (see Note 7). 3.2.3.1. DAY 3 (AFTER INITIAL PLATING) FEEDING 1. Remove media by aspiration. 2. Feed with 500 µL TS med + F4H (1/1000 FGF4 stock, 1/1000 heparin stock). 3. Continue every 48 h until outgrowth has reached an appropriate size for disaggregation (Fig. 2).
3.2.3.2. DAYS 4–5 (AFTER INITIAL PLATING) DISAGGREGATE
The blastocyst outgrowth should be formed by this time point (see Note 8). Disaggregation must occur before the outgrowth becomes too large. Figure 2 outlines an appropriate outgrowth size to harvest TS cells efficiently. Beyond this point, the TS cells will not be derived as efficiently and an endoderm-like cell type may form in the cultures (11) (Fig. 3) (see Note 9). 1. Select an appropriate outgrowth for disaggregation (between days 3–8). 2. Aspirate media. 3. Rinse plate with 500 µL PBS.
Mouse Trophoblasts
133
Fig. 2. Blastocyst outgrowth 4 d after initial plating. This outgrowth is an appropriate size for dissaggregation. Note the field of giant cells (GC) surrounding the outgrowth (trophoblast stem [TS] cells) and the embryonic fibroblasts (EMFIs) covering the plate. Phase contrast, scale bar 50 µm. 4. 5. 6. 7. 8.
Add 100 µL trypsin. Place in the incubator for 5 min at 37°C/5% CO2. Stop this reaction with 400 µL 70% FCM + 1.5X F4H. Pipet the contents of the well to near-single cell suspension. Return to the incubator.
3.2.3.3. DAY 6 (AFTER INITIAL PLATING/48 H AFTER DISAGGREGATION) FEEDING
Between 6 and 10 d after the disaggregation, TS cell colonies begin to form. TS cell colonies grow as tight, flat epithelial sheets and are present in the culture along with giant cells, which are differentiated TS cells (Fig. 4). These cells require fresh 70% FCM + 1.5X F4H every 48 h until the plate becomes approx 50% confluent. 1. Aspirate the media. 2. Replace with 500 µL of 70% FCM + 1.5X F4H.
134
Quinn, Kunath, and Rossant
Fig. 3. Early trophoblast stem (TS) cell colony surrounded by endoderm-like cells. These round refractile cells are present in TS cell cultures if the blastocyst outgrowth is allowed to get too large prior to disaggregation. The endoderm-like cells are difficult to alleviate since they do not require fibroblast-conditioned medium or fibroblast growth factor-4 to continue to grow. Phase contrast, scale bar 250 µm.
3. This process needs to be repeated every 48 h until the TS cells reach approximately 50% confluent and require passaging.
3.2.4. First Passage The colonies that have arisen from the disaggregated outgrowths require their first passage when they are approx 50% confluent. This typically occurs between 15 and 25 d after initial disaggregation. The first passage of TS cells is the most likely time that these cells can differentiate (see Note 10). For each of the disaggregated outgrowths that require passaging: 1. Prepare a four-well dish (one well per disaggregated outgrowth) by plating EMFIs (5 × 104 cells/mL) with fresh TS medium + 1.5X F4H (400 µL). 2. Place new plates in a incubator for at least one h to condition the medium and limit the amount of TS cell differentiation. 3. Remove media from original well by aspirating. 4. Rinse the well with 500 µL PBS. 5. Aspirate PBS.
Mouse Trophoblasts
135
Fig. 4. Trophoblast stem (TS) cell colony grown on plastic tissue culture dish in TS cell conditions. The stem cell colony has tight epithelial borders. Giant cells (GC) can be seen at the edge of the colony. Phase contrast, scale bar 250 µm.
Add 100 µL of trypsin/EDTA. Place in the incubator for 5 min. Add TS medium + 1.5X F4H (400 µL) from new plate to stop trypsinization. Pipet up and down to prepare a near single cell suspension. Transfer all of the cells in suspension to a new well in a four-well plate with EMFIs. 11. Change the medium approx 8 h after this passage. 12. Continue to feed cells every 2 d with 500 µL TS med + 1.5X F4H. 6. 7. 8. 9. 10.
3.2.5. Early Passages (Passages 2–7) TS cells are still vulnerable to differentiation throughout the early passages. Allow the cells to become at least 70% confluent between passages (see Note 10). 1. 2. 3. 4. 5.
Repeat steps 1–9 as listed under Subheading 3.2.4. Transfer cell suspension to a 14-mL Falcon tube. Spin at 200g for 3 min. Aspirate supernatant. Resuspend in 1 mL 70% FCM + F4H.
136
Quinn, Kunath, and Rossant
6. If the majority of the TS cells have differentiated as a result of passaging or the culture dish is less than 70% confluent and the cells have stopped expanding, passage to new well (1:2) (proceed to step 9). 7. If the cells have maintained their stem cell morphology and are growing rapidly, split into four new wells (1:4). 8. Ensure that each well has a total volume of 500 µL 70% FCM + F4H. 9. Continue to feed cultures every 48 h with fresh medium (see Note 10). 10. Passage as required. 11. By passage 7, it is possible to expand the line to a six-well dish (35 mm), which can be maintained as described under Subheading 3.3.
3.3. TS Cell Maintenance Subheadings 3.3.1.–3.3.5. cover protocols required for the maintenance and storage of a stable TS cell line, including feeding, passaging, plating, and freezing and thawing techniques, which can be used on stable TS cell lines (Fig. 4). A stable line can be defined as one in which at least 70% of the cells maintain typical stem cell morphology. It is normal to have some giant cells in any TS culture, but if they make up the majority of the population of cells, the culture is not stable and it may not be possible to recover TS cells through a freeze/thaw cycle. It is also important to note that, because TS cells and giant cells are adherent, cells floating in the medium are indicative of dead or dying cells. The protocols in this section can be applied to cells grown on EMFIs or to cells grown directly on tissue culture plates. They do not require gelatin as previously demonstrated (10).
3.3.1. Feeding In order to maintain TS cells, fresh medium and growth factors are required every 48 h. TS cells plated on EMFIs tend to recover more rapidly from a thaw or other detrimental conditions. For TS cell analysis, it is beneficial to have a pure population without EMFIs. Pure populations of TS cells grown on plastic require 70% feeder conditioned medium (see Note 11). 3.3.1.1. CULTURING TS CELLS ON EMFIS
EMFIs can effectively condition the TS medium for 10 d; thereafter, it is best to passage the TS cells onto fresh EMFIs. When these cells are on EMFIs, they require TS med + F4H. If the cells have not reached 70% confluency on the original EMFIs beyond 10 d, begin feeding with 70% FCM + F4H as described under Subheading 3.3.1.2. 1. Prepare fresh TS medium + F4H. 2. Aspirate old medium. 3. Feed TS cells on EMFIs with new TS med + F4H.
Mouse Trophoblasts
137
4. Place in a standard tissue culture incubator, 37°C/5% CO2. 5. Replace with fresh TS medium + F4H every 48 h up to 10 d after the initial plating of EMFIs.
3.3.1.2. CULTURING TS CELLS ON TISSUE CULTURE PLASTIC
TS cells grow well on standard tissue culture dishes if the medium is supplemented with 70% FCM + F4H. This is an ideal condition for analysis of DNA content, RNA isolation, or for visualizing the cells with immunohistochemistry techniques, because it provides a pure population of TS cells. These steps must also be followed in the TS cells grown on EMFIs that are more than 10 d old. 1. Prepare 70% FCM + F4H (e.g.,10 mL of 70% FCM +F4H = 7 mL FCM, 3 mL TS medium, 10 µL 1000X FGF4 stock, 10 µL 1000X heparin stock). 2. Aspirate old medium. 3. Add fresh medium.
3.3.2. Passaging When the cells reach approx 80–90% confluency, they must be passaged to a new plate so they can continue to grow and expand. Stable TS cells can be passaged at 1:20 every 5–7 d. TS cells that differentiate or are slow growing can be passaged at 1:5. Each line is unique and requires some level of optimization. To expand the line to a larger surface area, passage no less than 1:7 of the total cells. Cells can be passaged directly onto plastic tissue culture dishes or they may be plated onto EMFIs after they have adhered or co-plated with the EMFIs at the time of passaging. Density has an effect on cell growth and differentiation. Cells grown or passaged at too high a density can become overcrowded. This results in cell death and differentiation (see Note 12). Cells plated at too low a density have high rates of differentiation even when maintained in stem cell feeding conditions. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13.
Aspirate media. Rinse with PBS. Aspirate PBS. Add trypsin (one-half volume of medium) (see Note 11). Incubate at 37°C/5% CO2 for 5 min. Tap plate and cells should lift into suspension. If the cells do not lift, continue to incubate for another 2–5 min. Stop trypsinization with TS medium (same volume as trypsin). Pipet vigorously to attain near single cell suspension. Lift all media to 14-mL Falcon tube. Spin at 200g for 3 min. Aspirate supernatant. Resuspend pellet of cells with 1 mL TS medium. Plate into new dishes with 70% FCM at an appropriate volume (see Note 11).
138
Quinn, Kunath, and Rossant
3.3.3. Differential Plating This technique can be used for two main purposes. The first is to remove EMFIs from TS cell cultures to provide a pure population of TS cells. Second, differential plating can enrich either stem cells or giant cells. 3.3.3.1. REMOVING EMFIS FROM TS CELL CULTURES
When switching from EMFI cells to plastic dishes with 70% FCM, it may be desirable to get rid of the EMFI cells immediately. The different adherence rates of EMFI cells (fast) and TS cells (slow) can be used to obtain a pure TS cell population. Because some TS cells do settle along with the EMFIs, the desired passage density may be increased a bit (e.g., 1:14 instead of 1:16). 1. Passage cells to a new plate following the steps under Subheading 3.3.2. 2. Incubate the culture for 1.5 h at 37°C/5% CO2. 3. Remove the supernatant and plate onto another dish.
3.3.3.2. ENRICHING FOR GIANT CELLS OR TS CELLS
Giant cells can be removed from a culture based on their different adherence rates. Giant cells adhere more quickly and more strongly than stem cells to the culture dishes. The supernatant should have a reduced population of giant cells compared with the initial cell population, whereas the cells remaining on the plate should have an increased proportion of giant cells. 1. Follow the passaging protocol under Subheading 3.3.2. 2. Incubate for 15–30 min at 37°C/5% CO2. 3. Remove supernatant and passage onto another dish.
3.3.4. Freezing/Thawing TS cells can be frozen for indefinite periods and then later thawed for use. This allows a certain level of security, because it is not necessary to derive new TS cells every time one wants a new plate, and it is possible to expand and store lines of interest for extended periods of time. 3.3.4.1. FREEZING 1. Obtain cells in suspension (1 mL) using the protocol outlined under Subheading 3.3.2. 2. Add 1 vol of 2X Freezing medium cooled to 4°C. 3. Place 1 mL in a freezing vial. 4. If freezing several lines, keep those in the 2X freezing medium on ice until all can go in the freezer. 5. Place tubes in an isopropanol slow-freeze container. 6. Slowly freeze in –70°C Freezer for at least 48 h. 7. Transfer to liquid nitrogen.
Mouse Trophoblasts
139
3.3.4.2. THAWING
To recover a cell line from a frozen vial, culture and passage freshly thawed cells at least twice to ensure they have recovered sufficiently before beginning any experiments. After the initial thaw, it is normal to have a large number of floating cells, some giant cells and some stem cell colonies (see Note 12). If the plate appears confluent (it may require aspirating the media and rinsing with PBS to see through the floaters), the cells require a passage. Otherwise, continue to feed the cells until they reach 80% confluency then follow the protocol for passaging. Cells often recover more rapidly when they are thawed onto EMFIs. 1. Remove the vial of cells from liquid nitrogen or –70°C freezer. 2. Warm in 37°C water bath until just thawed, approx 3 min. 3. Use a 1 mL pipet to transfer contents of vial to a 14-mL Falcon tube containing 1 mL TS medium. 4. Spin at 200g for 3 min. 5. Aspirate to remove DMSO contained in the freezing medium. 6. Resuspend into an appropriate medium depending on if they are on EMFIs or on plastic. 7. Plate all cells from vial onto a surface area, which is smaller than the original plate. 8. 24 h after initial plating aspirate medium (expect many floaters). 9. Rinse with PBS. 10. Add appropriate fresh medium.
3.4. TS Cell Differentiation As TS cells differentiate in vitro, markers of later cell types of the trophectoderm lineage show an increased expression whereas markers of the blastocyst, extra-embryonic ectoderm, and ectoplacental cone show a decrease (see Note 1). The changes in gene expression are associated with changes in cell morphology and DNA content. These changes are indicative of cells that are changing from tight epithelial TS cell colonies to intermediate cell types and finally to terminal giant cells with expansive cytoplasm and large polyploid nuclei. Most TS cell cultures will differentiate to predominantly giant cells by the sixth day of differentiation although some genotypes require a longer period of time (Fig. 5). The rate of differentiation is influenced by several factors, including genotype and cell density. It is important to select a consistent density to work with. TS cell plated at a very low density differentiate very rapidly to giant cells and do not show an increased expression of intermediate markers of spongiotrophoblast and labyrinth cells. Typically, a density that results in the culture becoming nearly confluent by day 6 of differentiation is used (~2 × 105/ 60-mm plate). A protocol for the induction of differentiation is presented.
140
Quinn, Kunath, and Rossant
Fig. 5. Differentiated trophoblast stem cells grown on plastic dishes. These cells have been without fibroblast-conditioned medium + F4H for 6 d and show a characteristic giant cell morphology with a large cytoplasm and nucleus. Phase contrast, scale bar 250 µm.
1. Establish the number of plates required for selected time points. 2. Using the same density, plate all initial dishes with TS cells with 70% FCM + F4H. 3. Incubate for 24 h. 4. After 24 h collect the day 0 culture. 5. Prepare day 0 sample for further analysis. 6. Initiate differentiation of remaining plates by removing 70% FCM + F4H (see Note 13). 7. Rinse briefly with PBS. 8. Aspirate. 9. Add PBS for 5 min. 10. Aspirate. 11. Replace with TS medium. 12. Incubate. 13. Follow steps 7–12 every 2 d throughout the course of the differentiation experiment. 14. Collect plates at time points throughout differentiation (see Note 14).
Mouse Trophoblasts
141
3.5. Flow Cytometry Analysis and Sorting FACS sorting by flow cytometry is a method used to measure ploidy (see Subheading 3.5.1.) and to sort cells by DNA content or other markers (see Subheading 3.5.2.). This procedure can be done on living or fixed samples. It can be used to measure the percentage of diploid, tetraploid, and cells with a ploidy >8 N to quantify the percentage of giant cells in a population (Fig. 5). It is also an efficient method to sort for diploid TS cells or green fluorescent protein (GFP)-positive cells to isolate and expand these populations. The initial steps of these methods are outlined in this section. These methods have been adapted from procedures described by Darzynkiewicz and Juan (13).
3.5.1. To Analyze Ploidy 1. Collect cells at selected time points throughout differentiation by trypsinizing entire plate following protocol to passage. If giant cells are abundant at later time points in differentiation, use a cell scraper to ensure all giant cells are lifted (see Note 15). 2. Stop trypsinization with TS medium. 3. Lift all cells to a 14-mL Falcon tube. Ensure that all cells have been collected by rinsing plate with an additional 2 mL TS medium. 4. Count and record cell number. 5. Spin cells at 200g for 4 min. 6. Remove supernatant. 7. Resuspend cells in 500 µL PBS (see Note 16). 8. Add 6 mL 70% ethanol to fix the cells. 9. Store in –20°C freezer until ready to use. 10. When ready to analyze, make fresh PI/Triton X-100 staining solution with RNase A. 11. Spin cells at 500g for 5 min. 12. Remove ethanol. 13. Resuspend pellet in 5 mL PBS. 14. Let stand for 1 min. 15. Centrifuge cells for 5 min at approx 200g. 16. Remove supernatant. 17. Suspend cell pellet, 1 × 106 cells/mL based on cell count in step 4 in PI/Triton X-100 staining solution with RnaseA. 18. Keep at room temperature for 30 min or in incubator at 37°C for 15 min. 19. Filter cells through a 70-µm filter into 5 mL polypropylene or polystyrene test tubes. 20. Set up and adjust the flow cytometer for excitation with an argon ion laser (488 nm) and detection of PI emission using a 675 band pass filter. 21. Measure cell fluorescence using pulse peak–pulse area signal to discriminate between G2 cells and cell doublets. 22. Analyze the ploidy of cells using DNA content frequency histogram (Fig. 6).
142
Quinn, Kunath, and Rossant
Fig. 6. Fluorescence-activated cell sorting profile of undifferentiated trophoblast stem (TS) cells (day 0) and differentiated TS (day 12 in TS medium without embryonic fibroblasts, fibroblast growth factor-4, and Heparin). These data have been collected from a gated channel to exclude cell doublets. The first peak indicates diploid cells; the second peak shows tetraploid cells. The peaks included within line I are giant cells with a ploidy greater than or equal to 8 N. There is an increase in total percentage of high ploidy cells (>8 N) by day 12 of differentiation indicating an increased percentage of giant cells.
3.5.2. To Sort Live Cells A flow cytometer can sort TS cells for GFP expression and for diploid DNA content, which is indicative of stem cells. 1. 2. 3. 4. 5. 6. 7. 8. 9.
10.
Put cells into single cell suspension following the cell passage protocol. Count cells using hemocytometer. Spin at 200g for 3 min. Remove supernatant. Resuspend cells in TS medium (1 × 106 cells/mL). Add Hoechst 33342 staining solution to cell solution for a final dye concentration of 2–5 µg/mL. Incubate at 37°C for 20–90 min. Strain cells through 70 µm filter into 5 mL polypropylene or polystyrene tubes. Set up and adjust flow cytometer for ultraviolet excitation at 340–380 nm to detect Hoechst 33342 and GFP; enhanced green fluorescent protein (EGFP) can be detected at 488 nm. Measure cell fluorescence using pulse width–pulse area signal to discriminate between G2 cells and cell doublets.
Mouse Trophoblasts 11. 12. 13. 14. 15.
143
Set a gate to sort out cell doublets. Set a gate to sort out cells with DNA ploidy >8 N (giant cells). Single diploid TS cells will be collected in collection tube. Plate cells on EMFIs + TS med + F4H or on to plastic dishes with 70% FCM + F4H. Incubate and continue to maintain as outlined under Subheading 3.3.
3.6. DNA Transfection DNA transfection can be used to alter the genome of TS cells by introducing a specifically designed DNA fragment. The new DNA is only incorporated into a subpopulation of the cells treated. A positive selectable marker gene is needed to detect successfully transfected cells. Two methods have been used to transfect TS cells: lipofectamine (see Subheading 3.6.1.) and electroporation (see Subheading 3.6.2. and Note 17).
3.5.1. Transient Transfections With Lipofectamine 1. Obtain a plate of subconfluent cells (1 d after passage) in a six-well dish. 2. Combine circular plasmid carrying gene of interest (1 µg) and plasmid containing reporter gene (e.g., GFP) (0.2 µg) with RPMI 1640 (200 µL without antibiotics) and PLUS reagent (12 µL) (see Note 18). 3. Incubate for 15 min at room temperature. 4. Add RPMI 1640 (190 µL) and Lipofectamine (10 µL) mixture to the DNA/PLUS. 5. Incubate for 15 min at room temperature. 6. Wash TS cells in PBS. 7. Add 800 µL RPMI 1640. 8. Add DNA/PLUS/Lipofectamine solution. 9. Incubate at 37°C/5% CO2 for 3 h. 10. Add 2 mL FCM with 50 ng/mL FGF4 and 2 µg/mL heparin. 11. Incubate for 16 h. 12. Change the medium to 70% FCM with F4H. 13. Incubate 24 h. 14. Assay for reporter gene activity.
In transient transfections the GFP reporter construct has been shown to start expressing GFP 24 h after the transfection. This expression peaks by 48 h and the amount of protein shows a dramatic decrease by the fifth day after transfection.
3.5.2. Stable Transfections Using Electroporation Obtain a plate of near confluent cells (5 × 106). Prepare plasmid by isolating DNA using a DNA preparation kit (e.g., Qiagen). Linearize vector DNA with a restriction enzyme digest. Switch on electorporation apparatus and set it to electroporate at 0.25V and a capacitance of 500 uFD. 5. Follow passaging protocol to pellet cells and remove supernatant.
1. 2. 3. 4.
144
Quinn, Kunath, and Rossant
6. 7. 8. 9. 10. 11. 12. 13.
Resuspend in PBS (0.8 mL) (see Note 19). Transfer to GenePulser cuvet (0.4 cm electrode). Add linearized DNA (4–25 µg). Electroporate at 0.25 V and a capacitance of 500 uFD. Incubate cells on ice for 20 min. Plate cells on 100 mm plate with 10 mL 70% FCM +F4H. Incubate for 24 h. Start suitable drug selection depending on drug resistance gene on plasmid: G418 (200 µg/mL), puromycin (1 µg/mL), hygromycin (150 µg/mL). 14. Incubate. 15. Feed cells with 70% FCM + F4H + selectable marker every 48 h. 16. Pick colonies 12 d later (see Note 20).
4. Notes 1. TS cells show regulation of different genetic markers throughout differentiation. Table 1 outlines a few of these genes as well as some genes that can be used to screen colonies for endoderm-like cells, which might be contaminating a culture. 2. The protocols outlined in this chapter are for deriving TS cells from E 3.5 blastocysts. Embryos flushed at E 2.5 and cultured overnight can be used to plate on EMFIs for TS cell derivation. 3. TS cells have not been successfully derived from C57BL6 mice. Naturally mated ICR mice can carry 8–15 embryos. 4. Mouth pipets or finger pipets are required to manipulate blastocysts. Pulling pipets is a delicate process—practice first! To control the blastocysts within the pipet, ensure that there are at least three air bubbles before attempting to pick up. In order to keep the mouthpiece clean, place the cap of a 14-mL Falcon tube (with a hole in it) on the tubing below the mouthpiece. The mouth pipet can be covered when not in use with a cap of a 14-mL Falcon and the main body of the Falcon tube. Further directions for mouth pipetting can be found on page 177 in ref. 9. 5. When flushing blastocysts, the uterine horn will bulge when KSOM is added and a slightly cloudy liquid will emerge from opposite end. It is important not to squeeze or puncture uterine horn. 6. EMFIs can “condition” the medium for approx 10 d; after that point 70% FCM is required. 7. If adding new medium before the blastocysts have fully attached, be careful not to dislodge or aspirate them. 8. Ensure that each blastocyst and subsequent TS line are kept separate from all others to avoid contamination. 9. Primitive endoderm-like cells are round and highly refractile. They can be found in TS cultures if the blastocyst outgrowth becomes too large before the initial dissociation. These cells grow well in TS medium with or without F4H and are very difficult to remove.
Mouse Trophoblasts
145
Table 1 Genes Used to Characterize TS Cell Cultures Throughout Differentiation Gene Name
Expression
Cdx2 Eomesodermin
Trophectoderm E 3.5 Trophectoderm E 3.5 Extra-embryonic ectoderm (Exe) Exe E 5.5 Chorion E 8.5 Exe Chorion E 8.5 Labyrinth E 9.5 Exe E 7.5 Chorion E 8.5 Ectoplacental cone E 6.5 Spongiotrophoblast E 8.5–18.5 Spongiotrophoblast E 10
Errβ Esx1
Wnt7b 4311 Nodal Gcm1 Placental lactogen 1 Placental lactogen II α Fetoprotein Indian hedgehog
Chorion E 7.5–9.5 Labyrinth E 9.5–E 17.5 Primary giant cells E 5–E 12 Secondary giant cells E 12–term Visceral and parietal endoderm Visceral endoderm
TS cell expression profile
Reference
TS cell marker TS cell marker
14,15 10,16,17
TS cell marker
10,18
Chorion and labyrinth marker
19–21
Chorion marker
22
Spongiotrophoblast marker Spongiotrophoblast marker Chorion and labyrinth marker Giant cell marker Giant cell marker Endoderm marker Endoderm marker
23,24 25
26–29 30–32 30–34 35 36
10. Table 2 provides guidelines for the appropriate dish, amount of medium, and passage requirements for various stages throughout the derivation of TS cell lines. 11. Table 3 provides the area and requirements of commonly used tissue culture dishes in the maintenance and differentiation of TS cells. 12. Cultures that have a high rate of floating cells should be rinsed thoroughly. Aspirate the media, rinse with room temperature PBS, and aspirate. Add PBS for 5 min, aspirate, and feed cells with fresh medium. 13. Cells cannot be differentiated on EMFIs, because they will condition the media and will inhibit differentiation. 14. Giant cells are very adherent and are difficult to trypsinize. If after 5 min of trypsinization the cells remain attached, try to dislodge cells by pipetting up and down in trypsin only before stopping the reaction with TS medium. If the cells still remain attached, use a cell scraper to dislodge the rest of the cells. 15. Ensure that all cells are in suspension, especially giant cells, which adhere very strongly to the plate.
146
Quinn, Kunath, and Rossant
Table 2 A Guideline for Passaging at Different Stages Throughout Derivation Stage
Size of dish
Blastocyst plating Disaggregation First passage
Four-well + feeders Same four-well Four-well + feeders All or 1:2 Four-well + feeders Four-well–six-well Six-well + or – feeders 60-mm 60-mm
Passage 2–7 Passage 8 + to expand Six-well (60-mm) Maintaining on 60-mm
Amount of medium
Amount to passage
500 µL 500 µL 500 µL
Not applicable All
500 µL
1:2–1:10
2 mL 5 mL 5 mL
1:4–1:7 1:7 1:10–1:30
Table 3 Tissue Culture Dishes and Conditions Well Four-well Six-well (35 mm) 60-mm 100-mm
Area cm2
Volume to feed
9.62 28.27 78.54
0.500 mL 2 mL 5 mL 10 mL
Volume of trypsin 0.100 mL 1 mL 2.5 mL 5 mL
16. Cells used in FACS sorting must be in a single cell suspension or they will be lost in the filtration step. 17. Transient transfections in TS cell occurs with a success rate of approx 1%. 18. In transient transfections, the ratio of reporter plasmid to gene of interest must be optimized; often, higher concentrations of DNA are helpful. 19. Approximately 50% cell death is expected with optimal transfection efficiency when PBS is used. 20. On a 10-cm plate, there are often approx 100 drug-resistant colonies present after 12 d.
References 1. Gardner, R. L. (1982) Investigation of cell lineage and differentiation in the extraembryonic endoderm of the mouse embryo. J. Embryol. Exp. Morphol. 68, 175– 198. 2. Snell, G. D. and Stevens, L. C. (1966) Early embryology, in Biology of the Laboratory Mouse (Green, E. L., ed.). McGraw-Hill, New York: pp. 205–245.
Mouse Trophoblasts
147
3. Rossant, J. and Cross, J. (2002) Extraembryonic lineages, in Mouse Development; Patterning, Morphogenesis and Organogenesis (Rossant, J. and Tam, P. P., eds.). Academic, San Diego: pp. 155–180. 4. Dickson, A. D. (1963) Trophoblastic giant cell transformation of mouse blastocyts. J. Reprod. Fertil. 169, 465–466. 5. Barlow, P. W. and Sherman, M. I. (1972) The biochemistry of differentiation of mouse trophoblast: studies on polyploidy. J. Embryol. Exp. Morphol. 27, 447–465. 6. Bradley, A., Evans, M., Kaufman, M. H., and Robertson, E. (1984) Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 309, 255–256. 7. Evans, M. J. and Kaufman, M. H. (1981) Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156. 8. Martin, G. R. (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 78, 7634–7638. 9. Nagy, A., Gertsenstein, M., Vintersten, K., and Behringer, R. R. (2003) Manipulating the Mouse Embryo, 3rd Ed. (Inglis, J. and Cuddihy, J., eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 10. Tanaka, S., Kunath, T., Hadjantonakis, A. K., Nagy, A., and Rossant, J. (1998) Promotion of trophoblast stem cell proliferation by FGF4. Science 282, 2072– 2075. 11. Kunath, T. (2003) PhD thesis in Medical and Molecular Genetics, University of Toronto, Toronto 12. Uy, G. D., Downs, K. M., and Gardner, R. L. (2002) Inhibition of trophoblast stem cell potential in chorionic ectoderm coincides with occlusion of the ectoplacental cavity in the mouse. Development 129, 3913–3924. 13. Darzynkiewics, Z. and Juan, G. (1997) Nucleic acid analysis, in Current Protocols in Cytometry, John Wiley and Sons, New York: pp. 7.5.1–7.5.23. 14. Beck, F., Erler, T., Russell, A., and James, R. (1995) Expression of Cdx-2 in the mouse embryo and placenta: possible role in patterning of the extra-embryonic membranes. Dev. Dyn. 204, 219–227. 15. Chawengsaksophak, K., James, R., Hammond, V. E., Kontgen, F., and Beck, F. (1997) Homeosis and intestinal tumours in Cdx2 mutant mice. Nature 386, 84–87. 16. Ciruna, B. G. and Rossant, J. (1999) Expression of the T-box gene eomesodermin during early mouse development. Mech. Dev. 81, 199–203. 17. Russ, A. P., Wattler, S., Colledge, W. H., et al. (2000) Eomesodermin is required for mouse trophoblast development and mesoderm formation. Nature 404, 95–99. 18. Luo, J., Sladek, R., Bader, J. A., et al. (1997) Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta. Nature 388, 778–782. 19. Li, Y., Lemaire, P., and Behringer, R. R. (1997) Esx1, a novel X chromosomelinked homeobox gene expressed in mouse extraembryonic tissues and male germ cells. Dev. Biol. 188, 85–95. 20. Li, Y. and Behringer, R. R. (1998) Esx1 is an X-chromosome-imprinted regulator of placental development and fetal growth. Nat. Genet. 20, 309–311.
148
Quinn, Kunath, and Rossant
21. Cross, J. C. (2000) Genetic insights into trophoblast differentiation and placental morphogenesis. Semin. Cell. Dev. Biol. 11, 105–113. 22. Parr, B. A., Cornish, V. A., Cybulsky, M. I., and McMahon, A. P. (2001) Wnt7b regulates placental development in mice. Dev. Biol. 237, 324–332. 23. Lescisin, K.R., Varmuza, S., and Rossant, J. (1988) Isolation and characterization of a novel trophoblast-specific cDNA in the mouse. Genes. Dev. 2, 1639–1646. 24. Deussing, J., Kouadio, M., Rehman, S., Werber, I., Schwinde, A., and Peters, C. (2002) Identification and characterization of a dense cluster of placenta-specific cysteine peptidase genes and related genes on mouse chromosome 13. Genomics 79, 225–240. 25. Ma, G. T., Soloveva, V., Tzeng, S. J., et al. (2001) Nodal regulates trophoblast differentiation and placental development. Dev. Biol. 236, 124–135. 26. Basyuk, E., Cross, J. C., Corbin, J., et al. (1999) Murine Gcm1 gene is expressed in a subset of placental trophoblast cells. Dev. Dyn. 214, 303–311. 27. Anson-Cartwright, L., Dawson, K., Holmyard, D., et al. (2000) The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta. Nat. Genet. 25, 311–314. 28. Yu, C., Shen, K., Lin, M., et al. (2002) GCMa regulates the syncytin-mediated trophoblastic fusion. J. Biol. Chem. 277, 50,062–50,068. 29. Stecca, B., Nait-Oumesmar, B., Kelley, K. A., Voss, A. K., Thomas, T., and Lazzarini, R. A. (2002) Gcm1 expression defines three stages of chorio-allantoic interaction during placental development. Mech. Dev. 115, 27–34. 30. Colosi, P., Swiergiel, J. J., Wilder, E. L., Oviedo, A., and Linzer, D. I. (1988) Characterization of proliferin-related protein. Mol. Endocrinol. 2, 579–586. 31. Faria, T. N., Deb, S., Kwok, S. C., Talamantes, F., and Soares, M. J. (1990) Ontogeny of placental lactogen-I and placental lactogen-II expression in the developing rat placenta. Dev. Biol. 141, 279–291. 32. Shida, M. M., Jackson-Grusby, L. L., Ross, S. R., and Linzer, D. I. (1992) Placental-specific expression from the mouse placental lactogen II gene promoter. Proc. Natl. Acad. Sci. USA 89, 3864–3868. 33. Campbell, W. J., Deb, S., Kwok, S. C., Joslin, J. A., and Soares, M. J. (1989) Differential expression of placental lactogen-II and prolactin-like protein-A in the rat chorioallantoic placenta. Endocrinology 125, 1565–1574. 34. Hamlin, G. P., Lu, X. J., Roby, K. F., and Soares, M. J. (1994) Recapitulation of the pathway for trophoblast giant cell differentiation in vitro: stage-specific expression of members of the prolactin gene family. Endocrinology 134, 2390–2396. 35. Becker, S., Wang, Z. J., Massey, H., et al. (1997) A role for Indian hedgehog in extraembryonic endoderm differentiation in F9 cells and the early mouse embryo. Dev. Biol. 187, 298–310. 36. Dziadek, M. and Adamson, E. (1978) Localization and synthesis of alphafoetoprotein in post-implantation mouse embryos. J. Embryol. Exp. Morphol. 43, 289–313.
Connexins and Trophoblast Cell Lineage
149
12 Connexins and Trophoblast Cell Lineage Development Mark Kibschull and Elke Winterhager Summary The mouse is a valuable model for studying basic mechanisms of gene regulation in trophoblast cell lineage differentiation. Elements of placental development are conserved across species, including trophoblast proliferation, differentiation, migration, and vessel invasion. Among the regulatory processes, direct intercellular communication between trophoblast cells via gap junction channels seems to play a crucial role in placental development and physiology. Here we describe in detail the generation of trophoblast stem (TS) cell lines from connexin-deficient mice. The design of differentiation and proliferation assays are specified including marker gene sets which are important for analyzing and comparing the differentiation capacity of the connexin-deficient TS cell lines. Furthermore, we show that TS cells are capable of forming tumors after subcutaneous injection into nude mice, providing the opportunity to investigate trophoblast invasion into host vessels in vivo. Key Words: Connexins; gap junction; placenta; trophoblast stem cells; trophoblast stem cell tumors.
1. Introduction Despite the critical role of the placenta in governing the outcome of pregnancy, there is limited information available about the molecules involved in the differentiation of this organ. Failure of appropriate placental development, especially in the first trimester, is associated with significant complications in pregnancy, including miscarriage, preeclampsia, and intrauterine growth restriction (1). The human placenta is difficult to study for several reasons. Besides the ethical problems of abortion and the availability of sufficient tissues for research, one major point is that the most important steps of trophoblast differentiation occur within the first weeks of gestation. The mouse model is valuable and helpful for studying basic mechanisms of gene regulation in trophoblast cell lineage differentiation. Placentation in the mouse and human involves similar cell biological events, including trophoblast proliferation, differentiation, migration, and vessel invasion. Among the genes regulating these From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
149
12_Kibschull_149_158_F
149
8/29/05, 11:19 AM
150
Kibschull and Winterhager
processes, the direct intercellular communication between trophoblast cells via gap junction channels plays a crucial role in placental development and physiology. Gap junctions are clusters of intercellular membrane channels that connect the cytoplasm of two neighboring cells. Each cell contributes one half of the channel (connexon), which is comprised of six connexin (Cx) subunits. The hydrophilic central pore allows the transfer of ions and small molecules up to 1 kD including nucleotides (cAMP, cGMP), inositol 1,4,5-trisphosphate (IP3), Ca2+, and metabolites. The Cx gene family consists of 19 members in the mouse and 20 members in the human genome (2). Connexins show tissue-specific expression and are temporally regulated during embryonic and placental development. Gap junctions play an obligate role in cellular and tissue function that has been proven by generating knockout mice. Recently, evidence is accumulating for a dual role of gap junctions in signal transduction mediated not only by their channel properties but, in addition, by the carboxy-terminus (C-terminus) of the connexin protein (3). It has been shown that the C-terminus is able to interact with other cellular components and that these protein–protein interactions mediate intracellular signalling (4). Of interest are connexins that lead to a placental phenotype if deleted such as Cx26, Cx31, and Cx45, providing a strong rationale for examining the role of gap junctions in placental development (5–7). Cx26 knockout mice die in utero at day 9.5 post conception (pc) when the chorioallantoic placenta starts to function. The main reason for this early death in utero is impaired glucose uptake into the fetal compartment (5). Cx26 channels connect the two layers of syncytiotrophoblast in the labyrinth layer (5). No obvious changes in trophoblast differentiation could be detected. Thus, the Cx26 channel seems to serve as a channel for the diffusion of molecules across the placental barrier but is not involved in trophoblast cell lineage development. Cx31 is expressed in the trophectoderm and, subsequently, in early trophoblast derivatives (extra-embryonic ectoderm, ectoplacental cone, chorionic ectoderm; see ref. 8). In the mature placenta, Cx31 stays expressed in the spongiotrophoblast throughout pregnancy. If this channel is deleted, a loss of more than 60% of the embryos between day 10.5 and 13 pc is observed (6). The placental phenotype revealed a dramatically reduced size of the placenta on day 9.5 pc with nearly no labyrinth and spongiotrophoblast but an abundance of trophoblast giant cells. Clearly, the missing channel leads to an imbalance along the trophoblast cell lineage differentiation in favor of enhanced differentiation to giant cells. This phenomenon is accompanied by an accelerated decline of proliferating trophoblast stem cells in the placenta. Forty percent of the embryos survive because of a placental rescue starting around day 12 pc (6). Reasons for this partial rescue of Cx31-deficient placentas could be
12_Kibschull_149_158_F
150
8/29/05, 11:19 AM
Connexins and Trophoblast Cell Lineage
151
the induction of the Cx43 channel in the spongiotrophoblast at day 10 pc, which could serve the function of the Cx31 channel (6). The induction of additional Cx43 channels accompanies the differentiation of spongiotrophoblast cells to trophoblast giant cells. The terminally differentiated giant cells only express Cx43 (6). Thus, the different trophoblast populations of the mouse placenta are defined by a specific connexin expression pattern with Cx26 in the syncytiotrophoblast, Cx31 in the spongiotrophoblast, followed by a coexpression with Cx43, whereas the terminal differentiated giant cells produce Cx43 exclusively. Of particular interest is the Cx31 channel, because it is expressed in the early trophoblast cell lineage and its loss is associated with a failure in trophoblast differentiation (6). In the past, it was difficult to study molecular mechanisms in early trophoblast development because of a lack of appropriate in vitro systems and the technical problems of isolating trophoblast tissues without contamination with maternal and embryonic tissues. Progress in investigating signal cascades responsible for appropriate placental development has been achieved by generating trophoblast stem (TS) cells. Rossant and her colleagues have established permanently growing TS cell lines from the mouse blastocyst or the extraembryonic ectoderm in the presence of fibroblast growth factor (FGF)4 (see ref. 9 and Chapter 11 of this volume). Upon removal of FGF4 or addition of retinoic acid, TS cells are capable of differentiation (9,10). TS cells also effectively develop into all trophoblast cell lineages in vivo, as shown by aggregation experiments and by blastocyst injection (9,10). Furthermore, this approach gives the opportunity to establish TS cells from gene-deficient animals, such as the Cx mutants, to get more insight in the associated sets of signaling molecules that are in charge of controlling placental differentiation. In comparison with placental tissue, TS cells provide an easier tool with which to solve cell and molecular mechanisms, especially for the application of genomic and proteomic approaches. To study the effect of a specific connexin in trophoblast differentiation, we have established Cx26, Cx31, and Cx43 gene-deficient TS cell lines from blastocysts of the corresponding knockout mice. Using these TS cell lines, the influence of a specific Cx inactivation on differentiation, proliferation, and invasion capacity of the TS cell lines was investigated. TS cells provide a tool with which to understand the null phenotype and a means of distinguishing specific roles in trophoblast lineage development vs mature trophoblast cell function. For example, Cx31 is implicated in trophoblast cell lineage development, whereas Cx26 regulates transplacental transport (11). In this chapter, the generation of TS cell lines from Cx knockout mice will be described in detail, because generation of trophoblast stem cells from knockout blastocysts seems to be accompanied by more methodological problems, espe-
12_Kibschull_149_158_F
151
8/29/05, 11:19 AM
152
Kibschull and Winterhager
cially if the genes that are deleted alter the differentiation pathway. Here we describe marker gene sets, which are important to analyze the differentiation capacity of Cx-deficient TS cell lines. Furthermore, we show that TS cells are capable of forming tumors after subcutaneous injection into nude mice. These tumors, unlike embryonic stem (ES) cell tumors, are only transient because of the rapid differentiation into the invasive pathway (11). This differentiation results in the formation of trophoblast giant cells that are not proliferative but normally invade the decidual compartment and the maternal vessels. The differentiation of TS cells into invasive giant cells provides the opportunity to investigate trophoblast invasion into host vessels using the nude mouse model. 2. Materials 1. TS cell medium: RPMI 1640 (Gibco, Karlsruhe, Germany) supplemented with 20% heat-inactivated fetal bovine serum (Biochrom, Berlin, Germany), 1 mM sodium pyruvate (Gibco, Karlsruhe, Germany), 100 µM β-mercaptoethanol (Sigma, Munich, Germany), 2 mM L-glutamine (Gibco, Karlsruhe, Germany), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco, Karlsruhe, Germany). 2. Mouse embryonic fibroblast (EMFI)-conditioned TS cell medium (EMFI-CM). 3. C-TS cell medium: 75% EMFI-CM, 25% TS cell medium, 25 ng/mL human recombinant FGF4 (R&D-systems, Wiesbaden, Germany) and 1 µg/mL heparin (Sigma, Munich, Germany). 4. TS cell freezing medium: C-TS cell medium containing 10% dimethylsulfoxide (Merck, Darmstadt, Germany). 5. Cell dissociation medium: 1X trypsin-ethylenediamine tetraacetic acid (EDTA) solution (Gibco, Karlsruhe, Germany) containing 0.25% trypsin and 1 mM EDTA. 6. Standard protocol for RNA isolation from cell cultures and Northern blotting equipment. 7. cDNA probes for Northern blotting. GenBank accession numbers are indicated in parentheses: Cx26 (BC013634), Cx31 (X63099), Cx31.1 (M91236), Cx43 (NM010288), β-actin (X03672), Mash-2 (NM008553), Pl-1(M35662) and Tpbpa (NM009411). 8. Male athymic nude mice (Han: NMRI nu/nu), 8–12 wk old (Animal Facility of the University Hospital Essen, Essen, Germany).
3. Methods 3.1. Preparation of Fibroblast-Conditioned TS Medium 1. For preparation of EMFI-CM, 10.5 mL TS cell medium is incubated on confluent 10-cm plates of mitomycin C arrested EMFI for 72 h. 2. The conditioned medium is centrifuged (4000g, 15 min, room temperature), filtered (0.2 µm) and stored at –20°C (see Note 1). 3. The plates of mitomycin C arrested EMFI can be reused for two more rounds of EMFI-CM preparation.
12_Kibschull_149_158_F
152
8/29/05, 11:19 AM
Connexins and Trophoblast Cell Lineage
153
3.2. Preparation of FGF4 and Heparin Stock Solutions Stocks of FGF4 (25 µg/mL) and heparin (1 µg/mL) are prepared in 0.1% bovine serum albumin (BSA)/phosphate buffered saline (PBS), aliquoted (50 µL/ vial), and stored at –80°C. Unfrozen vials are stored at 4°C.
3.3. Culture of TS Cells Established TS cells are cultured in the undifferentiated state using C-TS composed of 75% EMFI-CM, 25% TS cell medium, 25 ng/mL FGF4, and 1 µg/ mL heparin. FGF4 and heparin are added to the culture medium immediately before use. The cells are routinely grown in six-well plates in a humidified incubator in a 5% CO2 atmosphere. The medium is changed every second day.
3.4. Passaging TS Cells TS cells are passaged at 80–90% confluency. The monolayer is washed with PBS and incubated with a trypsin-EDTA solution for 3 min. To stop the enzymatic reaction, TS medium is added to the culture well. After centrifugation the cells are resuspended in C-TS medium and split at a ratio of 1:10 (see Note 2).
3.5. Generation of TS Cells (As In ref. 9, With Some Modifications) 1. Briefly, a single blastocyst is plated in a four-well plate containing 1 mL C-TS medium and 3 × 104 preplated mitomycin C treated EMFIs (day 0). 2. The typical trophoblast outgrowth formed on day 3 is released by trypsin by adding 100 µL trypsin-EDTA solution for 15 min and disaggregated using a Pasteur pipet. Subsequently, 1 mL of C-TS medium is added to the well. 3. The next morning, the medium is changed, and the culture fed every second day. 4. From days 6–10 of culturing onward, a few colonies of TS cells appear, which are passaged (P1) at 30% confluency to six wells containing 1.6 × 105 mitomycin C-treated EMFIs. 5. For the next passages, the TS cells are dependent on EMFIs. 6. From P5 to P10, TS cells can be cultured without EMFIs but in the presence of C-TS medium. 7. Exact genotyping of the generated TS cell clones can be performed when the EMFIs are removed from the culture.
3.6. TS Cell Cryopreservation 1. For cryopreservation of TS cells, 5 × 105 – 1 × 106 cells/mL are resuspended in C-TS medium containing 10% dimethylsulfoxide. 2. 1-mL vials are placed in a –80°C freezer for 24 h and then transferred into liquid nitrogen. 3. Frozen vials are rapidly thawed at 37°C and mixed with TS medium. 4. After centrifugation, the cells are resuspended in C-TS medium and plated into culture plates.
12_Kibschull_149_158_F
153
8/29/05, 11:19 AM
154
Kibschull and Winterhager
3.7. TS Cell Differentiation Differentiation of TS cells can be induced by removal of FGF4, heparin, and EMFI-CM from the culture. 1. For standard differentiation, 40,000 cells per well in C-TS medium are plated (see Note 3) in a total of five six-well plates (30 single wells). 2. 24 h after plating, the C-TS medium is removed, the cells are washed twice with PBS, and TS medium is added to induce differentiation (day 0). 3. The TS medium is changed every second day. 4. Sufficient RNA can be isolated, using standard RNA isolation protocols, at 2-d (d) intervals from the wells: day 0 (six wells), d1 (four wells), d3 (three wells), d5 (three wells), d7 (three wells), d9 (three wells), d11 (four wells), and d13 (four wells). The differentiation process can be monitored using marker genes such as Mash2, Pl-1 and Tpbpα that show a coordinated induction of expression (Fig. 1 and refs. 9,11). The expression of connexins can be quantified using northern blotting and their cellular source determined using immunocytochemistry (6,11).
3.8. TS Cell Proliferation Assay Connexins are known to influence cell proliferation (2). The effect of a connexin knockout on the proliferation capacity of TS cells can be analyzed using an in vitro proliferation assay. 1. Five thousand TS cells are seeded per well in a 12-well plate either in C-TS (undifferentiating conditions) or in TS medium (differentiating conditions). 2. Cells are collected on days 1, 3, 5, 7, 9, 11, 13, or 15 by treating with trypsin, and the total cell number per well is determined. 3. For each day, three wells are plated for independent measurements (see Note 4).
3.9. TS Cell Invasion The invasive capacity of TS cells can be analyzed in vivo by injection into athymic nude mice (see Note 5). 1. TS cells are grown in C-TS medium in 75-cm2 flasks. 2. Cells are collected at 90% confluency by trypsination, washed in PBS, and 107 TS cells are resuspended in 250 µL of 100% EMFI-CM containing FGF4 and heparin. 3. Using a 27-gauge needle, the cells are subcutaneously injected into male nude mice. The knockout TS cells are injected into one flank of the mouse and the control cells (wild-type or heterozygous cells) are injected into the other flank of the same mouse. 4. The largest tumor size is reached 7–10 d after injection, and it is fully resorbed within the next 2–3 wk. The tumor growth and the dimension of the haemorrhagic lesions are observed within this time period.
12_Kibschull_149_158_F
154
8/29/05, 11:19 AM
Connexins and Trophoblast Cell Lineage
155
Fig. 1. Expression of connexins and trophoblast marker genes during differentiation of a wild-type trophoblast stem (TS) cell line. (A) Total RNA from a differentiating TS cell line was analyzed by Northern blot using RNA from liver, heart and skin as a positive control. For the densitometric analysis of trophoblast marker genes (B) and connexins (C), the intensity of each signal was normalized to the β-actin signal.
4. Notes 1. We routinely use 75% of EMFI-CM to prepare the C-TS medium for growing and maintaining TS cells in an undifferentiated state. Others report using 80% (12), 70% (9,10) or 50% of EMFI-CM (13) to keep TS cells undifferentiated. The optimal percentage should be empirically determined. In our experience, the FBS and the FGF4 used are the most critical factors for a successful culturing of TS cells. Several distributors and much FBS should be tested on established TS cell lines, because some sera lead to very poor proliferation or enhanced spontaneous differentiation of the cells. In our hands, FGF4 shows the best results on promoting TS cell proliferation. Established TS cell lines may also be cultured using FGF1 (14,15) or FGF2 (15), but when problems in TS cell cultures arise, we recommend using FGF4. We did not observe an influence of the plastic ware from different companies on cell viability.
12_Kibschull_149_158_F
155
8/29/05, 11:19 AM
156
Kibschull and Winterhager
Fig. 2. Morphology of a trophoblast stem (TS) cell tumor 7 d after subcutaneous injection of 107 undifferentiated TS cells into the flank of an athymic nude mouse. (A) Solid tumor with surrounding hemorrhagic lesion; (B) opened blood vessel in the host skin caused formation of blood filled lacunas; (C) cytokeratin-8 staining marks trophoblast cells inside the tumor. Arrows, trophoblast cells.
12_Kibschull_149_158_F
156
8/29/05, 11:19 AM
Connexins and Trophoblast Cell Lineage
157
2. Cells are routinely passaged at a ratio of 1:10. If knockout TS cells exhibit an endogenous tendency to differentiate, then lower splitting ratios should be used. Short exposure to trypsin-EDTA prevents detachment of giant cells arising from spontaneous TS cells differentiation, because giant cells are relatively insensitive to trypsin. Thus, short incubation with trypsin-EDTA can be used to “purify” the TS cell cultures from differentiated cells when passaging. 3. Differentiation of TS cells is dependent on the density of the culture. A low density leads to enhanced giant cell formation, whereas high-density cultures show reduced giant cell formation. Therefore, the same cell number should be seeded for differentiation experiments and proliferation assays so that the phenotype of different mutated TS cell lines can be compared. It is also recommended to use the same batch of EMFI-CM for a series of experiments. 4. For proliferation assays a density of 5000 cells per well in a 12-well plate is recommended. Lower densities (2500 cells per well) result in poor proliferation because of increased spontaneous giant cell formation. Higher cell numbers lead to premature confluency and inhibition of proliferation. Under undifferentiating conditions, the culture reaches confluency after day 9, whereas under differentiating conditions, cell numbers can be analyzed up to day 13. 5. TS cell differentiation is not restricted to giant cell and spongiotrophoblast pathways, as indicated by the marker genes Pl-1 and Tpbpa; it occurs to a lesser extent in syncytiotrophoblast pathways, as indicated by expression of Cx26. Therefore TS cells may also be used to study the factors which are necessary for syncytiotrophoblast differentiation. 6. TS cells form transient hemorrhagic tumors up to 1 cm in size after subcutaneous injection into nude mice (Fig. 2). It is important to inject at least 107 TS cells, because lesser numbers of cells do not lead to sufficient tumor formation (11,12). In addition to the solid tumor, a surrounding hemorrhagic lesion is formed. Both the tumor and the lesions are formed as a result of opened blood vessels in the host’s skin (Fig. 2B). Like the giant cells during placental development, TS cells are invasive in the mouse host tissue. This model can be used to study the influence of a gene knockout on the invasion properties of TS cells. Male nude mice are used to avoid the effect of female hormones on the trophoblast cells. To account for individual differences between the nude mice, the knockout TS cells and the respective control are each injected into one flank of the same nude mouse and the tumor size of the knockout tumor is normalized to the control tumor size.
Acknowledgments The authors would like to thank Dr. J. Rossant for providing the cDNA for Mash-2, Pl-1, and Tpbpa. We also thank Natalie Knipp, Gabriele Sehn, and Georgia Rauter for excellent technical assistance in developing these methods. This work was supported by grants from the National Institutes of Health (NIH) (1R01 HD42558-01), the Deutsche Forschungsgemeinschaft (DFG Wi 774/ 10-3), and the Deutscher Akademischer Austauschdienst (DAAD).
12_Kibschull_149_158_F
157
8/29/05, 11:19 AM
158
Kibschull and Winterhager
References 1. Kingdom, J., Huppertz, B., Seaward, G. and Kaufmann, P. (2000) Development of the placental villous tree and its consequences for fetal growth. Eur. J. Obstet. Gynecol. Reprod. Biol. 92, 35–43. 2. Willecke, K., Eiberger, J., Degen, J., et al. (2002) Structural and functional diversity of connexin genes in the mouse and human genome. Biol. Chem. 383, 725– 737. 3. Moorby, C. and Patel, M. (2001) Dual function for Connexins: Cx43 regulates growth independently of gap junction formation. Exp. Cell. Res. 271, 238–248. 4. Duffy, H. S., Delmar, M., and Spray, D. C. (2002) Formation of the gap junction nexus: binding partners for connexins. J. Physiol. Paris 96, 243–249. 5. Gabriel, H. D., Jung, D., Bützler, C., et al. (1998) Transplacental uptake of glucose is decreased in embryonic lethal connexin26 deficient mice. J. Cell Biol. 140, 1453–1461. 6. Plum, A., Winterhager, E., Pesch, J., et al. (2001) Connexin31-null mutation in mice causes transient placental dysmorphogenesis but does not impair hearing and skin differentiation. Dev. Biol. 231, 334–347. 7. Kruger, O., Plum, A., Kim, J. S., et al. (2000) Defective vascular development in connexin 45-deficient mice. Development 127, 4179–4193. 8. Dahl, E., Winterhager, E., Reuss, B., Traub, O., Butterweck, A., and Willecke, K. (1996) Expression of the gap junction proteins connexin31 and connexin43 correlates with communication compartments in extraembryonic tissues and in the gastrulating mouse embryo, respectively. J. Cell Sci. 109, 191–197. 9. Tanaka, S., Kunath, T., Hadjantonakis, A. K., Nagy, A., and Rossant, J. (1998) Promotion of tropholast stem cell proliferation by FGF4. Science 282, 2072–2075. 10. Yan, J., Tanaka, S., Oda, M., Makino, T., Ohgane, J. and Shiota, K. (2001) Retinoic acid promotes differentiation of trophoblast stem cells to a giant cell fate. Dev. Biol. 235, 422–432. 11. Kibschull, M., Nassiry, M., Dunk, C., et al. (2004) Connexin31-deficient trophoblast stem cells: a model to analyse the role of gap junction communication in mouse placental development. Dev. Biol. 273, 63–75. 12. Erlebacher, A., Lukens, A. K., and Glimcher, L. H. (2002) Intrinsic susceptibility of mouse trophoblasts to natural killer cell-mediated attack in vivo. Proc. Natl. Acad. Sci. USA 24, 16,940–16,945. 13. Ma, G. T., Soloveva, V., Tzeng, S. J., et al. (2001) Nodal regulates trophoblast differentiation and placental development. Dev. Biol. 236, 124–135. 14. Uy, G. D., Downs, K. M., and Gardner, R. L. (2002) Inhibition of trophoblast stem cell potential in chorionic ectoderm coincides with occlusion of the ectoplacental cavity in the mouse. Development 129, 3913–3924. 15. Kunath, T., Strumpf, D., Tanaka, S., and Rossant, J. (2001) Trophoblast stem cells, in Stem Cell Biology. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY: pp. 267–287.
12_Kibschull_149_158_F
158
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
159
13 Rcho-1 Trophoblast Stem Cells A Model System for Studying Trophoblast Cell Differentiation Namita Sahgal, Lindsey N. Canham, Brent Canham, and Michael J. Soares Summary The biology of trophoblast cell development can be investigated using in vitro model systems. The Rcho-1 trophoblast stem cell line was derived from a rat choriocarcinoma and is an effective tool for elucidating regulatory mechanisms controlling trophoblast cell differentiation. In this chapter, we describe methods used in the maintenance and manipulation of the Rcho-1 trophoblast cell line. Key Words: Trophoblast differentiation; rat placenta; trophoblast giant cells; Rcho-1 trophoblast stem cells; choriocarcinoma.
1. Introduction Trophoblast cells possess specialized phenotypes and arise from a common stem cell population directed along a multi-lineage differentiation pathway (1). Trophoblast stem cells develop from the blastocyst and are maintained by signals emanating from the inner cell mass (2,3). In the rat, trophoblast stem cells can be directed toward at least five recognizable differentiated trophoblast cell phenotypes: trophoblast giant cells, spongiotrophoblast cells, invasive trophoblast cells, glycogen cells, and syncytial trophoblast (Fig. 1) (4,5). Differentiated trophoblast cell populations can be distinguished on the basis of morphology, location, and patterns of gene expression. These cell types are arranged into two distinct zones of the chorioallantoic placenta—the junctional zone and the labyrinth zone—and contribute to a complex uteroplacental structure prominent during the last week of gestation, the metrial gland (Fig. 1). Each differentiated cell lineage specializes in activities supportive of pregnancy, some of which are well established whereas others are the source of both speculation and ongoing investigation. Some specific trophoblast funcFrom: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
159
13_Sahgal_159_178_F
159
8/29/05, 11:19 AM
Fig. 1. A schematic representation of rat trophoblast cell lineages and their location within the mature uteroplacental compartment. In the rat, trophoblast stem cells can be directed toward at least five recognizable differentiated trophoblast cell phenotypes: trophoblast giant cells, spongiotrophoblast cells, invasive trophoblast cells, glycogen cells, and syncytial trophoblast. These cell types are arranged into two distinct zones of the chorioallantoic placenta, the junctional zone and the labyrinth zone; and contribute to a complex uteroplacental structure prominent during the last week of gestation: the metrial gland.
160
13_Sahgal_159_178_F
Sahgal et al.
160
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
161
tions include remodeling uterine vasculature, hormone/cytokine production, energy storage, and transcellular transport. The normal growth and differentiation of trophoblast cells is crucial for the establishment and maintenance of pregnancy. Insights about placental development have been derived from the generation of mutant mice by gene targeting (6) and through the use of cell culture models. The latter efforts have been primarily based on two in vitro systems: blastocyst-derived trophoblast stem cell lines (2) and trophoblast stem cell lines derived from a rat choriocarcinoma (7–9). The choriocarcinoma derived cell lines are remarkable in their ability to differentiate into trophoblast phenotypes. More than two decades ago, Dr. Shinichi Teshima and his colleagues at the National Cancer Institute (Tokyo, Japan) induced a transplantable rat choriocarcinoma with extraordinary features (7). Initial observations suggested the trophoblast tumor contained trophoblast giant cells and produced lactogenic hormones (7,10,11). Subsequently, trophoblast stem cell lines were established from the same choriocarcinoma by Dr. Michel Vandeputte’s laboratory at the University of Leuven (Leuven, Belgium) (8) and by our laboratory (9). The cell line derived by Dr. Vandeputte and colleagues is termed RCHO, while we refer to our trophoblast stem cell line as Rcho-1. These trophoblast stem cell lines are aneuploid, are easy to maintain and expand, and possess the capacity to differentiate in vitro and in vivo into trophoblast giant cells. RCHO and Rcho-1 trophoblast stem cell lines have become part of the experimental arsenal for studying trophoblast cell biology (Table 1). These trophoblast stem cell lines have been used to investigate the regulation of trophoblast cell cycle (12–15), the regulation of trophoblast cell differentiation (8,9,16–32), the trophoblast cell phenotype (33–47), trophoblast cell-specific transcriptional regulation (48–67), trophoblast cell transport processes (68– 72), trophoblast cell DNA methylation (73,74), trophoblast cell invasion (19,75), and trophoblast tumor development (76,77). The merit of the RCHO and Rcho-1 trophoblast stem cell models is their plasticity. These cells can be maintained under conditions that facilitate proliferation, or the culture conditions can be changed to promote robust differentiation. Thus, relatively homogenous populations of proliferating and differentiating trophoblast cells can be retrieved from the cultures. The most prominent differentiated phenotype observed in RCHO and Rcho-1 trophoblast stem cell cultures is the trophoblast giant cell (7,8). This differentiated phenotype is easy to track by monitoring cell morphology (large nucleus) or a variety of functional endpoints. The trophoblast giant cell phenotype is also the most common direction for in vitro differentiation of blastocyst-derived trophoblast stem cells (2). Differentiation toward other trophoblast cell pheno-
13_Sahgal_159_178_F
161
8/29/05, 11:19 AM
162
Sahgal et al.
Table 1 Rcho-1 Trophoblast Stem Cell Line Applications for Studying Trophoblast Cell Biology Trophoblast cellular process
References
Regulation of cell cycle regulation Regulation of cell differentiation Characterization of trophoblast cell phenotypes Trophoblast cell-specific gene transcription Cell transport processes DNA methylation Cell invasion Trophoblast tumor development
12–15 8,9,16-32 33–47 48–67 68–72 73,74 19,75 76,77
types is possible, but is not optimal using classic monolayer culture practices (Canham, L. N. and Soares, M. J., unpublished results). Cancer cells, such as those represented by the RCHO and Rcho-1 trophoblast stem cell lines, are caricatures of normal development and represent potentially important models for dissecting molecular mechanisms controlling differentiation (78). The key is in identifying and appreciating which regulatory pathways are characteristic of normal development and which are associated with the transformed phenotype. Thus, it is imperative to perform complementary experimentation using primary cultures of trophoblast cells and in vivo models. In this chapter, we describe methods developed in our laboratory for using the Rcho-1 trophoblast stem cell model to study various aspects of trophoblast cell biology. 2. Materials 1. Culture media: a. Standard Growth Medium: RPMI-1640 culture medium (Mediatech Cellgro, Herdon, VA) containing 50 µM 2-mercaptoethanol (Bio-Rad Laboratories, Hercules, CA), 1 mM sodium pyruvate (Sigma Chemical Co., St. Louis, MO), 100 µg/mL penicillin, and 100 U/mL streptomycin (Mediatech Cellgro), and 20% heat-inactivated fetal bovine serum (FBS, Altanta Biologicals, Norcross, GA). b. Standard Differentiation Medium-Type I: NCTC-135 culture medium (Sigma) containing 50 µM 2-mercaptoethanol (Bio-Rad), 1 mM sodium pyruvate (Sigma), 100 µg/mL penicillin and 100 units/mL streptomycin (Mediatech Cellgro), and 1–10% heat-inactivated donor horse serum (HS; Atlanta Biologicals).
13_Sahgal_159_178_F
162
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20.
163
c. Standard Differentiation Medium-Type II: RPMI-1640 culture medium (Mediatech Cellgro) containing 50 µM 2-mercaptoethanol (Bio-Rad), 1 mM sodium pyruvate (Sigma), 100 µg/mL penicillin and 100 U/mL streptomycin (Mediatech Cellgro), and 1% heat-inactivated donor HS (Atlanta Biologicals). Hank’s balanced salt solution (HBSS; Sigma). Cell Dissociation Medium: Trypsin-ethylenediamine tetraacetic acid (EDTA) Solution (0.25% Trypsin/0.1% EDTA in HBSS) (Mediatech Cellgro). Cell Freezing and Storage Medium: Standard Growth Medium containing 10% dimethylsulfoxide (Sigma) and an additional 25% FBS (Atlanta Biologicals). Cryovials (2-mL, Nalge Company, Rochester, NY). StrataCooler® Cryopreservation Module (Stratagene, La Jolla, CA). Phosphate-buffered saline (PBS). Crystal Violet Solution: 5% formalin, 50% ethanol, 150 mM NaCl, and 0.5% crystal violet (Sigma). TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). 1% Formaldehyde-agarose gels. Formaldehyde (Fisher Scientific, Pittsburgh, PA); agarose (Sigma). Nylon membranes (Nytran Super Charge, Schleicher & Schuell Biosciences, Inc., Keene, NH). Crosslinker (Model XL-1000, Spectronics Corporation, Westbury, NY). [α-P32]dCTP (Perkin Elmer, Boston, MA). cDNAs and polyclonal antibodies for monitoring proliferating and differentiating trophoblast cells (Tables 2 and 3). Androstenedione and progesterone radioimmunoassay kits (Diagnostic Products Corporation , Los Angeles, CA). Extracellular matrix-coated BioCoat® Matrigel™ Invasion chambers (BD Biosciences, Bedford, MA). Diff-Quick stain for cells (Allegiance Scientific Products, McGaw Park, IL). Lipofectamine reagent and OPTI-MEM Reduced Serum culture medium (Invitrogen Life Technologies). Geneticin (Sigma) is prepared as a 40X stock solution (10 mg/mL) in HBSS (Sigma) and stored at 4°C. Holtzman Sprague-Dawley rats are obtained from Harlan Sprague-Dawley (Indianapolis, IN).
3. Methods 3.1. Routine Maintenance and Expansion of Rcho-1 Trophoblast Stem Cells 1. Rcho-1 trophoblast cells are routinely maintained in 75-cm2 flasks in Growth Medium, in an atmosphere of 5% CO2/95% air at 37°C in a humidified incubator. Cells are grown under subconfluent conditions. Initially, cells are plated at 1–2 × 106 cells per flask and fed at two day intervals (see Notes 1–3).
13_Sahgal_159_178_F
163
8/29/05, 11:19 AM
164
Sahgal et al.
Table 2 Genes Expressed in Proliferating Rcho-1 Trophoblast Stem Cells Gene
Functional group
GenBank accession no.
References
Cdx2 Eomes Id-1 Mash2 SOCS 3 Cyclin D3
Transcription Transcription Transcription Transcription Signal transduction Cell cycle
AJ278466 AY457971 L23148 X53724 AF075383 D16309
unpublisheda unpublisheda 17 and unpublisheda,b 17 and unpublisheda 32 and unpublisheda 14 and unpublishedb
Abbreviations: Eomes, Eomesodermin; Id-1, Inhibitor of DNA binding 1; Mash, mammalian achaete schute; SOCS3, suppressor of cytokine signaling 3. aSahgal, N., Canham, L. N., and Soares, M. J., unpublished results. bCanham, L. N., Sahgal, N., and Soares, M. J., unpublished results.
Table 3 Trophoblast Giant Cell-Associated Genes Expressed in Differentiating Rcho-1 Trophoblast Cellsa Gene
GenBank accession no.
PRL family PL-I D21103 PL-II M13749 PLP-A NM_017036 PLP-Fα NM_022530 PLP-M NM_053791 Steroidogenic regulators P450scc J05156 3β-HSD L17138 P450c17 NM_012753 Others PSG36 M32474 HAND1 NM_021592
Antibodies: source (cat. no.)
References
Chemicon International, Temecula, CA (AB1288) Chemicon (AB1289) Chemicon (AB1290) None currently available None currently available
9,13,26,38,44
Chemicon (AB1244, AB1294) None currently available See references
35,36 Unpublishedb 37
None currently available Santa Cruz Biotechnology, Santa Cruz, CA (sc-9413)
Unpublishedb 17 and unpublishedc
9,13,26,38,44 9,13,44 42,44 44
Abbreviations: PRL, prolactin; PL, placental lactogen, PLP, prolactin-like protein; P450scc, side chain cleavage; P450c17, 17α hydroxylase; 3βHSD, 3β hydroxysteroid dehydrogenase; PSG, pregnancy specific glycoprotein. aThis list of genes reflects the trophoblast giant cell phenotype of the differentiating Rcho-1 trophoblast stem cells. bCanham, L. N., Sahgal, N., and Soares, M. J., unpublished results. cSahgal, N., Canham, L. N., and Soares, M. J., unpublished results.
13_Sahgal_159_178_F
164
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
165
2. After 48 h of culture, 5 mL of Growth Medium is added to each flask. 3. Following an additional 24 h (72 h from the time of initial plating), the culture medium is removed, cells are washed with HBSS, and then briefly (1–2 min) exposed to 3–4 mL of Cell Dissociation Medium, followed by vigorous agitation of the culture flask. 4. Following dissociation of the cells from the culture flask, an equal volume of Standard Growth Medium is added to inactivate the trypsin-EDTA. 5. Cells are collected by centrifugation, resuspended in Standard Growth Medium, and re-plated at a splitting ratio of 1 to 3. 6. Under normal conditions the cells are usually passaged at 3-d intervals.
3.2. Cloning by Limiting Dilution (see Note 4) Limiting dilution strategies can be used to obtain clones of Rcho-1 trophoblast stem cells. Cells are harvested and counted with the aid of a hemacytometer. Cells are distributed into 96-well plates at an estimated concentration of one-half of a cell per well. The number of cells per well should be verified. Under standard growth conditions, colonies of cells can be observed within a week of culture in approx 40–50 wells of the 96-well plate. Colony outgrowths are then harvested and expanded.
3.3. Freezing, Storage, and Retrieval (see Note 5) Rcho-1 trophoblast stem cells can be routinely frozen, stored frozen in liquid nitrogen, and retrieved for the establishment of new cultures. 1. Cells are harvested and counted with the aid of a hemacytometer. 2. Cells are equilibrated in Cell Freezing and Storage Medium at a concentration of 1–2 × 106 cells/mL. 3. One milliliter aliquots of the cell suspension are then transferred into 2-mL cryovials. 4. Cryovials are positioned within a StrataCooler® Cryopreservation Chamber precooled to 4°C. 5. The Cryopreservation Chamber is transferred to –80°C. 6. After 3 d to 3 wk at –80°C, frozen vials are moved to a liquid nitrogen storage container, where they can be stored indefinitely. 7. Upon retrieval, frozen aliquots should be rapidly thawed at 37°C, washed once in Standard Growth Medium, and reseeded into culture plates.
3.4. Method to Monitor Trophoblast Cell Proliferation/Survival (13) (see Note 6) 1. Cells are harvested and counted with the aid of a hemacytometer. 2. A total of 500 cells per well are transferred in Standard Growth Medium to a 24-well plate. 3. Following cell attachment overnight, the culture medium is replaced and treatments added. Medium is changed as required over the treatment period. Standard Growth Medium is used as a positive control for maximal growth.
13_Sahgal_159_178_F
165
8/29/05, 11:19 AM
166
Sahgal et al.
4. After a maximum of seven days, the wells are rinsed with PBS, and stained with Crystal Violet Solution (300 µL/well) for 10 min with agitation. 5. Cell cultures are then washed repeatedly in tap water, and allowed to dry. 6. Crystal violet dye is then eluted with ethylene glycol. 7. Cell density can be quantified by measuring absorbance of each eluate at 600 nm. In this assay, cell number is directly correlated with absorbance of the cellular eluates.
3.5. Induction of Trophoblast Cell Differentiation (see Notes 7 and 8) Trophoblast giant cell differentiation is induced by growing Rcho-1 trophoblast stem cells to confluence in Standard Growth Medium and then replacing the medium with differentiating conditions. High cell density and the absence of mitogens (removal of FBS) facilitate trophoblast giant cell differentiation. 1. Cells are harvested and counted with the aid of a hemacytometer. 2. A total of 1–2 × 106 cells in Standard Growth Medium are plated in a 75 cm2 flask. 3. The cells are fed after 48 h with Standard Growth Medium. 4. After another 24 h, one of two protocols can be used to promote differentiation. 5. Protocol I involves replacing the culture medium with Differentiation Medium Type I. Cultures are re-fed daily and the appearance of giant cells is evident within 2–4 d (Fig. 2 ). Differentiation is progressive and differentiated cells maintained in culture for up to 3 wk. 6. Protocol II involves replacing the culture medium with Differentiation Medium Type II. Cultures are re-fed daily for 6 to 8 d and then the cells are returned to Standard Growth Medium with daily changes for another 6 to 8 d. Trophoblast giant cells are evident as in Protocol I; however, become more robust in size during the reintroduction of Standard Growth Medium (Fig. 2).
3.6. Methods to Evaluate Trophoblast Cell Differentiation (see Note 9) Trophoblast differentiation can be assessed by monitoring changes in cell morphology/endoreduplication, changes in gene expression, the production of steroid and polypeptide hormones, and invasiveness.
3.6.2. Morphology/Endoreduplication Differentiated trophoblast giant cells are easy to recognize and distinguish from undifferentiated trophoblast stem cells. They are large cells with an enlarged nucleus and prominent nucleoli. These cells arise by endoreduplication and their DNA content is polyploid. Nuclear size is proportional to DNA content. Differentiated trophoblast giant cells can be easily quantified by monitoring nuclear size by image analysis (9) or by monitoring cellular DNA content by flow cytometry (2).
13_Sahgal_159_178_F
166
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
167
Fig. 2. Morphology of Rcho-1 trophoblast cells at different stages of differentiation. (A) Proliferative phase, containing primarily trophoblast stem cells; (B) cells induced to differentiate using Protocol I (withdrawal of the mitogen); (C) cells induced to differentiate using Protocol II (withdrawal of mitogens + reintroduction of fetal bovine serum [FBS]); (D) development of new trophoblast stem cell colonies following reintroduction of FBS.
3.6.2. Gene Expression The differentiation status of the Rcho-1 trophoblast stem cells can be routinely monitored by Northern blotting. 1. Total RNA is extracted from cells using TRIzol reagent, resolved in 1% formaldehyde-agarose gels, transferred to nylon membranes, and crosslinked. 2. Blots are probed with α-P32-labeled cDNAs (Tables 2 and 3). 3. cDNA for a housekeeping gene is used to evaluate the integrity and equal loading of RNA samples (see Note 10).
13_Sahgal_159_178_F
167
8/29/05, 11:19 AM
168
Sahgal et al.
3.6.3. Hormone Production Steroid and peptide hormones accumulate in conditioned medium accompanying the differentiation of trophoblast giant cells. Progesterone and androstenedione are the two major steroid products. They can be measured with commercially available radioimmunoassays (35–37). Production of members of the prolactin family of polypeptide hormones (placental lactogen-I, placental lactogen-II, and prolactin-like protein-A) are monitored by Western blotting (34).
3.6.4. Invasion (see Note 11) The invasive phenotype of trophoblast cells can be assessed by determining the directional movement of cells through an extracellular matrix (75). 1. Rcho-1 trophoblast stem cells are seeded at 5 × 104 per 3 mL in Standard Growth Medium on the upper chamber of an extracellular matrix-coated BioCoat Matrigel Invasion chamber. 2. Cells are incubated at 37°C in a water-jacketed incubator set at 5% CO2. 3. The cultures are continued for various durations. 4. Chambers are then removed and the matrix and cells on the upper surface are scraped and the membrane fixed and stained with Diff-Quick. 5. Chamber membranes are then excised and placed on slides, overlayed in immersion oil, and cells that invaded and attached to the under surface of the chamber can be counted using a microscope ocular grid.
3.7. DNA Transfection of Rcho-1 Trophoblast Stem Cells DNA can be transferred into Rcho-1 trophoblast stem cells using liposomemediated procedures. Below is a description of our routine transfection protocol. 1. In a six-well plate, seed 2 × 104 cells per well in 2 mL of Standard Growth Medium. 2. After 2–3 d, the cells are then incubated with a DNA/Lipofectamine mixture (Lipofectamine reagent 10 µL, DNA construct 2 µg, Opti-MEM culture medium 200 µL) at 37°C for 7 h. 3. Following the incubation the DNA/lipofectamine mixture is removed and the medium is changed to either Standard Growth Medium or Standard Differentiation Medium. 4. The activity of proteins encoded by the transfected DNA can be monitored 48–60 h following transfection. 5. Stable DNA transfected Rcho-1 trophoblast stem cell sublines can be generated through the introduction of DNA plasmids containing cassettes for selectable genes such as those encoding for neomycin resistance. Effective selection for neomycin resistance generally requires exposure to geneticin at a concentration of 250 µg/mL for 2 to 3 wk.
13_Sahgal_159_178_F
168
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
169
3.8. Transplantation and In Vivo Maintenance of Rcho-1 Trophoblast Stem Cells (see Note 12) The kidney capsule serves as an effective growth environment for Rcho-1 trophoblast stem cells. 1. Cells are harvested from cultures and counted with the aid of a hemacytometer. 2. Cells (1–5 × 106) are transferred beneath the kidney capsule of 4-wk-old female rats (we routinely use Holtzman Sprague-Dawley rats) in a volume of 25–40 µL using a 27-gauge needle and 1-mL syringe. 3. The cells grow rapidly and must be harvested after 10–12 d. 4. Harvested transplants can also be minced and transferred beneath the kidney capsule of additional recipient animals. 5. Rcho-1 trophoblast stem cells transplanted beneath the kidney capsule have the potential to exhibit both endocrine and invasive phenotypes.
4. Notes 1. We routinely use RPMI-1640 culture medium as a base growth medium. Rcho-1 trophoblast stem cells grow vigorously in RPMI-1640 culture medium but sometimes at the cost of poor pH regulation. We compensate for the lack of pH control by changing the culture medium more frequently (daily) and/or by supplementing the cultures with HEPES (10–20 mM). High humidity is essential for optimal Rcho-1 trophoblast stem cell growth. A serum-free system has not been defined for propagating the Rcho-1 trophoblast stem cells. At this juncture the inclusion of FBS is essential. We routinely use high concentrations (20%) of FBS, which the cells appear to prefer. The high FBS concentration may also minimize some of the variabilities associated with different lots of serum. 2. Cell density is a key for the appropriate maintenance and expansion of the Rcho1 trophoblast stem cell line. The most common problem in working with Rcho-1 trophoblast stem cells is the desire to grow them to confluence. Confluence and proliferation are not compatible. As the cells become more dense, they begin to spontaneously differentiate or die. The differentiating cells have a more flattened appearance and will ultimately develop into trophoblast giant cells, whereas the dead cells lift from the surface of the culture plate. In order to prevent spontaneous cell death or differentiation, the Rcho-1 trophoblast stem cells must be passaged as recommended. 3. Rcho-1 trophoblast stem cell cultures are heterogeneous. Both proliferative and differentiated cells can be observed in expanding cultures. Manipulating various aspects of the culture procedure can influence the cellular composition of the cell line. Cell composition can influence growth rates and features of differentiation. Maintaining the cells at higher densities or any type of significant stress (humidity, pH, CO2 deprivation, and so on) can lead to differentiation (giant cell formation) or cell death, both of which result in an irreversible termination of the culture. Harvesting the Rcho-1 trophoblast cells following brief treatment with
13_Sahgal_159_178_F
169
8/29/05, 11:19 AM
170
4.
5.
6.
7.
Sahgal et al. trypsin-EDTA results in isolation of a population of cells enriched in stem cells. This procedure also results in the enrichment of differentiated cells (trophoblast giant cells) that are more adherent and not removed by brief exposure to the trypsin-EDTA solution. Harvesting the differentiated cells generally requires more vigorous dissociation methods such as scraping with a rubber policeman. Unfortunately, the yield of intact trophoblast giant cells by this technique is not optimal. Consistency in cell culture practices is extremely important in working with the Rcho-1 trophoblast stem cell line. Variations in culture densities, passaging methods, and splitting ratios significantly influence the phenotype of the cell line. Rcho-1 trophoblast stem cells grow well at low density, especially in the presence of culture medium containing 20% FBS, and clonal lines can be easily derived. The main concern in isolating clonal lines from Rcho-1 trophoblast stem cells is obtaining a single cell suspension and preventing cell aggregation during their dispersal into multi-well plates. Freezing, storage, and retrieval of Rcho-1 trophoblast stem cells require considerable care. In recent years, we have increased the concentration of FBS in the freezing medium, which seems to improve cell viability at retrieval. We are also careful to rapidly thaw the cells at 37°C and remove the freezing medium by centrifugation before culture. If performed well, the cultures are revived within 24 h and ready to passage in another 48 h. Nonetheless, retrieval of cultures from frozen cell aliquots has been our biggest problem in distributing the Rcho-1 trophoblast stem cells to other laboratories. Because of these problems, we routinely distribute the cells as live cultures. We have described a simple dye-based colorimetric technique for monitoring cell proliferation. There are many other strategies that can be used (cell counts, flow cytometry, and so on). However, it is important to appreciate that a key component of differentiation in Rcho-1 trophoblast stem cells is endoreduplication, e.g., DNA synthesis, without karyokinesis and cytokinesis. Thus, strategies for monitoring Rcho-1 stem cell proliferation that involve monitoring the incorporation of a nucleotide or nucleotide analog will not discriminate between DNA synthesis associated with proliferation and differentiation. One of the experimental advantages of the Rcho-1 trophoblast stem cell line is its capacity to differentiate. We have developed a couple of protocols for enriching differentiated trophoblast cells. These involve achieving high cell density and removal of mitogenic factors. We have the most experience in shifting the cells to an NCTC 135 basal medium containing HS. Morphological and biochemical indices of trophoblast giant cell differentiation are evident within a few days. However, we have noted that the size of the trophoblast giant cells that appear in these cultures is generally much smaller than those appearing spontaneously in the expanding cells cultured in FBS. Consequently, we have recently implemented a second protocol for differentiation. The new strategy involves cell expansion, followed by mitogen withdrawal, and then re-introduction of Standard Growth Medium. Within a few days large trophoblast giant cells appear
13_Sahgal_159_178_F
170
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
8.
9.
10.
11.
12.
171
throughout the cultures (Fig. 2). As these cultures are maintained in Standard Growth Medium, colonies of stem cells will also begin to appear. Cells in these colonies are tightly packed and rise above the surface of the plate. If needed, the stem cell colonies can be removed by brief trypsinization without detachment of the differentiated trophoblast giant cells. In both protocols, mitogen withdrawal is the key. In the absence of FBS, some cells differentiate, others die, and some stem cells apparently become dormant. The enhanced trophoblast giant cell formation following re-introduction of Standard Growth Medium suggests that endoreduplication is stimulated by factors present in FBS. Under our culture conditions, Rcho-1 trophoblast stem cell differentiation is most prominently directed toward the trophoblast giant cell lineage. Giant cell formation proceeds over time and may be accelerated by re-introduction of FBS containing medium. Evidence for differentiation along other trophoblast cell lineages (Fig. 1; spongiotrophoblast cells, glycogen cells, syncytial trophoblast, and the specialized invasive trophoblast cells of the metrial gland) is apparent but generally modest to minimal. This restricted differentiation to trophoblast giant cells is likely, at least in part, a reflection of culture conditions rather than developmental capabilities of the Rcho-1 trophoblast stem cells. We may be able to learn from differentiation strategies developed for studying embryonic stem cells (79). Other cell lineages can be detected by monitoring the expression of genes or gene products specific for spongiotrophoblast cells, syncytial trophoblast, and the specialized invasive trophoblast cells of the metrial gland (Table 4). Glycogen cells are generally identified by their accumulation of glycogen. Exposure of differentiating cells to dimethylsulfoxide can inhibit trophoblast giant cell differentiation and reactivate part of the trophoblast stem cell phenotype (Sahgal, N., Canham, L., and Soares, M. J., unpublished results). Balzarini and colleagues use alkaline phosphatase enzyme activity as a measure of differentiation of RCHO trophoblast stem cells (22,25). The assay is simple and can readily be adapted to a multi-well format. We have not utilized the assay mainly because alkaline phosphatase is known to be expressed in many cell types and thus does not reflect a specific measure of trophoblast cells. We have utilized an assortment of different housekeeping genes to monitor RNA integrity and loading efficiency. These have included β-actin, glyceraldehyde-3'phosphate dehydrogenase (G3PDH), β-tubulin, and 28S ribosomal RNA. Some of these, including G3PDH and β-tubulin are sometimes problematic in that their expression is affected by cell differentiation or the treatments employed. Aspects of the invasive phenotype can also be monitored by determining the expression of gelatinase B and/or α1 integrin and through the analysis of gelatinase B activity in conditioned medium by substrate gel electrophoresis (zymography; see ref. 75). Rcho-1 trophoblast stem cells can be maintained in vivo by transplantation into various host tissues. We have routinely used the kidney capsule but these cells have also been successfully transplanted to other sites, including the liver, cerebral ventricles, lungs, testes, and uteri of rats (7,10,11,85–92). In vivo transplan-
13_Sahgal_159_178_F
171
8/29/05, 11:19 AM
172
Sahgal et al.
Table 4 Other Trophoblast Cell Lineage-Specific Gene Markers Trophoblast Cell lineage
Gene name
GenBank accession no.
References
Spongiotrophoblast
PLP-B PLP-Fβ SSP GCM-1 PLP-L PLP-N
M31155 AY741310 NM_172073 NM_017186 NM_138527 NM_153738
80,81 Unpublisheda 82 Unpublishedb 5,83 84
Syncytial trophoblast Invasive trophoblast
Abbreviations: PLP, prolactin-like protein; SSP, spongiotrophoblast-specific protein; GCM-1, Glial cell missing-1. aHo-Chen, J., Bustamante, J. J., and Soares, M. J., unpublished results. bSahgal, N., Canham, L. N., and Soares, M. J., unpublished results.
tation of the Rcho-1 trophoblast cells has been effectively used to elevate circulating levels of lactogenic hormones. The predominant lactogen expressed by the transplants appears to be PL-I. Lactogenic and luteotrophic actions on the mammary glands and ovary, respectively, represent effective indicators of systemic action of the products of the transplants. Please be aware that Rcho-1 trophoblast cells are potentially capable of producing other peptide and steroid hormones; thus the physiological consequences of trophoblast stem cell transplantation may be complex.
Acknowledgments We would like to thank past and current members of our laboratory for their efforts in developing and characterizing the methods described in this chapter. This work was supported by a National Institutes of Health (NIH) KO8 award to NS (HD42171) and grants from the NIH (HD20676, HD39878, HD48861) and the Hall Family Foundation. References 1. Gardner, R. L. and Beddington, R. S. P. (1988) Multi-lineage ‘stem cells’ in the mammalian embryo. J. Cell Sci., Suppl. 10, 11–27. 2. Tanaka, S., Kunath, T., Hadjantonakis, A. K., Nagy, A., and Rossant, J. (1998) Promotion of trophoblast stem cell proliferation by FGF4. Science 282, 2072–2075. 3. Rossant, J. (2001) Stem cells from the mammalian blastocyst. Stem Cells 19, 477–482. 4. Soares, M. J.,Chapman, B. M., Rasmussen, C. A., Dai, G., Kamei, T., and Orwig, K. E. (1996). Differentiation of trophoblast endocrine cells. Placenta 17, 277–289. 5. Ain, R., Canham, L. N., and Soares, M. J. (2003) Gestation stage-dependent intrauterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype and regulation. Dev. Biol. 260, 176–190.
13_Sahgal_159_178_F
172
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
173
6. Rossant, J. and Cross, J. C. (2001) Placental development: lessons from mouse mutants. Nat. Rev. Genet. 2, 538–548. 7. Teshima,S., Shimosato, Y., Koide, T., Kuroki, M., Kikuchi, Y., and Aizawa, M. (1983) Transplantable choriocarcinoma of rats induced by fetectomy and its biological activities. Gann. 74, 205–212. 8. Verstuyf, A., Sobis, H., Goebels, J., Fonteyn, E., Cassiman, J. J., and Vandeputte, M. (1990) Establishment and characterization of a continuous in vitro line from a rat choriocarcinoma. Int. J. Cancer 45, 752–756. 9. Faria, T. N. and Soares, M. J. (1991) Trophoblast cell differentiation: establishment, characterization, and modulation of a rat trophoblast cell line expressing members of the placental prolactin family. Endocrinology 129, 2895–2906. 10. Verstuyf, A., Sobis, H., and Vandeputte, M. (1989) Morphological and immunological characteristics of a rat choriocarcinoma. Int. J. Cancer 44, 879–884. 11. Faria, T.N., Deb, S., Kwok, S. C. M., Vandeputte, M., Talamantes, F., and Soares, M. J. (1990) Transplantable rat choriocarcinoma cells express placental lactogen: identification of placental lactogen-I immunoreactive protein and messenger ribonucleic acid. Endocrinology 127, 3131–3137. 12. Verstuyf, A., Goebels, J., Sobis, H., and Vandeputte, M. (1993) Influence of different growth factors on a rat choriocarcinoma cell line. Tumour Biol. 14, 46–54. 13. Hamlin, G. P. and Soares, M. J. (1995) Regulation of DNA synthesis in proliferating and differentiating trophoblast cells: involvement of transferrin, transforming growth factor-β, and tyrosine kinases. Endocrinology 136, 322–331. 14. MacAuley, A., Cross, J. C., and Werb, Z. (1998) Reprogramming the cell cycle for endoreduplication in rodent trophoblast cells. Mol. Biol. Cell. 9, 795–807. 15. Hattori, N., Davies, T. C., Anson-Cartwright, L., and Cross, J. C. (2000) Periodic expression of the cyclin-dependent kinase inhibitor p57(Kip2) in trophoblast giant cells defines a G2-like gap phase of the endocycle. Mol. Biol. Cell. 11, 1037–1045. 16. Balzarini, J., Verstuyf, A., Hatse, S., et al. (1995) The human immunodeficiency virus (HIV) inhibitor 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a strong inducer of differentiation of several tumor cell lines. Int. J. Cancer 61, 130–137. 17. Cross, J. C., Flannery, M. L., Blanar, M. A., et al. (1995) Hxt encodes a basic helix-loop-helix transcription factor that regulates trophoblast cell development. Development 121, 2513–2523. 18. Yamaguchi, M., Kawai, M., Kishi,K., and Miyake, A. (1995) Regulation of rat placental lactogen (rPL)-II secretion: cAMP inhibits rPL-secretion in vitro. Eur. J. Endocrinol. 133, 342–346. 19. Grummer, R., Hellmann, P., Traub, O., Soares, M. J., and Winterhager, E. (1996) Regulation of connexin 31 gene expression upon retinoic acid treatment in rat choriocarcinoma cells. Exp. Cell Res. 227, 23–32. 20. Kamei, T., Hamlin, G. P., Chapman, B. M., Burkhardt, A. L., Bolen, J. B., and Soares, M. J. (1997) Signaling pathways controlling trophoblast cell differentiation: Src family protein tyrosine kinases in the rat. Biol. Reprod. 57, 1302–1311. 21. Yamamoto, T., Chapman, B. M., and Soares, M. J. (1997) Protein kinase C dependent and independent mechanisms controlling rat trophoblast cell DNA synthesis and differentiation. J. Reprod. Fertil. 111, 15–20.
13_Sahgal_159_178_F
173
8/29/05, 11:19 AM
174
Sahgal et al.
22. Hatse, S., Naesens,L., De Clercq, E., and Balzarini, J. (1998) Potent differentiation-inducing properties of the antiretroviral agent 9-(2phosphonylmethoxyethyl)adenine (PMEA) in the rat choriocarcinoma (RCHO) tumor cell model. Biochem. Pharmacol. 56, 851–859 23. Nakayama, H., Scott, I. C., and Cross, J. C. (1998) The transition to endoreduplication in trophoblast giant cells is regulated by the mSNA zinc finger transcription factor. Dev. Biol. 199, 150–163. 24. Kraut, N., Snider, L., Chen, C. M., Tapscott, S. J., and Groudine, M. (1998) Requirement of the mouse I-mfa gene for placental development and skeletal patterning. EMBO J. 17, 6276–6288. 25. Hatse, S., Naesens, L., De Clercq, E., and Balzarini, J. (1999) N6-cyclopropylPMEDAP: a novel derivative of 9-(2-phenylphonylmethoxyethyl)-2,6diaminopurine (PMEDAP) with distinct metabolic, antiproliferative, and differentiation-inducing properties. Biochem. Pharmacol. 58, 311–323. 26. Peters, T. J., Chapman, B. M., Wolfe, M. W., and Soares, M. J. (2000) Placental lactogen-I gene activation in differentiating trophoblast cells: extrinsic and intrinsic regulation involving mitogen-activated protein kinase signaling pathways. J. Endocrinol. 165, 443–456. 27. Scott, I.C., Anson-Cartwright, L., Riley, P., Reda, D., and Cross, J.C. (2000) The Hand1 basic helix-loop-helix transcription factor regulates trophpblast giant cell differentiation via multiple mechanisms. Mol. Cell Biol. 20, 530–541. 28. Ma, G. T., Soloveva, V., Tzeng, S. J., et al. (2001) Nodal regulates trophoblast differentiation and placental development. Dev Biol. 236, 124–135. 29. Parast, M. M., Aeder, S., and Sutherland, A. E. (2001) Trophoblast giant-cell differentiation involves changes in cytoskeleton and cell motility. Dev. Biol. 230, 43–60. 30. Kamei, T., Jones, S. R., Chapman, B. M., McGonigle, K., Dai, G., and Soares, M. J. (2002) Activation and involvement of the phosphatidylinositol 3-kinase/aktsignaling pathway in the endocrine differentiation of trophoblast cells. Mol. Endocrinol. 16, 1469–1481. 31. Hinck, L., Thissen, J. P., Pampfer, S., and De Hertogh, R. (2003) Effect of high concentrations of glucose on differentiation of rat trophoblast cells in vitro. Diabetologia 46, 276–283. 32. Takahashi, Y., Carpino, N., Cross, J. C., Torres, M., Parganas, E., and Ihle, J. N. ( 2003) SOCS 3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 22, 372–384. 33. Verstuyf, A., Fonteyn, E., Sobis, H., and Vandeputte, M. (1992) A rat cytotrophoblast antigen defined by a monoclonal antibody. Am. J. Reprod. Immunol. 28, 6–11. 34. Hamlin, G. P., Lu, X.-J., Roby, K. F., and Soares, M. J. (1994) Recapitulation of the pathway for trophoblast giant cell differentiation in vitro: stage-specific expression of members of the prolactin gene family. Endocrinology 134, 2390–2396. 35. Yamamoto, T., Roby, K. F., Kwok, S. C. M., and Soares, M. J. (1994) Transcriptional activation of cytochrome P450 side chain cleavage enzyme expression during trophoblast cell differentiation. J. Biol. Chem. 269, 6517–6523.
13_Sahgal_159_178_F
174
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
175
36. Yamamoto, T., Chapman, B. M., Clemens, J. W., Richards, J. S., and Soares, M. J. (1995) Analysis of cytochrome P450 side-chain cleavage gene promoter activation during trophoblast cell differentiation. Mol. Cell. Endocrinol. 113, 183–194. 37. Yamamoto, T., Chapman, B. M., Johnson, D. C., Givens, C. R., Mellon, S. H., and Soares, M. J. (1996) Cytochrome P450 17α-hydroxylase gene expression in differentiating rat trophoblast cells. J. Endocrinol. 150, 161–168. 38. Dai, G., Imagawa, W., Liu, B., et al. (1996) Rcho-1 trophoblast cell placental lactogens: complementary DNAs, heterologous expression, and biological activities. Endocrinology 137, 5020–5027. 39. Shirai, T., Itonori, S., Soares, M. J., Shiota, K., and Ogawa, T. (1996) Changes in ganglioside composition of the rat choriocarcinoma cell line, Rcho-1. Glycoconjugate J. 13, 415–421. 40. Chun, J. Y., Han, Y. J., and Ahn, K. Y. (1999) Psx homeobox gene is X-linked and specifically expressed in trophoblast cells of mouse placenta. Dev. Dyn. 216, 257–266. 41. Hwang, I. T., Lee, Y. H., Moon, B. C., Ahn, K. Y., Lee, S. W., and Chun, J. Y. (2000) Identification and characterization of a new member of the placental prolactin-like protein-C (PLP-C) subfamily, PLP-Cβ. Endocrinology 141, 3343– 3352. 42. Sahgal, N., Knipp, G. T., Liu, B., Chapman, B. M., Dai, G., and Soares, M. J. (2000) Identification of two new nonclassical members of the rat prolactin family. J. Mol. Endocrinol. 24, 95–108. 43. Oda, M., Sun, W., Hattori, N., Tanaka, S., and Shiota, K. (2001) PAL31 expression in rat trophoblast giant cells. Biochem. Biophys. Res. Commun. 287, 721–726. 44. Dai, G., Lu, L., Tang, S., Peal, M. J., and Soares, M. J. (2002) The prolactin family miniarray: a tool for evaluating uteroplacental/trophoblast endocrine cell phenotypes. Reproduction 124, 755–765. 45. Mehta, D. V., Kim, Y. S., Dixon, D., and Jetten, A. M. (2002) Characterization of the expression of the retinoid-related, testis-associated receptor (RTR) in trophoblasts. Placenta 23, 281–287. 46. Morris Buus, R. and Boockfor, F. R. (2004) Transferrin expression by placental trophoblastic cells. Placenta 25, 45–52. 47. Novak, D., Quiggle, F., and Matthews, J. (2004) Androgen secretion by Rcho-1 cells is independent of extracellular glutamate concentration. Placenta 25, 548–552. 48. Shida, M. M., Ng, Y.-K., Soares, M. J., and Linzer, D. I. H. (1993) Trophoblastspecific transcription from the mouse placental lactogen I gene promoter. Mol Endocrinol. 12, 181–188. 49. Vuille, J. C., Cattini, P. A., Bock, M. E., et al. (1993) Rat prolactin-like protein A partial gene and promoter structure: promoter activity in placental and pituitary cells. Mol. Cell. Endocrinol. 96, 91–98. 50. Ng, Y. K., George, K. M., Engel, J. D., and Linzer, D. I. H. (1994) GATA factor activity is required for the trophoblast-specific transcriptional regulation of the mouse placental lactogen I gene. Development 120, 3257–3266.
13_Sahgal_159_178_F
175
8/29/05, 11:19 AM
176
Sahgal et al.
51. Dai,G., Liu, B., Szpirer, C., Levan, G., Kwok, S. C. M., and Soares, M. J. (1996) Prolactin-like protein-C variant: complementary DNA, unique six exon gene structure, and trophoblast cell-specific expression. Endocrinology 137, 5009–5019. 52. Scatena, C. D. and Adler, S. (1996) Trans-acting factors dictate the species-specific placental expression of corticotropin-releasing factor genes in choriocarcinoma cell lines. Endocrinology 137, 3000–3008. 53. Orwig, K. E., Dai,G., Rasmussen,C. A., and Soares, M. J. (1997) Decidual/trophoblast prolactin-related protein: characterization of gene structure and cell-specific expression. Endocrinology 138, 2491–2500. 54. Lin, J. and Linzer, D. I. H. (1998) Identification of trophoblast-specific regulatory elements in the mouse placental lactogen II gene. Mol. Endocrinol. 12, 418–427. 55. Matsumoto, K., Yamamoto, T., Kurachi, H., et al. (1998) Human chorionic gonadotropin-α gene is transcriptionally activated by epidermal growth factor through cAMP response element in trophoblast cells. J. Biol. Chem. 273, 7800–7806. 56. Shah, P., Sun, Y., Szpirer, C., and Duckworth, M. L. (1998) Rat placental lactogen II gene: characterization of gene structure and placental expression. Endocrinology 139, 967–973. 57. Sun, Y., Robertson, M. C., and Duckworth, M. L. (1998) The effects of epidermal growth factor/transforming growth factor-α on the regulation of placental lactogen I and II mRNAs in a rat choriocarcinoma cell line. Endocr. J. 45, 297–306. 58. Dai, G., Wolfe, M. W., and Soares, M. J. (1999) Distinct regulatory regions from the prolactin-like protein-C variant promoter direct trophoblast giant cell versus spongiotrophoblast cell-specific expression. Endocrinology 140, 4691–4698. 59. Liang, R., Limesand, S. W., and Anthony, R. V. (1999) Structure and transcriptional regulation of the ovine placental lactogen gene. Eur. J. Biochem. 265, 883–895. 60. Orwig, K. E. and Soares, M. J. (1999) Transcriptional activation of the decidual/ trophoblast prolactin-related protein gene. Endocrinology 140, 4032–4039. 61. Sun, Y. and Duckworth, M. L. (1999) Identification of a placental-specific enhancer in the rat placental lactogen II gene that contains binding sites for members of the Ets and AP-1 (activator protein 1) families of transcription factors. Mol. Endocrinol. 13, 385–399. 62. Okamoto, Y., Sakata, M., Yamamoto, T., et al. (2001) Involvement of nuclear transcription factor Sp1 in regulating glucose transporter-1 gene expression during rat trophoblast differentiation. Biochem. Biophys. Res.Commun. 288, 940–948. 63. Yamamoto, T., Matsumoto, K., Kurachi, H., et al. (2001) Progesterone inhibits transcriptional activation of human chorionic gonadotropin-alpha gene through protein kinase A pathway in trophoblast cells. Mol. Cell. Endocrinol. 182, 215–224. 64. Szafranska, B., Miura, R., Ghosh, D., et al. (2001) Gene for porcine pregnancyassociated glycoprotein 2 (poPAG2): its structural organization and analysis of its promoter. Mol. Reprod. Dev. 60, 137–146. 65. Gabriel, H. D., Strobl, B., Hellmann, P., Buettner, R., and Winterhager, E. (2001) Organization and regulation of the rat Cx31 gene. Implication for a crucial role of the intron region. Eur. J. Biochem. 268, 1749–1759.
13_Sahgal_159_178_F
176
8/29/05, 11:19 AM
Studying Trophoblast Cell Differentiation
177
66. Firulli, B. A., Howard, M. J., McDaid, J. R., et al. (2003) PKA, PKC, and the protein phosphatase 2A influence HAND factor function: a mechanism for tissuespecific transcriptional regulation. Mol. Cell 12, 1225–1237. 67. Limesand, S. W., Jeckel, K. M., and Anthony, R. V. (2004) Pur alpha, a singlestranded deoxyribonucleic acid binding protein, augments placental lactogen gene transcription. Mol. Endocrinol. 18, 447–457. 68. Hershberger M. E. and Tuan, R. S. (1998) Placental 57-kDa Ca(2+)-binding protein: regulation of expression and function in trophoblast calcium transport. Dev. Biol. 199, 80–92. 69. Hershberger, M. E. and Tuan, R. S. (1999) Functional analysis of placental 57kDa Ca(2+)-binding protein: overexpression and downregulation in a trophoblastic cell line. Dev. Biol. 215, 107–117. 70. Knipp, G. T., Liu, B., Audus, K. L., Fujii, H., Ono, T., and Soares, M. J. (2000) Fatty acid transport regulatory proteins in the developing rat placenta and in trophoblast cell culture models. Placenta 21, 367–375. 71. Evans, T. J., James-Kracke, M. R., Kleiboeker, S. B., and Casteel, S. W. (2003) Lead enters Rcho-1 trophoblastic cells by calcium transport mechanisms and complexes with cytosolic calcium-binding proteins. Toxicol. Appl. Pharmacol. 186, 77–89. 72. Novak, D. and Matthews, J. (2003) Glutamate transport by Rcho-1 cells derived from rat placenta. Pediatr. Res. 53, 1025–1029. 73. Kimura, H., Takeda, T., Tanaka, S., Ogawa, T., and Shiota, K. (1998) Expression of rat DNA (cytosine-5) methyltransferase (DNA MTase) in rodent trophoblast giant cells: molecular cloning and characterization of rat DNA MTase. Biochem. Biophys. Res. Commun. 253, 495–501. 74. Ohgane, J., Hattori, N., Oda, M., Tanaka, S., and Shiota, K. (2002) Differentiation of trophoblast lineage is associated with DNA methylation and demethylation. Biochem. Biophys. Res. Commun. 290, 701–706. 75. Peters, T. J., Albieri, A., Bevilaqua, E., et al. (1999) Differentiation-dependant expression of gelatinase B/ matrix metalloproteinase-9 in trophoblast cells. Cell Tiss. Res. 295, 287–296. 76. Hatse, S., Naesens, L., Degreve, B., et al. (1998) Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine in choriocarcinoma-bearing rats. Int. J. Cancer 76, 595–600. 77. Naesens, L., Hatse, S., Segers, C., et al. (1999) 9-(2-phosphonylmethoxyethyl)N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats. Oncol. Res. 11, 195–203. 78. Pierce, G. B. (1985) Carcinoma is to embryology as mutation is to genetics. Am. Zool. 25, 707–712. 79. Rudnicki, M. A. and McBurney, M. W. (1987) Cell culture methods and induction of differentiation of embryonal carcinoma cell lines, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, IRL, Oxford, UK: pp. 19–29.
13_Sahgal_159_178_F
177
8/29/05, 11:19 AM
178
Sahgal et al.
80. Duckworth, M. L., Schroedter, I. C., and Friesen, H. G. (1990) Cellular localization of rat placental lactogen-II and rat prolactin-like proteins A and B by in situ hybridization. Placenta 11, 143–155. 81. Cohick, C. B., Xu, L., and Soares, M. J. (1997) Prolactin-like protein-B: heterologous expression and characterization of placental and decidual species. J. Endocrinol. 152, 291–302. 82. Iwatsuki, K. Shinozaki, M., Sun, W., Yagi, S., Tanaka, S., and Shiota, K. (2000) A novel secretory protein produced by rat spongiotrophoblast. Biol. Reprod. 62, 1352–1359. 83. Toft, D. J. and Linzer, D. I. (2000) Identification of three prolactin-related hormones as markers of invasive trophoblasts in the rat. Biol. Reprod. 63, 519–525. 84. Wiemers, D. O., Ain, R., Ohboshi, S., and Soares, M. J. (2003) Migratory trophoblast cells express a newly identified member of the prolactin gene family. J. Endocrinol. 179, 335–346. 85. Tomogane, H., Mistry, A. M., and Voogt, J. L. (1991) Late pregnancy and rat choriocarcinoma cells inhibit nocturnal prolactin surges and serotonin-induced prolactin release. Endocrinology 130, 23–28. 86. Arbogast, L. A., Soares, M. J., Tomogane, H., and Voogt, J. L. (1992) A trophoblast-specific factor(s) suppress circulating prolactin levels and increases tyrosine hydroxylase activity in tuberoinfundibular dopaminergic neurons. Endocrinology 131, 105–113. 87. Mathiasen, J. R., Tomogane, H., and Voogt, J. L. (1992) Serotonin-induced decrease in hypothalamic tyrosine hydroxylase activity and corresponding increase in prolactin release are abolished at midpregnancy and by transplants of rat choriocarcinoma cells. Endocrinology 131, 2527–2532. 88. Arbogast, L. A., Soares, M. J., Robertson, M. C., and Voogt, J. L. (1993) A trophoblast-specific factor increases tyrosine hydroxylase activity in fetal hypothalamic cell cultures. Endocrinology 133, 111–120. 89. Tomogane, H., Arbogast, L. A., Soares, M. J., Robertson, M. C., and Voogt, J. L. (1993) A factor(s) from a rat trophoblast cell line inhibits prolactin secretion in vitro and in vivo. Biol. Reprod. 48, 325–332. 90. Sobis, H., Waer, M., and Vandeputte, M. (1996) Normal and malignant trophoblasts do not recruit granulated metrial gland cells. Tumour Biol. 17, 13–19. 91. Flietstra, R. J. and Voogt, J. L. (1997) Lactogenic hormones of the placenta and pituitary inhibit suckling-induced prolactin (PRL) release but not the ante-partum PRL surge. Proc. Soc. Exp. Biol. Med. 214, 258–264. 92. Lee, Y. and Voogt, J. L. (1999) Feedback effects of placental lactogens on prolactin levels and Fos-related antigen immunoreactivity of tuberoinfundibular dopaminergic neurons in the arcuate nucleus during pregnancy in the rat. Endocrinology 140, 2159–2166.
13_Sahgal_159_178_F
178
8/29/05, 11:19 AM
Bovine Trophoblast Cell Culture
179
14 Bovine Trophoblast Cell Culture Systems A Technique to Culture Bovine Trophoblast Cells Without Feeder Cells Kazuyoshi Hashizume, Arata Shimada, Haruo Nakano, and Toru Takahashi Summary Bovine trophoblastic cells are the first cells to differentiate during embryogenesis and play pivotal role in morphological and physiological development of the placenta. We have developed culture systems for bovine trophoblast stem cells isolated from in vitro fertilized blastocysts in the absence of feeder cells. These cells continuously proliferate in Dulbecco’s modified Eagle’s/F12 culture medium supplemented with bovine endometrial fibroblast-conditioned medium. The cells possess epithelial morphology, express cytokeratin, and form dome-like structures (vesicles). Methods for the maintenance, subculture, storage, and measurement of bovine trophoblast stem cell growth are described. The cells exhibit characteristics of bovine trophoblastic stem cells and possess the ability to differentiate into binucleate cells and express placental lactogen, prolactin-related protein-1, pregnancy-associated glycoprotein-1, and interferon τ. Key Words: Trophoblastic cell line; BT-1; binucleate cells; trophoblast differentiation; placental lactogen; collagen gel; microarray; gene expression; bovine.
1. Introduction Trophectoderm is the first cell type to differentiate from the embryo at the blastocyst stage and its cell lineage contributes to placental formation. Factors controlling early decisions in the development of inner cell mass (ICM) and trophectoderm cell lineages are not completely understood. Embryonic stem cells derived the ICM are pluripotent, whereas trophoblast stem cells have a more restricted developmental capacity (1). Some trophoblast cell lines have been developed in various species and have been used for cell differentiation studies (2–4). Fibroblast growth factor (FGF)4 has a critical role in maintaining mouse trophoblast stem cells in an undifferentiated status. From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
179
14_Hashizume_179_188_F
179
8/29/05, 11:19 AM
180
Hashizume et al.
We have generated bovine trophoblast stem cell populations from in vitro cultured blastocysts supplemented with fibroblast cell culture conditioned media (5–8). One of our trophoblast stem cell lines is referred to as bovine trophoblast (BT)-1. BT-1 trophoblast cells are not dependent upon the addition of exogenous FGF4 for maintenance of their stem cell state. These cells have the ability to differentiate into bovine placental-specific binucleate cells on collagen substrata. The expression of trophoblast cell-specific transcripts, including placental lactogen (PL), prolactin-related proteins (PRPs), pregnancy-associated glycoproteins (PAG), and interferon (IFN)-τ , were confirmed by reverse-transcription (RT)-polymerase chain reaction (PCR) and a custom microarray. In this chapter, we describe: (1) a method for the establishment of a bovine trophoblast stem population, and (2) a method for the induction of binucleate cells from the BT-1 cell line. 2. Materials 1. Culture medium: Dulbecco’s modified Eagle’s/F-12 medium (DMEM/F-12; Sigma, St. Louis, MO, USA) containing 100 international units (IU)/mL penicillin and 100 mg/mL streptomycin (Sigma), and 10% heat-inactivated fetal bovine serum (FBS; Sigma). 2. Cell substratum: acid-soluble porcine type I collagen solution (3 mg/mL) and gel reconstitution solution (0.05 N NaOH solution containing 2.2% NaHCO3 and 200 mM HEPES). 3. Tenfold-concentrated physiological salt solution consisting of 1.52 M NaCl, 54 mM KCl, 10 mM CaCl2, 8 mM MgCl2, 56 mM glucose, and 100 mM HEPES, pH 7.4. 4. Cell extraction medium: 0.1 M crystal violet (Wako Chemical, Osaka, Japan), 0.1% citric acid (Wako chemical), and 0.1% Triton X-100 (Sigma). 5. Collagen solution: acid-extracted collagen, 3 mg/mL (Cell Matrix, Nitta gelatin, Osaka, Japan). 6. Freezing reagent: CellBanker (Zenyaku kogyo Co, Tokyo, Japan). 7. 5-Bromo 2'-deoxyuridine 5'-triphosphate (BrdU) Labeling and Detection Kit II (Roche Diagnostics, Mannheim, Germany). 9. Hoechst 33342 (Molecular Probes, OR, USA). 10. Paraformaldehyde (Wako Chemical). 11. Bovine serum albumin (BSA, Sigma). 12. Transfer pipet (Becton Dickinson Labware, Franklin Lake, NJ, cat. no. 357575). 13. Mouse monoclonal and rabbit polyclonal anti-bovine PL (5). 14. Alexa 546-conjugated goat anti-mouse immmunoglobulin (Ig)G antibody (Molecular Probes). 15. Alexa 488-conjugated goat anti-rabbit IgG antibody (Molecular Probes). 16. 24-well culture plates and 25-cm2 culture flasks (Becton Dickinson). 17. Cell freezing vessel: BICELL (Nihon Freezer Co., Ltd, Tokyo, Japan). 18. Screen Cup with a 80 mesh screen (pore size 180 µm, Sigma). 19. Sterile plastic transfer pipets and 35-mm plastic culture dishes (Becton Dickinson).
14_Hashizume_179_188_F
180
8/29/05, 11:19 AM
Bovine Trophoblast Cell Culture
181
3. Methods 3.1. Establishiment of Bovine Trophoblast Stem Cell Cultures Bovine trophoblast stem cells can be established from in vitro cultured blastocysts. 1. In vitro matured (IVM)/in vitro fertilized (IVF) bovine blastocysts are obtained as described previously (6,9). 2. Blastocysts are individually plated into 24-well culture dishes that are coated with acid-extracted collagen and cultured in DMEM/F-12 supplemented with 10% FBS, 50% fibroblast-conditioned medium, and 50 µM beta-mercaptoethanol (see Note 1). 3. Following attachment cells outgrow from blastocysts in a week. These cells are collected and maintained as follows under Subheading 3.1.1.
3.1.1. Maintenance of Bovine Trophoblast Stem Cells 1. Bovine trophoblast stem cells are cultured in collagen-coated culture flasks (see Note 2). 2. The cells are maintained in 25-cm2 flasks until confluent in DMEM/F12 containing 10% FBS. 3. Media are changed every 2 or 3 d and subcultured every 7 d.
3.1.2. Subculture of BT-1 Cells 1. Pipetting dissociation: when cells have spread out and reached confluence, they are detached from the culture dish surface by agitation with the transfer pipet. The cell sheets are dissociated into small cell clumps by further pipetting. The cell suspension is plated into a new culture flask at 1:2 dilution (see Note 3). Within 24 h, cellular outgrowths can be observed (Fig. 1). 2. Transfer of vesicles: during continuous culture, some cells form vesicles ranging in size from 100 µm to more than 1 mm in diameter. When these freely floating vesicles are transferred into a new flask, they attach and form new outgrowths (Fig. 1).
3.1.3. Freezing, Storage, and Retrieval of the Bovine Trophoblast Stem Cells 1. Cells are agitated with pipetting and dissociated into small cell clumps, and then transferred into sterile conical tubes. 2. After centrifugation at 600g for 1 min, supernatants are removed and cells are resuspended with CellBanker (cells in 25-cm2 culture flask/1 mL). 3. The cell suspensions are transferred to cryovials and placed into a freezing vessel (BICELL) and transferred to a –80°C freezer for at least 24 h, then to liquid nitrogen. 4. Frozen vials are rapidly thawed at 37°C, washed once in standard culture medium containing FBS, and seeded into culture dishes (see Note 4).
14_Hashizume_179_188_F
181
8/29/05, 11:19 AM
182
Hashizume et al.
Fig. 1. Bovine trophoblast (BT)-1 cell features. (A) Small cell explants just after plating in a new culture dish; (B) BT-1 cells 1 d after plating; (C) 2 d after plating; (D) 7 d after plating; (E) freely floating BT-1 vesicles; (F) BT-1 vesicles 1 day after plating. Note that vesicles attach and exhibit cellular outgrowth. Scale bar = 500 µm
3.1.4. Measurement of Cell Proliferation 1. Nuclear count: cell proliferation is determined by counting nuclei. Cells are dissociated by pipetting and collected by centrifugation at 10,000g for 10 min at room temperature. Pelleted cells are suspended in nuclei extraction solution. After extraction, nuclei are counted with a hemocytometer under microscopy.
14_Hashizume_179_188_F
182
8/29/05, 11:19 AM
Bovine Trophoblast Cell Culture
183
2. BrdU incorporation assay: cell growth rate is examined by incorporation of BrdU. Cells are labeled with BrdU for 15 min, and BrdU incorporation is detected with an antibody to BrdU according to the manufacturer’s instructions. Cells are also stained with Hoechst 33342 at a concentration of 5 µg/mL to visualize the nuclei.
3.2. Induction of Binucleate Cell Differentiation in BT-1 Cells Trophoblastic binucleate cells, a bovine trophoblast specific endocrine cell, possessing two nuclei per cell are induced from bovine trophoblast stem cells cultured on a collagen gel substratum system.
3.2.1. Collagen Gels To prepare collagen-gel coated culture dishes, 8 vol of the collagen solution are gently mixed with 1 vol of 10-fold concentrated physiological salt solution, and then 1 vol of the gel reconstitution solution with a transfer pipet in a conical tube on ice. The mixed gel solution is dispensed onto culture dishes (1 mL/ 35 mm dish), and incubated at 37°C for 20–30 min for gel reconstitution.
3.2.2. Induction of Binucleate Cell Formation Trophoblast binucleate cell differentiation is induced by growing BT-1 vesicles in culture medium on collagen gel-coated dishes. BT-1 vesicles (200 µm to 1 mm in diameter) are isolated from confluent cell cultures by passage through a Screen Cup (180-µm pore size), resuspended in the fresh medium, and then plated on collagen gel-coated dishes. About 100 vesicles in 2 mL of the medium are dispensed in each dish. Dishes are gently shaken to disperse vesicles and are incubated at 37°C in an atmosphere of 5% CO2. The medium is first changed after 4 d, and then every 2 or 3 d. Vesicles attach to the collagen gel and cell outgrowth from the vesicles is evident within 2 d. After more than 10 d in culture, clusters of binucleate cells appear, especially at the peripheral region of the colony (Fig. 2).
3.2.3. Assessment of Binucleate Cells Differentiation can be assessed by monitoring endoreduplication and the expression of PL (Fig. 2). 3.2.3.1. ENDOREDUPLICATION
Endoreduplication can be assessed by monitoring cellular DNA contents. We measure DNA content in cells with an image analysis system, AQUACOSMOS (Hamamatsu Photonics, Hamamatsu, Japan) (8). 3.2.3.2. PL IMMUNOCYTOCHEMISTRY 1. For PL immunocytochemistry, cells in dishes are fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at 4°C for 15 min.
14_Hashizume_179_188_F
183
8/29/05, 11:19 AM
184
Hashizume et al.
Fig. 2. Phase contrast (A), Hoechst 33342 (B), and (C) placental lactogen (PL) staining (with monoclonal anti-PL antibody) images of bovine trophoblast (BT)-1 cells cultured on collagen gels for 17 ds. Some binucleate cells are indicated by arrows. These binucleate cells have an intense Hoechst fluorescence in their nuclei and express PL. Scale bar =100 µm.
2. After three washes with phosphate-buffered saline (PBS), the cells are blocked and permeabilized with PBS containing 10% normal goat serum and 0.5% Triton X-100 for 30 min at room temperature. 3. Incubation with the mouse monoclonal (diluted 1:1000) or the rabbit polyclonal (1:8,000) anti-PL antibody is carried out in PBS containing 1% BSA, 0.05% NaN3, and 0.3% Triton X-100 for 2 h at room temperature. 4. After three washes with PBS, Alexa 546-conjugated goat anti-mouse IgG antibody (1:400) or Alexa 488-conjugated goat anti-rabbit IgG antibody (1:200) in PBS containing 1% BSA, 0.05% NaN3, and 0.3% Triton X-100 is applied for 1 h at room temperature. 5. Hoechst 33342 (5 µg/mL) is added into the secondary antibody solution to stain nuclei. 6. After three washes with PBS, PL and Hoechst 33342 signals can be viewed using an inverted epifluorescence microscope with appropriate filters.
3.2.3.3. BOVINE UTEROPLACENTAL CUSTOM DNA MICROARRAY
Bovine trophoblast stem cells can differentiate into binucleate cells and express an array of transcripts including placental prolactin family proteins, pregnancyassociated glycoproteins and IFN-τ. Detailed gene profiles can be analyzed using a custom bovine uteroplacental cDNA microarray (7) (see Note 5).
14_Hashizume_179_188_F
184
8/29/05, 11:19 AM
Bovine Trophoblast Cell Culture
185
4. Notes 1. Fibroblast-conditioned medium. We generally use DMEM/F12 containing 10% FBS culture medium for maintenance of bovine trophoblast stem cells. As previously described, the BT-1 cells were established from blastocysts using fibroblast-conditioned medium (6). However, conditioned medium is not necessary for the maintenance of cell growth following the establishment of the cell line. 2. Collagen-coated culture dishes. Acid-extracted collagen suspension is diluted 10-fold with distilled water and poured into dishes. After a 60-min incubation at room temperature, they were rinsed with culture medium and used for culture. 3. Cell concentration. Adequate density of bovine trophoblast stem cells is important for sustaining cell growth. When cells are plated at low density, cells tend to become flatten and stop proliferating. Passaging the cells at a 1:2 ratio is optimal for subculture. 4. Freezing for storage and thawing for re-culture. After cyropreservation, bovine trophoblast stem cell viability is low. To successfully establish a culture from a frozen vial, seed cells from a cryovial into a small culture dish (35 mm or smaller). Supplementation of the cultures with BT-1 trophoblast stem cell conditioned medium may facilitate recovery and growth of previously frozen bovine trophoblast stem cells. 5. A custom-designed cDNA microarray using uteroplacental cDNAs has been successfully utilized for analyzing transcriptome in BT-1 cells as well as in the placenta and uterus (7). Results from DNA microarray studies should be confirmed by other appropriate procedures (e.g., RT or real-time PCR). Table 1 provides an overview of the gene expression profile in BT-1 cells. The BT-1 cells express an array of transcripts including placental prolactin family proteins, pregnancyassociated glycoproteins and IFN-τ, and other genes involved in steroidogenesis and cytokine signaling. In this experiment, BT-1 cells were maintained with DMEM/F12 supplemented with 20% FBS. The intensity of expression is shown as a relative value compared to that of the glyseraldehyde-3-phosphate dehydrogenase (GAPDH) as internal reference. Figure 3 shows the expression profiles of selected genes under different culture conditions. The cells are routinely grown in a medium supplemented with 10 % FBS. In this experiment, differences in gene expression pattern under different culture conditions with 20% FBS, 2% FBS or 10 % horse serum (HS)-supplemented medium were determined. BT-1 cells express an assortment of trophoblast marker genes (PL, PRP-I, PAG, and IFN-τ) when maintained in 20% FBS-supplemented medium. However, the cells cease or decrease expression of these genes when the serum supplementation is switched to 10% HS. This is in marked contrast to the Rcho-1 rat trophoblast cell line (11). BT-1 cells represent both proliferative and endocrine phenotypes depending on the presence of FBS. In contrast, both bone morphogenetic protein (BMP)4 and Oct 3/4 are stably expressed regardless of sera. Both eomesodermin and Oct 3/4 are thought to be markers representing the undifferentiating status in mouse trophoblast stem cell (1). It has been reported that BMP4 triggers
14_Hashizume_179_188_F
185
8/29/05, 11:19 AM
Table 1 186 Hashizume et al. Expression Levels of Selected Genes in Bovine Trophoblast (BT)-1 Cells Accession #
Gene name
Intensity/GAPDH
M73962 L06151 AF020506 AF020507 AF020508 AF020509 AF020510 AF020511 AF020512 AF020513 AF020514 AF192330 AF192332 AF192333 AF192334 AF192336 AF192338 J02840 J02944 M27239 X59504 X15975 X53587 NM000210 AF074706 S54973 AF210379 D30750 M18344 X53553 M76478 NM001553 M37210 AF110801 AB005148 U16239 L22095 S75723 NM003155 AF196320
Bovine PAG-1 Bovine PAG-2 Bovine PAG-4 Bovine PAG-5 Bovine PAG-6 Bovine PAG-7 Bovine PAG-8 Bovine PAG-9 Bovine PAG-10 Bovine PA G-1l Bovine PAG-12 Bovine PAG-13 Bovine PAG-15 Bovine PAG-16 Bovine PAG-17 Bovine PAG-19 Bovine PAG-21 Bovine PL Bovine PRP-1 Bovine PRP-2 Bovine PRP4 Bovine PRP-5 Human integrin β 4 Human integrin α 6 Bovine 111-β-HSD type 2 Bovine 20 α-HSD Bovine matrix Gla Bovine Msx-1 Bovine Calbindin Bovine IGF-1I Bovine IGFBP-3 Human IGFBP7 Bovine IL-1-α Human IL-18 binding protein c Bovine IL-1 receptor antagonist Bovine βA inhibin/activin Bovine U-serpin Ovine GRP Human STC1 Bovine IFN-τ1C
0.27 0.63 0.12 0.23 0.19 0.23 0.53 0.26 0.18 0.39 0.36 0.35 0.29 0.25 0.30 0.30 0.21 0.18 0.21 0.19 0.16 0.15 0.22 0.33 0.00 1.02 0.13 0.18 0.27 0.19 0.44 0.11 0.93 0.16 0.18 0.17 0.19 0.28 0.23 0.22
GAPDH, glyseraldehyde-3-phosphate dehydrogenase; PAG, pregnancy-associated glycoproteins; PL, placental lactogen; PRP, prolactin-related protein; HSD, hydroxysteroid dehydrogenase; IGF, insulin-like growth factor; IL, interleukin; GRP, glucose-related protein; STC, Stanniocalcin; IFN, interferon.
14_Hashizume_179_188_F
186
8/29/05, 11:19 AM
Bovine Trophoblast Cell Culture
187
Fig. 3. Revers-transcriptase polymerase chain reaction analysis of selected genes expressed in bovine trophoblast (BT)-1 cells cultured with either 20% (first lane) or 2% (second lane) fetal bovine serum (FBS), or 10% horse serum (HS). PL, placental lactogen; PRP-I, prolactin-related protein-I; PAG-1, pregnancy-associated glycoprotein-1; IFN-τ, interferon τ; BMP4, bone morphogenetic protein 4; GDF9, growth and differentiation factor 9;. Eomes, eomesodermin.
human trophoblast differentiation (12). There is a mixture of both undifferentiating and differentiating marker genes in BT-1 cells. Considering the previously described accounts, it is plausible that BT-1 cells have some characteristics that differ from those of rat Rcho-1 trophoblast cells and mouse trophoblast stem cells.
Acknowledgments The authors thank Dr. K. Imai for in vitro fertilization and culture of bovine embryo. We also thank Drs. H. Ishiwata and K. Kizaki (N.I.A.S.), and G. Tsujimoto (Kyoto University) for fabricating and analyzing bovine utero-placental cDNA microarray.
14_Hashizume_179_188_F
187
8/29/05, 11:19 AM
188
Hashizume et al.
References 1. Tanaka, S., Kunath, T., Hadjantonakis, A. K., Nagy, A., and Rossant, J. (1998) Promotion of trophoblast stem cell proliferation by FGF4. Science 282, 2072–2075. 2. Flechon. J. E., Laurie, S., and Notarianni, E. (1995) Isolation and characterization of a feeder-dependent, porcine trophectoderm cell line obtained from a 9-day blastocyst. Placenta 16, 643–658. 3. Talbot, N. C, Caperna, T. J., Edwards, J. L., Garrett, W., Wells, K. D., and Ealy, A. D. (2000) Bovine blastocyst-derived trophectoderm and endoderm cell cultures: interferon tau and transferrin expression as respective in vitro markers. Biol. Reprod. 62, 235–247. 4. Miyazaki, H., Imai, M., Hirayama, T., et al. (2002) Establishment of feeder-independent cloned caprine trophoblast cell line which expresses placental lactogen and interferon tau. Placenta 23, 613–630. 5. Nakano, H., Takahashi, T., Imai, K., and Hashizume, K. (2001) Expression of placental lactogen and cytokeratin in bovine placental binucleate cells in culture. Cell Tissue Res. 303, 263–270. 6. Shimada, A., Nakano, H., Takahashi, T., Imai, K., and Hashizume, K. (2001) Isolation and characterization of a bovine blastocyst-derived trophoblastic cell line, BT-1: development of a culture system in the absence of feeder cell. Placenta 22, 652–662. 7. Ishiwata, H., Katsuma, S., Kizaki, K., et al. (2003) Characterization of gene expression profiles in early bovine pregnancy using a custom cDNA microarray. Mol. Reprod. Dev. 65, 9–18. 8. Nakano, H., Shimada, A., Imai, K., Takezawa, T., Takahashi, T., and Hashizume, K. (2002) Bovine trphoblastic cell differentiation on collagen substrata: formation of binucleate cells expressing placental lactogen. Cell Tissue Res. 307, 225–235. 9. Konishi, M., Aoyagi, Y., Takedomi, T., Itakura, H., Itoh, T., and Yazawa, S. (1996) Production and transfer of IVF embryos from individual inhibin-immunized cows by ultrasound-guided transvaginal follicular aspiration. J. Vet. Med. Sci. 58, 893–896. 10. Quackenbush, J. (2002) Microarray data normalization and transformation. Nat. Genet. 32(Suppl.), 496–501. 11. Faria, T. N. and Soares, M. J. (1991) Trophoblast cell differentiation: establishment, characterization, and modulation of a rat trophoblast cell line expressing members of the placental prolactin family. Endocrinology 129, 2895–2906. 12. Xu, R. H., Chen, X., Li, D. S., et al. (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat. Biotechnol. 12, 1261–1264.
14_Hashizume_179_188_F
188
8/29/05, 11:19 AM
Trophoblast From Human ES Cells In Vitro
189
15 In Vitro Induction of Trophoblast from Human Embryonic Stem Cells Ren-He Xu Summary Human embryonic stem (ES) cells can proliferate without a known limit and can form advanced derivatives of all three embryonic germ layers. What is less widely appreciated is that human ES cells can also form the extra-embryonic tissues that differentiate from the embryo before gastrulation. The use of human ES cells to derive early human trophoblast is particularly valuable, because it is difficult to obtain from other sources and is significantly different from mouse trophoblast. Here we describe a method by using bone morphogenetic protein (BMP)4 , a member of the transforming growth factor (TGF)-β superfamily, to induce the differentiation of human ES cells to trophoblast. Immunoassays (as well as DNA microarray and reverse-transcription polymerase chain reaction analyses—data not shown) demonstrate that the differentiated cells express a range of trophoblast markers and secrete placental hormones. When plated at low density, the BMP4-treated cells form syncytia that express chorionic gonadotrophin (CG). This technique underscores fundamental differences between human and mouse ES cells, which differentiate poorly, if at all, to trophoblast. Human ES cells thus provide a tool for studying the differentiation and function of early human trophoblast and could provide a new understanding of some of the earliest differentiation events of human postimplantation development. Key Words: Human embryonic stem cells; trophoblast; bone morphogenetic protein.
1. Introduction The trophectoderm is the first differentiated cell type in the mammalian embryo, and it forms the outer epithelium of the blastocyst and later contributes (as the trophoblast) to the outer layers of the placenta. The trophectoderm is crucial for implantation and maintenance of pregnancy. When formed into chimeras with intact preimplantation embryos, mouse embryonic stem (ES) cells rarely contribute to the trophoblast, and the manipulation of external culture conditions has, to date, failed to direct mouse ES cells to differentiate to trophoblast (1). Mixed populations of spontaneously differentiated rhesus monFrom: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
189
15_Xu_189_202_F
189
8/29/05, 11:19 AM
190
Xu
key or human ES cells secrete modest amounts of chorionic gonadotrophin (CG), which suggests the presence of trophoblast (2,3). The contrast in the ability to form trophoblast represents a basic difference between mouse and human ES cells, and may suggest basic differences in the allocation of lineages in the early embryo. This difference is also suggested by the behavior of embryonal carcinoma cells, the stem cells of teratocarcinomas, which are tumors that recapitulate events of early embryogenesis. Human teratocarcinomas often contain a trophoblast component, but mouse teratocarcinomas do not (4). Given basic differences between mouse placenta and human placenta, and given the lack of experimental access to early postimplantation human embryos, human ES cells provide an important new in vitro model to study early trophoblast differentiation and function, with important implications for infertility, miscarriage, and birth defects. Following addition of a transforming growth factor (TGF)-β superfamily member, bone morphogenetic protein (BMP)4, to culture conditions that would otherwise support self-renewal of human ES cells, the cells undergo a highly synchronous differentiation to trophoblast (5). This features by expression of a range of trophoblast markers, secretion of placental hormones, and formation of CG-positive syncytia. 2. Materials 1. Human ES cells. Human ES cell lines H1, H7, H9, and H14 were used for the trophoblast induction by BMPs. Their National Institutes of Health (NIH) registry numbers are WA01, WA07, WA09, and WA14, respectively (http:// stemcells.nih.gov/research/registry/index.asp#warf). These cell lines are available at the WiCell Research Institute upon application and licensing (http:// www.wicell.org/forresearchers/index.jsp?catid=4). 2. Mouse embryonic fibroblast (MEF) (see below for details). 3. Human uterine fibroblast (HUF) cell line (6). 4. Four-well and six-well culture plates, 50-, 75-, and 90-mm Filter Units (Nalge Nunc International, Rochester, NY). 5. Six-well Transwell plate (Corning Incorporation, Corning, NY). 6. 0.22-mM Filter Unit (Millipore, Bedford, MA). 7. 40 mM mesh (BD Labware, Bedford, MA). 8. Falcon (35/2054) 5 mL polystyrene round bottom tube (BD Labware). 9. Knockout Dulbecco’s modified Eagle’s/F12 medium (DMEM/F12), knockout serum replacement (SR), 100X MEM nonessential amino acid solution, L-glutamine, and Trypsin/ethylenediamine tetraacetic acid (EDTA) solution (Invitrogen, Carlsbad, CA). 10. Human basic fibroblast growth factor (bFGF) (Invitrogen). Dissolve 10 µg bFGF in 1 mL of 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) (without Ca2+ and Mg2+). Aliquot and store at –80°C. 11. Collagenase type IV (Invitrogen). Dissolve it at 1 mg/mL in DMEM/F12 and sterilize with a 0.2-µm cellulose acetate filter. Store at 4°C. Use within 2 wk.
15_Xu_189_202_F
190
8/29/05, 11:19 AM
Trophoblast From Human ES Cells In Vitro
191
12. Matrigel (BD Labware). 13. BMP2, -4, -7, growth differentiation factor (GDF)5 , noggin, and soluble BMP receptor IA (R&D Systems, Minneapolis, MN). 14. HUF cell culture medium: RPMI culture medium supplemented with penicillin and streptomycin, 1 mM sodium pyruvate, and 10% fetal bovine serum (FBS) (6). 15. β-Mercaptoethanol, Brefeldin A, Hoechst 33342 solution, and mouse immunoglobulin (Ig)G (Sigma, St. Louis, MO). 16. Mouse anti-human CG-antibody (Abcam, Cambridge, UK). 17. Fluorescein-labeled rabbit anti-mouse IgG antibody (Pierce, Rockford, IL). 18. AxSYM Total β-hCG kit (Abbott, Lake Forest, IL). 19. FACSCalibur flow cytometer (Becton Dickson, San Jose, CA). 20. Cellquest acquisition and analysis software (Becton Dickinson).
3. Methods The methods described below outline (1) cell culture, (2) trophoblast induction, and (3) biological assays of the induced trophoblast.
3.1. Cell Culture (3,7) 3.1.1. Preparation of Human ES Cell Medium (100 mL) This medium is also referred to as unconditioned medium in contrast to MEFconditioned human ES cell medium. Final Concentration: 80% knockout DMEM/ F12, 20% knockout SR, 1% nonessential amino acid solution, 100X MEM nonessential amino acid solution, 1 mM L-glutamine, 0.1 mM β-mercaptoethanol. 1. Add 10 mL PBS (without Ca2+ and Mg2+) to 0.146 g L-glutamine in a 15-mL tube. 2. Add 7 µL of β-mercaptoethanol to the L-glutamine/PBS, and mix well. 3. Into a 250-mL, 0.2-µm cellulose acetate filtering unit add: a. 80 mL knockout DMEM/F12. b. 20 mL knockout SR. c. 1 mL of the L-glutamine/β-mercaptoethanol solution. d. 1 mL 100X nonessential amino acid solution 4. Filter to sterilize. 5. Store at 4°C and use within 2 wk.
3.1.2. Preparation of the MEF Medium (100 mL) 1. Into a 250-mL, 0.2-µm cellulose acetate filtering unit add: a. b. c. d.
15_Xu_189_202_F
90 mL DMEM medium. 10 mL heat-inactivated (30 min at 57°C) FBS. 1 mL 200 mM L-glutamine solution. 1 mL 100X nonessential amino acid solution.
191
8/29/05, 11:19 AM
192
Xu
Fig. 1. Mouse embryonic fibroblast (MEF) cells. MEF cells plated at 2.12 × 105 cells/mL in a T75 flask serve as feeder cells to produce conditioned medium.
2. Filter to sterilize. 3. Store at 4°C and use within 2 wk.
3.1.3. Preparation of MEF Cells and MEF-Conditioned Medium 1. Isolate MEF cells from CF-1 mouse embryos at 13–14 d gestation and store frozen as described (8). Frozen vials of MEF cells are thawed and plated in 20 mL MEF medium in a T75 flask. Split the cells when confluent. 2. Harvest MEF cells, irradiate at 40 Gy, and seed at 2.12 × 105 cells/mL in MEF medium (Fig. 1). After at least 4 h, exchange the medium with ES cell medium (0.5 mL/cm2). 3. Collect the conditioned medium daily and supplement with an additional 4 ng/ mL human bFGF before feeding hES cells. 4. Feed the MEF cells again with ES cell medium daily and use for 7–10 d for the conditioned medium collection. The conditioned medium can also be frozen for storage at –20°C for 1 mo and thawed for later use.
3.1.4. Culture of Human ES Cells 1. Coat six-well culture plates by incubating with Matrigel diluted 1:20 in cold knockout DMEM at 1 mL per well at 4°C overnight or at room temperature for 1 h. 2. Preparation of 1 mg/mL collagenase solution: a. Dissolve 10 mg collagenase IV in 10 mL DMEM/F12 medium.
15_Xu_189_202_F
192
8/29/05, 11:19 AM
Trophoblast From Human ES Cells In Vitro
193
Fig. 2. Trophoblast induction. Human embryonic stem cell line H1 cells were treated with (C,D) or without (A,B) 100 ng/mL bone morphogenetic protein-4 for 7 d. The cells were photographed at 5× (A,C) and 20× (B,D). b. Sterile filter the solution with a 0.22-mm filter unit. c. Keep the solution at 4°C. 3. Passage human ES cells as cells become confluent (Fig. 2), i.e., about once a week, as follows: a. Add 1 mL collagenase solution to each well of human ES cells cultured in a six-well plate, and incubate the plate at 37°C for at least 5 min. b. To confirm colony separation from the plate, look for the edge of the colonies to peel off under a microscope. c. Using a glass 5 mL pipet, scrape cells off the surface of the plate. d. Transfer the cell suspension into a 15 mL tube. e. Gently pipet cells up and down a few times in the tube to further break-up cell colonies. f. Add DMEM/F12 to a final volume of 10 mL and mix gently. g. Pellet the cells by spinning at 200g for 5 min. h. Meanwhile, remove unbound Matrigel solution from the coated plate. i. Resuspend the cell pellet with conditioned medium, plate the cell suspension into the coated plate at a split ratio of 1:3–1:6 (cells from each original well are split to three to six new wells).
15_Xu_189_202_F
193
8/29/05, 11:20 AM
194
Xu j. Return the plate to incubator. Move the plate back-and-forth and side-to-side several times to evenly disperse the cells across the surface of the wells. k. Incubate cells overnight without touch to ensure that colonies attach. l. Add fresh conditioned media daily.
3.2. Trophoblast Induction and Culture (5) (see Note 1) 3.3.1. Trophoblast Induction 1. Split human ES cells into a six-well plate as described previously. 2. When the cells become approx 30% confluent (usually on day 2–3 following split), treat the cells with or without 100 ng/mL BMP4. 3. Add fresh conditioned media and BMP4 every other day (see Note 2). 4. Observe morphological changes with following features (see ref. 5 [http://genome-www.stanford.edu/es_cell/supplement.shtml]): a. At about day 2 (48 h) following the initiation of BMP4 treatment, a synchronous wave of differentiation occurs from the edge of the colonies, characterized by flattened and enlarged cell types and reduced proliferation (Fig. 2). b. Gradually, the differentiation continues inward to the center of the colonies. c. The morphological changes become obvious by day 2 for BMP4 at 100 ng/ mL, days 3–4 for 10 ng/mL, and days 5–6 for 1 ng/mL. d. BMP family members such as BMP2 (300 ng/mL), BMP7 (300 ng/mL), and GDF5 (30 ng/mL) induce similar morphological changes to that induced by BMP4 (100 ng/mL). e. Addition of inhibitors of BMP signaling, such as the soluble BMP receptor IA (500 ng/mL) or the BMP antagonizing protein noggin (500 ng/mL), can block the morphological changes induced by the BMPs.
3.2.2. Formation of Syncytial Trophoblast 1. Aspirate spent medium from a well of human ES cells cultured in a six-well plate. 2. Add 1 mL Trypsin/EDTA Solution to the well, and incubate at 37°C for at least 5 min. 3. Scrape the cells from the plate with a glass pipet, and transfer the cells to a 15-mL tube. 4. Break up the cell colonies by pipetting up and down several times, and add knockout DMEM/F12 medium to a final volume of 10 mL. 5. Pellet the cells by spinning at 200g for 5 min. 6. Remove the supernatant and re-suspend the pellet in conditioned medium, which contains mostly single cells. 7. Plate the cells at 105 cells per well, and incubate at 37°C overnight to allow the cells to attach. 8. Treat the cells with or without 100 ng/mL BMP4 the next day. 9. Add fresh media and BMP4 every other day. 10. Observe formation of syncytial cells, which usually occurs within 1–2 wk of the treatment, featuring giant and irregularly shaped cells containing more than two
15_Xu_189_202_F
194
8/29/05, 11:20 AM
Trophoblast From Human ES Cells In Vitro
195
Fig. 3. Syncytial cell. The left panel shows a syncytial cell formed after 2 wk of treatment of individualized embryonic stem cells by bone morphogenetic protein-4. The right panel shows immunofluorescence for CG-β and Hoechst 33342 fluorescence for the nuclei in the cell.
nuclei. The observed highest number of nuclei in one single syncytial cell was 100 (Fig. 3). These differentiated phenotypes remain for a long time without obvious changes (see ref. 5 [http://genome-www.stanford.edu/es_cell/supple ment.shtml]).
3.3.1. Suspended Culture of Trophoblast Vesicles 1. Induce human ES cells to differentiate into trophoblast with BMP4 in a six-well plate as described under Subheading 3.2.1. 2. At day 7, aspirate spent media from the plate, and wash the cells with PBS once. 3. Use collagenase solution to detach the cells and prepare cell suspension as described under Subheading 3.1.4. 4. Pellet the cells, resuspend the pellet in human ES cell medium, and transfer the cell suspension onto an uncoated six-well plate. 5. Culture the plate on a rotator in incubator. 6. Observe the formation of trophoblast vesicles in the medium (Fig. 4). 7. Refresh 50% of the spent medium twice a week. 8. To passage, break up the vesicles by pipetting them up and down with a glass pipet, and split the vesicle suspension at 1:2 or 1:3.
3.2.4. Co-Culture of Trophoblast With Human Uterine Fibroblast HUF Cells 1. Coat the inner chamber of a six-well Transwell plate with Matrigel as described under Subheading 3.1.4.
15_Xu_189_202_F
195
8/29/05, 11:20 AM
196
Xu
Fig. 4. Trophoblast vesicle. Following bone morphogenetic protein-4 treatment for 7 d, the differentiated human embryonic stem (ES) cells were dislodged from the culture plate by collagenase treatment. They form vesicles when suspended in human ES cell medium.
2. Passage human ES cells into the inner chamber, and culture them in a total of 3 mL conditioned medium added to the inner chamber and the outer chamber of the Transwell plate (both chambers link through openings on the side wall of the inner chamber). 3. Two days post passage, add 100 ng/mL BMP4 to the culture for 7 d to induce trophoblast. 4. HUF cells are maintained and expanded in RPMI culture medium supplemented with antibiotics, sodium pyruvate, and FBS. 5. Seed 2 × 104/well HUF cells in MEF medium in a new six-well plate, and culture them for 2 d. 6. Remove the spent media, and wash with PBS once. 7. Aspirate the spent media from the Transwell, transfer each of the inner chambers that contains BMP4-induced trophoblast to the well that contains HUF cells. 8. Add 3 mL human ES cell medium to the inner and outer chambers. 9. Co-culture the cells for 7 d. 10. Collect spent media daily to test for the production of placental hormones.
15_Xu_189_202_F
196
8/29/05, 11:20 AM
Trophoblast From Human ES Cells In Vitro
197
3.4. Characterization of the Induced Trophoblast (5) (see Note 3) 3.4.1. Immunocytochemistry 1. Culture human ES cells in a four-well plate that contains 0.5 mL conditioned medium. 2. Treat the cells with or without 100 ng/mL BMP4 for 7 d as above. 3. On day 7 of the treatment, remove the spent medium from the treated cells, add fresh human ES cell medium containing brefeldin A, a Golgi blocker, at 1.25 g/ mL, and incubate for 4 h at 37°C (see Note 4). 4. Remove the medium, wash the cells with PBS once, and fix them with 2% paraformaldehyde for 10 min at room temperature. 5. Remove the fixative and wash the cells with PBS once. 6. Block and permeabilize the cells by incubating them in PBS containing 0.1% Triton X-100 (T-PBS) and 5% milk powder at room temperature for 30 min. 7. Remove the blocking solution and wash the cells with T-PBS. 8. Add 0.2 mL T-PBS containing mouse anti-human CG-β antibody at 1:100 dilution to the test well, and 0.2 mL T-PBS containing equal amount of mouse IgG to the control well. 9. Incubate the cells at 4°C overnight. 10. Remove the solution, and wash the cells with 0.5 mL T-PBS three times (5 min each time). 11. Add 0.2 mL T-PBS containing fluorescein-labeled rabbit anti-mouse IgG antibody at 1:200 to each well. 12. Incubate the cells at room temperature for 30 min. 13. Remove the solution, and wash the cells with 0.5 mL T-PBS three times (5 min each time). 14. Incubate the cells with the Hoechst 33342 solution for at least 5 min to stain the nuclei. 15. Aspirate the solution (to reduce light reflection) and photograph at 20× magnification under both phase and epifluorescence microscope (Fig. 3).
3.4.2. Placental Hormone Measurement 1. Collect 2 mL spent media daily from cultures of BMP4-treated ES cells (Fig. 5A), suspended trophoblast vesicles, or co-culture of trophoblast with human uterine fibroblast HUF cells (Fig. 5B). 2. Keep the media at –70°C or immediately test for CG-β concentrations using the AxSYM Total hCG-β kit, and estradiol (9) and progesterone concentrations (10) by enzyme-linked immunosorbent assay (ELISA) (Fig. 5).
3.4.3. Flow Cytometry Assay of the Induced Trophoblast 1. Culture human ES cells in a six-well plate that contains 2.5 mL conditioned medium. 2. Treat the cells with or without 100 ng/mL BMP4 for 7 d as described previously.
15_Xu_189_202_F
197
8/29/05, 11:20 AM
198
Xu
Fig. 5 (caption on facing page)
3. Prepare fluorescence-activated cell sorting (FACS) buffer as follows. To calcium- and magnesium-free PBS, add 2% FBS and 0.1% sodium azide. 4. On day 7 of the BMP4 treatment, remove the spent medium from the treated cells, add fresh human ES cell medium containing brefeldin A at 1.25 g/mL, and incubate for 4 h at 37°C (see Note 4). 5. Remove the medium, and wash the cells with PBS once.
15_Xu_189_202_F
198
8/29/05, 11:20 AM
Trophoblast From Human ES Cells In Vitro
199
Fig. 5. Tests for placental hormone production. chorionic gonadotrophin (CG)-β, estradiol, and progesterone levels were detected in media collected from the culture of bone morphogenetic protein (BMP)4-treated human embryonic stem (ES) cells (A) and from the co-culture of BMP4-induced trophoblast with human uterine fibroblast (HUF) line cells (B). Mouse embryonic fibroblast (MEF) cells were used to generate the conditioned medium (CM; see Subheading 3.1.3.). BMP4 was added to this medium (CM + BMP4) to detect hormone production from the BMP4-treated cells. Unconditioned medium (UM) was used as a control for CM, because ES cells in UM spontaneously differentiate and generate low levels of the placental hormones, whereas the cells remain undifferentiated in CM and do not produce, or produce undetectable levels of, the hormones. Consequently, BMP4 actions are best tested in the CM to exclude the non-specific differentiation caused by UM. 6. Add 1 mL Trypsin/EDTA solution to the well, and incubate at 37°C for at least 5 min, break up the cell colonies by pipetting up and down several times, and then add 1 mL ES cell medium to neutralize the Trypsin/EDTA solution. 7. Scrape the cells from the plate with a glass pipet, and transfer the cells to a 15-mL tube. 8. Break up the cell colonies by pipetting up and down several times, and add human ES cell medium to a final volume of 10 mL. 9. Pellet the cells by spinning at 200g for 5 min. 10. Remove the supernatant and re-suspend the pellet in FACS buffer and count the cells.
15_Xu_189_202_F
199
8/29/05, 11:20 AM
200
Xu
11. Pellet the cells by spinning at 200g for 5 min, remove the supernatant (leave about 0.1 mL supernatant), and briefly mix to re-suspend the cells in the residual supernatant. 12. Add 1 mL 2% paraformaldehyde to the tube, mix well, and incubate at room temperature for 10 min. 13. Pellet the cells by spinning at 200g for 5 min, and remove the supernatant. 14. Add FACS buffer plus 0.1% Triton X100 to resuspend and permeabilize the cells, and also achieve a cell concentration of 5 × 106/mL. 15. Add 100 µL of the cell suspension containing 5 × 105 cells per tube to both a test tube and a control tube (using a Falcon 5-mL polystyrene round-bottomed tube). 16. Add 1 µL mouse anti-human CG-β antibody (5 mg/mL) to the test tube, and 5 µL of mouse IgG (1 mg/mL) to the control tube. 17. Briefly vortex the tubes to mix and incubate the tubes at 4°C overnight. 18. Add 1 µL fluorescein-labeled rabbit anti-mouse IgG antibody to both tubes, and incubate for 30 min on ice. 19. Wash the cells twice with 1-mL FACS buffer plus 0.1% Triton X100 by centrifugation at 200g for 5 min for each wash. 20. Re-suspend the cells in 0.3 mL of FACS buffer. 21. Analyze the samples on a FACSCalibur flow cytometer using the Cellquest acquisition and analysis software (see Note 5).
4. Notes 1. For synchronous differentiation of human ES cells to trophoblast, ES cells should be passaged as small colonies (about 200 µm in size), and BMP4 added when the cells are about 30% confluent. Big colonies often end up with the cells in the middle of the colonies remaining undifferentiated. 2. We have observed that the potency of BMP4 added to ES cell cultures twice on alternative days is equivalent to that of BMP4 added daily for 7 d, as evaluated by morphology and CG secretion. 3. According to microarray and reverse transcription-polymerase chain reaction assays (5), the expression levels of ES cell- and trophoblast-related genes change dynamically in the ES cells during BMP4 treatment. From 3 h through 7 d of BMP4 treatment, the expression of the following trophoblast-related genes are elevated: TFAP2A, TFAP2C, MSX2, GATA2, GATA3, SSI3, HEY1, FZD, PlGF, CGB, CGA, LHB, GCM1, INSL4, PAEP, PAPPE, DEPP, MET, and HLAG1 (see ref. 5 [http://genome-www.stanford.edu/es_cell/supplement.shtml]). At day 7, ES cell marker genes OCT4 and TERT are downregulated. 4. For detection of CG-β expression in trophoblast by immunocytochemistry or flow cytometry, it is essential to enhance the signal by pretreating the cells with the Golgi blocker brefeldin A for 4 h, permeabilizing the fixed cells with Triton X100, and incubating the cells with anti-CG-β antibody at 4°C overnight. 5. A total of 10,000 events are required. Analysis is restricted to live events based on light scatter properties. The fluorescein signal is collected through a 530/30
15_Xu_189_202_F
200
8/29/05, 11:20 AM
Trophoblast From Human ES Cells In Vitro
201
Fig. 6. Flow cytometry analysis for chorionic gonadotrophin (CG)-β positive cells in human embryonic stem cells cultured in conditioned medium (CM) with or without bone morphogenetic protein-4 treatment for 7 d. HCG stands for human CG.
band pass filter, and the mean fluorescence for both the IgG control and the test samples are determined. All data are normalized via division of the test mean by the control mean (Fig. 6).
Acknowledgments I thank Dr. James Thomson, his laboratory and the WiCell Research Institute for contributions to this work. It was supported by WiCell Research Institute, a non-profit subsidiary of the Wisconsin Alumni Research Foundation. References 1. Beddington, R. S. P. and Robertson, E. J. (1989) An assessment of the developmental potential of embryonic stem cells in the midgestation mouse embryo. Development 105, 733–737. 2. Thomson, J. A., Kalishman, J., Golos, T. G., et al. (1995) Isolation of a primate embryonic stem cell line. Proc. Natl. Acad. Sci. USA 92, 7844–7848. 3. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147. 4. Andrews, P. W., Oosterhuis, J., and Damjanov, I. (1987) Cell lines from human germ cell tumors, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach (Robertson, E., ed.). IRL, Oxford: pp. 207–246. 5. Xu, R. H., Chen, X., Li, D. S., et al. (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat. Biotechnol. 20, 1261–1264.
15_Xu_189_202_F
201
8/29/05, 11:20 AM
202
Xu
6. Strakova, Z., Srisuparp, S., and Fazleabas, A. T. (2000) Interleukin-1beta induces the expression of insulin-like growth factor binding protein-1 during decidualization in the primate. Endocrinology 141, 4664–4706. 7. Xu, C., Inokuma, M. S., Denham, J., et al. (2001) Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 19, 971–974. 8. Robertson, E. J. (1987) Embryo-derived stem cell lines, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach (Robertson, E., ed.). IRL, Oxford: pp. 71–112. 9. French, J. A., Abbott, D. H., Scheffler, G., Robinson, J. A., and Goy, R. W. (1983) Cyclic excretion of urinary oestrogens in female tamarins (Saguinus oedipus). J. Reprod. Fertil. 68, 177–184. 10. Munro, C. and Stabenfeldt, G. (1984) Development of a microtitre plate enzyme immunoassay for the determination of progesterone. J. Endocrinol. 101, 41–49.
15_Xu_189_202_F
202
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
203
16 Isolation and Culture of Term Human Trophoblast Cells Margaret G. Petroff, Teresa A. Phillips, Hakhyun Ka, Judith L. Pace, and Joan S. Hunt Summary Experimentation with most human cell types is restricted to the use of cell lines, and this limits our ability to extrapolate interpretations to the in vivo condition. However, in studying human trophoblast cells, we have a unique opportunity to obtain large quantities of readily available human tissue. In this chapter, we outline the methodology for purification of human trophoblast cells from term placentas. The procedures are based on enzymatic dissociation of villous placental tissue, followed by gradient centrifugation and immunomagnetic bead purification. Purity may be assessed by immunocytochemistry or flow cytometry using a number of markers to identify both cytotrophoblast cells and cellular contaminants. The resulting cytotrophoblast cell populations have excellent viability and purity, and may be subjected to longterm culture. Key Words: Human; placenta; cytotrophoblast cell; cell culture.
1. Introduction The ability to establish primary cell cultures from human organs is a rare opportunity. Even when it is possible, the investigator must often rely on limited quantities of tissues obtained from clinical biopsies. Furthermore, it is implicit that tissues could be diseased, particularly when samples are obtained from nonelective surgery. In contrast, those who study the trophoblast cell benefit from the large size of a readily available source material: the term placenta. An individual can easily process up to 50 g of villous placental tissue, harvesting upwards of 250 million cells. A further benefit is that there is little ethical controversy surrounding the use of human placenta for biomedical research because it is almost invariably discarded following delivery. In this chapter, we describe the isolation and purification of villous cytotrophoblast cells from the term placenta. In situ, these cells serve as precursor cells for the continually regenerating syncytiotrophoblast, and are located From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
203
16_Petroff_203_218_F
203
8/29/05, 11:20 AM
204
Petroff et al.
Fig. 1. Histology of a term placental villus. Arrows denote villous cytotrophoblast cells. sTB, syncytiotrophoblast; IVS, intervillous space.
basally in relation to the syncytiotrophoblast (Fig. 1). Upon histological examination of the term placenta, the cells are seemingly rare because they are present in a discontinuous layer beneath the syncytiotrophoblast. However, the total quantity of cytotrophoblast cells is highest at term in comparison with earlier stages of pregnancy as a result of their continual proliferation and to the presence of innumerable villi (1). Thus, the term placenta is a rich source of trophoblast cells. Once isolated, term cytotrophoblast cells rapidly lose the capacity to proliferate (2). Cultured cytotrophoblast cells undergo a limited amount of spontaneous morphological and endocrinological differentiation, as evidenced by formation of multinucleated syncytia and a small rise in secretion of hCGβ (Fig. 2 and ref. 2). In contrast, with the addition of recombinant cytokines that target epitheloid cells such as epidermal growth factor (EGF), the cells undergo robust differentiation, forming multinucleated syncytiotrophoblast-like monolayers that secrete high amounts of hCGβ, placental lactogen, and progesterone. Cytotrophoblast culture models have proven to be very useful for the study of endocrinological and immunological functions of the placenta, cytotrophoblast differentiation and apoptosis, and mechanisms of infectious and noninfectious disease (3–9).
16_Petroff_203_218_F
204
8/29/05, 11:20 AM
Fig. 2. Immunomagnetically purified from the term placenta. (A) Cells bound to the immunomagnetic column, representing nontrophoblastic cells. (B) Cells not bound to the column, representing trophoblastic cells in a state of early differentiation; (C) Cells not bound to the column and treated with 10 ng/mL epidermal growth factor (EGF); these cells have undergone extensive syncytialization. Cells were plated in 60 mm Primaria dishes at a density of approx 5 × 106 per dish (A) or 6 × 106 (B,C) in Iscove’s modified Dulbecco’s medium supplemented with 10% fetal bovine serum. After allowing adherence for 4 h, the nonadherent cells were removed by gentle washing. Thereafter, media were removed and replaced every 48 h 6 d.
Isolation and Culture of Human Trophoblast
205
16_Petroff_203_218_F
205
8/29/05, 11:20 AM
205
206
Petroff et al.
Table 1 Summary of Immunostaining After Purification Protocol (Reference)
Steps
Markers
Staining
Kliman et al. (10)
Percoll gradient
hCG (sTB) hPL (sTB) SP1 (sTB) Vimentin (non-TB) Chymotrypsin (non-TB)
1–5% Absent Absent Absent Absent
Douglas & King (11)
Percoll gradient and Immunopurification (Anti-HLA class I/II) Vimentin (non-TB)
Cytokeratin-18 (CTB)
100% Absent
PLAP (sTB)
4–46%
β-hCG (sTB) Cytokeratin-7 (sTB, CTB) CD14 (Macrophage) CD9 (non-CTB)
<1% ~100% <1% <3%
Guilbert et al. (12)
Current protocol
Immunopurification (Anti-CD9 and Anti-MHC class I/II) Percoll gradent and immunopurification (Anti-HLA class I)
Abbreviations: CTB, cytotrophoblast; hCG, human chorionic gonadotropin; hPL, human placental lactogen; PI, propidium iodide; PLAP, placental alkaline phosphatase; PS, phosphatidyl serine; SP1, pregnancy-specific β1-glycoprotein; sTB, syncytiotrophoblast; TB, trophoblast; FACS, fluorescenceactivated cell sorting.
Most published methods for purification of cytotrophoblast cells are based on methodology originally developed by Kliman et al. (10–13; Table 1). Standard methods involve digestion of villous tissue in a mixture of trypsin and DNase I, followed by density gradient centrifugation to remove cellular debris, red blood cells, and cells of higher density such as leukocytes. Some investigators utilize the resulting population directly, although purity is relatively low and cultures will eventually be overrun by proliferating placental fibroblasts (ref. 14 and unpublished observations). Purity can be improved to nearly 100% by inclusion of a negative selection procedure to eliminate nontrophoblast cells. To this end, villous fibroblasts, endothelial cells, and macrophages are bound and immobilized by antibody-conjugated beads. Antibodies may include anticlass I and class II human leukocyte antigen (HLA), CD9, or hepatocyte growth factor activator inhibitor (HAI)-1 (11,13,15,16). A final purification step is simple adherence to tissue culture vessels, which serves to eliminate contaminating multinucleated syncytial fragments (12).
16_Petroff_203_218_F
206
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
207
Fig. 3. Schematic representation of the trophoblast purification method. (1) Villous tissue is dissected, minced, and dissociated in trypsin/DNase I. (2) The resulting cell suspension is layered over a Percoll gradient, centrifuged, and thus fractionated on the basis of size and cellular density. (3) The semi-purified cells are incubated with mouse anti-human leukocyte antigen (HLA) class I and anti-mouse immunoglobulin (Ig)Gconjugated magnetic beads, and passed through a magnetic column. Nontrophoblast cells, which bind the HLA antibody, are retained in the column, whereas trophoblast cells pass through.
The methods described in this chapter outline the enzymatic dispersion, density gradient centrifugation, and HLA class I-depletion of trophoblast cells (Fig. 3). The latter step exploits the fact that virtually every placental cell type other than the villous cytotrophoblast cell expresses classical HLA class Ia molecules, so that these contaminating cell types are depleted. We routinely harvest >97% pure cytotrophoblast cells based on immunocytochemical staining for cytokeratin-7 and the absence of CD14-positive cells.
16_Petroff_203_218_F
207
8/29/05, 11:20 AM
208
Petroff et al.
2. Materials 2.1. Collection of Semipurified Trophoblast Cells 1. Sterile field sheets (Baxter, Deerfield, IL). 2. Sterile 4 in. × 4 in. gauze pads (Baxter). 3. Two pairs of small straight blade, sharp point scissors (Fine Science Tools, North Vancouver, BC). 4. Two pairs of fine-toothed forceps (Fine Science Tools). 5. Sterile 250-mL beaker for tissue collection, preweighed. 6. Sterile 1-L beaker for liquid waste. 7. Sterile 500-mL Erlenmeyer flask for tissue dissociation. 8. Sterile 150-mm Petri dish for tissue mincing. 9. Cell dissociation sieve, fitted with 40 mesh screen (Sigma-Aldrich, St. Louis, MO; cat. no. CD-1). 10. Benchtop water-bath shaker (for example, LabLine model SHKE7000; Barnstead Intl., Dubuque, IA). 11. Shandon cytospin centrifuge (Shandon, Pittsburgh, PA). 12. 15-mL sterile polypropylene or polystyrene centrifuge tubes. 13. 100-µm Falcon nylon mesh cell strainers (Becton Dickinson, Franklin Lakes, NJ, cat. no. 2360). 14. Biohazard bags. 15. Bleach. 16. Falcon Opticul 50-mL sterile polypropylene centrifuge tubes (Becton Dickinson). 17. Cryogenic cell storage vials. 18. Cell-freezing chamber. 19. 1 L 0.9% NaCl: dissolve 9 g NaCl in deionized H2O to yield a 1 L solution. Filter-sterilize (0.2 µm). 20. 10X Hank’s balanced salt solution (10X HBSS), 1 L: 5.36 mM KCl (4 g), 4.4 mM KH2PO4 (0.6 g), 1.37 M NaCl (80 g), 3.37 mM Na2HPO4 ( 0.4788 g), 55.5 mM D-glucose (10 g). Dissolve each of the constituents in deionized H2O to yield 1 L solution. Filter-sterilize (0.2 µm). 21. 1X Ca/Mg-free HBSS (CMF-Hank’s): Combine 100 mL 10X HBSS with 25 mL 1-M HEPES (Sigma, cat. no. H-0887) with deionized H2O to yield 800 mL H2O. Adjust pH to 7.4 and bring volume to 1 L. Filter sterilize. 22. Enzyme digestion buffer: combine 35 mL 10X HBSS with 1.65 mL 7.5% Na Bicarbonate (Sigma, cat. no. S-8761), 8.75 mL 1-M HEPES, and 266.1 mL deionized H2O; filter-sterilize and distribute into three bottles containing 133.5 mL, 89 mL, and 66.8 mL. Store at 4°C. 23. 2.5% Trypsin: 10X concentrate (Invitrogen, cat. no. 15090-046). Thaw a 100-mL bottle of trypsin and distribute 33 mL over three sterile tubes. Store at –20°C, and thaw just prior to use. 24. DNase I: (Sigma, cat. no. D-5025, 150,000 U, approx 50 mg solid, ~3000 U/mg). Just before use, add 5 mL sterile 0.9% NaCl to a 150,000-U vial of DNase. Filtersterilize and keep on ice until use or store at –20°C for later use.
16_Petroff_203_218_F
208
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
209
25. Enzyme digestion buffer (working solution): Batch no. Digestion buffer 10X trypsin DNase
26.
27.
28.
29.
I
II
III
133.5 mL 15 mL 1.5 mL
89 mL 10 mL 1 mL
66.8 mL 7.5 mL 0.75 mL
Just prior to each of the three digestion stages, add the appropriate volume of trypsin and DNase to prewarmed enzyme digestion buffer. When trypsin and DNase are added, concentrations will be 1X HBSS, 25 mM HEPES, 0.25% Trypsin, and approx 300 U/mL DNase. Cytotrophoblast cell culture medium: Iscove’s modified Dulbecco’s medium (IMDM) (Mediatech, Herndon, VA; cat. no. 15-016-CV), containing 10% heatinactivated FBS (56°C for 30 min) (Atlanta Biologicals, Norcross, GA; cat. no. S11150), 2 mM L-glutamine (Mediatech, Cat. No. 25-005-CI), and 1X penicillin/ streptomycin/amphotericin B (100X solution: Mediatech cat. no. 30-004-CI). Percoll gradients (see Note 1). a. Prior to preparing gradients, be sure to mix Percoll well, as Percoll undergoes spontaneous formation of gradients. Prepare 90% Percoll stock: 117 mL Percoll (Sigma, cat. no. P-4937) + 13 mL sterile 10X HBSS. b. Into sterile 50 mL tubes, prepare 14 dilutions of the Percoll using the 90% stock solution with sterile CMF-Hank’s, referring to Table 2 for appropriate volumes. c. Starting with the 70% solution of Percoll, slowly layer 3 mL of each concentration into the Falcon Opticul 50 mL conical centrifuge tubes (see Note 2). Expected fluid levels of each concentration are shown in Fig. 4. Store the gradients at room temperature away from disturbance. Percoll Density Marker Bead Kit (Optional) (Sigma, cat. no. DMB-10). Density marker beads may be used to verify the accuracy of the Percoll gradient preparation. To use, resuspend each vial of beads (nine vials total) in water, and mix 40 µL of each into a centrifuge tube. Slowly pipet the 360-µL mixture onto the surface, and centrifuge at 1200g for 20 min at room temperature. This can be done alongside an actual cell preparation. Approximate locations of the density marker beads after centrifugation are shown in Fig. 4, but may vary according to lot number. Cell freezing medium: 10% dimethylsulfoxide in FBS.
2.2. Immunomagnetic Purification of Cytotrophoblast Cells 1. Human placenta villous mononuclear cells purified by density gradient centrifugation. 2. MACS® separation system (Miltenyi Biotec, Auburn, CA): magnet (separation unit) (cat. no. 130-042-10); MultiStand (cat no. 130-042-303), MS+ Separation Columns (cat. no. 130-042-201); preseparation filters (cat. no. 130-041-407). 3. Primary antibody: mouse W6/32 (anti-human HLA-ABC). This antibody recognizes a nonpolymorphic epitope of HLA class I molecules that are associated
16_Petroff_203_218_F
209
8/29/05, 11:20 AM
210
Petroff et al. Table 2 Dilution Scheme for Preparation of Percoll Gradients 90% Percoll (mL) 15.6 14.4 13.3 12.2 11.1 10.0 8.9 7.8 6.7 5.6 4.4 3.3 2.2 1.1
4. 5.
6. 7.
CMF-Hanks (mL)
Final concentration
4.4 5.6 6.7 7.8 8.9 10.0 11.1 12.2 13.3 14.4 15.6 16.7 17.8 18.9
70% 65% 60% 55% 50% 45% 40% 35% 30% 25% 20% 15% 10% 5%
with β2-microglobulin (17,18). It can be purchased from several vendors (eBioscience, San Diego, CA; Novus Biologicals, Littleton, CO); alternatively, the hybridoma may be obtained from ATCC (Manassas, VA). Secondary antibody: MACS goat anti-mouse IgG microbeads (Miltenyi Biotec, cat. no. 130-048-401). Cell separation buffer (CSB): Dulbecco’s phosphate-buffered saline (PBS) without Ca2+ or Mg2+ (Sigma, cat. no. D-8537) containing 0.5% bovine serum albumin (BSA) (Sigma, cat. no. A-9056) and 2 mM ethylenediamine tetraacetic acid (EDTA) (Invitrogen, cat. no. 15575-038). Combine solutions and degas under vacuum. DNase (Sigma, cat. no. D-5025). DNase left over from the villous cytotrophoblast preparation may be used. Cytotrophoblast culture medium: IMDM supplemented with 10% heat-inactivated FBS (heat-inactivated at 56°C for 30 min; Atlanta Biologicals, cat. no. S11150), 2 mM L-glutamine (Cellgro, cat. no. 25-005-CI), and 1X penicillin/ streptomycin/amphotericin B (100X solution; Cellgro, cat. no. 0-004-CI).
3. Methods 3.1. Collection of Semipurified Trophoblast Cells (see Note 3) 1. Obtain a human placenta and process as soon as possible after delivery (see Note 4). If variation due to potential effects of labor is a concern, placentas from Caesarian section deliveries may be used. Always use caution when handling human biological material.
16_Petroff_203_218_F
210
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
211
Fig. 4. Schematic representation of expected locations of diluted Percoll solutions, density marker beads, and cell types. PMN, polymorphonuclear cells; RBC, red blood cells.
2. Place the placenta on a sterile field, with the maternal side (basal plate) facing up. Prepare histological, RNA or protein samples if desired (see Note 5). Using sharp, fine-point scissors and blunt forceps, dissect one cotyledon at a time. Remove the overlying basal plate tissue, about 3 mm from the surface. Avoiding the chorionic plate, collect 40–50 g of villous tissue into the preweighed 250-mL beaker. 3. Rinse tissue several times with 0.9% NaCl by swirling with forceps, using the 1-L beaker for liquid waste. Transfer all of the tissue to a 150-mm Petri dish and mince finely with scissors. Transfer half the tissue to the cell dissociation sieve and rinse with 0.9% NaCl extensively until the eluate becomes clear. Transfer the minced tissue to a 500-mL sterile Erlenmeyer flask, and repeat with the second half of the tissue.
16_Petroff_203_218_F
211
8/29/05, 11:20 AM
212
Petroff et al.
4. The dissociation is performed in three stages. During the dissociation of the second and third batches, the cell suspensions from the first and second batches are centrifuged and resuspended in turn. To prewarmed enzyme dilution buffer (labeled batch I), add DNase and trypsin as indicated above. Add the mixture to the Erlenmeyer flask containing the tissue, and incubate for 15–20 min at 37°C in a rotating water-bath shaker (150 rpm). During this incubation, add 1.5 mL FBS to 22 15-mL centrifuge tubes. 5. After the first 15-min dissociation, set the digestion flask at a tilt until tissue settles. Remove about 13.5 mL of the supernatant, taking care not to collect undissociated tissue. Slowly layer the suspension over the 1.5 mL serum in 15-mL conical centrifuge tubes. Repeat for seven additional tubes or until most of the digestion supernatant is transferred. Centrifuge the tubes at 1000g for 15 min at 25°C at room temperature. 6. While batch I is in the centrifuge, add 100 mL warm enzyme digestion solution containing enzymes (labeled batch II) and repeat digestion. Again collect supernatant and layer over FBS as for batch I. Repeat digestion a third (final) time. 7. For each batch, following centrifugation, aspirate the supernatant without disturbing the pellet. The trophoblast cells are predominantly in the white portion of the pellet, overlying the red blood cells. 8. Resuspend the cell pellet in each tube in 1 mL culture medium, and combine the resuspended pellets for each digestion group. Hold cells at room temperature. 9. After collecting the cells from all three digestion stages, filter the suspension using a 100-µm nylon cell strainer inserted in the top of a sterile 50-mL conical centrifuge tube. If the filtration of the cell suspension slows, lift upward on the filter to draw a vacuum within the tube. Centrifuge at 1000g for 10 min, and resuspend in 6 mL CMF-Hank’s. The total volume of the resuspended cells should be approx 8 mL. 10. Carefully layer half of the cells onto each of two preformed Percoll gradients. Centrifuge the gradients at 1200g for 20 min at room temperature in a swinging bucket rotor without a brake. 11. Aspirate upper diffuse “band” (Fig. 4; usually down to approx 25–30 mL mark on tube), and use a Pasteur pipet fitted with a bulb to manually collect the cells that fractionate near center of tube into each of two sterile 50-mL tubes. The band containing the cytotrophoblast cells is diffuse and usually between the 30-mL and 12to 15-mL graduations on tube. If using a separate reference tube containing density marker beads, the cells will correspond to the location between the 1.048 and 1.060 marker beads. Dilute the cell fractions fourfold with culture medium and centrifuge at 1000g for 5 min. Resuspend cells in each tube in 10 mL culture medium, combine, and determine yield by trypan blue dye exclusion. Typical yields are between 1.5 and 3 × 108 cells per approx 40 g tissue at greater than 95% viability. 12. To assess cell characteristics by immunocytochemistry, cytocentrifuge slides can be prepared. For one spot, use 50,000–100,000 cells in a 200-µL vol containing at least 50% serum. Centrifuge in the Shandon cytospin unit at 700 rpm for 3 min. Remove funnel, turn slide and filter paper end-for-end in holder, replace funnel and repeat. Place slides on bench to air dry, and store slides at –20°C.
16_Petroff_203_218_F
212
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
213
13. If not proceeding immediately with immunopurification or cell culture, centrifuge remaining cells (approx 250g for 10 min) and resuspend in freezing medium at 1 × 107 cells/mL. Aliquot 1 mL cells per cryovial, place vials in a room temperature cell freezing unit and store at –80°C overnight. Transfer cryovials to a liquid nitrogen freezer the next day.
3.2. Immunomagnetic Purification of Cytotrophoblast Cells 1. If starting from a frozen stock of villous mononuclear cells, thaw cells quickly in a 37°C water bath. Transfer the cells into a 50-mL conical centrifuge tube and resuspend slowly in about 20 mL cool cytotrophoblast culture medium per 5 × 107 cells. 2. Centrifuge at 200g for 10 min at 4°C and resuspend in 10 mL cold CSB. Keeping the cells on ice, count the cells and determine viability using trypan blue dye. 3. If cell clumping is evident, treat the cells with DNase as follows: centrifuge at 200g for 10 min at 4°C; resuspend in 20 mL cool (4°C) D-PBS (pH 7.0–7.2) containing 0.5 mM MgCl2, 1 mM CaCl2, 0.5% BSA, and 100 U/mL DNase. Incubate for 45 min at room temperature (25°C) or 15 min at 37°C in a shaking water bath. Centrifuge at 200g for 10 min at 4°C. Carefully remove supernatant. Resuspend in CSB and check for clumping. Repeat DNase digestion until no DNA remains (cell clumping). Repeat counting of cells. 4. Transfer cells to sterile 15-mL conical tube(s) (no more than 5 × 107 per tube), centrifuge again, and resuspend in 500 µL CSB per 5 × 10 7 cells containing 40 µg/mL W6/32. The cell suspension will be very viscous; mix well by flicking the tube several times and incubate for 10 min in the refrigerator (6–12°C). 5. After the incubation, add 3 mL cold CSB and centrifuge at 300g for 10 min. Remove and discard the supernatant, add 3 mL cold CSB, and repeat centrifugation. Resuspend cells in 400 µL (per 5 × 107 cells) CSB. 6. Label the cells with MACS anti-mouse IgG MicroBeads. To the 400 µL cells, add 100 µL (per 5 × 107 cells) microbeads to the cell suspension and incubate 15 min in the refrigerator. 7. Following the 15 min incubation of secondary antibody with cells, wash the cells once by adding 3 mL CSB and centrifuging as described above. Resuspend cells in 0.5 mL CSB per ≤ 5 × 107 cells; keep on ice. 8. Prepare the MACS separation system. Attach the MiniMACS magnet(s) to the MACS MultiStand and place an MS+ separation column in the MiniMACS magnet. To the column, attach a 23–27-gauge needle to act as a flow resistor (we use 25 gauge × five-eighths-inch needles). Prepare the column by applying 500 µL ice-cold CSB to the top of the column; let the buffer flow through and discard the effluent. Prewet the preseparation filter by vigorously pipetting 0.5 mL ice-cold CSB onto the membrane. Place the filter atop the separation column. Place a clean 15-mL centrifuge tube under the column. This will serve to collect the purified trophoblast cells. 9. Separate the immunomagnetic bead-labeled cells in the prepared MiniMACS column. Apply 500 µL cell suspension to the preseparation filter. Allow the cell suspension to run through the prefilter and column, collecting the effluent in a sterile tube (see Note 6). A yellow-tipped micropipet can be used to aspirate any cellular suspension from the underside of the preseparation filter.
16_Petroff_203_218_F
213
8/29/05, 11:20 AM
214
Petroff et al.
10. Rinse the tube that contained the cells with 500 µL ice-cold CSB and apply to column. Wash the column two to three times with 500 µL ice-cold CSB, each time collecting in same effluent tube. If using more than one column, combine effluents from the columns. 11. If desired, recover the bound cells (i.e., noncytotrophoblastic cells that remain trapped within the column). Remove column from separator by pulling the column horizontally out of the magnet. Remove flow resistor from bottom of column, and place column above a fresh collection tube. Add 1 mL ice-cold CSB onto the column. Using the plunger supplied with the column, flush cells from column. 12. Centrifuge the cells at 400g and resuspend in cytotrophoblast culture medium. Prepare a dilution in trypan blue and determine yield and viability. Typical yields are 60–70% of the starting population. For characterization, prepare cytospin preparations of each cell type (see Note 7). 13. Plate the purified cells in culture medium at a minimum of 2 × 105 cells/cm2 in appropriate culture vessels (see Note 8). Allow cells to attach to the surface of the plate for 4–24 h, after which rinse twice with prewarmed culture medium to remove the nonattached cells. Refresh medium every 24–48 h.
4. Notes 1. This procedure allows for preparation of six tubes of stepwise 5–70% Percoll gradients. Each cytotrophoblast preparation from 40 g placental tissues requires two of these gradients; therefore, six are sufficient for three cytotrophoblast cell preparations. All six gradients can be prepared at one time, but for best results, use the gradients within 24 h of preparation. The diluted Percoll solutions may be stored for later preparation of gradients. 2. Preparation of Percoll gradients is time-consuming. Some laboratories utilize peristaltic pumps to reduce the workload. We have found that pipetting time can be greatly reduced by resting the tip of the 5-mL pipet on the side of the tube just above the liquid level and gently swinging the tip side-to-side against the tube to induce layering of a broad stream of liquid. The result is that liquid can be pipetted at a faster rate because the broader stream will reduce the pressure per unit of surface area of the liquid. 3. We usually reserve 2 or 3 d for isolation of semi-purified cytotrophoblast cells. The first day is devoted to preparation of reagents and Percoll gradients, and the second day to the purification procedure itself. At the conclusion of the second day, one may either cryopreserve the semipurified cytotrophoblast cells, or proceed directly to the final step of trophoblast isolation, immunomagnetic purification (see Subheading 3.2.). 4. In the United States, term placentas are regarded as discarded tissues and can therefore be obtained without patient consent. Obtaining additional information about the medical background of the patient will be subject to regulation by the Health Insurance Portability and Accountability Act (HIPAA), and investigators must go through the appropriate channels to ensure privacy and consent of the patient.
16_Petroff_203_218_F
214
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
215
5. It is often desirable to obtain histological specimens that include basal plate placenta as well as villous tissue, because the basal plate tissue contains extravillous trophoblast cells. To do this, score a 1-mm × 3-mm rectangular portion of the surface of the basal plate with sharp scissors. Make the deeper cuts, blotting away unclotted blood if necessary, and use blunt, flat-tipped forceps to gently lift the tissue upwards. Trim the tissue to the desired size and fix or freeze as necessary. To obtain amniochorion histological samples, lay a section of amniochorion membrane on a sterile field with the amnion face downward. Trim a 1-mm × 5-mm slice, and either fix in desired fixative or, for frozen histology, use the scissors and forceps to roll the membrane. Place the roll on its side for embedding; upon microscopy, it will be possible to simultaneously observe the amnion, chorion, and decidua. For extraction of RNA and/or protein, we usually obtain specimens from the villous portion of the placenta after removal of the basal plate connective tissue. This can therefore be done concomitantly with collection of the tissue to be dissociated. We collect and pool these samples from several cotyledons to avoid potential intercotyledonary differences. To snap-freeze, samples can be dropped directly into liquid nitrogen in an RNase-free container and subsequently transferred into sterile, precooled polypropylene tubes for storage at –80°C. 6. If the MACS columns run slowly, there are several steps that may be taken to improve flow. First, a micropipet fitted with a yellow tip can be used to disrupt any cells that may have settled on the top of the column. Without introducing bubbles into the cell suspension over the column, pipet up and down to dislodge settled cells. If this fails to speed up the column, use the plunger supplied with the column to introduce light pressure. Place the plunger over the head of the column and gently press down. Applying too much pressure by forcing the plunger into the column will shear and detach the nontrophoblast, antibody/beadbound cells from the magnet, thus contaminating the eluted cell population. If application of pressure fails to hasten the elution, we have found that the problem often resides within the needle, which can get clogged with cells. Thus, the needle can simply be removed and replaced with a new, sterile needle. If the problem is indeed due to the needle, the flow will immediately hasten upon removal of the clogged needle; thus, a new needle must be in place as quickly as the old one is removed. As a last resort, the column itself can be replaced, and the unfiltered cells transferred to a new column. However, this will result in the sacrifice of any cells that may be trapped within the original column. 7. At this point, the cells can be analyzed by flow cytometry (19) or immunocytochemistry on cytospin preparations. By the latter method, we have used anticytokeratin-7 (Dako, Carpinteria, CA; clone OVTL 12/30), anti-CD14 (Zymed, San Francisco, CA; clone RPA-M1), and anti-hCGβ (Neomarkers, Freemont, CA; clone CG05) (4,20). 8. Cytotrophoblast cells may be cultured on Permanox Chamber Slides (Nalge Nunc). Although adherence to this type of plastic is better than glass chamber slides, it is still relatively poor. Thus, we seed at a very high density to guarantee that sufficient numbers of cells attach to the slide (e.g., seed 300,000 cells per well in eight-well slides).
16_Petroff_203_218_F
215
8/29/05, 11:20 AM
216
Petroff et al.
Acknowledgments The authors thank Mr. Stanton Fernald and Ms. Erin Skorina for their assistance in preparation of graphics. This work was supported by grants R01 HD045611 (M.G.P), P01 HD39878 Project III (J.S.H.), U54 HD33994 (J.S.H) Project III, and R01 HD24212 (J.S.H) from the National Institutes of Health. References 1. Benirschke, K. and Kaufmann, P. (2000) Pathology of the Human Placenta. Springer-Verlag, New York: pp. 55–56. 2. Morrish, D. W., Dakour, J., Li, H., et al. (1997) In vitro cultured human term cytotrophoblast: a model for normal primary epithelial cells demonstrating a spontaneous differentiation program that requires EGF for extensive development of syncytium. Placenta 18, 577–585. 3. Kamat, A., Alcorn, J. L., Kunczt, C., and Mendelson, C. R. (1998) Characterization of the regulatory regions of the human aromatase (P450arom) gene involved in placenta-specific expression. Mol. Endocrinol. 12, 1764–1777. 4. Petroff, M. G., Chen, L., Phillips, T. A., Azzola, D., Sedlmayr, P., and Hunt, J. S. (2003) B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol. Reprod. 68, 1496–1504. 5. Morales, P. J., Pace, J. L., Platt, J. S., et al. (2003) Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J. Immunol. 171, 6215–6224. 6. Huppertz, B., Frank, H. G., Reister, F., Kingdom, J., Korr, H., and Kaufmann, P. (1999) Apoptosis cascade progresses during turnover of human trophoblast: analysis of villous cytotrophoblast and syncytial fragments in vitro. Lab. Invest. 79, 1687–1702. 7. Ka, H. and Hunt, J. S. (2003) Temporal and spatial patterns of expression of inhibitors of apoptosis in human placentas. Am. J. Pathol. 163, 413–422. 8. Abbasi, M., Kowalewska-Grochowska, K., Bahar, M. A., Kilani, R.T., WinklerLowen, B., and Guilbert, L. J. (2003) Infection of placental trophoblast by Toxoplasma gondii. J. Infect. Dis. 188, 608–616. 9. Li, H., Dakour J., Kaufman S., Guilbert, L. J., Winkler-Lowen, B., and Morrish, D.W. (2003) Adrenomedullin is decreased in preeclampsia because of failed response to epidermal growth factor and impaired syncytialization. Hypertension 42, 895–900. 10. Kliman, H. J., Nestler, J. E., Sermasi, E., Sanger, J. M., and Strauss, J. F. (1986) Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 118, 1567–1582. 11. Douglas, G. C., and King, B. F. (1989) Isolation of pure villous cytotrophoblast from term human placenta using immunomagnetic microspheres. J. Immunol. Methods 119, 259–268. 12. Guilbert, L. J., Winkler-Lowen, B., Sherburne, R., Rote, N. S., Li, H., and Morrish,
16_Petroff_203_218_F
216
8/29/05, 11:20 AM
Isolation and Culture of Human Trophoblast
13.
14.
15.
16.
17.
18.
19.
20.
217
D. W. (2002) Preparation and functional characterization of villous cytotrophoblasts free of syncytial fragments. Placenta 23, 175–183. Potgens, A. J., Kataoka, H., Ferstl, S., Frank, H. G., and Kaufmann, P. (2003) A positive immunoselection method to isolate villous cytotrophoblast cells from first trimester and term placenta to high purity. Placenta 24, 412–423. Morrish, D. W., Shaw, A. R., Seehafer. J., Bhardwaj, D., and Paras, M. T. (1991) Preparation of fibroblast-free cytotrophoblast cultures utilizing differential expression of the CD9 antigen. In Vitro Cell. Dev. Biol. 27A, 303–306. Yui, J., Garcia-Lloret, M., Brown, A. J., et al. (1994) Functional-long-term cultures of human term trophoblasts purified by column-elimination of CD9 expressing cells. Placenta 15, 231–246. Nagamatsu, T., Fuji, T., Ishikawa, T., et al. (2004) A primary cell culture system for human cytotrophoblasts of proximal cytotrophoblast cell columns enabling in vitro acquisition of the extra-villous phenotype. Placenta 25, 153–165. Brodsky, F. M., Bodmer, W. F., and Parham, P. (1979) Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur. J. Immunol. 7, 536–545. Ladasky, J. J., Shum, B. P., Canavez, F., Seuanez, H. N., and Parham, P. (1999) Residue 3 of beta 2-microglobulin affects binding of class I MHC molecules by the W6/32 antibody. Immunogenetics 49, 312–320. Potgens, A. J., Gaus, G., Frank, H. G., and Kaufmann, P. (2001) Characterization of trophoblast cell isolations by a modified flow cytometry assay. Placenta 22, 251–255. Ka, H. and Hunt, J. S. (2003) Temporal and spatial patterns of expression of inhibitors of apoptosis in human placentas. Am. J. Pathol. 163, 413–422.
16_Petroff_203_218_F
217
8/29/05, 11:20 AM
16_Petroff_203_218_F
218
8/29/05, 11:20 AM
Human Trophoblast Cell Line Production
219
17 Production of Human Trophoblast Cell Lines Guy St J. Whitley Summary Our understanding of important biological phenomena such as invasion, migration, and apoptosis has advanced greatly through the prudent use of in vitro models based on isolated cells in culture. Established cell lines are readily manipulated using simple molecular biological techniques and their abundance as homogenous populations allows the rapid accumulation of statistically significant data. The study of human trophoblast function in vitro has been hampered by the difficulties associated with obtaining and culturing primary human trophoblasts including the paucity of material and contamination with other cell types. This chapter describes a cheap and simple method for the production of human trophoblast cell lines using poly-L-ornithine. It details the production, isolation and initial characterization of these cells and provides simple tips on how to store and maintain a bank of cells for future needs. Key Words: Cytotrophoblasts, transfection, cell line, poly-L-ornithine, SV40.
1. Introduction The power of interventional over purely observational studies is immense and our understanding of important biological functions such as cell division, apoptosis and migration has advanced significantly following studies using cells grown in culture. The two options for these experiments are either to use primary cells isolated from fresh tissue or to use established cell lines. It is the aim of this chapter to describe the methods used to generate cell lines. Cell lines may be obtained spontaneously as out-growths from malignant tissue or from normal primary cultures that have been manipulated to express viral oncogenes which overcome the cells normal growth controls. The study of human trophoblast function in vitro has been hampered by the difficulties associated with obtaining and culturing trophoblasts. Although pure preparations of the different subpopulations of trophoblast can be obtained by fluorescence-activated cell sorting (1) yields can be low and the procedures require specialized equipment. Pure extravillous trophoblasts may be obtained From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
219
17_Whitley_219_228_F
219
8/29/05, 11:20 AM
220
Whitley
following out-growth from chorionic explant cultures (2), although this again results in relatively low cell yields. Normal human cells cultured in vitro have a limited proliferative lifespan, dividing a given number of times before they undergo a permanent growth arrest, known as replicative senescence. This seems particularly true of trophoblasts cells that grow poorly in culture. Other problems associated with using primary cells are heterogeneity between preparations, phenotypic instability of the isolated cells and, in some circumstances, availability of tissue. Established cell lines would therefore seem to offer a number of advantages since they are homogenous populations that grow readily in culture providing a plentiful supply of cells with a stable phenotype over many passages. Conversely, the methods employed to extend lifespan (transfection or spontaneous immortalization/transformation) may alter regulation of cell division that could impact on differentiated functions and gene expression. However, it should be emphasised that no matter which route is taken (either primary culture or established cell line), no in vitro model is perfect. Therefore, one of the most important considerations when using in vitro models is that we recognize their limitations and design the experiments and interpret the results accordingly. A number of human trophoblast cell lines already exist; some of the more widely used lines are listed in Table 1. Early trophoblast lines were derived from choriocarcinomas and these include BeWo, JEG, and JAR (Table 1). These lines have proved useful in many studies, but may have characteristics related to their malignant origins. More recently, a number of lines that have retained phenotypic function have been reported that arose spontaneously from primary cultures of normal first trimester chorionic villous explants or chorionic villous samples; these lines include the HTR-8 (3) and the ED series of trophoblast cell lines (4,5). Unfortunately, caution should now be taken when using ED27 as they have at some stage become contaminated with the nontrophoblast cell line HeLa (6). Transfection of cells with viral oncogenes from Simian virus-40 (SV40), adenovirus, or human papilloma virus (HPV) have been used to establish lines. The most common of these used in the production of trophoblast cell lines is the early region of SV40 containing the small and large T-antigen. The large T-antigen binds to and inactivates the protein products of p53 and retinoblastoma (RB), two tumor suppressor genes. Expression of the T-antigen increases the proliferation of the cells in culture and delays the onset of cellular senescence. As increased growth can lead to a reduction in differentiated function, constructs containing conditional mutants including the temperature sensitive variants of SV40 have been used to generate these lines. At the permissive temperature the large T-antigen is expressed and functional and the cells proliferate however at the nonpermissive temperature the stability of the mutant
17_Whitley_219_228_F
220
8/29/05, 11:20 AM
Human Trophoblast Cell Line Production
221
Table 1 Commonly Used Human Trophoblast-Derived Cell Lines Cell line
Source
Means of production
BeWo ED27 ED31 ED77 HP-A1 HP-A2 HP-W1 HT HT-116 HTR-8 HTR-8/SVneo JAR JEG IST-1
Choriocarcinoma First trimester
Spontaneous Spontaneous
Term placenta
Infection Adenovirus(ori)SV40tsA209 Infection Adenovirus(ori)SV40tsA209 Infection Adenovirus(ori)SV40wt Spontaneous Spontaneous Spontaneous Electroporation with pSV3neo Spontaneous Spontaneous HPV16 E6/E7
NHT NPC RSVT-2, 2/C SGHPL-4 SPA-26 TCL-1 TL
Term placenta First trimester First trimester HTR-8 Choriocarcinoma Choriocarcinoma First trimester villous explant First trimester First trimester HTR-8 First trimester First trimester Term choriodecidua Term
Reference
Spontaneous Spontaneous Electroporation with pRSVT Poly-L-ornithine with pSV3neo Infection SV40tsa255 pZipSV40 Spontaneous
24 5 5 4 9
25 26 3 3 27 28 11 29 30 30 31 8 32 33
gene product is compromised and division of the cells falls. The theory is that at the nonpermissive temperature, the resulting cell will re-establish lost functions. This type of construct has been used to produce both first and third trimester trophoblast cell lines (7–9). Although the expression of the T-antigen does extend the lifespan of the cultures, it seldom produces immortal human cell lines. Eventually, cells undergo a delayed phase of growth arrest and enter what is termed SV40crisis. This is associated with a reduction of telomere length (10). Recent work has suggested that the expression of human telomerase catalytic component could overcome this, although further work is required to determine if this has adverse effects on the phenotype of the resultant cell lines. Another commonly used construct for the production of cell lines is the early region of HPV-16. This contains two gene products known as E6 and E7, expression of which is also known to overcome cellular senescence in human cells. Although E6 and E7 alone have been used to derive lines in some cell
17_Whitley_219_228_F
221
8/29/05, 11:20 AM
222
Whitley
types, a construct containing both E6 and E7 is considered more efficient and has been used to produce trophoblast cell lines derived from first trimester villous explants (11). It is reported that cells expressing HPV-16 E6–E7 are nontumorigenic in nude mice and retain most of the phenotypic characteristics of primary cultures. We have spent a number of years developing a series of cell lines derived from first-trimester extravillous trophoblasts. The resulting lines express many markers characteristic of the extravillous trophoblast cells, including HLA-G, hPL, and CD-9 (12,13). The best-characterized line is called SGHPL-4. This cell line was produced following transfection with the large T-antigen of SV40. Unlike some reported trophoblast cell lines, this line is neither immortal (although rather long-lived) nor transformed, and has been used in a number of studies to investigate the mechanisms regulating invasion, motility (14–17), and apoptosis (18,19). In this chapter, we will describe the common ways to produce cell lines and give specific details of the method we have found most useful for the production of extravillous trophoblast cell lines. We will discuss the isolation of clones and the establishment of low-passage frozen stocks. The characterization of newly produced cell lines will also be discussed. 2. Materials 1. Culture medium: a. Standard growth medium will depend on the method of primary cell isolation. We use Ham’s-F10 containing 10% (v/v) heat-inactivated fetal calf serum (FCS), 2 mM glutamine and penicillin (100 U/mL), and streptomycin (0.1 mg/mL). b. Transfection medium Dulbecco’s modified Eagle’s medium (DMEM; Sigma, Dorset UK) containing 2 mM glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin, and 5% (v/v) FCS. c. Selection medium is Ham’s-F10 plus 0.3 mg/mL geneticin (G418) and 10% (v/v) FCS. d. Cell freezing and storage medium: standard growth medium containing 10% (v/v) dimethylsulfoxide (DMSO; MERCK, Poole, Dorset, UK). 2. Poly-L-ornithine (Sigma Chemicals, cat. no. P4538) is prepared as a 5 mg/mL stock in water, filter-sterilized through a 0.2-µm syringe and stored as 50-µL aliquots at –20°C (see Note 1). 3. Chloroquine diphosphate 100 mM stock solutions (60 mg/mL in H2O) filter-sterilized and stored in foil wrapped tubes at –20°C. 4. Geneticin is prepared fresh in medium and filter sterilized through a 0.2-µm syringe filter. 5. The recombinant plasmid used for transfection, pSV3-neo, contains both the large and small T-antigens of the early region of SV40 and the bacterial neomycin
17_Whitley_219_228_F
222
8/29/05, 11:20 AM
Human Trophoblast Cell Line Production
223
phosphotransferase gene that confers resistance to the antibiotic geneticin (G418). The plasmid pSV3-neo was originally described by Southern and Berg (20) and is available from the American Tissue Culture Collection (Manassas, VA, cat. no. 37150). 6. Antibodies for the identification of different trophoblast populations are CK7 (Dako Corporation, Carpinteria, CA, cat. no. M 7018), HLA-G (Serotec, Oxford, UK, cat. no. MCA2044) and CD9 (Dako, cat. no. M 7055) (see Note 2).
3. Methods 3.1. Transfection The first and, possibly, most important step in the process of developing a cell line is to obtain a primary culture rich in the cells of interest. The methods for isolating and purifying different populations of trophoblast are presented elsewhere in this volume, and so will not be considered here. Suffice it to say a pure population of cells is not essential, but the greater the purity the greater the chance of successfully obtaining useful transfectants. DNA introduced into mammalian cells can be either retained in the cytoplasm and transiently expressed or transported to the nucleus and integrated into the genome of the cell. Transient expression is appropriate for the production of proteins in relatively high concentrations over short periods of less than 10 d but will not result in the production of stable lines. Stable integration is a more rare event—perhaps as few as 0.1% of the transfected cells will result in stable integration. It is therefore important to optimize the efficiency of transfection. 1. Seed cells into 9-cm dishes 24 h prior to transfection in order to achieve approx 80% confluence on the day of transfection (see Note 2). 2. For each 9-cm dish, place 3 mL of DMEM into a flat bottomed Bijou container and add 10 µg of plasmid DNA and 5 µg/mL of poly- L-ornithine (see Note 1). Mix gently and allow standing for 30 min at room temperature. Remove the medium from the cells and add the DNA solution. Return the cells to the incubator and gently rock the plate every 45 min (see Note 4). 3. After 6 h, aspirate the medium and replace with 2 mL DMEM 5% (v/v) FCS containing 30% (v/v) DMSO (see Note 5). After 2 min, remove the supernatant and wash gently with Ham’s-F10 plus 10% (v/v) FCS. Aspirate and replace with a further 10 mL of Ham’s-10 plus 10% (v/v) FCS and maintain the cells in a humidified incubator at 37°C in 5 % CO2.
3.2. Selection of Stable Transfectants Maintain cells in standard growth medium for 48–72 h to allow expression of the transferred genes to occur. Then aspirate the medium and replace with standard growth medium containing G418 at a concentration of 0.3 mg/mL. Replace the medium every 2–3 d for 3–4 wk (see Note 6).
17_Whitley_219_228_F
223
8/29/05, 11:20 AM
224
Whitley
3.3. Isolation and Expansion of Cell Colonies With time, colonies will form. When they reach a size of approx 2000 cells or approx 0.5–1 mm in diameter, transfer the colonies into standard medium in the absence of G418 to a single well of either a 96- or 24-well plate. As the wells become confluent, transfer the cells into increasingly larger dishes. Keep a careful record of the number of passages. There are a number of ways for the initial removal of colonies from the plate. The most common method is to place a cloning ring around the colony, add trypsin to the inside of the ring, and gently remove the cells/colony (see Note 7).
3.4. Characterization of Cell Lines Each of the isolated and expanded clones must be tested and its cellular origins identified. In many respects, this is an ongoing process. Not only is it important to establish the characteristics of the clone, but it is also essential to determine how stable the phenotype is. The latter can only be achieved by repeated testing after periods in culture. Identification of different subpopulations of cytotrophoblasts has been a topic of great discussion for a number of years (12,13). As a result, a number of workshops at meetings of the International Federation of Placental Associations (IFPA) have discussed what markers should be expressed by each subpopulation of trophoblasts. The results of these discussions can be summarized as follows: the minimum characteristic requirements for a villous trophoblast cell line would be CK7+, HLA-class I–, and CD9–, and for an extravillous cell line the requirements would be CK7+, HLA-G+, and CD9+ (see Note 8).
3.5. Storage Long-term storage of transfected cells is essential. As with other cells, trophoblasts are readily stored in liquid nitrogen. Cells should be removed from the plate with trypsin in the normal manner, centrifuged and re-suspended in standard growth medium containing 10% (v/v) FCS and 10%(v/v) DMSO at a concentration of 106 cells/mL. Normal freezing protocols should then be employed (see Note 9). 4. Notes 1. Poly-L-ornithine is available from Sigma in a number of different molecular weights, a molecular weight of 11,000 is desirable (cat. no. P4538); with a molecular weight in the range of 5000–15,000 is recommended for this purpose. 2. There has been some controversy over antisera that should be used in the detection of HLA-G. At the 14th Rochester Trophoblast Conference (12) it was suggested that the two antibodies of choice were 87G (21), and G233 (22). As the
17_Whitley_219_228_F
224
8/29/05, 11:20 AM
Human Trophoblast Cell Line Production
3.
4. 5.
6. 7.
8.
225
commercial availability of these antisera is unclear at the time of writing an alternative is MEM-G/9 (23) (Serotec, cat. no. MCA2044). Chloroquine may be used to increase DNA uptake. The concentration of chloroquine used and the time it is left with the cells will need to be optimized for each cell system. Addition of 100 µM 30 min prior to the addition of the DNA would be an appropriate place to start. This should be left in contact with the cells throughout the transfection period along with the DNA and for a maximum of 8 h. Three milliliters is just sufficient to cover the dish. The cells must be rocked at regular intervals to prevent the cells in the center of the dish from drying out. DMSO shock is used to increase the efficiency of transfection and this medium should not be left in contact with the cells for prolonged periods. Cell viability during this phase of the transfection will depend on the exact culture conditions. If there is a significant loss of cell viability using this protocol the concentration of DMSO and/or the time of exposure can be reduced. Cells will begin to die after 3–4 d of exposure to G418. The regular change of medium removes cell debris. There are a number of other ways to obtain a clonal population. The easiest way is by limiting dilution. This method is often used for the cloning of hybridomas and is therefore not suitable for all cells. After removing cells from the plate they are re-suspended at a density of 1000 cells/mL, 100 µL of cell suspension is plated into each well of the first column of a 96-well plate. Then doubling dilutions of the cells is carried out across the plate using a multi-channel pipet. With this strategy, there will be less than one cell per well in column 8 onward. There are disadvantages to this approach as cells at low to very low density may not grow as a result of a lack of growth factors. However, the use of conditioned trophoblast medium may over come this. An alternative approach that has proved more appropriate for the production of trophoblast cell lines has been to removed the cells from the transfection plate the day after the transfection procedure and seed them onto 24 well plates. Once they have recovered (usually following an overnight incubation) the selection medium can be added as above. This approach relies on the fact that DNA incorporation into the genome is a rare occurrence and therefore the chance of more than one resistant colony growing per well is small. Regular inspection of each well throughout the selection procedure will identify those that do have more than one colony. This approach does have the further advantage that the cells will establish more readily due to the autocrine/paracrine production of growth factors. Clones should be screened for expression of relevant phenotypic markers. We have found that SGHPL-4 cells express cytokeratin-7 when grown on collagen, fibronectin and gelatin. Therefore, for full characterization it is advisable for the cells to be tested following growth on different extracellular matrices. In our experience, transfection with the early region of SV40 results in cells with an extended lifespan; however, prolonged periods in culture will lead eventually to both phenotypic and proliferative instability (i.e., SV-40 crisis). In the early stages
17_Whitley_219_228_F
225
8/29/05, 11:20 AM
226
Whitley
of characterization, the cellular phenotype should be tested every 5–10 passages. Changes in phenotype with passage should be documented. It may also be advisable to karyotype the cells early and repeat this periodically. Testing the cells after prolonged periods of storage is also advisable. 9. Cells should be stored from the earliest passage, because this will ensure that should the clones prove useful there are sufficient early stocks available for many studies. Each time cells are removed from storage, a proportion of the initial passages should be frozen down again; by this means, stocks of cells can be rapidly established. In this way, if cells are inadvertently contaminated one can trace back to a time before that happened. A useful cell line will be of interest to other laboratories. To protect stocks, it is advisable not to give very early stocks but be willing to supply later passage cells more frequently and never take cells back. This will maintain cell stocks and reduce the chances of contamination either by other cell types or micro-organisms.
Acknowledgments I wish to thank Judith Cartwright and Alan Johnstone for helpful discussions while preparing this chapter. References 1. King, A., Jokhi, P. P., Smith, S. K., Sharkey, A. M., and Loke, Y. W. (1995) Screening for cytokine mRNA in human villous and extravillous trophoblasts using the reverse-transcriptase polymerase chain reaction (RT-PCR). Cytokine 7, 364–371. 2. Aplin, J. D., Haigh, T., Jones, C. J., Church, H. J., and Vicovac, L. (1999) Development of cytotrophoblast columns from explanted first-trimester human placental villi: role of fibronectin and integrin alpha5beta1. Biol. Reprod. 60, 828–838. 3. Graham, C. H., Hawley, T. S., Hawley, R. G., et al. (1993) Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp. Cell Res. 206, 204–211. 4. Diss, E. M., Gabbe, S. G., Moore, J. W., and Kniss, D. A. (1992) Study of thromboxane and prostacyclin metabolism in an in vitro model of first-trimester human trophoblast. Am. J. Obstet. Gynecol. 167, 1046–1052. 5. Morgan, M., Kniss, D., and McDonnell, S. (1998) Expression of metalloproteinases and their inhibitors in human trophoblast continuous cell lines. Exp. Cell Res. 242, 18–26. 6. Kniss, D. A., Xie, Y., Li, Y., et al. (2002) ED(27) trophoblast-like cells isolated from first-trimester chorionic villi are genetically identical to HeLa cells yet exhibit a distinct phenotype. Placenta 23, 32–43. 7. Chou, J. Y. (1978) Human placental cells transformed by tsA mutants of simian virus 40: a model system for the study of placental functions. Proc. Natl. Acad. Sci. USA 75, 1409–1413.
17_Whitley_219_228_F
226
8/29/05, 11:20 AM
Human Trophoblast Cell Line Production
227
8. Chou, J. Y. (1978) Establishment of clonal human placental cells synthesizing human choriogonadotropin. Proc. Natl. Acad. Sci. USA 75, 1854–1858. 9. Lei, K. J., Gluzman, Y., Pan, C. J., and Chou, J. Y. (1992) Immortalization of virus-free human placental cells that express tissue-specific functions. Mol. Endocrinol. 6, 703–712. 10. Rhim, J. S. (2000) Development of human cell lines from multiple organs. Ann NY Acad. Sci. 919, 16–25. 11. Shih, I., Wang, T., Wu, T., Kurman, R. J., and Gearhart, J. D. (1998) Expression of Mel-CAM in implantation site intermediate trophoblastic cell line, IST-1, limits its migration on uterine smooth muscle cells. J. Cell Sci. 111, 2655–2664. 12. Frank, H. G., Morrish, D. W., Potgens, A., Genbacev, O., Kumpel, B., and Caniggia, I. (2001) Cell culture models of human trophoblast: primary culture of trophoblast—a workshop report. Placenta 22(Suppl A), S107–S109. 13. Shiverick, K., King, A., Frank, H., Whitley, G., Cartwright, J. E., and Schneider, H. (2001) Cell culture models of human trophoblast II: trophoblast cell lines - a workshop report. Placenta 22(Suppl), s104–s107. 14. Cartwright, J. E., Holden, D. P., and Whitley, G. S. (1999) Hepatocyte growth factor regulates human trophoblast motility and invasion: a role for nitric oxide. Br. J. Pharmacol. 128, 181–189. 15. Cartwright, J. E., Kenny, L. C., Dash, P. R., et al. (2002) Trophoblast invasion of spiral arteries: a novel in vitro model. Placenta 23, 232–235. 16. Cartwright, J. E., Tse, W. K., and Whitley, G. S. (2002) Hepatocyte growth factor induced human trophoblast motility involves phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and inducible nitric oxide synthase. Exp. Cell Res. 279, 219–226. 17. Tse, W. K., Whitley, G. S., and Cartwright, J. E. (2002) Transforming growth factor-beta1 regulates hepatocyte growth factor-induced trophoblast motility and invasion. Placenta 23, 699–705. 18. Dash, P. R., Cartwright, J. E., Baker, P. N., Johnstone, A. P., and Whitley, G. S. (2003) Nitric oxide protects human extravillous trophoblast cells from apoptosis by a cyclic GMP-dependent mechanism and independently of caspase 3 nitrosylation. Exp. Cell Res. 287, 314–324. 19. Dash, P. R., Cartwright, J. E., and Whitley, G. S. (2003) Nitric oxide inhibits polyamine-induced apoptosis in the human extravillous trophoblast cell line SGHPL-4. Hum. Reprod. 18, 959–968. 20. Southern, P. J., and Berg, P. (1982) Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet. 1, 327–341. 21. Yang, Y., Geraghty, D. E., and Hunt, J. S. (1995) Cytokine regulation of HLA-G expression in human trophoblast cell lines. J. Reprod. Immunol. 29, 179–195. 22. Loke, Y. W., King, A., Burrows, T., et al. (1997) Evaluation of trophoblast HLAG antigen with a specific monoclonal antibody. Tissue Antigens 50, 135-146. 23. Fournel, S., Huc, X., Aguerre-Girr, M., et al. (2000) Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules. Tissue Antigens 55, 510–508.
17_Whitley_219_228_F
227
8/29/05, 11:20 AM
228
Whitley
24. Pattillo, R. A. and Gey, G. O. (1968) The establishment of a cell line of human hormone-synthesizing trophoblastic cells in vitro. Cancer Res. 28, 1231–1236. 25. Ho, C. K., Li, S. Y., Yu, K. J., Wang, C. C., Chiang, H., and Wang, S. Y. (1994) Characterization of a human tumorigenic, poorly differentiated trophoblast cell line. In Vitro Cell Dev. Biol. Anim. 30A, 415–417. 26. Zdravkovic, M., Aboagye-Mathiesen, G., Guimond, M. J., Hager, H., Ebbesen, P., and Lala, P. K. (1999) Susceptibility of MHC class I expressing extravillous trophoblast cell lines to killing by natural killer cells. Placenta 20, 431–440. 27. Hussa, R. O., Story, M. T., and Pattillo, R. A. (1975) Regulation of human chorionic gonadotropin (hCG) secretion by serum and dibutyryl cyclic AMP in malignant trophoblast cells in vitro. J. Clin. Endocrinol. Metab. 40, 401–405. 28. Kohler, P. O. and Bridson, W. E. (1971) Isolation of hormone-producing clonal lines of human choriocarcinoma. J. Clin. Endocrinol. Metab. 32, 683–687. 29. Rong-Hao, L., Luo, S., and Zhuang, L. Z. (1996) Establishment and characterization of a cytotrophoblast cell line from normal placenta of human origin. Hum. Reprod. 11, 1328–1333. 30. Khoo, N. K., Bechberger, J. F., Shepherd, T., et al. (1998) SV40 Tag transformation of the normal invasive trophoblast results in a premalignant phenotype. I. Mechanisms responsible for hyperinvasiveness and resistance to anti-invasive action of TGFbeta. Int. J. Cancer. 77, 429–439. 31. Choy, M. Y. and Manyonda, I. T. (1998) The phagocytic activity of human first trimester extravillous trophoblast. Hum. Reprod. 13, 2941–2949. 32. Lewis, M. P., Clements, M., Takeda, S., et al. (1996) Partial characterization of an immortalized human trophoblast cell-line, TCL-1, which possesses a CSF-1 autocrine loop. Placenta 17, 137–146. 33. Ho, C. K., Chiang, H., Li, S. Y., Yuan, C. C., and Ng, H. T. (1987) Establishment and characterization of a tumorigenic trophoblast-like cell line from a human placenta. Cancer Res. 47, 3220–3224.
17_Whitley_219_228_F
228
8/29/05, 11:20 AM
Choriocarcinoma Cell Culture and Transfection
229
18 Culture and Transfection of Human Choriocarcinoma Cells Michael W. Wolfe Summary In vitro models for human trophoblasts were initially established more than three decades ago from isolated choriocarcinomas. They have proven to be extremely valuable for the study of the cellular, molecular, and endocrine aspects of human trophoblasts. This chapter describes basic methods for culture and maintenance of the Jeg-3, Jar, and BeWo human choriocarcinoma cell lines as well as an effective paradigm for introducing DNA into the cells. Key Words: Trophoblast cells; Jeg-3 cell; Jar cell; BeWo cell; medium; transfection; lipofectamine.
1. Introduction In vitro models for studying human trophoblast function were initially established more than three decades ago. Dr. Roy Hertz (1) isolated choriocarcinomas from affected women and transferred them to the cheek-pouch of hamsters. The tumors were maintained over a number of years by serial transfer to additional animals. Three different strains of tumors were developed. Interestingly, animals harboring the tumors exhibited endocrine changes consistent with the presence of human chorionic gonadotropin (hCG), a known endocrine hormone secreted by human trophoblasts and choriocarcinomas. One of these strains was subsequently used to develop a number of the choriocarcinoma cell lines that are extant today. Pattillo and coworkers obtained choriocarcinoma tissue from Dr. Hertz at serial transfer 304 and placed it in a co-culture with human decidual explants (2,3). From this co-culture, they established the BeWo choriocarcinoma cell line. This cell line maintains many of the morphological characteristics of human trophoblasts including the ability to form syncytia. BeWo cells, like
From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
229
18_Wolfe_229_240_F
229
8/29/05, 11:20 AM
230
Wolfe
human trophoblasts, secrete a number of hormones including hCG, human placental lactogen, progesterone, estrone and estradiol (3–6). Serially transferred choriocarcinoma tissue (same strain as used by Pattillo) was obtained at the 387th transfer by Kohler and coworkers and subsequently used to establish additional choriocarcinoma lines (7). In this case, explants were placed in culture and outgrowths were isolated and clonally selected. Six different clonal cell lines were developed: JEG-1, -2, -3, -4, -7, and -8. The lines possessed different morphologies, but none were observed to form syncytia (8). Like BeWo cells, the JEG cell lines synthesized and secreted hCG, human chorionic somatomammotropin (placental lactogen), progesterone, estrone, and estradiol (7,8). The lines appear to be distinct in that the rate of secretion of hCG and progesterone varied across the six clonal lines. In addition to the choriocarcinoma cell lines originating from the serially transferred tissue obtained from Dr. Hertz , Pattillo and coworkers established a second line directly from a trophoblastic tumor of the placenta (9). This line, Jar choriocarcinoma cells, maintains many of the morphological and endocrine characteristics found in human trophoblasts (6,9). Over the last three decades the BeWo, JEG, and Jar choriocarcinoma cell lines have been adapted to standard cell culture conditions and have proven to be extremely valuable for studying various aspects of human trophoblast differentiation and function. Furthermore, they tend to readily accept DNA when introduced through many different DNA transfection paradigms. This has allowed them to serve as the model of choice in studies involving the characterization of promoter function. Instructions for basic culture and maintenance of the JEG-3, Jar, and BeWo human choriocarcinoma cell lines as well as two paradigms for introducing DNA into the cells follow. 2. Materials 2.1. JEG-3 and Jar Cells 1. The JEG-3 and Jar cell lines are available through American Type Culture Collection (ATCC, Manassas, VA; Cat. Nos. JEG-3 - HTB-36; Jar - HTB-144). 2. Cell culture medium: Dulbecco’s modified Eagle’s medium (DMEM) (with L -glutamine and 4500 mg glucose/L; Invitrogen, Carlsbad, CA, cat. no. 11965-084), fetal bovine serum (FBS) (Invitrogen, cat. no. 16000-044), and penicillin/streptomycin (10,000 U/mL; Invitrogen, cat. no. 15140-122). 3. Trypsinization solution: Trypsin-ethylenediamine tetraacetic acid (EDTA) (0.25% trypsin, 1 mM EDTA, 4 Na), 1X liquid (Invitrogen, cat. no. 25200-056). 4. Phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4. Adjust pH to 7.4 and filter-sterilize or autoclave. 5. Freezing medium: cell culture medium containing 5% dimethylsulfoxide (DMSO) (Sigma, St. Louis, MO; cat. no. D-2650), filter-sterilized.
18_Wolfe_229_240_F
230
8/29/05, 11:20 AM
Choriocarcinoma Cell Culture and Transfection
231
6. Freezing container: Nalgene Cryo 1°C Freezing Container (Nalgene Nunc International, Rochester, NY, cat. no. 5100-0001). 7. Tissue culture plates: 100 cm2 (Greiner Bio-One, Longwood, FL).
2.2. BeWo Cells 1. The BeWo cell line is available through ATCC (cat. no. CCL-98; see Note 1). 2. Cell culture medium: DMEM/F12, a 1:1 mixture (with L-glutamine and 15 mM HEPES; Invitrogen, cat. no. 11330-032), MEM nonessential amino acids solution (100X, liquid; Invitrogen, cat. no. 11140-050), FBS (Invitrogen, cat. no. 16000-044), and penicillin/streptomycin (10,000 U/mL; Invitrogen, cat. no. 15140-122). 3. Trypsinization solution: Trypsin-EDTA (0.25% trypsin, 1 mM EDTA, 4 Na), 1X liquid (Invitrogen, cat. no. 25200-056). 4. PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4. Adjust pH to 7.4 and filter-sterilize or autoclave. 5. Freezing medium: cell culture medium containing 5% DMSO (Sigma, cat. no. D-2650), filter-sterilized. 6. Tissue culture plates: 100 cm2 (Greiner Bio-One).
2.3. Transfections 1. Trypsinization solution: Trypsin-EDTA (0.25% trypsin, 1 mM EDTA, 4 Na), 1X liquid (Invitrogen, cat. no. 25200-056). 2. PBS: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4. Adjust pH to 7.4 and filter-sterilize or autoclave. 3. Culture medium. 4. Hemacytometer (Fisher, cat. no. 02-671-6). 5. Sterile polypropylene snap-cap culture tubes (Greiner, from ISC Bioexpress, cat. no. T-2840-5). 6. Opti-MEM I reduced serum media (Invitrogen, cat. no. 31985-070). 7. LipofectAmine transfection reagent (Invitrogen, cat. no. 18324-012). 8. Plus reagent (Invitrogen, cat. no. 11514-015). 9. TK-, CMV-, or SV40-driven Renilla expression plasmid (Promega, Madison, WI). 10. Tissue culture plates: 12-well (Greiner Bio-One). 11. Passive lysis buffer (Promega, cat. no. E1941). 12. Dual-Luciferase reporter assay system (Promega, cat. no. E1960).
2.4. β-Galactosidase Staining 1. 2. 3. 4. 5.
2% paraformaldehyde in PBS. 0.1 M potassium ferricyanide (Sigma, cat. no. P8131). 0.1 M potassium ferrocyanide (Sigma, cat. no. P9387). 1 M MgCl2 (Fisher, cat. no. BP214-500) in PBS. 40 mg/mL of X-Gal (Invitrogen, cat. No. 15520-034) in N,N-diemethylformamide (DMF; Sigma, cat. no. D4254).
18_Wolfe_229_240_F
231
8/29/05, 11:20 AM
232
Wolfe
3. Methods 3.1. Culture Medium 3.1.1. JEG-3 and Jar Cells 1. In a laminar flow hood or biosafety cabinet (see Note 2), add the following to a sterile, 500-mL bottle: 445 mL of DMEM, 50 mL of FBS, and 5 mL of penicillin/ streptomycin (see Note 3). 2. The medium can be filtered through a 0.22-µm disposable filter if desired. 3. Store at 4°C in the dark.
3.1.2. BeWo Cells 1. In a laminar flow hood or biosafety cabinet (see Note 2), add the following to a sterile, 500-mL bottle: 440 mL of DMEM/F12, 50 mL of FBS, 5 mL of MEM nonessential amino acids, and 5 mL of penicillin/streptomycin (see Note 3). 2. The medium can be filtered through a 0.22-µm disposable filter if desired. 3. Store at 4°C in the dark.
3.2. Cell Removal From Liquid Nitrogen: JEG-3, Jar, and BeWo Cells 1. Warm the cell culture medium to 37°C. 2. Remove a vial of frozen cells from a liquid nitrogen storage tank and thaw the cells in a 37°C water-bath. Record vial removal in the liquid nitrogen storage log. 3. Immediately after the cells are thawed, transfer the cell suspension to a sterile, conical 50-mL tube containing 30 mL of culture medium, and mix the cell suspension gently (see Note 4). 4. Place 10 mL of the cell suspension into each of three 100-cm2 tissue culture plates and label the plates with the cell line name, passage number, and date. 5. Grow cells in a 37°C incubator supplied with 5% CO2 and 95% air. 6. Replace the cell culture medium every 2–3 d.
3.3. Passage of Cells: JEG-3, Jar, and BeWo Cells 1. Warm all solutions (e.g. trypsin/EDTA, culture medium, PBS) to 37°C. 2. When the cells reach 75–90% confluence, the monolayer can be treated with trypsin to detach the cells (see Note 5). 3. Aspirate media from the plate of cells to be passaged (see Note 6). 4. Add 3 mL trypsin–EDTA solution to each plate (see Note 7). Incubate within the hood at room temperature for approx 3 min. 5. Aspirate most of the trypsin solution from each plate (leave approx 0.5 mL in the plate) and place them into a 37°C incubator for an additional 3 min. At this point the cells should be detaching from the plate. To assist in the detachment, rap the side of the plate on your hand two to three times. 6. Add approx 5 mL of culture medium to each plate to stop trypsinization. Carefully tilt the plate at an angle and detach the remaining adherent cells by flushing medium across the plate using a pipet. Transfer the cell suspension into a sterile 50-mL conical tube, pooling cells from similar plates.
18_Wolfe_229_240_F
232
8/29/05, 11:20 AM
Choriocarcinoma Cell Culture and Transfection
233
7. Determine the volume of the cell suspension. 8. These cells can be passaged or split at a ratio of 1:3 to 1:5. Determine the number of plates needed to passage the cells and the volume of cells per plate (volume of cell suspension divided by the total number of plates). 9. Aliquot the proper volume of fresh culture medium onto each plate such that the total volume (cell suspension plus culture medium) is 10 mL. 10. Carefully invert the tube containing the cell suspension to mix and aliquot the proper volume of the cell suspension onto each plate. Swirl each plate to mix. 11. Label each plate with the cell line name, passage number (one greater than the previous passage), and date. 12. Grow cells in a 37°C incubator supplied with 5% CO2 and 95% air. 13. Feed the cells the next day and then every 2–3 d subsequently. 14. Visualize cells under a microscope for viability and confluency.
3.4. Liquid Nitrogen Storage of Cells: JEG-3, Jar, and BeWo Cells 1. Harvest the cells from the plates by trypsinization as described in Subheading 3.3., steps 1–6. 2. Centrifuge to pellet the cells at 216g for 10 min at room temperature. 3. Aspirate the supernatant media and gently resuspend the cell pellet in 1 mL of freezing medium per plate of harvested cells. 4. Label 1.0- or 2.0-mL cryo vials: cell line, passage number (one greater than the previous passage), date, and your initials. Use vials that are appropriate for liquid nitrogen storage. 5. Transfer 1.0 mL of cell suspension into each vial. 6. Transfer the vials to the freezing container and place in a –80°C freezer for 6 h to overnight. Transfer the vials to a liquid nitrogen storage container for long-term storage (see Note 8). Update the liquid nitrogen storage log with these entries.
3.5. Transient Transfection of Cells Numerous techniques with which to introduce exogenous DNA into cells exist: calcium phosphate co-precipitation, electroporation, virus mediated entry, and so on. Many of these have been successfully used to transiently transfect DNA into choriocarcinoma cell lines. Our laboratory has utilized a lipid-based method to introduce DNA into choriocarcinoma cells (10,11). It is a simple, highly reproducible, and efficient method for transiently transfecting these cells. Two different approaches are presented below, both of which (with minor adjustments) are effective. The first approach using LipofectAmine (JEG-3 cells are used as an example) is simple, cost effective and achieves a moderate level of transfection efficiency. The second approach using LipofectAmine and Plus reagent (Jar cells are used as an example) is more costly and labor-intensive, but achieves a higher level of transfection efficiency (two- to threefold). The second protocol is the one of choice when trying to overexpress a protein of interest in a high proportion of the cells in culture.
18_Wolfe_229_240_F
233
8/29/05, 11:20 AM
234
Wolfe
3.5.1. Transfection of JEG-3 Cells Using LipofectAmine 1. Day 1. Harvest the cells from one to three plates by trypsinization as described in Subheading 3.3., steps 1–6. 2. Bring the total volume of the cell suspension up to 30–40 mL with culture medium. Determine the density of the cells harvested using a hemacytometer (see Note 9). 3. Seed the appropriate number of 12-well culture plates with cells at a density of 35,000 cells per mL, adding 1 mL per well. 4. Place the plates into a 37°C incubator (supplied with 5% CO2 and 95% relative humidity) and allow the cells to attach overnight. 5. Day 2. The following morning, warm the Opti-I MEM solution to 37°C. 6. Determine the concentration of all DNAs to be transfected using a spectrophotometer (see Note 10). 7. For each DNA to be transfected, add 0.75 mL of Opti-I MEM to separate snapcap tubes (see Note 2). This represents the appropriate volume for transfections performed in triplicate (0.25 mL per well). 8. Add 1.5-µg of DNA to the appropriate tubes (e.g., human α-subunit promoterLuciferase construct or Rous sarcoma virus (RSV) β-galactosidase expression vector) (0.5 µg per well). 9. Add 0.3 µg of a Renilla expression vector (TK-, CMV-, or SV40-driven vector) to each tube as an internal control (0.1 µg per well). 10. In a sterile conical tube, prepare a solution containing 12 µL of LipofectAmine and 0.75 mL of Opti-I MEM per DNA to be transfected. 11. Add 0.75 mL of the LipofectAmine/Opti-I solution to each tube prepared in steps 7–9. Swirl to mix and incubate at room temperature for 45 min (4 µL LipofectAmine and 0.25 mL Opti-I MEM per well). 12. Place in the hood the 12-well plates containing the JEG-3 cells seeded the previous day. At the end of the 45-min incubation, aspirate the medium from one to two plates at a time and add 0.5 mL of the DNA/LipofectAmine/Opti-I solution to each well. Carefully label the plates and record the DNA transfected into each well. 13. Place the plates back into the 37°C incubator. 14. Day 3. In the morning, warm the JEG-3 culture medium to 37°C. 15. Aspirate the DNA/LipofectAmine/Opti-I solution from each well and replace with 0.5 mL of JEG-3 culture medium (see Note 11). Return the plates to the 37°C incubator. 16. Cultures can be harvested 6–72 h later and assayed for reporter activity (Fig. 1; time is experiment dependent; method depends on assay used to detect reporter activity) (see Note 12).
3.5.2. Transfection of Jar Cells Using LipofectAmine and Plus Reagent 1. Harvest the cells from one to three plates by trypsinization as described in Subheading 3.3., steps 1–6. 2. Bring the total volume of the cell suspension up to 30–40 mL with culture medium. Determine the density of the cells harvested using a hemacytometer (see Note 9).
18_Wolfe_229_240_F
234
8/29/05, 11:20 AM
Choriocarcinoma Cell Culture and Transfection
235
Fig. 1. JEG-3 and Jar cell lines were transiently transfected with either a human α-subunit promoter (–845/+48) linked to luciferase or a promoterless control (0.5 µg per well) along with a Renilla expression plasmid as an internal control (0.1 µg per well) as described under Subheadings 3.5.1. and 3.5.2. (see Note 12). Approximately 6 h after the transfection medium was removed, cells were washed two times with phosphate-buffered saline (PBS) and lysed using 100 µL of Passive lysis buffer. Lysates (30 µL) were assayed for luciferase and renilla activity using the Dual-Luciferase assay system. Luciferase activity (relative light units [RLU]) of the human α-subunit promoter was adjusted to that of Renilla and presented as the mean + SE (n = 3). Activity of the promoterless luciferase vector was 293 ± 50 (LipofectAmine only) and 442 ± 58 (LipofectAmine and Plus) RLUs in JEG-3 cells and 1129 ± 175 (LipofectAmine only) and 610 ± 49 (LipofectAmine and Plus) RLUs in Jar cells.
3. Seed the appropriate number of 12-well culture plates with cells at a density of 30,000 cells per mL, adding 1 mL per well. 4. Place the plates into the 37°C incubator (supplied with 5% CO2 and 95% relative humidity) and allow the cells to attach overnight. 5. Day 2. The following morning, warm the Opti-I MEM solution to 37°C. 6. Determine the concentration of all DNAs to be transfected using a spectrophotometer (see Note 10). 7. For each DNA to be transfected, add 0.75 mL of Opti-I MEM to separate snapcap tubes (see Note 2). This represents the appropriate volume for transfections performed in triplicate (0.25 mL per well). 8. Add 1.5 µg of DNA to the appropriate tubes (e.g., human α-subunit promoterluciferase construct or RSV β-galactosidase expression vector) (0.5 µg per well). 9. Add 0.3 µg of a Renilla expression vector (TK-, CMV-, or SV40-driven vector) to each tube as an internal control (0.1 µg per well).
18_Wolfe_229_240_F
235
8/29/05, 11:20 AM
236
Wolfe
10. Add 9 µL of Plus reagent to each tube and swirl to mix. Incubate at room temperature for 15 min (3 µL per well). 11. In a sterile conical tube, prepare a solution containing 6 µL of LipofectAmine and 0.75 mL of Opti-I MEM per DNA to be transfected. 12. Add 0.75 mL of the LipofectAmine/Opti-I solution to each tube prepared in steps 7–10. Swirl to mix and incubate at room temperature for 15 min (2 µL LipofectAmine and 0.25 mL Opti-I MEM per well). 13. Place in the hood the 12-well plates containing the Jar cells seeded the previous day. At the end of the 15 min incubation, aspirate the medium from one to two plates at a time and add 0.5 mL of the DNA/Plus/LipofectAmine/Opti-I solution to each well. Carefully label the plates and record the DNA transfected into each well. 14. Place the plates back into the 37°C incubator for 5 h. 15. At the end of the 5 h incubation, add 0.5 mL of Jar culture medium (prewarmed) to each well (see Note 13). 16. Day 3. In the morning, warm the Jar culture medium to 37°C. 17. Aspirate the DNA/Plus/LipofectAmine/Opti-I solution from each well and replace with 0.5 mL of Jar culture medium (see Note 11). Return the plates to the 37°C incubator. 18. Cultures can be harvested 6–72 h later and assayed for reporter activity (Fig. 1; time is experiment dependent; method depends on assay used to detect reporter activity) (see Note 12).
3.6. β-Galactosidase Staining of Cultures 1. 2. 3. 4.
Wash cells three times with cold PBS. Fix cells at 4°C for 5 min with 2% paraformaldehyde. Wash cells three to four times with PBS. Add 400 µL of staining solution (20 mM potassium ferricyanide, 20 mM potassium ferrocyanide, 2 mM MgCl2 in PBS) to each well. 5. Add 10 µL of the X-Gal solution (1 mg/mL final concentration) to each well. 6. Incubate at 37°C overnight or until the appropriate amount of blue staining is achieved.
4. Notes 1. A clonal variant of the BeWo cell line exists (b30) that has characteristics that differ slightly from the parental line (forms a tight monolayer) and is cultured under slightly different conditions (see Volume 2, Chapter 11). 2. All procedures should be performed in a laminar flow hood or biosafety cabinet to maintain sterile conditions. 3. Alternative growth media suggested by ATCC is as follows: JEG-3 cells: 90% MEM with 2 mM L-glutamine and Earles’ balanced salt solution to contain 1.5 g/ L sodium bicarbonate, 0.1 mM nonessential amino acids, and 1.0 mM sodium pyruvate; 10% FBS; Jar cells: 90% RPMI-1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES,
18_Wolfe_229_240_F
236
8/29/05, 11:20 AM
Choriocarcinoma Cell Culture and Transfection
4.
5.
6. 7. 8. 9.
10.
11. 12.
13.
237
and 1.0 mM sodium pyruvate; 10% FBS; BeWo cells: 90% - Ham’s F12K medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate; 10% FBS. We typically do not remove the cells from the freezing medium. The 1:30 dilution is adequate to remove any inhibitory effects that the DMSO may cause on cell growth and viability. Nonetheless, the cells can be pelleted (216g for 10 min) at this step to remove the DMSO-containing medium and subsequently resuspend the cell pellet in 30 mL of fresh culture medium. The BeWo cells grow much more slowly than do the JEG-3 and Jar cells; therefore, it will take longer for plates to reach confluency. In addition, because the cells are on the plate for a longer period of time, they tend to attach more tightly. Longer incubations with trypsin/EDTA may be required in order to effectively detach the cells from the plate. At this point, the cells can be washed two times with 5 mL of PBS to speed up the subsequent trypsinization. Only trypsinize a maximum of five plates at a time to prevent overtrypsinization. If there are more than five, tryspinize them in groups with staggered additions. The cells can remain in the –80°C freezer for longer periods of time (a few days), but extended time at –80°C reduces cell viability when thawed. With the coverslip in place and using a Pasteur pipet, transfer a small amount of the undiluted cell suspension (invert tube three to five times to ensure that cells are resuspended) to both chambers of the hemacytometer (allow the chambers to fill by capillary action; do not overfill). Using an inverted microscope, count all of the viable cells in four of the 1-mm squares (a 1-mm square is composed of a 4 × 4 grid of smaller squares) in one chamber. Repeat this with the other chamber. Determine the cell density using the following equation: Cells per mL = (total cell count/eight squares) × dilution (1 in this case) × 104. The total number of cells harvested would be: Cells per mL × volume of cell suspension. We have determined that more consistent results are obtained when all of the DNAs to be transfected in a single experiment are quantified at the same time and near the time (within a few days) of performing the transfection. It is also important to use super-coiled DNA that is mycoplasma-free. Alternatively, treatments can be administered at this point. The LipofectAmine protocol is adequate for experiments where a high level of transfection efficiency is not required. Transfection efficiency in JEG-3 cells can be boosted two- to threefold (Figs. 1 and 2) by following a modification of the approach described under Subheading 3.5.2., which uses a combination of LipofectAmine and Plus reagent (3 µL of LipofectAmine and 3 µL of Plus reagent per well). Conversely, transfection of the Jar cells can be simplified (although at the cost of lower transfection efficiency) by modifying the approach under Subheading 3.5.1. (3 µL of LipofectAmine). Finally, although a specific protocol for the transfection of BeWo cells is not provided, we have had success using LipofectAmine in combination with the Plus reagent as described for JEG3 cells. Alternatively, add 0.5 mL of serum-free Jar culture medium.
18_Wolfe_229_240_F
237
8/29/05, 11:20 AM
238
Wolfe
Fig. 2 (see companion CD for color version). JEG-3 and Jar cell lines were transiently transfected with a construct containing the Rous sarcoma virus (RSV) promoter linked to a β-galactosidase reporter gene or a promoterless control β-galactosidase vector (0.5 µg per well) as described under Subheadingss 3.5.1. and 3.5.2. (LipofectAmine alone or LipofectAmine in combination with Plus reagent; see Note 12). Approximately 6 h after the transfection medium was removed, cells were stained for β-galactosidase activity (12–14).
Acknowledgments This work was supported by National Institute of Child Health and Human Development (NICHD) (HD39695). References 1. Hertz, R. (1959) Choriocarcinoma of women maintained in serial passage in hamster and rat. Proc. Soc. Exptl. Biol. Med. 102, 77–80. 2. Pattillo, R. A. and Gey, G. O. (1968) The establishment of a cell line of human hormone-synthesizing trophoblastic cells in vitro. Cancer Res. 28, 1231–1236. 3. Pattillo, R. A., Gey, G. O., Delfs, E., and Mattingly, R. F. (1968) Human hormone production in vitro. Science 159, 1467–1469. 4. Pattillo, R. A., Hussa, R. O., Delfs, E., et al. (1970) Control mechanisms for gonadotropic hormone production in vitro. In Vitro 6, 205–214. 5. Pattillo, R. A., Gey, G. O., Delfs, E., et al. (1971) The hormone-synthesizing trophoblastic cell in vitro: A model for cancer research and placental hormone synthesis. Ann. NY Acad. Sci. 172, 288–298.
18_Wolfe_229_240_F
238
8/29/05, 11:20 AM
Choriocarcinoma Cell Culture and Transfection
239
6. Pattillo, R. A., Hussa, R. O., Huang, W. Y., Delfs, E., and Mattingly, R. F. (1972) Estrogen production by trophoblastic tumors in tissue culture. J. Clin. Endocrinol. Metab. 34, 59–61. 7. Kohler, P. O. and Bridson, W. E. (1971) Isolation of hormone-producing clonal lines of human choriocarcinoma. J. Clin. Endocrinol. Metab. 32, 683–687. 8. Kohler, P. O., Bridson, W. E., Hammond, J. M., Weintraub, B., Kirschner, M. A., and Van Thiel, D. H. (1971) Clonal lines of human choriocarcinoma cells in culture. Acta Endocrinol. Suppl. 153, 137–153. 9. Pattillo, R. A., Ruckert, A., Hussa, R., Bernstein, R., and Delfs, E. (1971) The Jar cell line - continuous human multihormone production and controls. In Vitro 6, 398. 10. Thway, T. M. and Wolfe, M. W. (2001) Epidermal growth factor regulation of equine glycoprotein hormone α subunit expression in trophoblast cells. Biol. Reprod. 65, 197–203. 11. Thway, T. M. and Wolfe, M. W. (2002) An activator protein-1 complex mediates epidermal growth factor regulation of equine glycoprotein α subunit expression in trophoblast cells.Biol Reprod. 67(3), 972–980. 12. Sanes, J. R., Rubenstein, J. L., and Nicolas, J. F. (1986) Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J. 5, 3133–3142. 13. Gray, G. E., Glover, J. C., Majors, J., and Sanes, J. R. (1988) Radical arrangement of clonally related cells in the chicken optic tectum: lineage analysis with a recombinant retrovirus. Proc. Natl. Acad. Sci. USA 85, 7356–7360. 14. Hamernik, D. L., Keri, R. A., Clay, C. M., et al. (1992) Gonadotrope- and thyrotrope-specific expression of the human and bovine glycoprotein hormone α-subunit genes is regulated by distinct cis-acting elements. Mol. Endocrinol. 6, 1745–1755.
18_Wolfe_229_240_F
239
8/29/05, 11:21 AM
18_Wolfe_229_240_F
240
8/29/05, 11:21 AM
In Vitro Methods for Studying Vascularization
241
19 In Vitro Methods for Studying Vascularization of the Murine Allantois and Allantoic Union with the Chorion Karen M. Downs Summary Despite the importance of the definitive chorio-allantoic placenta in fetal survival, fetal development, and long-term health of the adult, little is known about how the placenta’s individual components, the allantois and the chorion, proliferate and develop. In this chapter, two techniques will be described: (1) explanting murine allantoises for culture in isolation, and (2) grafting murine allantoises into living whole mouse embryos. Together, these will enable study of differentiation of allantoic mesoderm into the umbilical vasculature, and the mechanism(s) by which the allantois unites with the chorion to form the chorio-allantoic placenta. Key Words: Allantois; chorion; chorio-allantoic fusion; explants; placenta; vasculogenesis.
1. Introduction The definitive chorio-allantoic placenta of eutherian mammals is a composite of two tissues, the umbilical cord and the chorionic disk. The umbilical vasculature carries fetal blood to and from the chorionic disk for exchange of nutrients, wastes, and gases with the mother. Despite their importance in fetal survival and development, little is known concerning how the two major tissues of the placenta develop, with an especial paucity of information on development of the umbilicus. Although the details of chorio-allantoic placentation vary between species, humans and rodents share major features (1). First, both possess a hemochorial placenta, in which maternal blood directly bathes trophoblastic cells of the chorionic disk. Second, fetal/maternal exchange is carried out within the chorionic labyrinth. Third, the umbilicus and future chorionic disk are initially well separated in the conceptus, uniting to become the chorio-allantoic placenta.
From: Methods in Molecular Medicine, Vol. 121: Placenta and Trophoblast: Methods and Protocols, Vol. 1 Edited by: M. J. Soares and J. S. Hunt © Humana Press Inc., Totowa, NJ
241
19_Downs_241_272_F
241
8/29/05, 11:21 AM
242
Downs
Given the similarities between rodent and human placentae, that genetic mutations are readily available in the mouse, and that microsurgery and other experimental manipulations can be carried out in living mouse embryos during placentation, the mouse is thus a sound choice for establishing fundamental paradigms of early placental ontogeny. The focus of this review will be on the umbilical component of the chorioallantoic placenta. In the mouse, the umbilical cord is derived from a wholly mesodermal organ, the allantois, which grows as an extension of the anteroposterior axis, the primitive streak (reviewed in ref. 2). Until recently, little was known about the allantois other than what it looked like and where it came from in the conceptus (3,4) (Fig. 1). As a result of studies carried out over the past decade, the timing of formation and whereabouts of three allantoic cell types have been elucidated. Mesothelium ensheathes the allantois as soon as the allantoic bud appears in the exocoelom (early neural plate stage, approx 7.25 d post conception [dpc]) (5). Angioblasts, the precursor cells of endothelium (6), are apparent in the distal allantoic core slightly later as a small population of Flk-1-containing cells (late neural plate stage, approx 7.5 dpc) (5,7,8). Chorio-adhesive cells are a subset of distal mesothelium; they mediate allantoic union with the chorion (12), and are recognized by their content of vascular cell adhesion molecule (VCAM)-1 (headfold stage, approx 7.75 dpc), which is required for chorioallantoic union (9,10). Recently, thanks in large part to the classical methods of embryology described in this chapter, a model of differentiation of allantoic mesoderm into mesothelium, angioblasts/endothelium, and chorio-adhesive cells has been put forth (5). Thus, allantoic mesoderm differentiates into the umbilical vasculature, which is then secured onto the chorionic disk. Detailed methods through which to study allantoic vascularization and fusion with the chorion are discussed under Subheadings 3.6. and 3.7. General protocols for addressing these major biological questions are described under Subheadings 3.1.–3.5., and include directives for animal husbandry (see Subheading 3.1.), obtaining rat serum (see Subheading 3.2.), preparation of dissection and culture media (see Subheading 3.3.), sharpening forceps (see Subheading 3.4.), and dissecting and culturing whole embryos (see Subheading 3.5.). Please note that, strictly speaking, the correct terminology for the product of the fertilized egg, which contains both the embryonic and extraembryonic components, is “conceptus”; however, because use of the word “embryo” is more common throughout modern literature, “embryo” will be used in place of “conceptus” in the detailed protocols.
19_Downs_241_272_F
242
8/29/05, 11:21 AM
In Vitro Methods for Studying Vascularization
243
Fig. 1 (see companion CD for color version). Morphology of the murine allantois. A–C, Brightfield photomicrographs of pre-fusion allantoic stages in histological sections (6 µm) stained with hematoxylin and eosin. D, Histological section (6 µm) of the chorio-allantoic fusion junction immunostained with anti-Flk-1 (white arrowhead, brown color on the accompanying compact disk) to demonstrate penetration of Flk-1positive allantoic blood vessels into chorionic ectoderm. A, Allantoic bud (al), neural plate stage/early bud stage (7.25 days post conception [dpc]) (20). The mesodermal allantoic core is covered in a simple squamous epithelium, called mesothelium (5). B, Enlargement of the allantois in the exocoelomic cavity (x), three-somite pair stage (8.25 dpc). C, The allantois is just making contact with the chorion (14), in preparation for enduring fusion (14), five-somite pair stage (8.5 dpc). D, Chorio-allantoic fusion and penetration of the allantoic vasculature into the chorion, 12-somite pairs (9.5 dpc). Other abbreviations: ac, amniotic cavity; am, amnion; ps, primitive streak region; ys, yolk sac. Scale bars: 50 µm (A,D); 75 µm (B,C).
19_Downs_241_272_F
243
8/29/05, 11:21 AM
244
Downs
1.1. Creation of Allantoic Explants Differentiation of allantoic mesoderm into Flk-1-containing angioblasts begins in the distal allantoic region, farthest away from the embryo, and spreads proximally (7). Distal angioblasts form endothelium by flattening and coalescence, a morphological sequence that is reiterated in the allantoic midregion, and finally in the base, with precise temporal regularity. By four- to six-somite pairs (approx 8.25–8.5 dpc), the nascent endothelial plexus of the allantois amalgamates with those of the yolk sac and fetus, all of which collectively form a vascular continuum in the conceptus (5,7). When plated directly onto tissue culture plastic, explanted allantoises behave similarly to intact ones (8). During the first 24 h in culture, almost all explants derived from headfold-stage embryos vascularize stereotypically, and maintain distal-to-proximal directionality of endothelial tubule formation; allantoic blood vessels contain proteins typical of angioblasts/endothelial cells (Fig. 2). With daily feeding, explants proliferate for at least 48 h more, during which the vasculature undergoes remodeling. When explanted allantoic cells are returned to intact allantoises, many integrate into appropriate cell lineages, demonstrating that culture does not adversely affect differentiation. In low serum, allantoic angioblasts neither robustly vascularize nor survive beyond 24 h but their survival can be rescued with exogenous vascular endothelial growth factor (VEGF165). Use of allantoic explants has contributed to the discoveries that (1) the murine allantois vascularizes de novo (7), (2) allantoic vasculogenesis is not accompanied by erythropoiesis (7), (3) allantoic vascularization depends on cues internal to the allantois rather than on contact with the chorion (7) or the underlying primitive streak (5), and (4) allantoic angioblasts contain and respond to many of the same signaling factors (8) used by the yolk sac and cardiovascular system (11). Thus, because the murine allantois vascularizes de novo, is dedicated to the establishment of a major vascular system, can be removed from the conceptus free of contamination, and vascularizes in isolation, there is currently no whole-organ system as ideally suited to the study of early mammalian blood vessel formation as the murine allantois.
1.2. Chorio-Allantoic Union When we began study of chorio-allantoic fusion, or “union” (12), the cellular and genetic mechanisms of early placental ontogeny were unknown. We hypothesized that chorio-allantoic union might occur by one of three models (reviewed in ref. 2). In the first, contact between the allantois and the chorion would stimulate expression of appropriate genes controlling cell adhesion on both tissues. In the second model, the molecules required would be found constitutively on both the allantois and the chorion prior to fusion. The third model
19_Downs_241_272_F
244
8/29/05, 11:21 AM
In Vitro Methods for Studying Vascularization
245
Fig. 2 (see companion CD for color version). Vascularization in allantoic explants. Headfold-stage allantois cultured in the well of a 24-well plate for 24 h. Blood vessels are darkly stained (arrow; brown color in accompanying compact disk) as a result of immunostaining with anti-Flk-1; they are sitting on a layer of unstained cells (arrowhead) derived from the mesothelium (5). Scale bar, 100 µm.
proposed that requisite adhesion molecules might be acquired gradually by one or both components as they matured. To distinguish between these possibilities, distal halves of individual labeled donor allantoises were placed into the exocoelomic cavity of similarly staged unlabeled hosts whose own allantois had been removed (12) (Fig. 3). Operated and control conceptuses were then cultured for varying periods and examined. Use of this grafting method revealed that chorio-allantoic union (1) is specific to the allantois and the chorion, (2) is mediated by the allantois and chorion’s mesothelial surfaces, (3) occurs gradually, peaking at six- to eight-somite pairs, and (4) is dependent upon the developmental maturity of the allantois. Further, results predicted that the molecules required for chorio-allantoic union would appear gradually on the allantois, but localize constitutively to the chorion,
19_Downs_241_272_F
245
8/29/05, 11:21 AM
246
Downs
Fig. 3 (see companion CD for color version). Microsurgical technique to introduce labeled donor allantoises (al) or donor allantoic subregions into the exocoelom of unlabeled host embryos. A, The allantois (al) of a labeled donor embryo is aspirated from the exocoelomic cavity (x) by anterior yolk sac puncture (long arrow) and placed into the exocoelomic cavity (B) of an unlabeled host via the anterior yolk sac puncture (long arrow) through which its own allantois has been removed. The small arrows within the host’s exocoelom indicate the possible sites of donor fusion within the exocoelom, which include the chorion (ch) and the host’s allantoic regenerating allantois. C, The operated conceptus is then cultured for up to 24 h.
according to the third model. Serendipitous knockouts of the receptor/counterreceptor pair, VCAM1 and α4-integrin (9,10,13), revealed a major role for each gene’s protein product in chorio-allantoic union. Moreover, VCAM-1 was localized to the allantois, whereas α4-integrin was confined to the mesodermal component of the chorion. Later studies spatio-temporally fine-mapped VCAM-1/α4-integrin to the allantois and chorion, and confirmed gradual acquisition of VCAM-1 by allantoic mesothelium, whereas chorionic mesoderm contained α4-integrin throughout its development (14). Together, these data validated the study of chorio-allantoic union by classical methods of embryology. In later experiments, grafting whole allantoises rather than distal halves resulted in the creation of chimeric allantoises with the host allantois (Fig. 4). Staining chimeric allantoises and allantoic explants with benzidine, a marker of hemoglobinized red blood cells, supported the conclusion that allantoic vasculogenesis is not accompanied by erythropoiesis (7), as it is in the yolk sac (15,16). 2. Materials 2.1. Mice 1. F2 generation of embryos from intercrosses of the F1 inbred hybrid strain (C57Bl/ 6 × CBA) (B6CBAF1/J; Jackson Laboratories, Bar Harbor, Maine) (see Note 1).
19_Downs_241_272_F
246
8/29/05, 11:21 AM
In Vitro Methods for Studying Vascularization
247
Fig. 4 (see compaion CD for color version). Chimeric allantois. Donor allantois (dal) is darkly stained (blue on the accompanying compact disk) and has fused with both the host’s regenerating allantois (hal-r) and chorion (ch). Other abbreviations: am, amnion; b, embryonic brain; ys, yolk sac. Scale bar, 100 µm. 2. Embryos hemizygous for the Rosa26 lacZ transgene (17), which are produced by mating an F1 hybrid female (see Subheading 2.1., item 1) with a male of similar (C57Bl/6 × CBA) genetic background but which bears two copies of the Rosa26 lacZ transgene (18) (see Note 2).
2.2. Rat Bleeding 1. Male or nonpregnant female Sprague-Dawley rats ⱖ 300 g (Harlan Teklad, Madison, WI), are temporarily housed in an AALAC-approved animal quarters until exsanguination. 2. 70–100% ethanol in a squeeze bottle. 3. Bunsen burner. 4. Carcass bag. 5. Two clinical tabletop centrifuges, swinging-bucket style. 6. Container for used syringes and test tubes. 7. Cryogenic vials: Nalgene, 5-mL capacity, sterile (Fisher Scientific, Pittsburgh, PA, cat. no. 03-337-7H). 8. Long, 6-in., straight (“dressing”) forceps: for squeezing serum clots (Fisher, Cat. No. 13-812-40). 9. Two pairs short (4-inch) straight, fine-pointed forceps , (Fisher, cat. no. 08-880) for grabbing the rat’s skin and removing fat from descending dorsal aorta.
19_Downs_241_272_F
247
8/29/05, 11:21 AM
248
Downs
10. Disposable gloves. 11. Five-inch, straight hemostat (“Halstead Mosquito Forceps”) (Fine Science Tools, Foster City, CA, cat. no. 13008-12), for safe removal and disposal of syringe needles. 12. Isofluorane (MidWest Veterinary Distribution, Winnipeg, Manitoba, Canada, cat. no. 558.09058.3). 13. Isofluorane anesthetizing apparatus (Surgivet/Anesco, Waukesha, WI). 14. Kimwipes. 15. Lab coat. 16. Lamp (table-poise) or cool lighting. 17. Two tanks pure oxygen. 18. Nine-inch, sterile Pasteur pipets. 19. Two scavenging filter canisters (Surgivet). 20. Six-inch, straight scissors (Fisher, cat. no. 08-951-20) for making incisions into the rat’s abdomen. 21. Sharps container for needle disposal. 22. 21-gauge × 1.5- in. syringe needles. 23. 10- and 20-mL sterile syringes. 24. 15-mL polypropylene test tubes (Fisher, cat. no. 05-538-53D). 25. Timer (multichannel).
2.3. Dissection and Culture Media 1. Double-distilled (tissue culture-grade) sterile water (Sigma Chemical Co., St. Louis, MO, cat. no. W-3500). 2. Color pHast indicator strips, 5.0–-10 (VWR International, West Chester, PA, cat. no. EM-9588-3); 6.5–10 (VWR, cat. no. EM-9583-3). 3. Two sterile, 1000-mL Erlenmeyer flasks. 4. 500-mL–0.22-µm cellulose acetate filter units (Fisher, cat. no. 09 740 28C). 5. Freezer (–86°C). 6. Pure carbon dioxide. 7. Gas regulator for CO2 tank. 8. 1000-mL, tissue culture-dedicated, sterile graduated cylinder. 9. 500-mL, tissue culture-dedicated, sterile graduated cylinder. 10. Nine-inch, sterile, nonabsorbent, cotton-plugged Pasteur pipets for bubbling CO2 gas to medium. 11. Volumetric, disposable, sterile pipets. 12. Tissue culture-dedicated automatic pipettor. 13. Chemical and biological reagents (see Table 1). 14. Tissue culture-dedicated stir flea. 15. 15-mL, sterile, polypropylene conical test tubes (Fisher, cat. no. 05 538 53D). 16. 50-mL, sterile, polypropylene conical test tubes (Fisher, cat. no. 14 959 49A). 17. Laminar-flow tissue culture hood. 18. Clear tubing for delivering CO2 gas to medium. 19. Vacuum apparatus. 20. Weigh boats and glass paper.
19_Downs_241_272_F
248
8/29/05, 11:21 AM
In Vitro Methods for Studying Vascularization
249
Table 1 Reagents and Suppliers for Dissection and Culture Media for Mouse Embryos Between 7.25 and 8.5 Days Post Coitum
Media component DMEM (Invitrogen-Gibco, Carlsbad, CA, 12800-017) with 4500 g/L glucose, L-glutamine (584 mg/L) and NaPyruvate (110 mg/L); w/o NaHCO3 HEPES, free acid (Sigma H-3375) NaHCO3 (Sigma S-8875) NaCl Amino acids (Sigma)b: cysteine-HCl (C-1276) L-alanine (A-7469) L-asparagine (A-0884) L-aspartic acid (A-8949) L-proline (P-5607) L-glutamic acid (G-1626) Penicillin-streptomycinc (Invitrogen-Gibco 15070-063) (100 U/mL pen, 100 mg/mL strep) Heat-inactivated Fetal Calf Serum (FCS)d (Invitrogen-Gibco 16000-044) Heat-inactivated rat serum (prepared in house)
Dissection medium (DMEM + H + S) (per liter)
Culture medium (DMEM–S) (per liter)a
13.5 g
13.5 g
2.385 g – 0.8 g
– 3.7 g –
4.8 mg 3.6 mg 6.0 mg 5.3 mg 4.6 mg 5.9 mg 2 mL
4.8 mg 3.6 mg 6.0 mg 5.3 mg 4.6 mg 5.9 mg 2 mL
7.5% –
– 50.0%e
DMEM, Dulbecco’s modified Eagle’s medium. aBefore rat serum is added, all components are combined and the pH of the culture medium is adjusted to 7.3 by bubbling in CO2. The solution is then filter-sterilized, aliquoted, and stored indefinitely at –86°C. bThe amino acids are made as a 100X stock, i.e., 100 times the amounts shown above are combined in approx 980 mL sterile double-distilled water, the pH is adjusted to 9.0 with 5 N NaOH. Bring the volume to 1000 mL with double-distilled sterile water. Dispense 10 mL aliquots to 15 mL sterile polypropylene tubes and store, unfiltered, indefinitely at –86°C. cPenicillin-streptomycin stock: 5000 U/mL penicillin G sodium and 5000 µg/mL streptomycin sulfate in 0.85% (physiological) saline. Upon delivery from the manufacturer, thaw solution in warm water and dispense in 6 mL aliquots to 15 mL sterile polypropylene tubes via a sterile volumetric disposable pipette. Store the aliquots indefinitely at –86°C. When making dissection or culture media, completely thaw a 6-mL aliquot and remove 2 mL; refreeze the remaining 4 mL. dAs soon as the fetal calf serum (FCS) is delivered to the lab, thaw it in warm water; monitor the bottle for breakage during the thaw. If the